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ABSTRACT
Consideration of broader outcomes of disease, especially those exclusively experienced and 
reported by the patient, such as HRQOL, is not only consistent with the ‘whole person’ view of 
health contained in the 1948 WHO definition, but is also a prerequisite to building health-care 
systems that are responsive to the needs of the patients. For chronic skin diseases, such as 
hyperhidrosis, these provide a useful indicator of how a patient feels and functions disease for both 
practical and methodological reasons. The aims of this study therefore were to investigate the 
impact of hyperhidrosis on patients’ HRQoL using a mix of qualitative and quantitative methods. 
In addition, a further aim was to develop and validate a disease-specific instrument for assessing 
HRQoL in hyperhidrosis. In pursuing the above aims, the feasibility of applying online social 
networking sites for outcomes research in dermatology was assessed.
Patients were recruited through online social networking communities related to hyperhidrosis for 
all stages of the study. Interviews, focus groups and surveys were used for collecting qualitative 
data from patients (n = 71) to understand quality of life issues of patients, and to provide the content 
of the new instrument. Dermatologists (n= 5) and patients (n=7) took part in the content validation 
of the HidroQoL©. Item reduction and the development of the scale’s structure was carried out 
through several field-testing studies (n: USA, 559; UK, 115), using the item response theory (IRT)
Rasch model and factor analyses. Further psychometric testing was performed in a separate study 
(n = 241). Distribution-based methods were applied in establishing minimum clinically important 
difference (MCID).
A thematic analysis of the qualitative data collected produced 29 quality of life themes and 102
sub-themes, forming the content for the initial 49-item HidroQoL©. The two expert panels judged 
the instrument as content valid, with a few suggestions. The Rasch analysis modelling led to the 
collapsing of response categories (from five to three) and the reduction in number of items (from 
49 to 18), to ensure a perfect model fit. Factor analyses supported both a single- and a two-factor
structure. In subsequent construct validation study the HidroQoL correlated with the DLQI (rs =
0.572, p < 0.01) and the Skindex-17 (rs = 0.551, p < 0.01). Reliability was high (Cronbach alpha 
= 0.9; test-retest ICC = 0.93). The scores were sensitive to change in patients’ disease severity 
(standard response mean = 0.8, 95% C.I: 0.34-1.27). The scale banding proposed for the HidroQoL 
score is as follows: 0 – 1, no effect at all; 2 – 11, small effect; 12 – 22, moderate effect; 23 – 32, 
large effect; 33 – 36, very large effect. The MCID values were 1.94 – 3.07, for generalised 
vhyperhidrosis, 2.16 – 4.36, for axillary hyperhidrosis, 2.15 – 3.39, for palmo-plantar hyperhidrosis.
An MCID of three is currently being proposed for all types of hyperhidrosis.
This study has provided the initial evidence supporting the appropriateness of the content of the 
HidroQoL and validity of inferences from its scores for assessing HRQoL in hyperhidrosis. In 
addition, the availability of MCID estimates for the HidroQoL will facilitate its clinical 
interpretation in both research and routine clinical practice. This study has also demonstrated how 
CTT and IRT can be integrated in the development and validation of a new generation of HRQoL 
instruments, using social network for patient recruitment.
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GLOSSARY OF TERMS
Differential Item Functioning This occurs where respondents with different characteristics 
have varying probabilities of getting a particular item
response holding the underlying construct constant.
Applicability This relates to the appropriateness of a measure’s content 
and emphasis to the target population.
Content validity this refers to the adequacy with which sampled items of an 
instrument reflect its aims as articulated in the conceptual 
framework.
Construct validity The degree to which theoretical hypothesis relating to an 
underlying construct being assessed by an instrument are 
actually supported, providing evidence justifying particular 
or inferences or interpretation of scores.
Convergence validity the relationship between a scale and other measures 
assessing a similar construct.
Divergent validity the absence of a relationship between a scale and measures 
of dissimilar construct.
Factor Analysis An analysis that identifies the least number of latent
variables accounting for covariation among a set of items.
Primary hyperhidrosis Excessive sweating beyond the physiological needs of the 
body that is without aetiology, often localised to the
underarms, palms, feet or other body areas.
Secondary hyperhidrosis Excessive sweating that has a known cause e.g. due to 
menopause, often generalised. 
Internal Consistency The inter-relationship between items in a multi-item scale, 
reflecting homogeneity within a scale.
Interpretability Decoding of qualitative meaning from QOL scores
viii
Kruskall-Wallis tests A non-parametric alternative to the one way ANOVA 
typically applied for comparisons among two or more 
groups.
Rasch analysis An analysis intended to assess how well data conforms to the 
unidimensional Rasch model, its assumptions and 
properties.
Responsiveness The capability of a measure to capture true changes in the 
patient’s conditions even if they are small.
Scale banding Categorisation of scale scores to aid in their interpretation 
and application for decision especially in routine clinical 
practice.
Unidimensionality Variation in the scores of an instrument can be attributed to 
a single dominant latent variable.
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1CHAPTER 1
General Introduction
2BACKGROUND
Outcomes reported by the patient, such as symptoms, physical function, well-being, HRQoL, 
perceptions of treatment effect, satisfaction with care received, have now gained recognition as a 
credible and key endpoint of therapy. For example, improvement in HRQoL is now recognised as 
the ultimate goal of health care (MacKeigan and Pathak 1992). This has paved the way for 
application of Patient Reported Outcome Measures (PROMS), for example in the assessment of 
efficacy of pharmaceutical therapies in clinical trials, as evidenced by the issuance of guidelines 
by drug regulatory agencies such as the US FDA and the European Medicines Agency (EMEA)
on the use of PROMS for market authorisation application of new medicines. HRQoL and other 
PRO data appeared in the scientific discussions of 34% of products submitted between 1995 and 
2005 (Bottomley et al. 2009). Gnanaskthy et al. (2013) observed that out of the 308 new molecular 
entities (NME) and biologic licence applications (BLA) granted approval by the US FDA between 
2000 and 2012, Patient Reported Outcome (PRO) claims were approved in 70 (23%), with the 
PROs being the primary endpoint in the majority (81%) of cases. Furthermore, there has been a 
growing use of PROs in routine clinical practice in various therapeutic areas. For patient 
management, to assess the impacts of disease and its treatment; in screening for patients 
experiencing major effects; and in multidisciplinary teams discussions among others (Greenhalgh 
2009). Recently, there have been efforts to use patient reported outcome measures (PROMS) for 
monitoring the performance of the health-care system, in the UK, but also in other countries such 
as Sweden and the USA. In Sweden, disease-specific clinical databases (quality registers) have 
been established under the watch of the medical profession and in the USA, this has covered spinal 
conditions in New England and for primary care in Pittsburgh (Black 2013). In the English NHS, 
since 2009, all health care providers treating NHS patients for hip or knee replacement, groin 
hernia repair and varicose vein surgery have been required to assess PROs before and after 
treatment involving 485 000 patients (Devlin and Appleby 2010). This highlights the pace and 
scope with the use of PROs.
Various developments in recent decades might explain the growing recognition of the need to 
capture patients’ perspective of illness and health-care interventions. First, there has been a marked 
change in disease-epidemiology not only in the western world but also in the developing countries, 
with non-communicable and life-style diseases replacing communicable diseases. Conditions such 
3as cancer, diabetes and cardiovascular disease, which are long-term rather than acute, are 
increasingly a growing health challenge. Often complete cure from disease may not be realisable, 
which makes maintaining a comfortable, functional and satisfying life an important goal of therapy 
for such conditions (Salek and Luscombe 1992).  Improvements in medical care and general living 
conditions have on the other hand meant that people are now living longer, leading to increase in 
conditions related to aging, such as Dementia and Parkinson’s disease. While dealing with a 
condition such as cancer as a biological and pathological condition might be imperative, it is not
necessarily of paramount concern to patients (Lohr 2002). Their worries extend to how the 
condition and its treatment will impact on their lives (Lohr 2002), for example: Can I go out with 
friends without worrying that I may vomit due to the chemotherapy? On the other hand, the 
management of conditions heavily relies on the experience of the patient in their everyday life to
strive to conduct a “normal” life. 
In chronic skin conditions, although decreasing the amount of sweating or the thickness, redness 
and number of lesions may be valid endpoints in assessing therapeutic effect, such endpoints may 
not necessarily be of most relevance from the patient’s standpoint (Grob 2007). Moreover, such 
endpoints may not provide the full picture of the impacts of disease or therapy. In addition, there 
might be some aspects related to the disease-condition that only the patient might be aware of, and 
therefore able to report on. A broad perspective of the impacts of disease or therapy may offer a 
better framework for risk-benefit assessment of therapies (Finlay 1998). For example, where 
therapy is successful in eliminating the primary symptoms associated with a condition but results 
in other limitations in patient’s life (e.g. Endoscopic thoracic Sympathectomy in hyperhidrosis 
may affect the nervous system or lead to compensatory sweating). The PROs such as HRQoL, 
provide a more comprehensive measure of the impact of skin disease apart from capturing what 
the patients care about most, for example, how their condition affects their daily life activities and 
their social lives. Thus, these offer a robust means for assessing disease activity in chronic skin 
disease (Grob 2007).
Although clinicians may want to forgo measuring QoL because of the associated challenges; a 
presumption that QoL is captured by observing biomedical outcomes; and that they (the clinicians)
have the ability to judge the impact experienced by the patient, current evidence suggests 
otherwise. Schmitt and Ford (Schmitt and Ford 2007) showed the uniqueness of 'HRQoL' from 
4symptoms or 'disease severity', in spite of the two being linked, making it difficult to accurately 
infer one from the other. There is evidence of a poor relationship between disease severity and 
HRQoL, patients may experience great impairment even with low disease severity and the opposite 
can also be the case, they may have high disease severity and yet experience low HRQoL impact 
(Bowling 2001). Moreover, clinician's evaluation does not always agree with patients own 
assessment of their QoL (Jemec and Wulf 1996; Hermansen et al. 2002).  Moreover, patients with 
a low severity but experiencing high levels of HRQoL impairment, often inaccurately assessed by 
clinicians, tend to be least satisfied with their care (Renzi et al. 2001).
HEALTH RELATED QUALITY OF LIFE: A THEORECTICAL FRAMEWORK
Definitions
The concept of QOL has been employed across multiple-disciplines and settings (academic 
research, policy making environment, everyday speech), with varying understanding of its 
components, determinants and interpretation used in each context, hindering the emergence of a 
unified definition.  At the population level, the concept of QOL has been used to study national 
well-being by governmental agencies as well as international organisations such as the 
Organisation of Economic Cooperation and Development (OECD), the World Bank and the World 
Health Organisation (WHO), with a focus on social indicators of living conditions and how 
individuals evaluate their satisfaction.  At this level, a high QoL may be indicated by high earnings; 
absence of poverty and unemployment, decent housing, health spending and life expectancy, an 
educated population, high levels of cultural participation and low rates of crime, equity in social 
opportunities, and the absence of political corruption in the broader context of responsible 
environmental management (Rapley 2003). A lack of attention to the priorities of communities and 
individuals in the population-level QoL due to the aggregation has provided the space for 
individual level QoL construct. Therefore, QoL fundamentally includes two elements, an objective 
and a subjective element. Although numerous definitions exist, simply put, QoL is how individuals
consider their material situation. 
 The WHOQOL group (1995) defined QOL as, an individual’s perception of their position 
in life in the context of the culture and value systems in which they live and in relation to 
their goals, expectations, standards and concerns. It is a broad ranging concept affected 
in a complex way by the person’s physical health, psychological state, level of 
5independence, social relationships and their relationships to salient feature of their 
environment.  
 Cummins (1997) considers QoL as both objective and subjective, each axis being the 
aggregate of seven domains: material well-being, health, productivity, intimacy, safety, 
community and emotional well-being. Objective domains comprise culturally relevant 
measures of objective wellbeing. Subjective domains comprise domain satisfaction 
weighted by their importance to the individual.
The list of objective elements considered important to well-being may be influenced by societal 
cultural and political values, which may differ across communities, cities or nations. On the other 
hand, how particular individuals relate to their material circumstances may be due to their 
personality, personal beliefs and values. In this regard a universally agreed understanding of good 
QoL may be challenging (Phillips 2006). Although socioeconomic factors such as sanitation, 
health, education, housing, employment and other factors are key to QOL more so as targets of 
social and economic policy, except for health, the others lie outside the remit of 'health policy' and 
may not necessarily be influenced by medical-care. The concept of HRQoL, therefore, has as its 
rationale the intention to distinguish those aspect of QoL that pertain to health, disease or its 
treatment from the rest (Coons and Kaplan 1992). Still, the extent to which this is feasible remains 
questionable, given that multidimensional HRQoL addresses most of QoL domains (Fitzpatrick 
1996). Moreover, HRQOL may be influenced by factors other than those fitting the classification 
of ‘health-related’, linked to the socioeconomic factors such as level of education, income or 
family-relations.  This redefines QoL in line with the intentions for measurement in health and 
medical care. 
Numerous definitions of HRQoL have been proposed, reflecting differing perspectives on the 
content and scope of what should be relegated as 'health-relevant' aspects of QoL as well as 
differences in theoretical underpinnings of the concept.  It is difficulty to deny the influence of 
WHOs monumental whole-person definition of health on the current understanding of HRQoL, 
where “health is not merely the absence of disease but a state of complete physical mental, social 
well-being” (Group 1948). 
 Bowling (2001) defines HRQoL as “optimum levels of physical role (e.g. work, carer, 
parent etc.) and social functioning, including relationships and perceptions of health, 
6fitness, life satisfaction and well-being. It should also include some assessment of the 
patient’s level of satisfaction with treatment outcome and health status and with future 
prospects”. Short of including material circumstances such as education, physical 
environment and level of income, this definition encompasses both positive and negative 
aspects of health. Some aspects included may not easily be affected by medical care. 
Nonetheless, this definition strongly reflects WHOs ‘whole person’ definition of health 
(Phillips 2006). 
 Schipper et al. (1990) defines HRQoL as “the functional effect of an illness and its 
consequent therapy upon a patients, as perceived by the patients”. They further highlight 
physical and occupational function; psychological state; social interaction and somatic 
sensation as the being the domains influencing overall effect. Intrinsic in this definition is 
a presumed level of functionality, which is considered as the norm, thus this perspective 
focuses on assessing “dysfunction” or negative aspects of disease. This definition, 
therefore, focuses on those aspects that can be influenced by clinicians and medical care.
 Ebrahim (1995) has offered an alternative definition of HRQoL, where it is defined as self-
perceived well-being  related to or affected by the presence of disease or treatment. With 
'well-being' understood as an individual’s inner-personal state (Doward and McKenna 
2004), this definition opens up to other impacts of disease, including those that may not 
be directly influenced by clinical therapy, for instance, personal relationships, self-image 
and future health concerns. Nonetheless, there are some reservations over the inter-
changeable use of the notion of well-being with QoL (Doward and McKenna 2004). 
 Padilla et al (1996) defines HRQoL as a personal, evaluative statement summarizing the 
positivity or negativity of attributes that characterize one’s psychological, physical, social, 
and spiritual well-being at a point in time when health, illness, and treatment conditions 
are relevant. This definition takes a broad view, encompassing all aspects of life of an 
individual with a disease condition, including negative, while acknowledging potentially 
positive influences of a medical condition. 
The consequences of disease on the patient’s life have also been captured using other concepts. 
For example the ICIDH described the concepts of ‘impairment’, disability and handicap. 
Impairment refers to the loss of normal physiological or psychological function due to disease for 
example, symptoms and adverse events from treatment (Doward et al 2004). Disability refers to 
7the restriction on normal performance of activities in various aspects of a patient’s life as a result 
of impairment from disease (Finlay and Kelly 1987; Doward et al. 2004). The disadvantage in the 
fulfilment of roles in society due to impairments and disability associated with a disease is referred 
to as ‘handicap’ (Finlay, 1998). The concepts of impairment and disability directly relate to QoL 
as they represent clinical and functional status perspective of the impacts of disease, respectively. 
On the other hand, handicap is not directly related to an individual’s QoL as it is measured from a 
societal point of view and reflects impacts on society (Doward et al. 2004).
Theoretical Foundation 
A number of theories have been presented as genesis or foundation to the measurement of QoL, 
including the needs-satisfaction-approach; the being, belonging and becoming model and 
Calman’s gap theory. The needs-satisfaction approach is rooted in Maslow’s human motivation 
theory. Maslow (1973) cited in Bowling (2001) argued that people are motivated by a desire to 
fulfil their needs, which are grouped as physiological, safety, love and belonging, esteem and self-
actualisation, presented hierarchically. Once a given set of needs are met, they cease to be a source 
of motivation, the focus is on the next level of needs which then become a source of motivation. 
As such, QoL reflects the ability and capacity of the individual to satisfy certain needs, where 
needs are fulfilled QoL is good, otherwise it is poor (Doward and McKenna 2004). QoL, in this 
perspective, is seen as quite distinct from health status and function, for example whereas 
‘walking’ is a function, it may affect ‘doing shopping’ or ‘recreational activities’ which may be 
seen as ‘needs’ to an individual.
In the Raphael’s being, belonging and becoming model (Raphael et al. 1996), QoL is considered 
as the extent to which an individual enjoys the important possibilities in their life (Phillips 2006). 
Key to this theory is the individual who is crucially at the centre of determining what a possibility 
is and how it is important to them. QoL is seen as a multidimensional concept comprising of three 
domains: being, representing who one is, with physical health, psychological and spiritual 
elements; belonging, reflecting a person’s relations to their surrounding environment, social and 
community; and becoming, reflecting deliberate activities pursued to express personal goals, hopes 
and aspirations (Raphael et al. 1996).  While this approach concentrates on functioning and role 
performance, the importance of the interaction of the individual with others and the environment 
in influencing QoL is highlighted. 
8In Calman’s gap theory QoL is determined by the discrepancy between a patient’s expectations 
and achievements (Calman 1984). This may also refer to the gap between patients’ potential 
achievement and their actual achievements (Powell and Powell 1987). Where such discrepancy is 
small, QoL would be high, while a large discrepancy would lead to a low QoL. Other factors may 
influence the size of such a discrepancy, which would in turn affect QoL. This theory highlights 
the role of interventions such as communication/discussions about treatment options and their side 
effects; patient education supporting patients in coping with their condition in influencing QoL. 
The connection between previous experiences, current situation and aspirations for the future with 
QoL is clarified (Bowling 2001). Calman’s gap theory seems to share much in common with 
Raphael’s theory presented above, in both cases lowering expectations has a positive influence on 
QoL (Phillips 2006). On the other hand, this theory can be seen as an adapted version of the needs-
satisfaction theory, replacing the notion of ‘need’ with ‘relative deprivation’. The Patient 
Generated Index (PGI) is an example of a measure underpinned by this theory. 
The measurement of HRQoL must take into account its unique properties and the associated 
idiosyncrasies. First, the multidimensional nature of HRQoL as a concept is in keeping with the 
broad and holistic definition of ‘health’ presented by the WHO (Schipper et al. 1990) presented 
above. In reality  however, medical therapy, relates only to a narrow aspect of ‘health’ and 
consequently HRQoL (Bowling 2001), questioning the relevance of the concept relative to, for 
example, ‘health status’. HRQoL measures often lack reference to therapeutic goals, in their 
development, in comparison to ‘Clinimetric’ or ‘Health Status’ measures (Testa 2000).  
Furthermore, the multi-dimensionality of HRQoL introduces challenges with weighting of the 
importance of each domain in producing summary measures. While this may be done statistically, 
individual patients may value the domains differently.  
In its broadest sense health entails absence of infirmity, which reflects a negative aspect, but even 
more importantly it encompasses ‘well-being’, the ability of individuals live their life to its fullest 
potential, which reflects the positive elements of health. Both elements indeed belong to the 
concept of HRQoL, even though the focus within clinical research or routine clinical practice has 
tended to be on assessing the negative aspects of HRQOL. Cummins et al. (1998) critiques such 
an approach as leaning more towards a biomedical model of medicine. This also explains the 
9interchangeable usage of HRQOL with ‘health status’, due to the relevance of the latter in most 
clinical situations. Although a more comprehensive assessment of HRQOL is considered ideal, 
these may come at the cost of applicability and practicality of measurement instruments, 
explaining why the typical approach is to concentrate on those aspects of HRQOL that may be 
relevant for a particular patient group or which might be affected by therapy.
Components Of HRQoL
The plurality of views on HRQoL is reflected in varying scope of the definitions, for example in 
the inclusion of negative and/or positive aspects of health;  inclusion of aspects of HRQoL 
amenable to the influence by medical care and lying in the ambit of health-care (Ferrans 2005). It 
is also important to consider the variation in the components of HRQoL. Nevertheless, instrument 
developers seem more comfortable with focusing on negative elements of health, as these seem 
more linked to aims of medical therapy. The different views on the components of HRQoL seem
to focus on the following core domains: emotional status; physical functioning; social functioning; 
and medical symptoms (Fitzpatrick 1996). Various conceptual models have proposed for 
illustrating the components of HRQOL and how they are linked to each other and other outcomes. 
These are illustrated below. 
Ware’s model 
In one of the earliest models on HRQoL, Ware (1984) presented a framework for discussing 
disease and its impact on the patient’s life. Health status or well-being was argued to have the 
following components (domains):
 physiological status, measurable physiological parameters of the disease such as 
symptoms, lab-values; 
 personal functioning, performance of daily tasks such as self-care and other physical 
activities;
 Psychological health and wellbeing; this includes psychological effects of disease such 
as anxiety or frustration, but might also include positive affect, better mental health.
 General health perception, how the individual looked at their overall health 
considering their physical functioning, personal functioning, psychological distress and 
wellbeing. 
 Social well-being, performance of usual roles whether in the community, school/work 
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or home. 
The model is presented in Figure 1.1 where each domain, presented in a layer was hypothesised to
influence the concentric outer layer, while allowing some feedback influence of outer layers to the
domains inside. For example, while it is clear, problems in performance of tasks (personal 
functioning) may result in frustration or anger (psychological distress); similarly, anxiety 
(psychological distress) may not only result in limitations in some activities but may also affect 
individual's immune system. 
Figure 1.1: Health status domains proposed in Ware’s model
Source: adapted from Ware et al. (Ware 1984). 
The lack of personal interpretation and evaluation from the patient, assessing how important their 
perceived status is, means that this framework may not reflect full impact of disease (Bloom 1984). 
On the other, individual’s overall consideration of their health status is likely to encompass their 
ability to function socially, thus general perception and social role ought to be swapped. 
Recently, Ware (2003)suggested a re- conceptualisation of health status, into a model of three inter-
related multi-layered health onions, comprised of a physical component, a mental component and 
a participation component. He cites a huge volume of evidence for a two components model which 
includes empirical studies on generic health status measures such as the SF-36, SIP, NHP and HIE. 
The rationale for a third separate component for measuring participation is that: this is consistent 
with the view reflected in the new ICF, disability and health to measure and interpretation role 
Role functioning
General health 
perception
Psychological 
distress/ Well-
being
Personal 
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Physiological 
aspects of 
disease
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participation separately. In addition, from health economics perspective, the utility implication of 
reduced role participation is the same regardless of its causes. Considering that social functioning 
is already seen to be a part of HRQOL, the practical implications of the newly discovered-and-
proposed importance of social functioning, is yet to be understood.
Patrick and Chiang model
Patrick and Chiang (2000) proposed a comprehensive model illustrating the relationships between 
health/disease and the concepts of HRQoL and QOL (Figure 1.2). Their framework builds on a 
more basic model proposed earlier by (Wilson and Cleary 1995), where the causal relationship 
among 5 levels of health outcomes, from  biologic/physiological outcomes; through symptom 
status; functional status; general health perceptions to overall QOL was proposed and illustrated. 
The new model has included greater clarification on the external environment as well as aspects 
internal to the individual; and illustrated their integration with health status and HRQOL. This is 
not only valuable in interpreting results when evaluating treatments, but may also reveal effect 
modifiers, which may be targeted by interventions (Ferrans 2005).  Ultimately, therefore, general 
QOL is determined in a three-way interaction between external environment, health related quality 
of life, and the internal individual characteristics. 
Figure 1.2: Patrick and Chiang QOL and HRQOL model
Source: adapted from Patrick and Chiang (2000). 
Still, delineating determinants or inputs, and components of health status or HRQOL is essential 
in the conceptual purity of HRQOL, indispensable for the future development of the concept.  
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While this model seems to have successfully distinguished the “inputs” from the “components” of 
the health outcomes, the demarcation between “health status”, QOL and HRQOL still seems fuzzy.
Practical issues
Assessing QoL is like assessing the beauty of a rose, irrespective of the aspects considered, colour, 
smell and height, capturing its full beauty is almost impossible and ultimately lies in the eyes of 
the individual (Mount and Scott (1983) cited in Carr et al. (2002)). Subjectivity is one of the core 
attributes of HRQoL concept. The importance attached to the different elements and domains of 
the HRQoL vary across individuals apart from changing over time for the same individual. How 
individuals experience, value and perceive their illness/disease condition, may reflect internal 
values, preferences, priorities, personality, their ability to adapt to their condition, support network, 
beliefs and other socio-demographic factors. This suggests the same level of disease severity may 
show different HRQoL profiles. The majority of patients with chronic conditions may still 
experience favourable QoL; which may not be worse than that seen in healthy individuals 
(Fitzpatrick 1996). Moreover, disease severity has shown to be weakly related to HRQoL 
(Fitzpatrick 1996; Bowling 2001). The subjective nature of HRQOL has been further highlighted 
and crystallised in the ‘disability paradox’, whereby people disabled from birth have shown higher 
than expected QoL; while an increase in self-reported QoL was seen in individuals with recently 
acquired disabilities, or post-diagnosis of terminal illnesses (Rapley 2003; Phillips 2006). 
Furthermore, an often cited issue with applying HRQoL in clinical trials and routine practice 
relates to perceived lack of objective often assumed from the subjective nature of HRQoL 
outcomes (Grob 2007). While such perception is not necessarily obvious, the issue of objectivity 
of measurement is quite central to validity and reliability of any empirical measurement, therefore, 
it has a relevance to both subjective “soft” and objective “hard” endpoints. Unlike endpoints such 
as systolic BP or blood glucose levels, QoL is a theoretical construct, whose existence hinges upon 
a set of agreed upon indicators. Moreover, the lack of conceptual agreement implies that QoL 
construct is not only defined differently in different groups, but also the choice of its indicators 
will show dissimilarity, suggesting absence of a common unit of measurement. As a hypothetical 
construct, the link between what is being measured and the process of measurement may not 
necessarily be directly observable (Testa 2000). 
The subjectivity and individualistic nature of QOL information may cause a moral-dilemma, with 
ethical implications. To be ethically acceptable, the design and implementation of research need 
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to pay attention to the interests of research subjects, for example respecting the expertise of patients 
in living with their condition (Rapley 2003). This means involving patients in the development or 
selection of QOL instruments upon which they will be assessed. The measured QOL therefore 
would be a reflection of individual values, preferences and socio-cultural characteristics of the 
patients. 
Selecting HRQOL measures
Choice of the most appropriate instrument for assessing HRQoL depends on the objectives for 
collecting data, the environment of the application, methodological and practical considerations 
(Patrick and Deyo 1989). Researchers may need to choose between different types of instruments 
including individualised measures; disease specific; therapeutic-area specific; and generic 
instruments. Individualised instruments allow patients to choose what items are included in an 
instrument, as well as indicating how important they are to them (Luckett et al. 2009). These 
measures have failed to be generally accepted due to their large respondent and administrative 
burden (Luckett et al. 2009). 
Disease-specific measures are intended for assessing QoL in specific patient populations, 
including content that clinicians and patient consider important for a given condition.  Thus, they 
may have greater sensitivity to the clinical conditions allowing better discrimination between 
patients with different levels of disease severity, or for detecting change over time in the patient’s 
condition (Bowling 2001). These measures are also important for their high practicality as 
irrelevant content is excluded. These measures are most useful in routine clinical practice and in 
clinical research and more sensitive to change over time.
Therapeutic-area specific instruments are a hybrid between disease-specific and generic 
instruments. They have a broader scope than disease-specific instruments, to allow application in 
more than one disease while on the other hand they maintain content that is relevant to the group 
of diseases beyond generic measures (Salek 1998). This makes these instruments relevant for 
various applications, both clinical research and routine clinical practice. Examples include the
Dermatology Life Quality Index (DLQI) and the Skindex, used in dermatology.
Generic instruments capture impacts of the disease and its treatment on the general health-related 
quality of life. A major rationale for their use is their comprehensive outlook, going beyond 
impacts associated with particular symptoms or problems, to consider overall HRQoL. Therefore, 
they are broadly applicable across disease, health interventions, demographic and cultural 
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subgroups (Patrick and Deyo 1989). This makes them useful for addressing broad policy questions, 
addressing epidemiological questions, making comparisons across disease and patient groups 
(Bowling 2001). Nonetheless, these measures have limited usefulness in routine clinical practice 
which is related to their poor practicality and applicability as well as a relatively lower 
responsiveness (Greenhalgh et al. 2005).
Attributes of HRQOL instruments
Choice of instrument must also consider a number of key psychometric attributes in order to ensure 
the reliability, validity and interpretability of the data collected. These include:
 Content validity: The content of an instrument needs to be comprehensive, possess 
the right focus and emphasis, relevant to the target patient population and should 
reflect the stated aims of the instrument (Nunnally and Bernstein 1994; Salek 
1998).
 Construct validity: Empirical evidence from several validation procedures 
supporting particular interpretation of scale scores (Frost et al. 2007a). 
 Reliability: the instrument produces consistent and reproducible results (Streiner 
and Norman 2008).
 Responsiveness: The instrument must be capable of detecting important changes in 
the patient’s condition over time even when such changes are small (Guyatt et al. 
2002).
 Interpretability: Information supporting the qualitative meaning of the scale scores 
e.g. cut-offs for minimal clinical important difference (MCID) (Lohr 2002).
 Practicality: completing the instrument should impose minimal burden on 
respondents; and minimal administrative effort should be required in implementing 
the measure (Salek and Luscombe 1992).
HYPERHIDROSIS: DISEASE BACKGROUND
Hyperhidrosis is a pathologic skin condition characterised by sweat secretion in excess of the 
physiologic needs of the body necessary for thermo-regulation purposes (Atkins and Butler 2002). 
The condition has been classified in the WHO ICD-10 under code R-61 as localised and 
generalised excessive sweating symptoms. A distinction can be made between primary and 
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secondary hyperhidrosis. The former is related to excessive function of the sudo-motor sweat 
control system, otherwise the exact underlying cause is not fully understood (Vorkamp et al. 2010). 
The latter represents situations where the excessive sweating is caused by an underlying stimuli, 
for example infection, cancer, diabetes, medication, social phobia/anxiety or other disorders 
(Vorkamp et al. 2010).
The human skin contains 1.4 to 1.6 million apocrine and eccrine sweat glands (Leung et al. 1999). 
Hyperhidrosis is mainly associated with the latter, which are mainly concentrated on the palm, 
soles, face, axillae and to a lesser degree the chest and the back, while the former are confined to 
the axillary, the areola of the nipple, the anogenital area, and the excessive auditory areas (Leung 
et al. 1999). Although the exact cause of the dysfunction is not fully understood, size or number 
of sweat glands have been ruled out (Wörle et al. 2007). It is believed that the excessive sweating 
results from non-thermal sympathetic over stimulation, which explains why primary excessive 
sweating does not occur during sleep (Vorkamp et al. 2010). On the other, emotional stimuli seems 
to have a role in sweating as demonstrated in epidemiological studies reporting stress, emotions 
and social relationship as more important aggravating factors than physical exertion or heat (Park 
et al. 2010). The genetic transmission of the autonomic dysfunction has been hypothesised and 
explored (Ro et al. 2002). For instance, epidemiological studies have reported 30 – 65% positive 
family history in primary hyperhidrosis patients (Haider and Solish 2005; Lear et al. 2007). The 
limited understanding of the disease process  and the fact that patients are not able to predict and 
know exactly when a sweating episode will break out, is not only a hindrance to the development 
of a cure, but is also a major source of anxiety and fear associated with the condition (Hornberger 
et al. 2004). 
Diagnosis
The diagnosis of hyperhidrosis involves a thorough evaluation of the patient’s history and a 
physical examination (Solish et al. 2007).The following clinical criteria have been included in 
various treatment guidelines: sweating that is bilateral and relatively symmetric, positive family 
history, more than one episode of sweating a week, onset of excessive sweating condition below 
age of 25, the sweat must cease during sleep, any secondary causes must have been ruled 
(Hornberger et al. 2004; Solish et al. 2007; Wörle et al. 2007). Assessing the severity of impacts 
in daily life activities experienced by the patient is key to confirming the diagnosis (Solish et al. 
2007).
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The clinical management of the hyperhidrosis depends on its severity. Clinical based severity 
assessment utilises measures including gravimetry, minor’s iodine test and evaporimetry. The 
assessment of impairment in daily life activities, on the other hand, uses quality of life instruments 
and self-reported disease severity scales such as the HDSS or the DLQI (Vorkamp et al. 2010). 
Only the clinical-based measures are detailed in this section, a presentation of the QOL and disease 
severity measures will be presented in a separate section of this chapter.
Gravimetric assessment quantifies the amount of sweat produced over a particular skin area, within 
a given time period, by use of a filter-paper and a microbalance (Hund et al. 2002). The paper is 
weighed before and after its application to a thoroughly cleaned affected skin area, over a given 
time. Weight per unit of time can then be calculated from the before-and-after weight 
measurements. Kalkan (Kalkan et al. 1998) applied modification of this method in palmar 
hyperhidrosis. A pad glove made from gauze material was used in place of the filter paper and; 
surgical gloves were worn on top to prevent moisture from escaping. The weighing then used an 
electronic scale with sensitivity of 0.0001 g. The minor’s iodine test is used in demarcating the 
area affected by hyperhidrosis (Glogau 2001). The affected area is wiped by an iodine tincture, 
then a starch is applied after thorough drying. New sweat secreted leads to a colour change 
demarcating the area affected, following the reaction between the iodine molecule and the starch. 
Assessment may be facilitated by taking a digital photo. The Ventilation capsule method assesses 
sweat production based on moisture evaporating from the skin measured using an electronic device 
(skin moisture meter) (Keller et al. 2009) A cup of 1 cm diameter connected to the device is used 
to capture moisture leaving the skin; with the amount of sweating over time (e.g. mg/cm/minute) 
read off a digital sweat meter reading (Ohhashi et al. 1998).
Clinical measures may have, however, limited usefulness in the management of hyperhidrosis for 
a variety of reasons. First, their anticipated objectivity is questionable. Cut-off quantity of sweat 
between patients and non-patients is unclear, an artefact of intra-individual variation of sweat 
production at different times and situations (Hund et al. 2002).  Currently suggested cut-off values 
of 50 mg/5 min for females and 100 mg/5 min for males are arbitrary, their specificity or sensitivity 
has not been established (Hornberger et al. 2004). The other issue relates to the practicality of these 
measures.  The cumbersome nature of these clinical tests makes them challenging to apply in 
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routine clinical practice, limiting their usefulness to a few cases and research settings (Chang et al. 
2011). The assessment of quality of life impairment resulting from the sweating, therefore, is 
important to the diagnosis and management of hyperhidrosis in routine practice.
Treatment 
Treatment guidelines for hyperhidrosis have been proposed and published in Canada, the U.S. and 
Germany (Hornberger et al. 2004; Solish et al. 2007; Wörle et al. 2007) but not in the UK. The 
management of hyperhidrosis largely depends on its severity, impact on quality of life and the 
body area affected (Table 1.1). The available therapies include topical creams containing 
aluminium chloride, tap water iontopheresis, interdermal injection with botulinum toxin, systemic 
treatment with pharmaceutical intervention and surgery.
Topical treatment with salts:Aluminium chloride (10% - 35%) based topical creams are regarded 
as first line treatment for mild focal hyperhidrosis  (Hill and Glade 2012). These have shown to be 
most efficacious in axillary hyperhidrosis (Goh 2007; Streker et al. 2012). Lower concentration 
creams are available over the counter. 
Tap water Iontopheresis: Tap water Iontopheresis, used for treating palmo-plantar hyperhidrosis,
involves using a device to apply an electrical current to introduce ions into the affected skin, 
leading to an obstruction of the sweat glands (Hill and Glade 2012).  
Interdermal botulinum toxin-a injection: Interdermal injection with botulinum toxin-a results in 
flaccid paralysis and autonomic dysfunction, providing a treatment effect lasting 4 – 17 months 
(Heckmann et al. 2001). This therapy is used in palmar, plantar and axillary hyperhidrosis.
Oral systemic treatments: Systemic treatment uses agents with an anti-cholinergic or anti-
depressant effect such as methanthelium bromide or glycopyrrolate (Wörle et al. 2007). Though 
generally not recommended this therapy is relevant for generalised hyperhidrosis or as an adjunct 
therapy in focal hyperhidrosis (Hornberger et al. 2004; Solish et al. 2007).
Surgical treatment: In axillary hyperhidrosis sweat glands may be locally removed using 
retrodermal curettage or liposuction (Henteleff and Kalavrouziotis 2008). An alternative 
procedure, endoscopic thoracic sympathectomy, which targets disrupting the sympathetic nerves 
is used in axillar, plantar and palmar hyperhidrosis.
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Epidemiology
Quantifying the number of people with hyperhidrosis within the general population at a given point 
in time, incidence and understanding the epidemiologic characteristics of the suffers is not only 
useful for understanding the full burden and impacts of the condition, but is also a prerequisite to 
determining and meeting the specific health care needs of this patient population. Therefore, 
articles publishing epidemiological information of hyperhidrosis were reviewed. Six studies have 
published figures on prevalence and an additional four provide useful epidemiological details 
about the condition.
Prevalence
Brown et al. (Brown et al. 2005) using a retrospective analysis of medical and prescription codes 
obtained from the General Practice Research Database (GPRD) which contains medical records 
of up to 3 million patients, estimated the prevalence of hyperhidrosis in the UK to be at 1.6%. 
Strutton et al. (2004) in a mail survey of 150, 000 households in the U.S., found prevalence to be 
at 2.8%. Prevalence was higher in the 25 – 34 age group (4.5%) and did not show significant 
differences between male and females. Besides national and environmental differences which 
might give rise to differences, use of medical records in the UK study assumes that patients were 
correctly diagnosed and classified in records, which may not always be guaranteed. Moreover, 
prevalence may be different in the patient population not seeking for treatment. Three more studies 
estimated prevalence in different sub-populations. Schäfer et al. (Schäfer et al. 2012) estimated 
prevalence in a sample comprised of 14,336 employees of 52 companies in Germany. Overall 
prevalence was estimated to be 16.3%; of those affected, 6.1% had frequent or continuous 
sweating. Higher rate of generalised sweating (68%) reported in this study, suggests that the 
prevalence rate might have included those with secondary hyperhidrosis.
A retrospective analysis of data from routine medical examination carried out on military recruits, 
from 94,806 Israeli adolescents (16 – 22 yrs) reported a prevalence of 0.2% for males and 0.1% 
for females (Wohl et al. 2007). While hyperhidrosis was the most prevalent skin problem observed, 
these figures seem relatively lower than prevalence rates observed in Europe and North America. 
The differences in geography and culture, and their influence on the actual amount of sweating 
and general views on what sweating is considered normal, cannot be ignored. Tu et. al. (Tu et al. 
2007) carried out a survey of 13,000 adolescents (15 – 22yrs) from 10 high schools and 3 colleges 
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in Fuzhou People’s Republic of China based on cluster-sampled from 42 high schools and 12 
colleges. Prevalence was estimated at 4.59% for the full sample, but was significantly slightly 
higher in the high-school group; with no significant differences between male and female. Setting 
aside the differences in how data used in estimating prevalence was collected and analysed, these 
figures indicate a wide variation in hyperhidrosis according to age, geography & culture. 
Prevalence was highest in those of the active working group. There was no consensus on gender 
differences in prevalence rates.
Disease characteristics
The studies by Schäfer et al. (Germany) and Strutton et al. (U.S.) reported axillary hyperhidrosis 
as the commonest body site affected. Tu et al. (China), on the other hand, reported palmar-plantar
hyperhidrosis as the most prevalent. Mean age at onset has been reported to range from 15 – 25 
yrs, with  palmer-plantar hyperhidrosis showing childhood onset and axillary starting during or 
post-puberty (Strutton et al. 2004; Lear et al. 2007). This might explain the observed higher 
prevalence for palmar-plantar in the study with adolescents, while the studies including post-
adolescent participants showed the axillary as the commonest site. Conflicting conclusions were 
made on gender differences in self-reported disease severity in patients receiving treatment. 
Kirimian-Teherani et al. (2009) reported a higher level of self-assessed severity in women, while 
Lear et al. (2007) and Strutton et al. (2004) found no differences. Individuals with hyperhidrosis 
showed more dermatologic co-morbidity. Type IV allergies were more common in females with 
hyperhidrosis than in general female population (Karimian-Teherani et al. 2009); Risk for 
Psoriasis and tinea pedum was also higher in persons with hyperhidrosis than those without 
(Schäfer et al. 2012) which might be a consequence of the constant wetness or topical treatments 
being used.
Hyperhidrosis remains largely untreated: 47% of women and 28.6% of men were reported to have 
discussed their sweating problem with their health care provider in the US study (Strutton et al. 
2004). As much as 66%-88% of hyperhidrosis patients had tried various forms of self-treatment to 
manage their condition (Hamm et al. 2006; Lear et al. 2007). On the other hand, patients who seek 
for treatment tend to utilise health services more, for instance,  85% of participants in a study using 
a clinic sample  had visited their physician at least once in the previous year (Hamm et al. 2006).
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Table 1.1: Treatments for hyperhidrosis
Region First Line Second Line Third Line
Axillary Mild
Aluminium Chloride 10 – 12 % to 35%; 
applied at bedtime; up to twice daily if 
necessary and if well tolerated
Severe
i. 2nd Line treatment
iii. Oral systemic medications (e.g. anti-
cholinergics) alone or as adjuvant treatment.
Intra-dermal injection with Botulinum Toxin 50 - 100 
U/Axilla
i. Combination of 1st and 2nd line treatment.
ii. Oral systemic medications such as anti-
cholinergics, either alone or as adjuvant 
treatment.
iii. Surgical intervention - Liposuction
iv. Surgical intervention – ETS.
Palmar Mild
AC 10 – 12% up to 50%
Mild
i. BTX-A
ii. Tap-water iontopheresis therapy
Surgical intervention – Liposuction or ETS.
Severe
Aluminium Chloride or BTX-A or Combining 
both.
Severe
i. Oral systemic medications (anti-cholinergics) alone 
or as adjuvant therapy
ii. Use anti-cholinergics (glycopyrrolate solution)  
instead of water during iontophoresis
Plantar Mild
AC in absolute ethanol or Salicylic acid gel, 20 
– 50% concentration
Mild
i. Intra-dermal injection of BTX-A.
ii. Tap water Iontophoresis
Mild
Add topical AC to line 2 treatment
Severe
i. AC
ii. BTX-A
iii. Iontophoresis
Severe
i. Oral systemic medication (anti-cholinergic)
Severe
i. Surgical intervention  - ETS
ii. Iontophoresis therapy using Glycopyrrolate 
solution
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Psychological co-morbidities
The literature review also uncovered a strand of literature on psychiatric morbidity in patients with 
hyperhidrosis. While this is not part of the construct of QOL, its possible implications for QOL 
justified the inclusion of this set of evidence. Ak et al. (2013) investigated Alexithymia1 in Turkish 
patients with hyperhidrosis (N = 50) attending a dermatology clinic, in comparison with non-
patients (N = 44).  The structured clinical interview (SCID-I) for Diagnostic and Statistical Manual 
of Disorders fourth edition (DSM-IV Disorders) and the Toronto Alexithymia Scale (TAS-20)
instruments were employed for psychiatric diagnosis. Among the patients with PFH, 45.6% were 
alexithymic, comparison to 2.23% among the non-hyperhidrotic subject. A personality trait such 
as alexythymia might be a mental reflection of the abnormal central nervous system characteristic 
of hyperhidrosis (associated with abnormal response to emotional stresses) providing further 
indication of the genetic basis for hyperhidrosis (Ak et al. 2013). Whether such personality trait 
abnormalities are exclusive to HH, apart from other dermatological illnesses is unclear. 
Furthermore, the involvement of a third key parameter such as depression or anxiety, may not be 
ruled out. 
Another study on psychopathology in hyperhidrosis was carried out by Ruchinskas et al. (2002)
in patients from the USA  awaiting treatment with ETS. The Spielberg State-Trait Anxiety 
Inventory (STAI) was used for assessing anxiety while other psychological pathologies were 
identified by Minnesota Multiphasic Personality Inventory 2 (MMPI-2). Eighty-eight percent of 
the patients had normal MMPI-2 scores, with patients showing normal values for psychologic 
conditions including hypochondrias, depression, schizophrenia, hypothermia and social 
introversion. STAI scores for 86% of the patients was within ranges for normal population. 
Nonetheless, it is noteworthy that the patient population used does not represent the full continuum 
of patients with hyperhidrosis. The results obtained, therefore, may not apply across the board to 
other patients. 
Weber et al. (2005) investigated the possible association between PFH and psychopathology 
(anxiety, depression and social phobia) in 70 patients, with palmar, plantar and axillary 
hyperhidrosis across multiple centres in Germany. The STAI, Hospital Anxiety and Depression 
1 Personality disorder involving insufficiency in identification and expression of emotions.
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Scale – Depression (HADS-D), Symptom Checklist-90-Revised (SCL-90-R), Social Phobia Scale 
(SPS) were used in patient assessment. Values of STAI (55.6±10.3), HADS-D (55.5±11.3), SCL-
90 (51.6±10.6 - 56.3±13.3) and SPS (15.2 ± 13.5) were within normal ranges. No significant 
differences were observed across patients suffering from HH affecting different sites. Still, the 
subgroup of patients which was subsequently treated with Botulinum Toxin – A (BTX-A) (31 
patients) showed elevated scores for SPS reflecting social phobia. Eligibility for BTX-A includes 
having failed to benefit from first line treatment e.g. Aluminium chloride, which may reflect 
greater disease severity. 
The absence of anxiety disorders in patients with HH has been further supported by Ramos et al. 
(2006) in Spanish patients awaiting ETS surgery (N = 158) and Schneier et al. (2012) in two 
samples: HH patients awaiting ETS (N = 40) and patients suffering from Social Anxiety Disorder 
(N = 40) from the USA. Although Ramos et al. found the levels of social anxiety to be well within 
those for the normal population, based on the STAI, the anxiety experienced was considered to
still have a severely incapacitating effect on the patient’s life. The patients included in either studies 
represent highly selected patient populations.
Cost of illness
Evidence related to the costs associated with hyperhidrosis or its treatment was scarce (Kowalski 
et al. 2005) reported on the budget impact of including BTX-A in the treatment pathway for severe 
primary axillary HH inadequately managed with topical agents in US managed care populations. 
Their results are from the perspective of a 1 million member US managed care plan over a 1 year 
period and consideration of costs is limited to treatment and medical costs. The inclusion of BTX-
A in the treatment plan results in an incremental cost of 1,400 US$ per successfully treated patient. 
Annual costs per severe primary axillary hyperhidrosis patient were reported at $ 578 where BTX-
A is included in the treatment pathway and $ 312 for a treatment pathway without such costs. 
Considering that costs of office visit may be unique for a particular insurance organisation, these 
figures may be markedly different for members of a different insurance organisation. Ambrogi et 
al. (2009) has reported costs associated with treatment primary palmar hyperhidrosis, in a 
prospective comparative open-label study comparing BTX-A and ETS surgery, in Italian patients 
(N = 154). They considered medical and treatment costs, including the costs of hospital stay. They 
report € 2654 ± €145 per case of ETS surgery, and €655 ± 23 per case of BTX-A therapy. The role 
of the study protocol in the costs incurred on the patients in their study may not be ruled out. On 
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the other hand, as the reported figures are based on the actual costs at the hospital where the study 
was carried out, figures reported may also reflect organisational and operational features of the 
institution. Either issues may have a bearing on the generalizability of the findings
Assessing HRQoL in hyperhidrosis
The nature and extent of the handicap and impairment in the patient’s life resulting from skin 
disease is well understood (Jowett and Ryan 1985; Finlay and Ryan 1996). Its impact extends 
across various areas of life (such as emotional distress, impact on social life such as in 
relationships, professional-life, physical discomfort from itching or wet-skin, and the burden 
associated with managing the condition). This also has to be seen in the light of skin’s high 
visibility as well as its particular role in self-image (Beltraminelli and Itin 2008). On the other 
hand, for conditions such as hyperhidrosis, the laboratory-clinical- measures of sweat are difficult 
to interpret apart reliability and practicality issues (Hund et al. 2002), leaving self-reported impacts 
on the patient’s life as ‘vital sign’ of disease activity (Chren 2005) especially in routine clinical 
practice. 
This means that the assessment of the impacts of hyperhidrosis on QoL is crucial in studies 
evaluating effectiveness of treatments or in clinical management of hyperhidrosis patients. As a 
long term condition, treatment therapies (non-surgical treatments) in hyperhidrosis are largely 
concerned with enhancing the patients’ quality of life: their ability to manage everyday routine 
such as performing housework; interacting with others; participating and contributing to social 
activity; and performance at work/school. On the other hand, treatment therapies in hyperhidrosis 
are often  associated with unbearable side effects such as compensatory sweating (ETS surgery, 
Inter-dermal Botox Injection), mouth dryness (anti-cholinergics) or transient hand weakness 
(Inter-dermal Botox Injection), raising the question whether benefits of treatment outweigh the 
burden associated with side effects. Assessment of a patient’s quality of life, in such 
contexts/situations, therefore, may offer a comprehensive framework for a more holistic evaluation 
of benefits and risk. The assessment of patient reported outcomes, therefore, is just as important 
in hyperhidrosis as in other long term skin and non-skin conditions. Facilitating the understanding 
of the burden associated with the disease at the society level, for instance by looking impairment 
in quality of life and the lost of productivity. Moreover, understanding QoL impairment is key not 
only in determining the needs of patients for various health care services, but plays a vital role in 
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determining the severity of condition, useful for the effective diagnosis and management of the 
condition.
Impacts on QoL
The humanistic consequences of disease are not only an important element of the overall burden 
of disease but reflect issues that are of most relevance to patients, their families and society at 
large. As the patient is the expert in their experience with a condition, their voice should matter 
most when considering such outcomes. Qualitative research methods are, therefore/as such quite 
useful for delving into phenomenon, particularly obtaining insights into the beliefs, values and 
perceptions of informants capture in their own words (Pope and Mays 2008). This makes them the 
first choice in understanding the disease experience of patients. Thus, a literature review was 
carried out to uncover the impacts of HH on patients’ QoL. This was key to understanding the 
areas of HRQoL of importance in HH and how patients perceive and describe such effects. Apart 
from providing a rationale for assessing HRQoL, this provides an important foundation for 
developing a new measure for assessing QoL. 
A structured process was following in sourcing and selecting studies for inclusion in the review. 
The literature searches were carried in multiple bibliographic databases including Pubmed; Google 
Scholar, Ovid/Embase and Scopus. A combination of 3 blocks of terms was applied to the title, 
abstract and keywords of the databases: block 1: hyperhidrosis; block 2: effects, effects on patients, 
impact, impact on patients, block 3: health related quality of life, quality of life, patient’s life, daily 
life, everyday life, lifestyle. The initial eligibility criteria was that studies should be investigating 
QOL in patients with primary HH using qualitative research methods. When only one relevant 
study was found, eligibility criteria was changed to include studies that had employed quantitative 
methods. In this case the instrument used in the investigation should be validated and should be 
readily interpretable, in addition to reporting baseline results.  Only the qualitative study is reported
in this section. The quantitative studies are reported in the next section as clinical application of 
quality of life instruments.
Thomas et al. (2006) investigated lifestyle impact, compensating behaviours and treatment 
experiences of female hyperhidrosis patients, through three focus group discussions with 21 
female patients with HH from the US. Patients were recruited through the database of the 
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international hyperhidrosis society (IHHS). Patients reported effects on their relationships with 
family and friends, in their professional interactions. Additionally, effects were reported on 
patient’s self-confidence and self-esteem, besides the psychological distress. Patients mentioned 
feeling their life was taken over by the hyperhidrosis all the time. They worried about their clothes 
getting soiled which led embarrassment when it happened.  One participant was quoted as follows:
“we were running around...I had to put my shirt around my waist because I had a spot 
on the back of my pants from the waist down to the knees. It looked like I wet myself 
and I didn’t want people to make fun of me on the last day of school”
Patients reported on the inconvenience, effort and cost associated with strategies employed to deal 
with the sweating and its symptoms, for example choosing clothing that hid the sweat, using tissues 
and pads, using a fan when getting dressed. While this study provides valuable insights, exclusion 
of males means that gender-specific experiences of males were not reflected in the results. On the 
other hand, there is no indication whether the issues of relevance to patients had been exhaustively 
explored. 
Critical appraisal of HRQOL measures 
In view of the importance of HRQOL in hyperhidrosis, its accurate evaluation depends on the 
availability of the availability of robust and suitable instruments. Previously, critical reviews of 
HRQOL instruments used in hyperhidrosis have been carried out. Panhofer et al. (2005) focused 
on measures used in hyperhidrosis patients treated with sympathetic surgery. Other reviews by 
Cetindag et al. (2008) and Solish et al. (Solish et al. 2008) covered measures used across all types 
of hyperhidrosis and associated with all forms of treatment, although they did not include a critical 
evaluation of the psychometric properties of the measures identified. Therefore, an important aim 
of this chapter was to review the instruments used in HRQoL measurement in hyperhidrosis 
particularly including an appraisal of their psychometric properties. As a comprehensive overview 
of the field, such a review would be a useful resource to all stakeholders involved in measuring 
HRQoL in hyperhidrosis, including patients, healthcare practitioners, and health care decision 
makers. 
To identify instruments that have been used in HRQoL assessment in hyperhidrosis a literature 
search was carried out in PubMed, PsycINFO and EMBASE. The initial search was based on the 
following terms: “hyperhidrosis and quality of life”; “hyperhidrosis and daily life”; “hyperhidrosis 
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and clinical trial”; “hyperhidrosis and impact”. References of the papers initially extracted were 
also searched to identify more material for our review. An additional search strategy was based on 
the identified instrument e.g. “SF-36 and hyperhidrosis”, “DLQI and hyperhidrosis” to identify all 
studies using the instruments in hyperhidrosis patients. A study was included if it reported the 
measurement of HRQoL in hyperhidrosis patients using a HRQoL instrument; or if it reported the 
psychometric properties of such an instrument. An instrument was included if it was developed for 
the measurement of HRQoL and if it had been used in hyperhidrosis patients. Such instruments 
could be disease specific, dermatology -specific or generic. We limited ourselves to HRQoL self-
assessed by patients, either self-completed questionnaire or interviewer administered. Study-
specific instruments were excluded. 
Information related to the instruments was extracted following standard quality criteria for HRQoL 
instruments (Lohr 2002; Both et al. 2007). Information extracted included key psychometric 
properties, descriptive information and additionally details of studies applying the instrument. The 
criteria used in the evaluation of psychometric properties are presented in Table 1.2. Thirteen 
instruments have been applied in assessing HRQoL in hyperhidrosis; this includes four generic 
instruments, four dermatology-specific instruments and five hyperhidrosis-specific instruments
(Table 1.3, Table 1.4) .
Generic HRQoL Instruments
Short form 36 (SF-36)
The SF-36 is a generic measure of health status developed for use in population surveys and studies 
supporting health policy development (McDowell 2006). Its application, however, has extended 
beyond its initial purpose to include the evaluation of effectiveness of therapies. The content of 
the instrument was obtained from the most frequently measured concepts in widely used surveys 
and those mostly affected by disease and treatment (Stewart and Ware 1992; Quality-Metric 2013). 
A 5 point Likert scale is used for the 36 items of the second version of the instrument, SF36v2, 
translating into scores of 0 to 100. These use a recall period of 4 weeks. An additional item assesses 
change in general health over last year (i.e. 1 year recall period).
The 36 items form 8 domains (physical functioning, emotional role functioning, physical role 
functioning, social role functioning, mental health, vitality, bodily pain, and general health 
27
perception) and are further aggregated into two higher order scales (summary measures), the 
physical component scale and the mental component scale (Kini and DeLong 2012). This structure 
is supported by results of factor analysis and correlation analysis (Ware et al. 1994; Quality-Metric 
2013). Numerous construct validation studies have performed various tests of validity for the SF-
36, including content, concurrent, criterion, predictive validity (Bowling 2005; McDowell 2006; 
Quality-Metric 2013). Adequate internal consistency, test-retest reliability (2 weeks – 6 months) 
and responsiveness have, likewise, been established in diverse patient populations (Ware et al. 
1993; McDowell 2006). Only some psychometric attributes of the SF-36 in patients with skin 
disease are known and nearly no attributes are known in patients with hyperhidrosis. For example, 
the internal consistency in patients with skin diseases has not yet been reported (Both et al. 2007). 
Shikiar et al. (Shikiar et al. 2006), based on a phase II RCT of Adalimumab in psoriasis patients, 
assessed the construct validity, responsiveness and MID of the SF-36. The bodily pain and social 
functioning scales of the SF-36, correlated well with the DLQI and clinical endpoints. All SF-36 
sub-scales were sensitive to changes in clinical anchors. Another study, by Chren et al. (Chren et 
al. 1997) has also reported acceptable correlation between the SF-36 and the Skindex, although 
the former was more sensitive to physical symptoms or social effects.
The SF-36 may be administered in various ways, as a self-completion paper and pencil version, 
self-completed electronic delivery or using interview delivery. Other versions of the instrument 
are available, the acute version, using a 1-week recall period, the SF-12, with 12 items, which is 
discussed in the next section, and the SF-6D, where it is possible to calculate health utilities for 
use in economic evaluation studies. Furthermore, the practicality and acceptability of the SF-36 
has been established, with completion taking less than 10 minutes (Brazier et al. 1992; Bowling 
2005).
A number of limitations have been identified on the SF-36. For example with respect to the content, 
concepts including sleep adequacy, sexual function, health distress, eating, recreation and hobbies, 
communication have not been included. Hunt and McKenna (1993) have observed an over-reliance 
on psychometric techniques particularly in the early development of the instrument. The 
instrument has been used in at least four studies in hyperhidrosis, all of which were focused on 
assessing the efficacy of surgical therapy, alone or in comparison with other therapies. Sayeed et 
al. (1998) concluded that the SF-36 was not suitable for hyperhidrosis due to its irrelevance in 
hyperhidrosis patients. 
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Short form 12 (SF-12)
The SF-12 was designed as a short-version of the SF-36, to be brief enough to fit on a single A4 
page with completion taking no more than two minutes (McDowell 2006).  Selection of items 
included was based on their psychometric properties with the intention of explaining at least 90% 
of variance in (MCS and PCS) scales of the SF-36 (Ware et al. 1996). Studies on the factor structure 
of the SF-12 have reported varied results. Jenkinson (1997) based on a diverse UK community 
based patient population (N = 9332) supported the two factor structure. On the other hand,
Jakobsson et al. (2011) found the contrary evidence. Adequate test-retest reliability correlation has 
been established (Both et al. 2007; Jakobsson et al.).
Capability of the SF-12 to discriminate among diagnostic groups of patients was considered 
comparable to that of SF-36 (McDowell 2006). Significant but weak correlations have been 
observed between DLQI and the MCS and PCS of the SF-12 (Grozdev et al. 2012). The PASI, a 
measure of disease severity in psoriasis showed significant association with PCS, and only showed 
negligible association with MCS.
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Table 1.2: Criteria used in evaluating the measures
Aspect Definition Criteria & Code
Content
Validity
Evidence that the domain of an instrument is appropriate 
relative to its intended use (Lohr, 2002).
The conceptual and empirical basis for the items of the 
instrument.
The involvement of the target population
++  Target patients and experts were involved
+    No patient involvement, other form of content 
validation given.
- Inadequate content validity
0    No information reported.
Construct 
validity
Evidence that supports a proposed interpretation of scores based 
on theoretical implications associated with the constructs 
being measured (Ibid, 2002).
Does the tool confirm hypothesised differences (Both et al, 
2007)?
++ At least 75% of results in accordance with hypothesis, 
based on robust design and method.
+   Under 75% of results in accordance with specific 
hypothesis, adequate methods used.
- Hypothesis not confirmed or inadequate methods used
0   No information reported
Convergent 
Validity
Does the tool relate to other tools assessing the same construct 
(Both et al., 2007)?
++  Correlation > 0.70
+    Correlation < 0.70
- Correlations not statistically significant.
0    No information reported
Internal 
Consistency
The precision of the scale based on the homogeneity of the 
scale’s items at one point in time (Lohr, 2002).
++  Cronbach alpha   0.70 – 0.95
+    Cronbach alpha below 0.70 or above 0.95
- Very low Cronbach alpha, inconsistencies observed.
0    No information reported
Test – retest 
reliability
Does a repeated administration of the tool within a reasonable 
period of time results in similar results (Both et al. 2007)?
++ ICC above 0.70
+  ICC below 0.70
- No correlation observed
0  No information reported
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Table 1.2 (continued)
Aspect Definition Criteria & Code
Responsiveness The ability of the instrument to detect changes over 
time OR differences between patients, due to 
therapy or impact of disease
++ 75% of results showed confirmation of hypothesis, based on an 
adequate measure.
+    Less than 75% results confirm hypothesis/conflicting evidence.
- Poor or solely based on statistical evidence.
0   No information reported.  
Floor and Ceiling 
effects
Does the tool capture the detail and breadth of real 
differences among persons?
++ Less than 20% in extremities.
- More than 20% in extremities.
0    no information reported.
Interpretability Can qualitative meaning be assigned to the scores 
(Veenhof et al. 2007)? 
++ Thresholds provided based on anchor or banding techniques
+   Distribution based techniques used 
0   no information reported.
MCID Has the minimal change relevant to patients been 
reported?
++ MCID reported.
0   MCID not known.
Respondent 
Burden
Is length and content acceptable to patients? ++ Less than 10 minutes
- More than 10 minutes or problems with acceptability
0  no information reported 
Structure Evidence in support of the proposed structure or 
scaling of the instrument
++ Item Response theory confirms proposed structure
+   Factor analysis/regression analysis confirms proposed structure
- Factors analysis and item response theory does not confirm 
proposed structure
0  No information provided
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Nottingham health profile (NHP)
The NHP was developed as a measure of perceived social, physical and emotional health problems 
in primary health-care setting (Hunt et al. 1985). Its content development involved patients with 
acute and chronic ailments (McDowell 2006). The 38 items of the NHP, scored on a binary scale
(yes/no), form 6 domains. A frame of reference of ‘at the moment’ is used. Scores can be presented 
as a profile for each domain by summing all affirmed items, alternatively a weighting can be 
employed to give scores from 0 to 100 (2007). The proposed structure is not supported by empirical 
evidence, a study based on factor analysis, supports two higher order domains (Prieto et al. 1998). 
Convergence validity has been demonstrated, for instance moderate-strong correlation with SF-36 
has been reported. Favourable internal consistency and test-retest reliability has been reported in 
varied patient populations for instance in patients with Asthma, Migraine and leg-ulcers although 
no such evidence exists for hyperhidrosis. Ceiling effects have been reported, indicating poor 
sensitivity of the NHP in minor levels of disability; or in distinguishing between levels of good 
health (McDowell 2006). This raises further concerns regarding its suitability for hyperhidrosis. 
The application of this instrument in hyperhidrosis has been limited, two studies using the NHP 
were found. 
Illness intrusiveness ratings scale (IIRS)
The Illness Intrusiveness Rating Scale (IIRS) was developed as a measure of the degree of 
disturbance to a patient’s wellbeing, including lifestyle, activities and interests, resulting from a 
particular health problem, disease or its treatment (Devins 2010). The IIRS was originally 
developed for assessing the declining control over various life aspects in end-stage renal disease 
patients (Devins et al. 1983). The items of the instrument are based on a major social research 
project by Flanagan et al. (Flanagan 1978) undertaken in the U.S. to identify factors relevant to 
quality of life for Americans in the 1970’s (Devins 2010).
Responses to the 13 items of the instrument are given on a 7-point Likert scale, with a total score 
calculated as a simple summation of item scores, ranging from 91 (highest intrusiveness) to 13
(lowest intrusiveness). The IIRS has three domains established on various language versions of 
the instrument (Korean and English) and in diverse disease conditions (chronic illnesses and 
anxiety disorders) (Bieling et al. 2001; Devins et al. 2001; Kim et al. 2005). However, the factor 
analysis supports exclusion of 1 item (related to diet) from the subscale scores (Devins 2010).
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The validity, reliability and sensitivity of the IIRS in hyperhidrosis patients has been evaluated by 
(Cinà and Clase 1999). Moderate correlation was reported between total IIRS scores and new items 
assessing the global severity of hyperhidrosis, including limitations in the number of clothing-
changes and choice of clothing (Table 1). Strong reliability was established based on strong
internal consistency and test-retest reliability test. 
The IIRS has been translated into, and validated in, other languages including French, Hungarian, 
and Korean although no formal cultural equivalence studies have been undertaken (Devins 2010). 
The IIRS is can be administered in various means, self-completion paper and pencil, web-based 
version or interview (Devins et al. 1983; Cinà and Clase 1999; Ritter et al. 2004). The IIRS takes 
no more than 15 minutes to complete and on the other hand, has an easy scoring system. 
A few concerns regarding the IIRS are as follows. First, the use of a 7 point scale has an unclear 
rationale. While presenting a cognitive burden, it may unnecessarily introduce noise in 
measurement. The interpretation of the IIRS poses a unique challenge, especially in deciphering 
its clinical meaningfulness. This is because it is not possible to “experience illness intrusive in the 
absence of a health problem ...except those experience lifestyle disruptions vicariously” (Devins 
2010). Conceptually, illness intrusiveness may not be assessed in a non-diseased population.
Skin-Specific Quality of Life Instruments
Skindex
The Skindex is a 30-item questionnaire that measures the effects of skin disease on the quality of 
life of patients, based on a 4-week recall period. Items assess the frequency of bother from skin 
condition with responses scored on a 5 point scale, from 0 -‘never’ reflecting no effect, to 100 –
‘all the time’ for maximum effect. Excluding one item, the remaining 29 items form three subscales
(physical functioning, symptoms and emotional-wellbeing). This structure has been confirmed by 
factor analysis (Abeni et al. 2002; Augustin et al. 2004b).
Early development involved patients attending private dermatology clinics and a VA hospital 
(dermatology clinic) in the U.S. (Chren et al. 1996). Construct validation has been carried out. For 
example, patients with inflammatory dermatoses showed significantly higher scores than isolated 
skin lesions ((Chren et al. ; Abeni et al.)). Moderate correlations were obtained between: the 
Skindex scales and comparable scales of the SF-36; ‘symptom scale’ and the ‘physical functioning 
33
scale’ of the FLQA-d; ‘symptom scale’ and MHF’s circle of itching and scatching scales (Chren et 
al. 1997; Augustin et al. 2004b). Additionally, the Skindex showed sensitivity to change in the 
patients condition, reflecting disease severity measures (PASI and EASI) ((Chren et al. ; Augustin 
et al.)).
To facilitate interpretation of the Skindex scores, scale banding systems applying both anchor and 
distribution based approaches have been developed (Nijsten et al. 2009; Prinsen et al. 2010; 
Prinsen et al. 2011). The Skindex has been culturally adapted into German, Italian, Spanish (Both 
et al.). Apart from a paper and pencil version, an electronic version is available in the Netherlands. 
Two short-versions of the Skindex have been developed and validated, Skindex-16 and Skindex-
17, following two alternative psychometric theories, classical test-theory and item response theory 
(Rasch model) (Chren et al. 2001; Nijsten et al. 2006b). Skindex – 16 assesses extent of bother 
and also resolved the substantial floor effects some of the items. On the other hand, in the Rasch-
based Skindex 17, response categories were reduced to three levels with items regrouped into two 
scales: emotional and social functioning scale (with 17 items) and symptoms scale (with 5 items). 
This version can explain up to at least 85% of the variance in the Skindex 29 scores. A single study 
has applied the Skindex in hyperhidrosis (Weber et al. 2005).
Dermatology life quality index (DLQI)
The DLQI is a 10-item questionnaire developed as an easy to use assessment tool, for measuring 
dermatology specific health related quality of life in routine clinical practice (Finlay and Khan 
1994). The measure was developed for use in routine clinical practice and it fits on a single A4 
paper.  Items assess the intensity of the effects of skin condition on patient’s QoL on a 4 point 
scale, from not at all (0), for minimal effect to very much, (3) for maximal effect. These cover six 
domains including symptoms, daily activities, leisure, work/school, personal relationships and 
treatment. A summary score calculated as the summation of the item scores is used. However,
neither the proposed six-domain structure nor the total score subsuming unidimensionality are 
unequivocatnly supported by evidence. Factor analytic studies have reported from one to four 
factors (Basra et al. 2008). Rasch analysis on the DLQI has confirmed unidimensionality in 
patients with Atopic Dermatitis, but not those with Psoriasis (Twiss et al. 2011).
The development of the DLQI involved patients with various skin diseases attending an outpatient 
dermatologic clinic in the UK (Finlay, 1994). In the initial validation study which compared 
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patients with a normal population, the DLQI scores showed high specificity, repeatability and 
internal consistency (Finlay and Khan 1994). The validity, reliability and responsiveness has been 
extensively demonstrated in at least 115 studies (Basra et al. 2008). The DLQI has been used 
widely including: in 33 different skin conditions; formal translations for 55 languages, although 
only 9 cultural adaptation studies have been reported; use in parallel with at 30 generic and disease 
specific questionnaires. Data supporting interpretation of results for instance or banding system or 
MID is readily available (Hongbo et al. 2005; Basra et al. 2008). Specific MCID cut-off values for 
axillary and palmar hyperhidrosis have been proposed (Kowalski 2007). Nevertheless, a few 
shortfalls have been identified. High floor and ceiling effects have been noted (Both et al.). 
Furthermore, differential item functioning has been noted in some items with respect to culture, 
age and gender (Nijsten et al. 2007). Furthermore, some components of QoL such as emotional 
well-being have not been adequately covered (Basra et al.).
Patient benefit index (PBI)
The Patient Benefit Index (PBI) was developed for assessing the therapeutic benefit from 
dermatologic therapy, based on patient’s own therapeutic goals (Augustin et al. 2009). Its content 
was based on interviews with patients, regarding the burden resulting from their disease and 
relevant benefit from treatment; and an expert panel (including clinicians) (Augustin et al. 2008).
The instrument is comprised of a set of two questionnaires, the Patient Needs Questionnaire 
(PNQ), which assesses the patient’s therapeutic needs (goals), and the Patients Benefit 
Questionnaire (PBQ), which measures the magnitude to which the needs (goals) captured by the 
first questionnaire are met. Each questionnaire has 23 items, which are paired between the two 
instruments. Importance of the treatment goals (captured by the 23 items) is rated on a 5 point 
Likert scale, from not at all important (0), for an issue/area considered unimportant by the patient, 
to very important (5) for an issue/are considered very important. The final score, representing the
PBI, is calculated as the PBQ score of the individual weighed by the respective importance given 
to a specific need (item score on the PNQ) expressed as a proportion of total score on the PNQ 
(Augustin et al. 2008).
Construct validation of the instrument was carried out on a group of German dermatologic patients, 
with various diagnoses including hyperhidrosis. The PNQ was sensitive to differences in the 
treatment needs of patients with different skin conditions, Herpes Zoster, Chronic hand and foot 
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Eczema.  On the other hand, the PBI demonstrated sensitivity to therapeutic benefit from treatment 
(t-test between PBQ scores from different time periods showed significant differences – indicating 
the effect of treatment). The PBI has shown adequate internal consistency.  Disease-specific 
versions of the PBI have been validated in Acne, Vitiligo and Pruritus, Chronic hand eczema 
(Augustin et al. 2008; Augustin et al. 2009; Blome et al. 2009a; Blome et al. 2009b). One study 
has used the PBI in an observational study in hyperhidrosis (Muller and Augustin 2013).
The PBI has some floor effects - a disproportionately high frequency of zeros, which the authors 
attribute to “the proportion of patients in an early stage of treatment” in the validation sample
(Augustin et al.). Similar problems have persisted in the other modifications of the PBI.
Differential Item Functioning with regard to culture and demographic factors has not yet been 
assessed. Furthermore, language translation or cultural adaption studies were not found.
Disease-Specific Quality of Life Instruments
Hyperhidrosis impact questionnaire (HHIQ)
The Hyperhidrosis Impact Questionnaire (HHIQ) was designed for evaluating the effects of focal 
hyperhidrosis and its treatment on the daily life of patients (Teale et al. 2002). Its content 
development was based on the input of patients and physician-specialists from the UK and 
Germany, ensuring the cultural equivalence of concepts (Teale et al. 2002). The HHIQ consists of 
41 items administered at baseline and 10 items for subsequent follow-up visits (applicable to 
longitudinal studies). The baseline module includes items on disease and treatment background 
and the impact of the disease on medical and non-medical resource utilisation. Although Teale et 
al. (Teale et al. 2002) state that convergent and discriminant validity of the HHIQ was established 
based on SF-12 and DLQI in hyperhidrosis patients seeking treatment (n = 345) and a matched 
control group (n= 154), the magnitude of the correlations were not reported. This was also noted 
for reliability and responsiveness.
Although a number of clinical trials (Naumann et al. 2002; Naumann et al. 2003; Solish et al. 
2005) have shown change in HHIQ scores after treatment, the appropriate methods for assessing 
responsiveness have not been applied. Score change was not linked to criterion to ensure that the 
patient’s condition had indeed changed. Although the studies collected other information on the 
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patients, such as gravimetric sweating measures, scores on DLQI and SF-12, correlations or cross-
tabulation was not calculated, needed for establishing convergence validity.
No alternative versions of the instrument e.g. an electronic or interview delivered format have been 
published. Based on the parallel development of the instrument in Germany and in the UK it is 
assumed that a German and English version are available. Lack of brevity in this instrument may 
restrict its use in routine clinical practice. No data facilitating the interpretation of scores of the 
HHIQ has been published. No evidence on how to summarise results for example into subscale 
totals is available. The published studies using HHIQ have interpreted their findings at the item 
level.
Hyperhidrosis disease severity scale (HDSS)
The Hyperhidrosis Disease Severity Scale (HDSS) is a patient centred scale for assessing the 
disease severity and daily life impairment in daily activities, caused by hyperhidrosis. Its 
development involved patients with hyperhidrosis attending Canadian and U.S. clinics as well as 
a population of U.S. households. The HDSS has a single item, asking the patient to rate the severity 
of their hyperhidrosis on a 4-point scale, from 1, “My sweating is never noticeable and never 
interferes with my daily activities”, to 4, “My sweating is intolerable and always interferes with 
my daily activities” (Solish et al. 2005).  This makes it very practical in clinical practice, with the 
Canadian treatment guidelines recommending its application as a diagnostic tool for determining 
disease severity, for hyperhidrosis in a number of studies, including the Canadian clinical 
guidelines for hyperhidrosis (Solish et al. 2007).
Adequate validity, reliability and responsiveness has been demonstrated for this measure 
(Kowalski et al.). HDSS score corresponded to the levels of limitations in daily life activities in 
the individuals surveyed by Strutton et al. (Strutton et al. 2004). Changes in the HDSS score 
corresponded to: changes in gravimetric measurement (amount of sweat produced) (Lowe et al. 
2004); changes in scores for the HHIQ and the DLQI (Solish et al. 2005). The changes observed 
before and after treatment on HDSS score compared with that observed on the other instruments. 
Translation and cultural equivalence studies of the HDSS were not found, although a study 
published Spanish (Baez et al. 2007) was found. Additionally, although Kowalski et al. (Kowalski 
et al. 2004) mention that the instrument can be administered either via self-completion or 
interview, evidence comparing the two methods was not found. The HDSS has been used in a 
variety of settings as a primary efficacy outcome measure in clinical trials (Lowe et al. 2004; Solish 
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et al. 2005; Flanagan et al. 2008) as a patient selection criteria in clinical research or trials 
(Kowalski et al. 2004) and in epidemiological studies (Strutton et al. 2004; Connor et al. 2006).
Hyperhidrosis scale
The Hyperhidrosis Scale was developed for assessing the severity and quality of life impacts of 
palmar and plantar hyperhidrosis in particular physical symptoms and social impairment in 
evaluating the effectiveness of surgical treatment (Neumayer et al. 2005). Its development 
involved patients being considered for surgical treatment (Keller et al. 2009). The instrument’s 
items are scored on a 10 point Likert scale, from no distress (0) to most distress (10), and are 
organised under three domains. The first two domains cover distress related to palmar and plantar 
hyperhidrosis; the third domain covers hyperhidrosis of the axillar and the rest of the body. The 
authors of the measure proposed calculating an average of the item scores as a means of 
summarising measurement. In practice, item scores have been simply summed up to create a total 
score (Neumayer et al. 2004; Neumayer et al. 2005). No evidence has been published supporting 
the structure of the instrument.
Further validation showed strong association with gravimetric of sweating (Keller et al.).   A 
normalised summary score generated by dividing the sum of the item scores with the number of 
completed items has been suggested. A cut-off score has been determined based on ROC, 
supporting interpretation of scores (Keller et al. 2009). The suggested structure of the instrument 
has not been tested. Furthermore, no study has reported on DIF across different socioeconomic 
and demographic. The current response scaling for the items may affect practicality of the measure, 
10 response categories may unnecessarily overburden respondents. 
Hyperhidrosis questionnaire
The Hyperhidrosis questionnaire (HQ) was developed not only as a tool for evaluating QoL in 
hyperhidrosis but also as an educational tool in routine clinic (Kuo et al. 2004). Its development 
involved hyperhidrosis outpatients (n=85) awaiting thoracic surgery at a regional teaching hospital 
in Taiwan. Content validation was done by a group of experts (CVI = 0.70) following the 
generation of the original items. The instrument has a total of 34 items covering five domains 
(functional, psychological, social, affective and physical function). This structure has been 
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confirmed by a factor analysis. Adequate internal consistency was established based on optimal 
Cronbach alpha values for the instrument’s five domains. The authors indicate that completion 
takes between 8 – 10 minutes.  Construct validity has been assessed using factor analysis and inter-
item/item-subscale correlations (Kuo et al.). The extracted factors explained 68.9% of variance in 
total scores. Convergence validity, test-retest reliability and responsiveness have not been 
assessed. No study applying the instrument was found. 
‘Amir’ quality of life questionnaire
Amir et al. (Amir et al. 2000) published findings on the early development of a questionnaire for 
evaluating the impacts of hyperhidrosis on patient’s quality of life. The instrument contains 35 
items covering five domains (functional, social, Inter-personal, emotional, condition) scored on a 
7-point Likert scale from strongly agree to strongly disagree. No frame of reference has been 
provided. The content of the measure is based on in depth interviews with 10 patients, subsequent 
construct validation is based on 48 patients. Construct validity was demonstrated by evaluating the 
relationship between subjective suffering and QoL using stepwise regression analysis; and testing 
for expected relationship between gender and disease onset and the QoL impairment.
This instrument remains of limited usefulness. First, as development involved patients awaiting 
surgery at a dermatology clinic in Israel, the attributes established may be applicable to patients 
with a severe form of hyperhidrosis. Second, lack of a specified timeframe to reference responses 
means that this instrument can be applied in evaluative the impact of treatment or monitoring 
change over time. Moreover, further validation studies are needed to demonstrate the test-retest 
reliability and responsiveness of the instrument.
Hyperhidrosis quality of life questionnaire
The Hyperhidrosis Quality of life Questionnaire (HHQLQ) was developed for assessing quality of 
life following surgical therapy (de Campos, 2003a). The HHQLQ consists of 20 items covering 4 
domains (functional/social, personal, emotional self/others, under special circumstances) with 
responses based on a 5-point Likert scale, from highest quality of life (1) to lowest quality of life
(5). Patients rank their QoL when undertaking a number of activities (or in various contexts) that 
may be influenced by or that may lead to sweating (Ambrogi et al.). A total score is obtained by 
adding the item scores, thus the worst/lowest score is 20, while the best quality of life is reflected 
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by a score of 100. Two additional general items seek for a general evaluation of quality of life 
before and 30 days following surgery.
Construct validity is supported by a number of studies. In one prospective open label comparative 
study, (Ambrogi et al. 2009) found significantly greater improvement in disease severity and in 
QoL among palmar hyperhidrosis patients receiving surgery (n=86) from the sixth month  
following surgery (p = 0.007) and on subsequent follow-up visits (p < 0.001) relative to the 
improvement in BTX-A group (N = 68). The HHQLQ was used in parallel with clinical (Minor 
Iodine starch test and Pad glove test) and quality of life measures (DLQI, SF-36 and the 
Nottingham Health Profile). Reliability has not been reported. Although observational studies 
using the HHQLQ have reported statistically significant change in the measure’s scores, this may 
seem insufficient as an assessment of the responsiveness.
Studies applying the instrument published in Portuguese and Italian were found, although the 
formal translations of the measure into these languages were not found. This instrument may have 
minimal usefulness in patients with mild hyperhidrosis, as the purpose of its development, 
evaluating outcomes after surgical treatment, reflect patients with severe hyperhidrosis.
Freiburg life quality assessment (FLQA)
The Freiburg Life Quality Assessment is a measure of dermatologic quality of life.  It is comprised 
of a core set of items applicable to all dermatologic diseases and additional items specific for 
various dermatologic diseases, making up the various disease specific modules of the instrument 
e.g. for allergies, chronic skin diseases, leg ulcer and wounds  (Augustin et al. 2000; Augustin et 
al. 2004a; Augustin et al. 2010). The hyperhidrosis module has 46 items under six domains and an 
additional 4 VAS, with each item assessing the frequency with which patients experienced various 
restrictions within the previous week. Responses are given on a 5-point scale. The FLQA-
hyperhidrosis has an additional 4 generic items on general health, overall QOL and disease severity 
scored as VAS. The hyperhidrosis module can be scored in similar way as the wound module 
(Augustin, 2010, personal communication). A summary score can be obtained both at the scale 
and subscale levels, by calculating the item mean scores for subscales and for total scale, 
respectively (Augustin et al. 2010). Nonetheless, the proposed structure is not supported by 
evidence.
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The validity, reliability and responsiveness of the FLQA-hyperhidrosis module is yet to be 
established. Such information, on the other hand has been published for the core module (Augustin 
et al. 2004a). Subscales of the module show moderate correlation with comparable scales of DLQI 
and ALLTAG questionnaires. All sub-scales of the core module except the ‘treatment subscale’ 
showed optimal internal consistency (α > 0.75). Test-retest reliability has been reported for the 
chronic disease module (Augustin et al. 2000).  The core module was able to capture an 
improvement in all domains of quality of life, in psoriasis patients following treatment, reflecting 
responsiveness. A scale-banding system has been developed using distribution based techniques 
to facilitate interpretation of the core module scores (Augustin et al. 2004a). The modular design 
of the FLQA in general and more specifically the number of items in the FLQA hints limited 
applicability in routine clinical practice. 
Clinical Application of Measures: HRQoL Impacts Of Hyperhidrosis 
Six studies investigating generic HRQOL in patients with HH using the SF-36 were found, only 
four reported pre-treatment (baseline) scores (Table 1.5). There was consensus among the studies 
on the effects of hyperhidrosis on SF-36’s vitality and mental health domains as well as on the 
absence of any impacts on physical functioning domain (Sayeed et al. 1998; Young et al. 2003; 
Schmidt et al. 2006). There was a lack of agreement on impacts associated with Bodily Pain and 
Social Function domains. The differences in the results may be partially attributable to a relatively 
small size of the sample of the study by Sayeed et al. (1998). Naumann et al. (Naumann et al. 
2002) and Hamm et al. employed the SF-12 in evaluating QOL in HH patients. Naumann 
(Naumann et al. 2002) is a multi-centre RCT of the impact of treatment with BTX-A  on QOL in 
patients with bilateral primary axillary hyperhidrosis (N = 320). The pre-treatment were 52.5, for 
the PCS, 47.8 for MCS scores.  On the other hand, Hamm et al. (Hamm et al. 2006) used a cross-
sectional design to compare hyperhidrosis patients with controls without hyperhidrosis
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Table 1.3: Descriptive properties of instruments used in measuring QoL in hyperhidrosis
Questionnaire Target 
Population
Concept 
assessed
No. of 
Scales
No. of 
Items
Response 
options
Range 
of 
Scores
HHIQ Primary focal 
HH
daily life 
impairment
- 41-
baseline;
10-
follow up
Varies -
HDSS Primary axillary 
HH
subjective 
disease severity; 
daily life 
impairment
1 1 Likert type;
4
1-4
HS ETS* treated 
palmar- plantar 
HH patients
Physical 
Symptoms & 
Social 
impairment
1 15 Likert type; 
10
0 -150
HQ Surgically 
treated HH
patients
disease specific 
HRQoL
5 34 Likert type; 
5
34 -170
HQLQ Outpatients 
awaiting for 
surgery
disease Specific 
HRQoL – daily 
life impairment
- 20 Likert type; 
5
20 - 100
FLQA Dermatology 
patients
Dermatology -
HRQoL
6 46 plus 3 
VAS 
5 plus NA
DLQI Dermatology 
patients
Dermatology-
HRQoL
- 10 Likert type; 
4
0 -30
Skindex-29 Dermatology 
patients
Dermatology-
HRQoL
3 30 Likert type; 
5
0 - 100
PBI Dermatologic 
patients incl. HH
Therapeutic 
benefit
5 23 Likert type; 
5
0-4
SF-36 General 
population
HR-QoL 8 36 Varies 0 - 100
SF-12 General 
population
HR-QoL 8 12 Varies 0 -100
NHP General 
population
HR-QoL 6 38 2 0-100
IIRS Chronic illness 
patients
disease severity 
(Illness 
intrusiveness)
3 13 7 13 -91
* ETS – Endoscopic thoracic sympathectomy
42
Table 1.4: Psychometric properties of instruments
Questionnaire Content 
Validity
Construct 
Validity
Convergent 
Validity
Internal 
Consistency
Test-
Retest 
Reliability
Responsive-
ness
Floor 
& 
Ceiling 
effects
Inter -
pretability
MCID Respondent 
Burden
Structure
Disease Specific HRQol instruments
HHIQ1,2,3 ++ ++ ++ ++ 0 0 ++ 0 0 0 0
HDSS4,5,6,7 ++ ++ ++ na ++ ++ 0 + + ++ na
HS8,9 ++ ++ + ++ 0 ++ 0 + 0 0 na
HQ10 ++ + 0 ++ 0 0 0 0 0 ++ +
HQLQ11,12,13 - - 0 0 0 - 0 0 0 0 0
AMIR14 ++ + 0 ++ 0 0 - 0 0 0 +
Dermatology HRQol Specific Questionnaire
FLQA15,16 ++ ++ + + ++ ++ + ++ 0 0 0
DLQI17,18,19 ++ ++ ++ ++ + ++ + ++ ++ ++ -
Skindex20,21,22,23,24,25 ++ ++ ++ ++ ++ ++ ++ ++ 0 + +
PBI26,27,28 ++ ++ + ++ + + + + 0 0 +
Generic HRQol Questionnaire
SF-36 29, 30 ++ ++ ++ ++ ++ ++ + + ++ + +
SF-1230 ++ ++ ++ ++ ++ + ++ + ++ +
NHP24, 30 ++ ++ ++ + ++ + + 0 0 ++ +
IIRS31,32,33 + ++ ++ ++ ++ ++ 0 0 0 0 +
Note: Although Teale, Roberts et al. 2002 claim that the HHIQ has favourable internal consistency, test-retest reliability, construct and convergent validity, the relevant 
correlations were not reported. 
References: (1) Teale, Roberts et al. (2002); (2) Naumann, Hamm et al. (2002); (3) Jonathan, Nina et al. (2004); (4) Lowe, Campanati et al. (2004); (5) David, Jonathan 
et al. (2004); (6) Solish, Benohanian et al. (2005); (7) Solish, Bertucci et al. (2007); (8) Keller, Bello et al. (2009); (9) Keller, Sekons et al. (2001); (10) Kuo et al. (2004);
(11) Panhofer, Zacherl et al. (2006); (12) de Campos, Kauffman et al. (2003); (13) Ambrogi, Campione et al. (2009); (14) Amir et al. (2000); (15) Augustin, Zschocke et 
al. (2000); (16) Augustin, Lange et al. (2004); (17) Finlay and Khan (1994); (18) Basra, Fenech et al. (2008); (19) Kowalski (2007); (20) Chren, Lasek et al. (1996);(21) 
Augustin, Wenninger et al. (2004); (22) Abeni, Picardi et al. (2002); (23) Nijsten, Sampogna et al. (2006); (24) Both, Essink-Bot et al. (2007); (25) Prinsen, Lindeboom et 
al. (2010); (26) Augustin, Radtke et al. (2009); (27) Augustin, Reich et al. (2008); (28) Blome, Augustin et al. (2011); (29) Both, Essink-Bot et al. (2007); (30) McDowell 
(2006); (31) Devins, Binik et al. (1983); (32) Cinà and Clase (1999); (33)  Bieling, Rowa et al. (2001).
43
Patients achieved a significantly lower mean score than non-patients (patients vs. controls: MCS, 
44.4 vs. 50.8, p < 0.01; PCS, 52.9 vs. 54.9, p < 0.01). Such differences would be considered to be 
of clinical significance considering MCID value of 1.3 and 2.3 for the PCS and MCS scores, 
respectively (Bennett et al.2003). The two studies reflect a higher QoL impact in aspects related 
to patient’s mental health relative to the mental component of HRQoL, echoing results from studies 
using the SF-36. The MCS in patients with HH reported by Hamm et al. is lower than that seen in 
patients with psoriasis [45.6±11.4], dermatitis [47.1 ±10.7], Acne [45.1± 11.3], implying that the 
impairment resulting from HH is much greater or comparable to these conditions. On the other 
hand, the level of impairment in physical aspects of QoL (based on PCS) seems less than in 
psoriasis [48.1± 9.2], dermatitis [49.6±7.9] but slightly worse than that in Acne [55 ± 5.4] (Tabolli 
et al. 2011). 
Cina and Clase (Cinà and Clase 1999) investigated illness intrusiveness in a population of 
hyperhidrosis patients from an email discussion board (N = 84) following a cross-sectional design 
(Table 1.6). The total score obtained (45±18) was less than IIRS scores obtained by Cina et al. 
(Cina et al. 2006) in a prospective observational study in HH patients awaiting ETS surgery (N = 
30) (IIRS total score = 57±14).  Cina et al. (Cina et al. 2007) compared their earlier findings from 
the sample of patient awaiting ETS surgery with a control group (N = 13). Scores on the control 
group indicated the absence of intrusiveness (13.5±17). HH patients took more showers and baths, 
changed their clothes more often, were limited in the type of wardrobe that they could use and 
sweated more with the consumption of alcohol, spicy foods and caffeine containing foods (Cina 
et al. 2007). The greatest intrusion was reported in relation to work, social relations, relations with 
spouse and in recreational activities (Cina et al. 2006). The level of disruption in patient’s life in 
hyperhidrosis seems worse than in other chronic conditions such as ulcerative colitis [IIRS total 
score = 27.6 ±16.62], renal transplant [38.7±18.42], multiple sclerosis [44.8±18.59], schizophrenia 
[50.5±16.68]. The lower level of disruption observed in the study by Cina and Clase (1999) might 
be alluded to differences in their respective patient population, the former included patients with 
mild forms of disruption as well as those not seeking for treatment. On the other hand, the later 
represents a highly selected group.
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Table 1.5: Studies using generic HRQoL instruments: SF-36 and NHP
Author Country Setting Patient 
population
Study design N Gender Age (years) Before After Remarks
Lee et al. 2012 Korea patients with HH 
involving  hands,  
feet, axillar,  head  
and  neck, 
perineum,  and  
other
Retrospective, 
case-series 
36 M = 41.6% 27± 14.9 NR NR Highly selective 
patients, treated with 
glycopyrrolate
Schmidt et al. 2006 Germany Hospital Patients with HH 
(palmar, axillary, 
facial) treated with 
ETS
Open-label, 
observational
178 M = 28.7 % 32.9 +/- 9.7 NR NR Sample is highly 
selective, includes 
patients previously 
receiving surgical 
intervention
Elia et al. 2005 Italy University 
hospital
Patients with 
severe palmar HH
case-series 45 Male = 42% 28.76± 5.25 General, 54.6;  
PF,38.7; RP,70.0; 
SF,64.4; RE,55.1; 
MH,57.4; BP,35.5; 
GH,48.9; VT,68.9; 
MCS,46.5;  
PCS,38.3
MCS: 55.2
PCS: 43.3
Severe cases of HH, 
where previous 
treatments had failed
Follow-up after 6 
months
Elia et al. 2005*
[same study as 
above]
GE, 23.04; MO, 
12.09; EN, 30.83;
SL, 10.98; PA, 
47.84; IS, 1.58; EM, 
26.7.
GE,14.12; 
MO,8.52; 
EN,16.02;
SL,5.71;
PA,29.98; IS,0; 
EM,10.15
Notes: 1. *Study used Nottingham Health Profile (NHP); 
2. Domains of the SF-36: General, general health perception; PF, physical functioning; RP, Role physical; SF, 64.4; RE, role emotional; MH, mental health; BP, Bodily 
Pain; GH, general health; VT, vitality; MCS, mental component summary score;  PCS, physical component summary score.
4. Domains of the NHP: MO, mobility; PA, pain; EN, energy; SL, sleep; EM, emotional reaction; IS, social isolation; GE, general score.
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Table 1.5 (continued)
Author Country Setting Patient 
population
Study design N Gender Age 
(years)
Before After Remarks
Kumagai 
et al. 
Japan University 
hospital
3 patients (7%) 
palmar only; 14 
(33%), of 
craniofacial HH;
35 (83%), 
axillar; 28 
(67%), planter; 
and 17 (40%), 
blushing
Case series; follow-
up at 1, 3 and 6 
months.
40 M=42% Mean
(range)
29. 7 
(18 -
55)
NR NR Involved treatment 
with ETS, reflecting 
severe cases of HH.
Patients experienced 
reduced impairment 
except for bodily pain 
and physical 
functioning
Sayeed 
et al. 
UK University 
hospital
Patient with 
palmar and 
axillary HH, 
electing ETS 
surgery
Retrospective, case-
series;  Patient 
follow-up at 6.2 
months (range: 5.1 -
9.9)
16 M = 
45%
Median 
(range)
26 (18 -
48)
PF, RF, SF, RE, 
BP: 100
MH: 78, VT: 70, 
GH: 82
MCS: 52.7
PCS: 59.4
PF, RF, SF, RE, 
BP: 100
MH: 82, VT: 75, 
GH: 84 
MCS: 54.4
PCS: 59.3
SF-36 not sensitive to 
impairment in patients 
QoL, most patients 
achieved
high/maximum scores 
in 4 dimensions of the 
SF-36.
Young et 
al. 2003
Ireland Hospital Patients with 
palmar HH 
receiving ETS
Retrospective, case-
series
62 M = 
34%
Mean
(range)
29 (17 -
64)
PF: 950, RP: 300, 
RE: 300, MH/E: 
320, VT/EN: 200, 
SF: 220, BP: 100, 
GH: 350, Overall: 
2635 
PF: 950, RP: 400, 
RE: 300, MH/E: 
380, VT/EN: 200, 
SF: 200, BP: 100, 
GH: 325, Overall: 
2835
Highly selective 
patient population; 
severe HH.
Mean follow-up was 
38.46 months
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Table 1.5 (continued)
Author Country Setting 
Patient 
population
Study 
design
N Gender
Age 
(years)
Before After
Hamm et 
al. 2006
Germany Hospital patients with 
palmar/axillary  
HH and non-
patients
cross-
sectional 
study
Controls: 
N =154
axillary: 
N = 165
palmar: 
N = 116
Control: 
M = 
43%
axillary: 
M = 
42%
palmar: 
M = 
421%
Control: 
27+/-7
Axillar 32
+/-12
Palmar 
30+/-9
Mean score
MCS: 44.4, patients, 50.8, 
controls
PCS: 52.9, patients, 54.9, 
controls
Naumman 
et al. 
2002
Multiple 
European 
centres, 
plus DE 
and UK
hospital/clinic Patients with 
persistent HH
Multi-
centre 
RCT
320 M = 
46%
Mean
age(range)
31.5 (17 -
74)
PCS = 52.6 (No Diff. Between 
placebo and treatment group)
MCS = 49.1, BTX-A; 46.4, 
placebo
PCS Change 
BTX-A:  - 0.9, 
Placebo: - 1.2
MCS Change:
BTX-A: - 1.7, 
Placebo: 0.5
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Table 1.6: Effects of hyperhidrosis on lifestyle: IIRS
Author Country Setting Patient 
population
Study design n Gender Age (years) Before After Remarks
Cina et 
al. 2007
Canada Hospital primary 
HH 
patients 
electing for 
surgical 
treatment
Case-
series/open 
label
30 
patients
11 non-
patients
M = 50% 
(patients)
M= 36% 
(controls)
Mean
39± 13 
(patients)
26±10 (non-
patients)
57 ± 14 
(patients)
13.5±0.7 
(non-
patients)
19.3 ± 15 
(patients )
Number of 
controls small. 
Concept 
becomes 
hypothetical if 
presented to 
controls.
Cina et 
al. 1999
Community 
based; 
online HH 
discussion 
group
Community 
patient 
population; 
online
Cross-
sectional; 
Observational, 
exploratory
80 M = 65 % Mean
32± 9 
(patients)
45 ± 18 Reflects 
patients in 
community
Might have 
included those 
not suffering 
from HH
Cina et 
al.  
2006
Canada primary 
HH 
patients 
electing for 
surgical 
treatment
Prospective 
multi-centre 
cohort design
22 Mean
Scores
57 ± 14
Follow up took 
place at 2 and 
at 4 months.
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The authors also admit that caution is required in using their results, especially considering the 
risk of including patients who may not necessarily have had hyperhidrosis, based on their sampling 
strategy. On the other hand, exaggeration of the level of reported pre-treatment impairment may 
not be ruled out in the Cina et al. (2006) study
In the fifteen studies using the DLQI, scores ranged from 10 – 14 for axillary hyperhidrosis, 8.8 –
15, for palmar hyperhidrosis, 13, for cranio-facial hyperhidrosis, 9.4 for sweating of the trunk (
Table 1.7). Hamm et al. (2006) compared dermatology-specific-QoL in hyperhidrosis patients to 
that in controls. The DLQI total score was lower in non-patients than patients (DLQI scores: 
axillary HH, 10 ±5.6; palmar HH, 8.8±5.9; controls, 0.7±2). In patients with axillary HH, HRQoL 
effects were mainly linked to limitations on daily life activities (influence on choice of clothes), 
symptoms and feelings (embarrassment and self-consciousness) and effects on leisure and social 
activities activities (Swartling et al. 2001; Hamm et al. 2006) In palmar HH these were related to 
symptoms and feelings, daily life activities, leisure and social activities and personal relationships 
(Swartling et al. 2001; Hamm et al. 2006). Amini et al. Amini et al. (2008) in a retrospective, 
exploratory study including patients (N = 94 ) receiving treatment at a dermatology clinic in the 
Netherlands, obtained the highest baseline DLQI scores in patients with hh involving the ‘axillae 
and face’ (15±5.62). The lowest scores were in patients with palmar and/or plantar hyperhidrosis 
(9.24±5.08). The baseline DLQI score reported by Müller et al.(Muller et al. 2012) is notably 
higher than that seen in rest of the studies (DLQI Score = 16.5). This may reflect the 
inclusion/exclusion criterion of the study, being an RCT. 
Four studies reported using the Hyperhidrosis Impact Questionnaire (HHIQ) including Naumann 
et al. (2002), Solish et al. (2005) and Hamm et al. (2006) and Strutton et al. (2004) (Table 1.8). 
Patients (34% - 79%) experienced limitations at work, resulting in reduced effectiveness, thus 
patients changed how they worked. The majority of the patients (64.7 % - 86%) were 
moderately/severely affected emotionally. For example, all four studies reported a majority of 
patients (70% - 94%) having less confidence than they would like to have; Thirty six to seventy-
one percent reported being depressed or unhappy. Additional challenges were experienced in 
personal relationships and social situations. For example, 59% - 70% of patients reported 
difficulties with meeting new people for the first time; 25 % - 79% reported an inability to 
participate in family events or to spend to with friend. Various social situations presented 
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challenges to patients: meeting people for the first time was a concern in 47% - 90% of the patients; 
being in public places and shaking hands with people also reported to be challenging. 
The condition also affected patients’ daily life activities, with 30.4% - 61% of the patients getting 
frustrated with every day chores. To mitigate such effects, patients purchased additional items or 
accessories to help in completing routine tasks or by seeking help from family and friends. Solish 
et al. and Naumann et al. represent highly selective patient populations owing to their 
inclusion/exclusion despite including patients from multiple centres. A similar critique holds for 
the Hamm et al. study albeit to a smaller degree, in this case, while the patient population 
represents HH patients seeking care at a dermatology clinic, those with more severe condition may 
have been overrepresented. While the study by Strutton et al. is by and large free of the issues 
noted in the above studies, still some limitations can be noted. The reliance on one member to 
report on an entire household poses a risk on accuracy of reported information, as second hand 
experience may differ from first hand experiences. In particular, QoL impacts tend to differ 
depending on the source of such information, whether family member or patient is the one 
reporting. 
DISCUSSION
The quest to understand impacts of disease and its treatment as experienced and reported by 
patients has become ubiquitous in health-care, with Gill and Feinstein  (1994) describing the 
change in the field as growth from a small cottage industry to a large academic enterprise.  The 
drive towards a highly transparent drug regulatory regime and stricter risk-benefit assessment for 
new pharmaceutical products has provided a platform for consideration of broader and more 
comprehensive set of outcomes beyond clinical and pharmacologic endpoints in clinical research. 
Furthermore, the fact that patients may be more interested in how treatment of their condition 
affects their daily life or what sacrifices they may have to make in terms of their QOL, than just 
the alleviation of symptoms (Lohr and Zebrack 2009) has enhanced the relevance and importance 
of PROs such as HRQOL in routine clinical practice.  Given that patients are experts in their 
experience with a condition, they are the best source of information on their HRQOL (Salek 1998). 
This, the subjective nature of patient experiences and idiosyncratic perception on the same, lies at 
the heart of the conceptual issues related to HRQOL. 
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Table 1.7: Studies using a dermatology-specific QoL Instrument: Dermatology Quality of Life Index (DLQI)
Author Country Setting Patient 
population
Study design N Gender Age (years) Before After Remarks
Rosell et al. 
2013
Sweden specialist 
clinic
patients 
attending a 
specialist 
clinic
Open-label, 
observational 
study; 
comparison of 
BTX-A and 
BTX-B
58, 
axillary 
26, 
palmar 
NR Mean+/-SD
32.3 +/-10.4, 
axillary
26 +/-10.2, 
palmar
mean +/- SD
12+/- 5.5, axillae:
10.3 +/7.3, palmar
axillae: 
1.7+/-2.6
palmar: 
1.2+/-1.5
atients 
represent 
severe cases of 
HH
Amini et al. 
2008
Netherlands Dermatology 
clinic
HH patients 
attending 
clinic
Retrospective, 
observational
94 M = 34 % 32.6 9.24 ±5.08, hands and/or 
feet
10.98±4.51, axillar
12.91±2.95, axillar and/or 
feet
15.75±5.62, axillar and 
face
12.27±6.76, generalised
Patients and 
range of 
treatment 
represent 
typical for
dermatology 
clinic
Tupker et 
al. 2006
USA Dermatology 
clinic
patients with 
generalised 
HH treated 
with 
oxybutynin
Prospective, 
observational
13 NR NR 15.9±6.9 3.7±5.2 Patient 
characteristics 
were not 
reported in 
study
Solish et al. 
2005
Canada Dermatology 
clinic
Patient with 
axillary HH 
treated with 
BTX-A
Multicentre (N = 
30), prospective, 
open label
146 M = 33% 35 (range: 18 -
73)
10.6 1.7
DLQI  
decrease 
> 5,  76% 
of 
patients
DLQI = 
0, 53% 
of 
patients
Very stringent 
inclusion 
criterion; 
patients reflect 
severe cases 
(HDSS = 4, for 
64% of 
patients)
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Table 1.7 (continued)
Author Country Setting 
Patient 
population
Study 
design
N Gender
Age 
(years)
Before After Comment
Tan et al. 
2002
Canada Hospital patients with 
focal HH 
awating 
treatment with 
BTX-A
open-label, 
retrospective 
observational
22, axillary
2, forehead
10, palms
M = 38% mean
(range):
29.6 
(17 -
56)
Mean score
18, axillae
13, forehead
18.5, palmar
Mean score
Axillae: 4
Forehead: 2.5
Palms: 9
The DLQI was 
modified for greater 
relevance for sweating. 
Highly selective 
patient population, 
attending one practice.
Small number of 
patients with forehead 
HH 
Müller et al. 
2012.
Germany Specialist 
practices & 
Hospital
Patients with 
axillary or 
palmar and 
axillary HH
multicentre 
RCT
339, 
randomised
267, 
analysed
sites
267, axillar
217, palmar
M = 42% range: 
18 - 66
16.6 
(methantheline)
16.4 (placebo)
day 14
11+/-6.4, 
treatment group
13.2, +/- 6.6, 
placebo group
day 28
9.7 +/-6.8, 
Treatment group
12.2 +/-6.8, 
placebo
At least three quarters 
of the patients were 
severely affected by 
their condition.
RCT involved 
treatment with 
Methantheline 
(Vagantin) over 28 
days.
Swartling et 
al. 2001
Sweden Hospital Patients 
attending  
Neurology and 
dermatology 
depts. of Uni 
hospitals  
treated with 
BTX-A
Prospective 
open-label 
study
58
Palmar: 46
Plantar: 31
Axillary: 
30
M = 45% Range: 
15-49
10.3 (2 - 22), all 
patients
10.6, relapse-
patients
9.9, relapse-free
9.1, palmar, 
relapse free
11.6, axillary, 
relapse free
4.3, all patients
8.8, relapse-
patients;
2.4, relapse-free
1.8, palmar 
relapse free
2.4, axillary, 
relapse free
2 -15 months follow-
up 
Patient population 
reflects severe HH,
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Table 1.7 (continued)
Author Country Setting 
Patient 
population
Study design N Gender Age (years) Before After Comment
Campanati 
et al. 2003
Italy Hospital patients with HH 
treated with 
BTX-A
open label, 
observational 
study
41
Axillae: 
14
Palms: 16
Axillae 
and 
Palms: 11
M (%)
29.3%, 
palmar
36.8 %, 
axillary
median (IQR)
32.5 (24 -43), 
axillae
26 (22-5 - 41),
palms
25 (20 - 35), 
palms&axillae
median (IQR)
13 (11 - 15), 
axillae
13 (12 - 17), 
palms
14 (13 - 17), 
palms and 
axillae
0.5 (0 -1), 
axillae
1 (1 - 3), 
palms
1 (1 - 4), 
palms and 
axillae
patients reflect 
severe cases of 
HH, not 
responding to 
other treatments
Campanati 
et al. 2011
Italy Hospital plantar 
hyperhidrosis not 
responsive to 
other forms of 
treatment
Open-label, 
observational 
study
79
Palmar: 
41
Axillary: 
38
M = 32 
%
median (IQR)
27 (25 - 34), 
axillae
29 (27 - 40), 
palmar
14 (11 - 17), 
axillae
15 (12 - 18), 
palmar
1 (0 - 1), 
axillae and 
palmar
patients reflect 
severe cases of 
HH, not 
responding to 
other treatments
Harper et 
al. 2010
UK Hospital patients with HH 
treated  with 
BTX-A
Open label, 
service audit
37 NR NR Mean
12.9
2.5 includes severe 
cases of HH
Kim, Kil 
et al. 2010
S. Korea Hospital patients with CS 
in the trunk
Retrospective 
design
17 M = 
55%
Mean +/- SD
26.3 +/- 4.9
Mean +/- SD
9.4+/-2.0 2.8+/-1.0
R highly selective 
patient group: 
previous surgery/ 
severe CH
Bechara et 
al. 2007
Germany Specialist 
dermatology 
(hyperhidrosis) 
clinic
patients with 
axillary HH 
treated with 
suction curettage
Open-label, 
observational 
study
51 M = 
37.3%
mean+/-SD 
(range)
28.6+/-10.6 
(19 -48)
Median 
score(range)
12 (9 - 18)
4 (2 - 8)
Patient were 
severe cases of 
hyperhidrosis
9 months follow-
up period
Innocenzi 
et al. 2005
Open-label, 
exploratory 20 NR NR
Lupin et 
al. 2012
Canada hospital/clinic
patients with 
axillary HH 
treated with 
microwave-based 
device
Multi-centre, 
open-label 
study
31
M = 
26%
Mean (range)
33 (18 - 65)
Mean
11.8
1.6
highly selective 
patient population
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Table 1.7 (continued)
Author Country Setting 
Patient 
population
Study 
design
N Gender Age (years) Before After Comment
Hamm et 
al. 2006
Germany Hospital
patients with 
palmar/axillary  
HH and non-
patients
cross-
sectional 
study
controls: 
N =154
axillary: N 
= 165
palmar: N 
= 116
Control: 
M = 
43%
axillary: 
M = 
42%
palmar: 
M = 
421%
Control: 27+/-
7
Axillar 32 +/-
12
Palmar 30+/-9
Control: 0.7 +/-
2
Axillary: 10 +/-
5.6
Palmar 8.8 +/-
5.9
Patients seeking 
for dermatology 
treatment at a 
University clinic
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Table 1.8: Studies using the Hyperhidrosis Impact Questionnaire (HHIQ)
Author Hamm et al. 
2006
Strutton et 
al. 2004
Naumann et 
al. 2002
Solish et al. 
2005
Number of patients (N) 345, patients 
154, non-patients
150,000 
households
320 146
Country Germany USA Germany, UK
& other
Canada
Patient population
Single centre, 
dermatology 
clinic (Uni. 
Hospital)
community 
based patient 
population
Multicentre, 
dermatology 
clinics
Setting, study design Single centre, 
dermatology 
clinic 
National 
survey
International 
Multicenter 
RCT
Multicentre, 
open label, 
dermatology 
clinic
Impact on career choices and 
work habits
Moderate/extreme limitation 
at work 
axillary: 65%, 
palmar: 62%
33.6% 79%
Moderate/extreme impact on 
effectiveness at work
axillary: 46%, 
palmar: 38%
Accomplished less at work axillary: 33%, 
palmar: 24%
34%
Made changes on how they 
worked
axillary: 41%, 
palmar: 41%
43%
Patients worked less 
carefull/accurately
axillary: 27%, 
palmar: 24%
Overall satisfaction with 
ability to perform work 
activities
Btx-A: 20%
Placebo: 15%
8%
Time and effort spent treating 
HH
Changed clothes at least twice 
a day
axillary: 71%, 
palmar: 31%
BTX-A: 76%
Placebo: 75%
77%
Shower or bath at least once a 
day
axillary: 27%, 
palmar: 10%
Spend at least 15 min a day 
symptoms
axillary: 38%, 
palmar: 22%
30%
spent 15 min or less BTX-A:62.8%
Placebo: 52%
Currently, a unified standard conceptual definition for HRQOL is not available, as reflected in the 
multiple definitions provided in this chapter, reflecting the outstanding this.  Complicating the 
situation further, how individuals understand health varies across cultures, age, gender, 
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socioeconomic status, and may even vary depending on whether one is sick or healthy (Bowling 
1995 cited in Haas 1999).
Table 1.8 (continued)
Author Hamm et al. 
2006
Strutton et al. 
2004
Naumann et 
al. 2002
Solish et al. 
2005
Emotional
Feel Unhappy 54.8%
Feel Depressed 35.7%
Unhappy or depressed axillary: 71%, 
palmar: 54% 
48.70% 46%
Less confident than they would 
like
74% 69.8% 71.80% 94%
Moderately or significantly 
emotionally injured
64.7% Btx-A: 86%
Placebo: 85%
67%
Personal relationships and social 
situations
Moderately or extremely limited in 
establishing personal 
relationships
59% 70%
Moderate or extreme limitation 
with participation in family 
events or spending time with 
friends
54% 25% 79%
Moderate or extreme limitation 
with sexual activities
34% 46% 31.80% 52%
Moderate or extreme limitation in 
social situations e.g.
severe 
axillary, 50%
45.8%
meeting people for the first time 71% 46.7% BtX-A: 80.5%
Placebo: 75%
90%
being in public places 56% 35.1% 65% 84%
shaking hands 58% 31% 50%
changed type of leisure activities 53% 41.6% 44.60%
decreased leisure time 42% 34.6% 19.30%
Moderate or extreme limitations in 
sports
17.2%
Purchase additional items or 
accessories to help complete
routine daily activities
31.4%
Become frustrated with some daily 
life activities
58. 2% 30.40% 61%
Require help (eg from family and 
friends) to perform tasks that 
would otherwise do on own 
17.8%
Notes: 1. Results from Strutton et al. 2004 are for patients with severe axillary hyperhidrosis
Moons (Moons et al. 2006) discussed six major conceptual issues in HRQOL. For example, does 
HRQOL include ‘subjective’ or ‘objective’ elements or both? Is HRQOL separate from other 
concepts such as health-status and functioning? Can its determinants be separated from QOL and 
its indicators? Can HRQOL be clearly defined and distinguished from overall QOL? These issues
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have implications on the measurement of HRQOL, beyond their relevance for conceptual debate. 
Not only do they complicate the design of appropriate measurement tools, but also present a 
challenge to the interpretation, reporting and application of study results. Perhaps rather than 
seeking one theocratic concept to supersede or unite current definitions, the pluralistic nature of 
QOL should be accepted as the nature of the beast. Gill and Feinstein (1994) have suggested a 
practical way forward to ensure rigorous HRQOL measurement in the current conceptual 
conundrum. Researchers should be transparent in their use of QOL, by clarifying a definition. The 
domains being assessed should be made clear. The choice of measurement instruments used in 
data collection should be justified. But even more importantly, patients ought to be involved, in 
defining relevant HRQOL issues of study, and how important they are. Undertaking these steps 
would ensure that HRQOL is appropriately measured, and that such reference should only be done 
where it is warranted.
Besides the above concerns, choice of the most appropriate instrument for measuring QOL 
involves multiple-decisions: whether to use a generic, therapeutic area-specific or disease-specific 
instrument; whether the developmental purpose and patient population for the measure  relate to 
the research question and target population; psychometric properties of the measure (Streiner and 
Norman 2008). In routine clinical practice additional considerations include, whether the 
instrument is easy to complete and easy to administer; applicable – consider as relevant by the 
patients, responsive to individual change, with interpretable scores (Higginson and Carr 2001).
One therapeutic area where QOL considerations have a particular role is in skin disease, in view 
of the profound impact on the QOL of patients, often exceeding that in various chronic diseases 
conditions (Finlay 1998; Basra and Shahrukh 2009) Simultaneously, typical for most skin diseases, 
and hyperhidrosis in particular, easily measurable laboratory values is either scarce or difficult to 
interpret (Rani et al. 2005) as well as making QOL measurement particularly crucial. A core aim 
of this chapter was to review the QOL impacts of hyperhidrosis as well as the instruments that 
have been used in assessing them. Impairment in generic HRQOL was alluded to social 
functioning and emotional role limitation, whereas dermatology-specific impacts were related to 
daily activities, personal relationships and symptoms and feelings. The necessity for more showers, 
sweating after consumption of alcohol, spicy foods or coffee, and facing a limited choice of 
clothing representing disruptions in patients’ lives.
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Still, these results do not fully explain why dermatology-specific QOL impairment is worse in 
hyperhidrosis in comparison to other conditions such as psoriasis as noted by Hamm and 
colleagues (Hamm et al. 2006). Several explanations are plausible. First, patients with 
hyperhidrosis report feeling their life as being taken over by hyperhidrosis all the time. This 
reflects the persistence (and frequency) of sweating episodes and their related impacts. Sweating 
episodes are accompanied by feelings of anxiety (besides other negative emotions), in a chicken-
egg circle. Patients get anxious that they may sweat and in turn more anxiety leads to more 
sweating. This is consistent with earlier views on the disease, where psychiatric underpinnings 
were suspected (chicken-egg) (Ruchinskas 2007). This is also consistent with the view of 
hyperhidrosis as a multi-factorial condition (Beltraminelli and Itin 2008). The greater impact on 
QOL in this case being alluded to the strong feedback between the psychiatric impacts and 
sweating. 
Unlike other dermatological conditions, hyperhidrosis is poorly treated, with only 35% visiting the 
doctor (Strutton et al. 2004). Nonetheless, even those seeking treatment face a hard choice between 
expensive treatments such as Botox, high-risk surgical interventions such as ETS surgery or other 
much cheaper but less effective treatment. Consequently, the majority of patients survive with an 
unmanaged condition. In the long term this poses a real risk of patients developing psychological 
sequelae owning to persistent impact. Clinical trials in hyperhidrosis have tended to use all three 
types of measures, generic, therapeutic-area specific, and disease specific, and more often than not 
in combination. On the other hand, clinicians have tended to use more disease specific measures, 
(Solish et al. 2007).  Among the generic measures, only the IIRS had been validated in 
hyperhidrosis patients (Cinà & Clase 1999). This only adds on their natural limitation, namely, 
their inclusion of content which may be irrelevant to patients with particular disease (Halioua et 
al. 2000) threatening content-validity or ‘applicability’. Generic measures may still be of use in 
hyperhidrosis when making comparisons with the other non-dermatologic conditions, still this 
would have to be preceded by an evaluation of their psychometric attributes most especially 
content validity and responsiveness.
Among the skin-specific measures, only the DLQI and the PBI had been validated in hyperhidrosis 
patients. These measures are overall more relevant for hyperhidrosis patients in comparison to 
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generic measures. Given the DLQI’s brevity, simpler scoring system and availability of cut-offs 
for clinical significance (in the form of MID) for hyperhidrosis, it would be preferred of the two. 
Of the disease-specific measures found, the HDSS and the HHIQ were the most validated. 
Although the HDSS has be included in this review and has also been used in other trials as a 
measure of QoL, its developers intended it as a measure of disease severity and interference of 
hyperhidrosis in everyday life. Moreover, as a single item instrument it does provide a detailed
picture of QoL On the other hand, while the HHIQ is indeed promising both in terms of coverage 
issues relevant to patients, it was not designed for use in routine clinical practice; its internal 
structure has not been tested, it has no scoring system, and no information has been provided for 
interpretation of scores. 
The other disease-specific measures found, had incomplete details regarding key psychometric 
information. Even more worrisome, is the unusually high number of studies in hyperhidrosis 
assessing QoL using adhoc QoL questionnaires reflecting that considerations of rigor of 
measurement were not at all made. Practical recommendation on developing instruments in 
dermatology from the EADV task force on QoL is to apply both classical test theory and modern 
test theory (Prinsen et al. 2013). Particular emphasis was placed in testing that measures remain 
invariant in different patient populations and measuring situations. None of the current disease-
specific measures in hyperhidrosis has been tested using modern test theory or demonstrated 
invariance
This review has revealed a deficit in the current measurement of HRQOL in hyperhidrosis. There 
is need for a new measure which would assess HRQOL specific to patients with hyperhidrosis, 
with its content underpinned by patient experiences and quality of life issues they face, with 
demonstrated optimal psychometric attributes of construct validity, inter-temporal stability, 
internally consistent, tested internal structure and unidimensional scales. In order to ensure clinical 
feasibility of such a measure, adequate attention would have to be given to ensuring its practicality, 
for example having a small number of questions as much as possible to allow all questions to fit 
on one side of an A4 page, and using a simple scoring procedure.
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SUMMARY
 There is a growing recognition of the need to incorporate the patient’s perspective in 
understanding the impacts of disease and its treatment largely driven by a revolution in 
societal values as well as changes in disease epidemiology and the organisation and 
delivery of health care services.
 Increasingly, HRQoL is being acknowledged as the ultimate goal of health-care, leading to 
its growing application as an endpoint in clinical trials, in routine clinical practice, and 
much recently as a tool for driving system-innovation through its system wide application.
 Controversy surrounds the definition of HRQOL, its constituents and how to measure them 
and their linkage with other clinical endpoints, presenting challenges on its measurement.
HRQOL is subjective, varies over time and is a multidimensional concept
 The choice of the most appropriate instrument has to consider purpose for measuring QoL 
against those of available instruments. Psychometric attributes and appropriate conceptual 
coverage should also be considered.
 Hyperhidrosis results in profound HRQoL impairment, covering occupational related 
impacts, emotional distress, physical discomfort, limitations in social life, the extra 
activities involved in managing the condition.  This is comparable or worse than other 
common skin conditions such as psoriasis or eczema.
 The measurement of HRQOL in hyperhidrosis has made use of generic, skin-specific and 
disease-specific measures. While generic measures may not be recommended, the DLQI 
seems viable. For understanding disease-specific issues, none of the current measures can 
be considered optimal, although HHIQ seems the best among the lot.
 There is need for a new HRQOL instrument for measuring disease-specific QoL, based on 
patient’s input, with well tested psychometric properties, applicable to all forms of 
hyperhidrosis, having paid particular attention to ensuring its feasibility in the routine 
clinical 
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STUDY AIMS AND OBJECTIVES
AIMS
 To investigate the impact of hyperhidrosis on patients’ HRQoL. 
 To conceptualise, develop and validate a disease-specific instrument for assessing HRQoL 
in hyperhidrosis that would be applicable in clinical research as well as routine clinical 
practice.
OBJECTIVES
 To explore the experiences of patients with hyperhidrosis in order to obtain an in-depth 
understanding of the extent and nature of QoL impacts
 To create a conceptual framework for HRQoL in hyperhidrosis.
 To develop a disease-specific instrument for evaluating QoL impacts in hyperhidrosis 
based on the experiences of patients.
 To assess whether the content of the new disease-specific instrument was relevant to 
patients with hyperhidrosis; adequate and appropriate for measuring the concept of quality 
of life.
 To establish the dimensional structure of the new instrument and to perform item reduction.
 To assess the reliability and the construct validity of the new instrument.
 To establish the minimum important clinical difference (MCID) value of the new 
instrument.
 To develop and propose scale banding for the interpretation of scores from the new 
instrument.
 To assess the feasibility of applying online social networking sites for outcomes research 
in dermatology (using hyperhidrosis as an example).
61
CHAPTER 2
Rationale and Methodological Framework
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PART I: RATIONALE
The articulation of humanistic aspects in the 1948 constitution of the WHO signalled international 
consensus around the final outcome of healthcare ought to be: complete physical, mental and social 
well-being. This new paradigm meant that treatment of disease was not only curative but rather 
aimed at improving the outcomes that patient cared for most, related to their everyday functioning 
and quality of life. A broad view of treatment goals is also in keeping with the epidemiologic 
developments where non-communicable diseases such as diabetes, cardiovascular diseases and 
cancer are increasingly accounting for a greater portion of burden of disease globally. As most of 
such conditions tend to be chronic, maintaining or improving the functionality and quality of life 
of patients is considered a key endpoint of treatment. Furthermore, quality of life facilitates the 
understanding of the full impacts of disease on the patients, particularly for those elements of the 
impact which can only be known by them (Patrick et al. 2007). This therefore, elevates the 
importance of patient reported outcomes and QoL from merely a consequence of treatment to the 
ultimate goal that should be measured and attained by each treatment.
QoL considerations are of particular importance in skin diseases. First, as most skin conditions are 
not life-threatening, their major burden is associated with morbidity (Basra and Shahrukh 2009), 
more so considering that the degree of severity tends to be influenced by psychosocial effects (e.g. 
effects on self-image and social life) and physical discomfort more than symptoms (Grob 2007). 
As doctors are not always able to predict the QoL of their patients (Basra and Shahrukh 2009), the 
measurement of QoL in patients with skin disease becomes even more imperative. In 
hyperhidrosis, further practical considerations may make the assessment of QoL quintessential. 
First, the amount of sweating defining the condition is unclear (Wörle et al. 2007). Moreover, the 
reliability of current methods for quantifying sweat, such as gravimetric measures, has not been 
assessed. Additionally, these measures are neither feasible nor practical in the busy set up of a 
routine clinical practice.  This places patient reported disease impacts such as effects on QoL as 
reported by the patient as a particularly useful piece of information in the clinical management of 
hyperhidrosis.
Addressing the need for QoL measurement in hyperhidrosis requires instruments that are 
appropriate and fit for purpose. Current measures were reviewed in this regard and the full results 
have been presented in the general introduction chapter. The following observations were made:
 Generic HRQoL measures such as the SF-36 were seen to include items irrelevant for 
hyperhidrosis while omitting key issues relevant in this patient population. This also 
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applies to dermatology specific measures though to a lesser degree. Moreover, except for 
the Patient Benefit Index (PBI), the other measures have not been validated in this patient 
population.
 For the current disease-specific measures temporal stability is not known. Evidence of 
construct validity and responsiveness is not based on robust approaches. For example, only 
factor analysis exploring factorial structure has been undertaken in one measure only 
(Hyperhidrosis questionnaire).
Significance of a new instrument in hyperhidrosis
In view of the above, an adequately validated instrument for evaluating hyperhidrosis-QoL that 
would be feasible and practical in both routine practice and clinical research would enable the 
efficient measurement of the impacts of hyperhidrosis on the life of patients. This is not only vital 
in quantifying the burden associated with the condition but would also have implications on the 
diagnosis and management of the condition for instance leading to better decision making 
regarding use of systemic treatment in patients with great HRQoL impairment (Grob 2007). 
Moreover, the availability of an instrument with better acceptability and applicability in routine 
clinic practice would facilitate more discussions of patients HRQoL in hyperhidrosis during 
consultation, which constitutes an aspect of care important to patients (Salek et al. 2007). This 
would also support the understanding of the patients’ healthcare needs, leading to more appropriate 
care being given, which might include counselling or other forms of care as necessary. 
Furthermore, the improved precision and ability to detect important changes, in the measurement 
of HRQoL would have practical implications on clinical trials (Streiner and Norman 2008), 
particularly by reducing the sample sizes needed to achieve desired statistical power, reducing a 
major hurdle for research in the field.
A major obstacle to the use and acceptance of QoL information emanates from the subjective 
nature of such information and the lack of credibility of the approaches used in quantifying these 
(Grob 2007). This is further complicated by the fact that QoL is an unobservable hypothetical 
construct. These concerns are in part addressed in measurement theories such as classical test 
theory widely applied in psychology and education, to develop and validate instruments for 
assessing psychological constructs such as depression and intelligence. The efficiency and level 
of objectivity of measurement of such constructs has been further enhanced by the development 
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of modern test theory such as the Rasch model, which permits the translation of raw scores into an 
interval scale variable (Fisher Jr 2000). Both measurement theories provide a set of attributes to 
be reflected in an instrument for optimal measurement of constructs. This has been of even greater 
interest in the context of patient reported outcomes and several groups have made 
recommendations of the key attributes (Patrick and Chiang 2000; Lohr 2002; Frost et al. 2007b; 
Terwee et al. 2007).
KEY ATTRIBUTES OF HRQOL INSTRUMENTS
Conceptual Framework
A clearly articulated conceptual framework based on literature and the relevant qualitative data 
(from patients or therapeutic clinical experts), outlines the concepts being measured by an 
instrument; the rationale for assessment; domains and their inter-relationships (Lohr 2002; US-
F.D.A. 2009). This in turn facilitates the appropriate organisation of the instrument, in line with 
the intentions of measurement including the scaling structure and the related measurement model 
(Rothman et al. 2007). The process of developing a conceptual framework not only ensures that 
the purported constructs are measured but also facilitates the interpretation of the data. 
Acceptability And Practicality
Ultimately, the acceptability of an instrument by the final users, the patients, has a bearing on not 
only whether the respondents are motivated to complete the questionnaire but also the integrity of 
the data obtained. The instrument must be easy to complete, imposing the least burden on the 
respondents (Both et al. 2007). For instance, the measure should not be unnecessarily lengthy and 
must be well organised such that navigating through and completing the questionnaire should be 
easy. Loss of spontaneity to the response process as the respondents become fatigued may lead to 
avoidable errors or undesirable response behaviours, for example ‘satisficing’. On the other hand 
the effort required to administer the instrument, collect and process data must be minimal to make 
the application of the instrument in a clinical situation feasible (Salek 1998). Again if data 
collection and processing are excessively burdensome avoidable errors may creep in during the 
process as the administrators become less careful. 
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Validity 
As HRQoL is unobservable, evidence that an instrument assesses what is intended, demonstrating 
validity of the measurements, is a key property (Fayers and Machin 2007).  Where there is lack of 
evidence supporting this, inferences may be misleading as there is no certainty regarding what is 
actually being measured (Haynes et al. 1995). Thus, the validity attribute relates to particular use 
of the scale and is not an inherent trait of the instrument (Messick 1988). This then means that the 
validation exercise is a continuing process providing evidence supporting various inferences based 
on the instrument(Streiner and Norman 2008). Validity is typified in three forms: content validity, 
construct validity and criterion validity.
Content validity refers to the adequacy with which sampled items of an instrument reflect its aims 
as articulated in the conceptual framework (Salek 1998). First, this reflects the appropriateness of 
the items, domains and other elements of the instrument to the underlying construct being 
measured. This also captures how comprehensively the underlying construct has been covered by 
the instrument (Patrick et al. 2011b). Determination of content validity is both a quantitative and
qualitative process based on judgement by experts (Streiner and Norman 2008). This form of 
validity is ensured by having a clear conceptual framework, as a basis for the instrument, and 
following an organised and structured process in the development of the instrument, which should 
be carefully documented (Terwee et al. 2007). By capturing the connection between intended 
measurement concept and the way patients from the target population understand and discuss that 
concept (Patrick et al. 2011b), this form of validity serves as vital proof of concept for later 
development of the instrument. Quite often content validity is confused with face validity. The 
latter relates to the acceptance conferred by lay persons that the instrument appears to be sound 
and relevant (Lynn 1986). The conclusion that the instrument is indeed measuring what it is 
supposed to be measuring is by perception and thus assumption, there is no rigorous quantification 
or measurement (Lynn 1986; Frost et al. 2007b).
Construct validity assesses the degree to which theoretical hypothesis relating to an underlying 
construct being assessed by an instrument are actually supported, providing evidence justifying 
particular or inferences interpretation of scores (Terwee et al. 2007). Studies for demonstrating 
construct validity vary in design, although they all have common footing on testing hypothesis 
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related to the underlying construct. Common study designs for construct validity are presented 
below. A unified view of validity considers all forms of validity as being subsumed under construct 
validity based on the argument that construct interpretation undergirds all score based inferences, 
thus the various forms validity are indeed only supporting that the construct is valid (Messick 
1988)
 Known groups validity involves testing hypothesis relating to group differences in scores 
of patient, anticipated to differ. Such groups are usually based on some important clinical 
variable for instance level of disease severity or the localisation of the sweating, in the case 
of hyperhidrosis.
 Convergence and divergent validity is based on expected relationships between a scale 
and other measures assessing a similar construct. A scale is expected to show high 
correlation (convergence) with other scales assessing similar constructs and; conversely a 
low correlation (divergence) would be expected with other measures (scales) assessing 
unrelated constructs (Streiner and Norman 2008). 
Criterion validity assesses the extent to which a measure agrees with an external gold-standard 
measure, how well the new measure is consistent with and captures the essence of the gold-
standard (Frost et al. 2007b). This includes situations where the gold-standard is measured at the 
same time as the new measure, reflecting concurrent criterion validity; as well as where the gold 
standard is only observed at a later date, predictive criterion validity. Nonetheless, criterion validity 
may not be applicable in the context of QoL measurement due to lack of measures of proven 
validity suitable to be gold-standards (Salek and Luscombe 1992). Otherwise, existence of such 
gold-standards would obviate any needs to develop a new measure.
Reliability
Reliability refers to the degree to which scores of an instrument reflect the true score  (representing 
the underlying condition): the proportion of total variance in measurement accounted for by true 
score (underlying latent variable) after measurement error is accounted for  (Streiner and Norman 
2008). This is also viewed as the signal-to-noise ratio associated with measurement (Guyatt et al. 
1993). Reliability relates to both the consistency and reproducibility of scores from an instrument, 
as seen in the different forms of reliability. This suggest that reliability has an impact on other
psychometric attributes such as construct validity and responsiveness
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Internal consistency looks at ‘homogeneity’ among items belonging to a single scale or domain, 
whether the items are tapping into the underlying construct equally strongly (Fayers and Machin 
2007). The assumption made here is that as items in a single scale are meant to be assessing 
different aspects of the same underlying construct, the items are inter-related through their 
relationship with this construct. Internal consistency, therefore, captures the proportion of scale 
score total variance attributable to a common source among the items (DeVellis 2011).
Split-half reliability looks at a scale’s consistency by evaluating the inter-correlation between two 
halves of a scale (Streiner and Norman 2008). The many possibilities for creating the two halves 
can be challenging, the following common approaches are used: first half-second half split; odd-
even items; balanced based on external criteria to divide the scale in different ways may create 
challenge. Correlating one half of the scale to the other implies that the correlation represents 
reliability of a single half of the scale, to obtain the reliability of the entire scale the Spearman’s -
Brown formula has to be applied (DeVellis 2011). 
Inter-rater reliability assesses the level of agreement in ratings on subjects made by different 
judges, following two alternative approaches: ‘consistency’ or ‘absolute agreement’. Inter-rater 
consistency relates to the amount of proportion that deviates from means as different experts rate 
an item while absolute agreement constitutes the exact agreement in the ratings made by different 
judges (Wynd et al. 2003). This form of reliability is of particular importance in observer- or 
interviewer-administered instruments (Salek 1998).
Temporal stability (test-retest reliability) assesses the reproducibility of scores. It is expected 
that if the instrument is used in patients whose condition has not changed, the scores obtained on 
the two assessments should be similar. As the underlying construct will not have changed, the 
correlation of the two assessments gives the degree to which the measured concept actually 
determines the observed scores (DeVellis 2011, p.51).
Interpretation of results needs to be qualified by the factors that influence reliability. As total 
variance is the denominator in the reliability equation, assuming measurement error is held 
constant, it is possible to increase reliability of a measure simply by increasing total variability. 
This may be a consequence of increasing the number of items, sample heterogeneity and the 
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number of response options as suggested by the Spearman-Brown’s prophecy (Nunnally and 
Bernstein 1994). 
Responsiveness To Change
An important attribute in evaluative instruments, is the capability to capture important changes in 
the construct (patient’s condition) where such changes have taken place (Epstein 2000). As the 
purpose of such longitudinal use of an instrument is in identifying true change over and above 
inter-temporal variability in the scores, reliability becomes a prerequisite to responsiveness 
(Streiner and Norman 2008). Establishing responsiveness requires assessing an instrument in study 
following a longitudinal design. Testing for responsiveness then involves testing hypothesis 
relating to amount of change relative to the classification based on the anchor variable. On this 
basis, two major schools of thought have emerged: the first treats responsiveness as a separate 
attribute unique from validity or reliability (Guyatt et al. 1987), the other views responsiveness as 
part and parcel of an instrument’s validity (Hays and Hadorn 1992; Liang 2000). This demarcation 
seems to be of little practical importance.
Interpretability
Availability of data supporting the decoding of qualitative meaning from QoL scores is 
quintessential to the feasibility and usefulness of instruments evaluating HRQoL, thus from that 
standpoint it is one of the key attributes of such measures. Observing an effect beyond what chance 
can explain (i.e. statistical significance) alone is not informative as to what a given magnitude of 
effect means in practical terms, this in turn requires the definition/identification of cut-off scores 
for clinical significance, the amount of change in the score that is large enough to require a change 
in treatment (Wyrwich et al. 2005). Banding systems, normative-values, or minimal clinically 
important difference (MCID), utility conversion algorithm have been utilised to support 
interpretability. This reflects two major approaches to interpretability. The first, based on 
distribution of sample scores and the second, based on scores of an anchor. The latter uses an 
external variable to define amount of change taking place in the patient’s QoL, with the change 
score in the smallest change patient group giving MCID (Wyrwich et al. 2005).In the distribution-
based method, MICD is given as half-standard deviation of the scores or standard error of 
measurement (Norman et al. 2003) (Revicki et al. 2008).
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PRACTICAL ISSUES
Response Scaling
The scaling employed for capturing item responses plays a key role in how well the concept being 
addressed by an instrument’s item are assessed. The appropriateness of the choice of scale (e.g. 
visual analogue scales (VAS), rating scales, Likert, adjectival scale) may depend on the study 
aims, the nature of the disease condition and its treatment, the concept being measured, the mode 
of administration and target population (Patrick et al. 2011b). VAS and rating scales offer a 
continuous continuum hence may be more suitable for symptoms such as pain. On the other hand, 
adjectival and Likert scales are ordinal and might be more appropriate for assessing variables like 
frequency or intensity daily life impacts. While VAS seems more sensitive, the available finesse 
offered by the continuous nature of the scale is beyond the human capability to detect or distinguish 
small changes, such that this may introduce noise in the process (Streiner and Norman 2008). 
For Likert and adjectival scales the number of response categories and the adjectives used as labels 
influence their meaning and usage (Streiner and Norman 2008, p.45) nonetheless these seem to 
easier to complete and have less administrative burden. Offering less categories than people can 
discriminate unnecessarily leads to loss of information and on the other hand offering many 
categories beyond the recommended five (+/-2) also leads to unnecessary cognitive burden and 
more noise in the measurement (Streiner and Norman 2008, p.49). The choice of response may be 
influenced by the scaling used. Among fully labelled scales, polar-point labelled scales and number 
based ranking, labelled scales had the highest number of extreme positives (Dillman 2006, p.462).
Frame of reference
A frame of reference needs to be specified for an instrument reflecting the period of time 
respondents are to consider in providing their responses. As longer periods, for instance exceeding 
one month, are associated with greater recall bias (Frost et al. 2007b) the shortest recall period 
feasible is always preferred. (Norquist et al. 2011) propose criteria for judging the appropriateness 
of a recall period, where the construct being measured, its time course; the purpose for 
measurement, for instance assessing treatment benefit in clinical trials; and the target patient 
population, and burden on respondents. For example acute symptoms that show rapid fluctuation 
such as pain may best be assessed with a shorter time frame, such as ‘at present’ while concepts 
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related to psychosocial functioning or activities of daily living may not show much fluctuation on 
day to day basis, thus may optimally be assessed with a weekly to monthly recall period (Frost et 
al. 2007b). Choice of recall, therefore, needs to appropriate for the condition and the timing of 
assessment, while imposing minimal burden on the patient (Kerr et al. 2010). 
Mode of administration
The decisions related to the means to use for collecting the data and how the instrument is 
employed in data collection not only affects the psychometric attributes of the instrument but the 
final data collected to the extent that validity needs to be uniquely demonstrated for each data 
collection mode (Dalal et al. 2011). Because of this, pooling together QoL data collected using 
different modes is not recommended during clinical trials, as the observed effect size may be 
attenuated, unless equivalence of the modes is demonstrated (Coons et al. 2009). The 
appropriateness of a mode depends on purpose of HRQoL assessment, target population, their 
reading and writing abilities, the aims of the study, the characteristics of the disease condition and 
its treatment, the particular construct being assessed and the recall period (Patrick et al. 2011b). 
Observation is perhaps one of the most common means used to collect QoL information. Although 
the doctor’s conclusions regarding the patients quality of life may not always be accurate (Basra
and Shahrukh 2009), this constitutes an important aspect of the patient-doctor interaction during 
consultations. This approach may also see further use in clinical trials involving populations not 
capable of judging their own quality of life, for instance young children (Salek 1998), the elderly 
and the terminally ill.
Alternatively, QoL data can be collected through interviews, where an interviewer reads out the 
items of an instrument to a study participant and subsequently notes down the provided responses. 
The interaction between respondents and the interview offers an opportunity to verify who is 
actually responding to the instrument while simultaneously giving the respondents an opportunity 
to ask questions where  they do not understand, resulting in better compliance (Salek and 
Luscombe 1992).  This method can be resource intensive in terms of both finances and time and 
tends to be more prone to biases related to social desirability or faking good, as people intentionally 
or un-intentionally provide more desirable expected responses to the interviewer (Streiner and 
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Norman 2008). Moreover, the interviewer-respondent interaction is prone to influences of the 
interviewer on the process and the information provided.
An alternative approach to collecting data is to present an instrument to patients for self-
completion. This approach is attractive for its practicality, as it imposes the least administrative 
burden relative to other approaches. Moreover, there are several ways for implementing this 
approach: interview-delivered, mail-delivered or web-delivered. On the other hand, the instrument 
can use paper-and-pencil or electronic device as a medium depending on the method of delivery.
 Interview-delivery involves an interviewer being present during the completion process 
to provide instructions and respond to any questions that may come up (Salek and 
Luscombe 1992). This approach is practical for collecting QoL information in both routine 
clinical practice and research situations. For instance patients can complete the instrument 
in the waiting room prior to consultation, with a nurse being available to provide 
instructions and to respond to any questions and issues that may arise during the process. 
This approach requires that the instrument is of the reading level of the respondents, and 
that they are able to write, making it challenge in groups with reading and writing problems. 
 QoL information can also be collected through mail-delivery. The questionnaire is mailed 
to the respondents; with a stamped return envelope for the completed questionnaire. This 
approach is favoured for its relative low cost in comparison to the other approaches in 
addition to the minimal human resource investment needed for collecting the data (Bowling 
2009). Moreover, the respondents complete the instrument in their own environment, 
which might further enhance quality of data. This, on the other hand, entails that it may not 
possible to verify who is actually completing the questionnaire. A number of measures 
contained in total design method have been proposed to resolve low response rates 
associated with this approach  (Dillman 2006).
 The internet is increasingly being utilised to deliver HRQoL instruments. The phenomenal 
growth in internet usage means that the relevance of the approach will continue to grow 
and making the issue of representativeness obsolete. Data collection is not restricted by 
geography on the other hand web-administration facilitates data collection from hard to 
reach populations(Tweet et al. 2011). Furthermore, respondents may feel anonymous and 
more comfortable to disclose sensitive information due to the perceived impersonal nature 
of the computer, leading to minimal influences of biases such as social desirability, faking 
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good, in the responses. Nevertheless, in spite of the minimal variable costs of adding one 
additional questionnaire, the initial costs of setting up a web-system might be substantial 
(Dalal et al. 2011). Furthermore, the required computer literacy and internet connectivity 
may limit the use of this method in certain populations.
Electronic data collection
Electronic devices, including tablet computer, personal digital assistants and smart phones, are 
increasingly replacing paper-and-pencil questionnaires in interview delivered self-completion 
questionnaires. Also, interview-administration has also seen the encroachment of electronic 
devices leading to computer assisted interviewing, for instance in the sequencing of the questions 
and recording of the responses by interviewees (Streiner and Norman 2008). In self-completed 
delivery, reduced error rates and respondent burden have been reported, reflecting previously 
observed preference of patients for electronic devices (Dillman 2006).  Complex item skip patterns 
and additional information aiding the data completion process are easily implementable (Dillman 
2006). Administrative burden is reduced as some secondary data processing and management tasks 
can be automated which also helps to mitigate some data entry errors.
STUDY POPULATION
The rise in social media has provided a new platform and channel through which patient interact 
with other patients with their condition, sharing information, finding support and advocating for 
greater public awareness of their condition. Moreover, online data collection may have a number 
of advantages such as overcoming geographical limitations and providing a degree of anonymity 
to study subjects (Idriss, 2009). This suggests that social media could be an important source of 
subjects in outcomes research in hyperhidrosis. Participants in all stages of this study will be 
recruited from online social networking communities on hyperhidrosis including the International 
Hyperhidrosis Society, and the UK hyperhidrosis society, Very Sweaty Betty Forum
In the qualitative stage, two Facebook pages will be created for the study. Facebook advertising 
campaigns, targeting users aged 16 and above, resident in Germany or the UK will be carried out. 
Searches of existing patient groups dealing with hyperhidrosis on Facebook will be carried out. 
Identified pages will be reviewed for their focus and relevance to the study, based on wall postings, 
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introductory information provided about the group. Depending on the nature of the identified 
relevant groups (whether open or closed) a posting about the study will be made on the page or 
alternatively a request to post study related information on such pages will be sent to the 
administrators of such groups. 
To reach patients on other social networking sites platforms outside Facebook a search for 
discussion forums and patient groups will be carried out on Google, using the search terms 
[‘hyperhidrosis’, ‘excessive sweating’, ‘sweating’] AND [‘forum’, ‘support’]. Similarly, identified 
groups will be contacted and provided with information about the study for their membership.
In the quantitative phases of the study patients will be recruited through the two largest patient 
support groups, the International Hyperhidrosis Society (IHHS) and the UK Hyperhidrosis support 
group. Both groups maintain a website, a Facebook page and circulate a periodic email-based 
newsletter among their members. In December of 2012, their Facebook accounts had at least 800 
and 200 followers (‘fans’), respectively. Their newsletters have a circulation of 50,000 and 2000 
subscribers, respectively. The normal sharing of information among friends and group-members 
and the typical cross-group membership (Abram 2012), suggests that the number of persons 
receiving an original posting of information is exponential as it includes second and third parties
and more.
Selection of participants
The generalizability of results of a study critically depends on how participants are sampled, 
particularly whether such process is independent of characteristics of patients and whether each 
member of the target population has an equal probability of being selected into the sample (Bland 
1995). This implies random sampling. However, given the potential costs involved in 
implementing this, the exploratory nature of the current study and the interest in patients with 
specific characteristics, purposive sampling was employed. In addition, the target study population 
(online patient social networking communities) entails snowballing sampling. This sampling
approach involves a researcher asking an initial group of study participants to recruit other 
potential study participants they may know (Bowling 2009). Thus, patients recruited will be asked 
to invite other patients to participate in the study through their connections in the online social 
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communities. This is consistent with normal activities within an online patient social networking 
community, where members interact and share information, most especially studies going on. 
Data Collection
A new website will be created for the web-version of the new instrument. The landing page will 
contain background information to the study, with additional patient related information (e.g. 
downloadable full patient information sheet) placed in another location of the website. Access to 
the questionnaire-area will require a valid email address and a password. Apart from being a 
security/validity measure, the latter will facilitate completion of the questionnaire on multiple 
occasions. Before accessing the study instrument patients will be asked for their informed consent, 
which will be collected electronically by entering their name and email address. The completion 
of the study instruments was logically established to allow a logical flow will lead patients 
logically through the process from the landing page through the security check, receiving the 
patient information sheet and giving informed consent, to the screening process, and then 
completing the questionnaire.
PART II: METHODOLOGICAL FRAMEWORK
The new instrument will be developed with the following objectives in mind: i) to realise a tool 
that is practical and feasible in clinical practice as well as research setting; ii) with content and 
emphasis that is appropriate for all forms of hyperhidrosis, all level of disease severity, and relevant 
in evaluating the benefit from all forms of treatments, iii) to have robust scaling properties 
supported by both classical and modern test theories, iv) to have optimal reliability, validity and 
responsiveness, sufficient for evaluative use in individual patients.
The development of new instrument will involve the following steps (Figure 2.1):
Step 1: a review of the literature and existing hyperhidrosis-QoL instruments. 
Step 2: investigation of the QoL issues relevant to hyperhidrosis patients using qualitative research 
methods
Step 3: development of a conceptual framework and drafting of new instrument based on results 
from the previous phases 
Step 4: content validation by expert panel 
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Step 5: the new measure would be assessed for practicality and acceptability in target population.
Step 6: Initial construct validation and item reduction.
Step 7: Validation of the final version of the new instrument.
Step 1: Review Of Literature And HRQoL Instruments
The development of a new QoL instrument requires a clear rationale which contributes to the 
definition and measurement of the construct under assessment. Moreover, a strong theoretical basis 
for an instrument is essential to construct validity (Bond 2004). This involves a comprehensive 
review of the literature of the disease condition, its impacts and existing HRQoL measures. Such 
work has already been carried out for the current research and the results are reported in the first 
chapter. This established the need for a new QoL measure in hyperhidrosis overcoming the 
inadequacies of the existing measures. 
Step 2: Qualitative Study Of HRQoL Issues In Hyperhidrosis
The content of a patient reported outcomes instrument has to be relevant to the target population 
to ensure content validity (Lasch et al. 2010). The items should reflect the way in which the patients 
view and describe their experiences with the disease (Patrick et al. 2011a). This entails patient 
involvement in the instrument development process. Qualitative research, useful for gaining 
insights into beliefs, views, and conceptual understanding held by subjects on an issue (Pope and 
Mays 2008) might provide a means for doing this. Therefore, a qualitative study will be carried 
out in patients with hyperhidrosis with the aim of understanding the various impacts experienced 
by patients. Semi structured interviews, focus group discussions and a survey containing open 
questions will be used for data collection. A topic guide will be developed for interviews and focus 
group discussion. Its use will be limited to probing on issues omitted by the patient which are
known to be important in hyperhidrosis based on previous studies. Patients will be encouraged to 
elaborate more on their answers by probing them for reasons why or asking them for specific 
examples in their narratives. Subsequently the questions in the open survey will be generated based 
on the results from the focus groups and interviews. Combining multiple qualitative methods, for 
instance focus groups and interview is important in ensuring the validity of findings in qualitative 
research (Whittemore et al. 2001). In this way the data collected is enriched by the strengths of 
each method: interviews enable in-depth insights, focus groups offer unique data through the 
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interaction among subjects (Brod et al. 2009), survey is capable of reaching a wider larger of 
participants at a relatively lower cost.
During the qualitative phase of the study, a stand-alone PhP-based online discussion board will be 
developed. Discussion boards are typically used as platforms for internet forums, allowing text-
based discussions among any number of members and guests, and are managed by an 
administrator. In order to include only patients recruited to the study in discussions, participants 
will be given a username and password, for accessing the discussion board. Data will also be
collected using instant messaging platforms (e.g. Skype and Windows Live Messenger). Data 
collected from the interviews and focus groups will be tape recorded and transcribed verbatim. 
Thematic analysis, an atheoretical approach, will be used for data analysis. This means analysis 
will commence without a preconceived theory, rather a framework will be developed from the data 
as analysis proceeds, driving further data analysis and data collection (Braun and Clarke 2006). 
Issues emerging from the qualitative study analysis of the data transcripts will be organised as 
themes and common themes will form domains.
Step 3: Development Of The Conceptual Framework And The New Questionnaire
An instrument’s conceptual framework depicts the relationship among the observable items, their 
domains and the underlying latent variable (Rothman et al. 2007) reflecting how a particular 
construct is understood. It is critical that the development of the conceptual framework precedes 
the actual drafting and development of the instrument because of its influence on later phases of 
instrument development and validation.  Therefore before the drafting of the new instrument its 
conceptual framework will be developed first, based on results of prior steps (the literature review 
and the qualitative study). The new instrument will be drafted based on the conceptual framework 
and the qualitative issues collected from patients. Ensuring a structured process at this stage is an 
important aspect of ensuring content validity (Lynn, 1986). A team comprised of experts in clinical 
research and patient outcomes measurement will be created to undertake the drafting of the new 
questionnaire. Criteria relating to the inclusion of content, wording of the actual questions, and 
other elements of the questionnaire (layout, formatting, response options, instructions), will be set 
beforehand to guide the process. A transparent decision making process will be followed by the 
team.
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Step 4: Expert Panel for Content Validation
As critical proof of the link between the content of an instrument and the underlying concepts,
content validation of the new instrument will be carried out by asking therapeutic experts to make 
judgements on the appropriateness of the content for the intended concepts i.e. whether the items 
included are relevant, whether all important issues are included, whether language is clear enough 
for someone with a reading ability of a 12 year old to understand; whether the response 
categorisation is appropriate for each item. In order to provide adequate guidance to the experts, 
as well as to enhance the credibility of the process a validation questionnaire will be used for this 
purpose. Inter-rater agreement will be used in assessing the reliability of the ratings and the content 
validity index will be used for summarising ratings.
Step 5: Acceptability And Practicality Of The New Questionnaire
The usefulness of an instrument depends on whether it addresses issues relevant to patients, it is 
simple, easy to complete and does not required long time to do so (Thornicroft and Slade 2000). 
On the other hand, a measure should not impose undue burden on those administering in terms of 
data collection or analysis. The latter is of particular importance in routine clinical practice, where 
there might be particular constraints on time and monetary resources (Higginson and Carr 2001).
A pilot study will be carried out following a cross-section design. Study participants will complete 
the new instrument and a supplementary questionnaire collecting information on: relevance of the 
items, ease of completion, time to completion for the new instrument. Suggestions on possible
issues to be added will also be sought. Furthermore, problems encountered in completing the new 
instrument reflected in missing item responses or errors in completion will be noted. Items
highlighted as unclear or causing any difficulties will be reviewed.
Step 6: Item Reduction and Construct Validation of the new instrument
The summation of item scores at the scale level is underpinned by strong assumptions relating to 
the nature of the underlying construct i.e. that there is a single latent variable (Fayers and Machin 
2007). Such assumptions have implications on any inferential use of the instrument, as they touch 
upon the definition of the underlying construct. Therefore, to assess the latent structure of the new 
instrument a prospective cross-sectional study will be undertaken. Patients will complete the new 
instrument on a single assessment occasion. Exploratory factor analysis (EFA) will be carried out 
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to explore the most optimal dimensional structure for the new instrument. This will subsequently
be tested in confirmatory factor analyses. 
As the development of a new instrument tends to start with a large number of items undertaking 
item reduction is useful step in the development process (Terwee et al. 2007). Considering that the 
initial item development of the new instrument will aim to be inclusive, item reduction will be 
necessary subsequently. Classical test theory’s correlation analysis and exploratory factor analysis 
and modern test theory’s Rasch model will be used to carry this out. Nonetheless, apart from results
from statistical models, qualitative considerations will also be made (e.g. importance of issues to 
patients and overlap with existing items) (Guyatt et al. 1993). The intention is to realise a set of
items contributing to the measurement of the latent variable. On the other hand, this step will 
elucidate on the internal structure of the new instrument.
Step 7: Validation of the final version of the new instrument
Validity
As there is no single ‘ultimate test’ for construct validity (Streiner and Norman 2008), its 
assessment involves testing for various hypotheses relating to the relationship between the 
underlying variable and the items of the instrument in different situations. Therefore, assessing the 
validity of the final version of the instrument will involve testing a number of hypotheses.
Known-groups validity: Patients with more severe hyperhidrosis will be expected to show greater 
quality of life impairment. Patients where hyperhidrosis affects multiple areas (for instance, axilla, 
feet, and palms) are expected to experience greater quality of life impairment than those with a 
single area, controlling for everything else.
Convergence validity: It was hypothesised that patients’ hyperhidrosis-specific QoL has a 
positive relationship with their skin-specific QoL and their generic QoL. Therefore, a prospective 
cross sectional study of patients with hyperhidrosis will be carried out. Participants will complete 
the final version of the new questionnaire and additional questionnaires assessing dermatology-
QoL (the DLQI and the Skindex-17) and generic HRQoL (EQ-5D). Using both the DLQI and the 
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Skindex would allow the new instrument to be compared against the two key instruments for 
evaluating dermatology-QoL. 
Reliability
The degree of measurement error in an instrument has practical implications on the practical use 
of an instrument (Streiner and Norman 2008). For example, in clinical trials a less reliable measure 
may require a larger sample to show a particular effect size relative to a more reliable measure. 
Thus, internal consistency and test-retest reliability of the score for the new instrument will be 
tested. 
A study following a cross-sectional design will be carried out to assess internal consistency. 
Participants will complete the new questionnaire on a single assessment. Inter-item correlations,
item-partial total correlations and Cronbach’s alpha coefficient will be estimated based on the item 
scores.
A longitudinal study, where participants complete the new instrument on two assessment 
occasions, 7 days apart, will be carried out to assess the test-retest reliability. A period of 7 days 
has been recommended in test-retest assessment studies, to prevent practice effect, yet on the other 
hand, the condition should have remained stable (Salek and Luscombe 1992). The latter was 
ensured by collecting data on an additional variable for instance self-rated disease severity (using 
HDSS). Test – retest reliability will be assessed by measuring the level of agreement in the baseline 
and follow-up scores, assuming the patient’s condition should have remained the same.
Responsiveness 
Establishing responsiveness of an instrument requires not only showing that an instrument can 
capture statistically significant changes (changes beyond chance), but more importantly that it can 
capture minimal changes considered important by the patient (Revicki et al. 2008). A longitudinal 
study with three assessments (at baseline, on 8th day and on 21st day) will be carried out to establish 
this attribute. During each assessment patients will complete the new instrument and an additional 
questionnaires for determining magnitude of the experienced by the patients and its importance to 
them.
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In particular, the following hypotheses will be tested: 
 the new instrument can capture changes in the group of patients experiencing minimal but 
important changes in their condition,
 the magnitude of change in patients with minimal improvement in their condition was 
greater than those with no change in their condition. 
 change would be greater over a longer period (between baseline and 21st day in comparison 
to baseline and day 8) in those patients receiving active treatment.
Interpretability
The qualitative meaning of scores from HRQoL scales is not intuitively apparent (De Vet et al. 
2006) despite the importance this has on the credibility and usefulness of HRQoL information 
especially in clinical practice (Higginson and Carr 2001; Grob 2007). Thus, to facilitate 
interpretability of scores of the new instrument a banding system and MCID estimates will be 
established. A banding system establishes the score ranges of measure reflecting qualitative 
categorisations corresponding to a mild, moderate or severe level of impact of a condition (Prinsen 
et al. 2010). For the new instrument, this will be established based on data collected from the cross-
sectional validation study, on the new instrument and an anchor variable. The MCID, on the other 
hand, reflects the smallest change considered important to patients (Revicki et al. 2008). This will 
be estimated based on data collected for the cross-sectional validation study and the data from the 
longitudinal responsiveness assessment study. As a triangulating of multiple anchors is 
recommended in establishing MCID (Guyatt et al. 2002), two instruments, the HDSS and the PGA 
will be used as anchors for assessing change in the patient’s condition. The standard deviation and 
standard error of measurement from validation study will provide the distribution based estimates
of the MCID.
Sample size
Sample size considerations differ between qualitative and quantitative research. In the former, it is 
not possible to determine the needed sample size prior to data collection; rather sample adequacy 
is determined in the course of data collection. Data collection continues until ‘saturation’ has been 
reached, which reflects a situation where further data collection (e.g. interviews) is not yielding 
new data (Kerr et al. 2010). On the other hand in quantitative research sample size is dependent 
on the particular statistical analysis performed. Required sample size will reflect the intended 
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power of analysis, the magnitude of effect size to be observed and chosen level of significance and 
reliability of measurement (Lipsey 1990). Exploratory studies, where magnitude of effect size and 
reliability are unknown apriori may present some challenges in this regard. A useful 
recommendation is to use a sample matrix based on key disease or treatment characteristics for a 
particular disease, where each sub-category (each cell) should have at least 15 subjects (Johnson 
et al. 2011). For initial estimates of reliability and validity at least 200 subjects are recommended 
(Frost et al. 2007a). If a test-retest correlation of 0.85 is observed with a sample size of 100, the 
95% confidence interval is 0.78 – 0.90, while a sample size of 150 would narrow this to 0.8 – 0.89 
(Johnson et al. 2011). 
Rules of thumb on sample size requirements for correlation analysis and factor analysis vary in 
their guidance, ranging from 5 to 20 observations per variable with more suggestion above and 
below this ratio (Costello and Osborne 2005). However, the minimum sample size required for 
accurate recovery of population factor pattern matrix is influenced by many factors including the 
distribution and reliability of the variables, and degree of association among variables, 
communalities, degree to which factors are over identified (Reise et al. 2000; Schmitt 2011). Thus 
power and precision ought to be core consideration in parametric estimation based factor methods 
(Schmitt 2011), while in non-parametric approaches when communalities are high, sample size of 
100 may be adequate (Reise et al. 2000). 
Assessment of adequacy of sample size for given statistical test should be made along with other 
key considerations relating to the sample for instance ensuring that the target population is 
adequately represented along with all important disease characteristics. Otherwise, appropriate 
tools will be applied to indicate uncertainty surrounding estimates e.g. using confidence intervals
in presenting results. 
Data Collection Instruments
Apart from the new hyperhidrosis-HRQoL measure, other instruments/questions will be used in 
collecting data from patients regarding their HRQoL, level of disease severity, overall impact of 
disease and change in their condition over time. Disease severity was assessed using the 
Hyperhidrosis Disease Severity Index (HDSS) (Figure 2.1). The HDSS is a validated single item 
scale which measures the severity of hyperhidrosis and the related daily life interference on a four 
point scale (Kowalski et al. 2004). A 1 point decline represents up 50% reduction in sweating; 
while a 2-points reduction reflects a decrease of 80% (Solish et al. 2007). Data on generic HRQoL 
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Figure 2.1: The Hyperhidrosis disease severity scale
How would you rate the severity of your hyperhidrosis?
☐1. My sweating is never noticeable and never interferes with my daily activities
☐2. My sweating is tolerable but sometimes interferes with my daily activities
☐3. My sweating is barely tolerable and frequently interferes with my daily 
activities
☐4. My sweating is intolerable and always interferes with my daily activities
was collected using the EQ-5D, an instrument designed for use in both clinical and economic 
evaluation research and intended to be highly practical and useful in international-studies (The-
EuroQoL-Group 1990; Brooks 1996). The EQ-5D consists of a descriptive part, containing 5 items 
reflecting unique domains, with each rated on 3 levels; and a VAS scale assessing health. 
Responses to the descriptive component can be combined into a 5 digit number, which can in turn 
be used to identify a patient’s health status. A utility value, for calculating QALY’s can be read off 
from country-specific reference preference values generated from the general public. A 
modification of the instrument offering 5 levels for each domain/item and minor revisions to the 
item-descriptors, EQ-5D-5L, has been developed and has shown content validity (Herdman et al. 
2011). Although studies to generate reference values are currently underway algorithms for 
mapping the value sets for the original 3 level EQ-5D into the EQ-5D-5L have been published 
(Rabin et al. 2011).
Dermatology-specific QoL was assessed using the DLQI and the Skindex-17. The DLQI was 
developed as a practical measure of the impairment in patients QoL resulting from skin disease 
(Finlay and Khan 1994). The instrument consists of 10 items assessing the intensity with which 
patients experienced various impacts in preceding week. Items are scored from 0, not at all, to 3, 
very much and can be summed up to give an overall scale score (0, minimum impairment; 30, 
maximum impairment).The Skindex is a validated instrument developed as a measure of effects 
of skin disease on patients HRQoL (Chren et al., 1996). Its 30 items assess frequency with which 
patients experience various effects using a 4 weeks recall period. A brief version of the measure 
with 17-item, the Skindex-17, has been developed based on the Rasch model scaling (Nijsten et 
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al. 2006b). This has demonstrated strong correlation to the original measure as well as optimal 
psychometric properties consistent with modern test theory (Sampogna et al., 2013). A full review 
of these measures is available in chapter 1.
In addition, two general questions were administered, an overall-impact global question (Figure 
2.2) and a global assessment of change by the patient (Figure 2.3).  This is the first time that these 
questions are administered in hyperhidrosis, although a similar questions have been applied in 
dermatology to establish the scale banding for the DLQI (Hongbo et al. 2005) and in renal 
replacement therapy to establish the scale banding for the Renal Quality of Life Profile (Aawar 
2011). 
DATA PROCESSING AND ANALYSIS
The analysis of data will be carried out using STATA 11, SPSS and more specialised software 
including M-PLUS for CFA, and RUMM 2030 for Rasch analysis. This study will collect a variety 
of variables of different types including continuous, discrete, ordinal, categorical and binary scale: 
item scores from the QoL questionnaires; patient characteristics e.g. age and gender; disease 
characteristics and treatment such as location of hyperhidrosis and duration of disease; resource 
utilisation including time in minutes and amount of money in currency
Figure 2.2: Global question on overall impact of hyperhidrosis
Over the last seven days including today, how much has your sweating 
condition  affected your life?
Extremely large effect ☐
Large effect ☐
Moderate effect ☐
A small effect ☐
No effect at all ☐
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Figure 2.3: Question on Patients global assessment of change
How would you describe your condition today, in comparison to your last 
assessment?
Better ☐
Slightly better ☐
No change ☐
Slightly worse ☐
Worse ☐
The data will initially be explored through descriptive analysis of each variable, calculating 
measures of central tendency (mean, median), variability (SD), and interquartile range for 
continuous variable; Frequency counts for ordinal and categorical variables. Further analyses will 
involve making inferences based on various hypotheses tests. In order to reject a null hypothesis 
observed probability of a false positive, type I error, as reflected in P-value needs to be less than, 
level of significance (α) (Altman et al. 2000). This study will use a level of significance (α) of 5% 
. Where several hypotheses will be simultaneously tested Bonferroni adjustment will be applied to 
the level of significance, as (α / k), where K is the number of tests (Fayers and Machin 2007).
 Testing for differences between two means will use independent or paired t-test, depending 
on whether the two means are mutually exclusive or are related. The Mann-Whitney and 
Wilcoxons tests are the non-parametric alternatives, respectively, for situations where 
assumptions of the t-tests are not met. 
 Hypothesis tests involving differences among more than two groups will be carried out
using ANOVA test. Where the core assumptions of this test are not met, particularly, the 
assumption of homogenous variances across group, the Kruskall-Wallis test will be used 
alternatively. 
 Testing of hypothesis relating to associations between means of variables will be carried 
out based on Pearson’s correlations. Where the data is not continuous Spearman’s rank 
correlation will be used. 
 Polychorric correlations will be estimated in order to assess multicollinearity among the 
items. This type of correlation produces consistent and robust results in ordinal data. They 
are based on the assumption that the variable is linear and continuous but divided up in a 
series of categories (Holgado–Tello et al. 2010). Multicollinearity is identified when 
correlations coefficient is 0.8 or greater.
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Possible influences on the magnitude of observed inter item correlations including range 
of score values, homogeneity of items, distribution of the data (particularly departures from 
normality) and existence of outliers in the data (Fayers and Machin 2007, p.33) will be 
explored. Normality assumption implies skewness not exceeding |3|, while Kurtosis must 
not be greater than |7| (Ozer et al. 2009; Byrne 2011). While the former impacts on means, 
covariance tends to be vulnerable to kurtosis values (Byrne 2011).
Further statistical analyses carried out during construct validation will use various forms of 
regression methods, modelling latent variable including exploratory factor analysis, confirmatory 
factor analysis and the Rasch model:
Exploratory factor analysis 
Exploratory factor analysis provides a way for explaining variability in a large set of indicators 
using a few latent variables (Kline 1994) which is quite handy for investigating the latent structure 
of new instruments. The aim is to identify the smallest number of interpretable factors explaining 
the covariation among items (Muthén and Muthén 1998 - 2010). This involves first generating the 
variance-covariance matrix, followed by the estimation of the factors which entails putting 
together those items sharing the highest co-variation. Considering that a factor solution is not 
unique the initial estimated solution needs to be rotated in order to achieve a simple structure that 
is more interpretable (DeVellis 2011). 
To perform an EFA on the instrument, first a polychorric correlation matrix will be generated. 
These more appropriately take into account the ordinality of the data and remain robust when data 
are skewed, in comparison to the conventional Pearson’s correlation coefficients (Byrne 2011). 
The initial factor estimation will be carried out using robust diagonally least squares  estimator 
(WLSMV) which yields robust test statistics, parameter estimates and standard errors when 
indicator variables are categorical and where normality assumptions are violated (Byrne 2011, 
p.132). Rotation will be performed using the Geomin routine available in M-PLUS software, 
which allows correlation among factors. This rotation is particularly suitable for psychosocial 
domains known to be highly related (Lackey et al. 2003). Where the factors are not related, Geomin 
still performs well yielding results comparable to orthogonal rotation routines. Choice of 
appropriate number of factors to be extracted will be based on the parallel analysis and will be 
confirmed by statistical goodness of fit measures (Schmitt 2011). Kaiser’s rule, based on size of 
eigenvalues; scree-plot, which is a graph of number of factors against eigenvalues and parallel 
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analysis, comparing actual against ones randomly generated, will also be reported. The following 
criteria will be applied:
 Kaiser’s rule: factors with eigenvalues greater than are included (Kaiser (1960) in DeVellis 
2011, p.148). 
 Scree-plot: all factors to the left of the ‘ankle’ are extracted, where there is a change in the 
slope. 
 Parallel analysis: the last factor to be retained must have an eigenvalue greater than the one 
that would be produced randomly (Williams et al. 2010). 
Goodness of fit indices go alongside factor estimation based on Likelihood methods, in assessing 
how well the hypothesised model fits the data. These can be classified into three groups: i) chi-
square based indices, based on the null hypothesis that compared with a single factor model the 
chosen number of factors (k) are adequate; ii) practical fit indices, evaluate proportionate 
improvement in model by comparing a hypothesized model against a less restricted baseline model 
(Byrne 2011, p.70); and ii) absolute fit indices, which are based on analysis of residuals after fitting 
the model to the data (Brown 2006). The following indices will be used for the study:
 The ‘chi-goodness of fit test’: a non-significant chi-statistic represents good fit (Lackey et 
al. 2003, p.121).  
 Practical fit indices. Comparative Fit Index and Tucker-Lewis Index, where values of 
below 0.9 and 0.95 have been suggested for acceptable and adequate fit , respectively 
(Schmitt 2011). 
 Absolute fit indices. Root Mean Square Error of Approximation (RMSEA), where value 
below .05 show good fit, .08 to .1 mediocre fit  and; above 0.1  poor fit (Browne and 
Cudeck 1992; MacCallum et al. 1996); The Standardized Root Mean Square Residual 
(SRMR), is seen as reflecting ‘adequate fit’ when less than .05 and acceptable fit when less 
than 0.8; The Weighted Root Mean Square Residual uses a cut off value of 0.95 for good 
fit (Byrne 2011, p.76, p.140).
Confirmatory factor analysis
The goal in confirmatory factor analysis (CFA) is to evaluate whether a hypothesised factor 
structure fits a given dataset (Brown 2006). Thus unlike exploratory factor analysis CFA is a 
hypothesis testing tool and fits a regression model of the hypothesised latent variables and the 
indicator variables as specified by the researcher. Inferences are based on overall model fit, the 
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significance of the individual item parameters (loadings) and magnitude of the residuals. The 
goodness of fit indices presented above are also applied. Residuals of 0.05 are indicative of good 
fit (Byrne 2011). CFA implemented in this study will test the hypotheses of  a single factor solution 
and; the factor structure obtained from the EFA 
Rasch model analysis
The item response theory, in particular the Rasch model (RM), offers a framework for scaling 
unidimensional instruments. The model expresses the probability of choosing a particular response 
to an item as a function of the relative difference between the severity level assessed by an item 
and that of the respondent, respectively. As both are measured on a common linear scale, this 
represents the distance between the item location and respondents location on the single linear 
scale of the latent variable (Tennant and Conaghan 2007). The relationship between the latent 
variable and the item responses follows a monotonic logistic ogiv function, reflected in the item 
characteristic curve (ICC) (Masters 1982). This is similar to the curve representing a typical binary 
logistic function. The RM is based on core assumptions of unidimensionality and local 
independence, such that once the single latent variable (ϑ) is accounted for no further relationship 
should exist between any two items (Reeve and Mâsse 2004).  This gives rise to a probabilistic 
Guttman pattern whereby for any given item, persons with greater severity (ability) should have a 
higher probability of choosing a higher category on an item in comparison to persons with less 
severity; the opposite also applies that for a given person, the probability of choosing a ‘higher 
category’ should be higher for items at lower severity level than those at a higher severity level for 
any person (Tennant et al. 2004).
Appropriate fit to the RM ensures that an instrument is sufficiently unidimensional and that it 
complies with conjoint measurement principles, a precondition for converting the data from the 
instrument into interval scales (Bond 2004).  The intention of Rasch analysis, therefore, is to 
evaluate whether data have sufficient fit to the model to warrant such claims.  
Assessing conformity to the Rasch model, its assumptions and properties involves the following:
1. Assessing whether response categories are functioning optimally.  Average latent measure
across observations in a response category and category thresholds should monotonically 
increase with the category; each response category should have a distinct peak on the 
category probability curve graph reflecting the space along the latent variable where it is 
most probable (Linacre 1999). Category characteristic curves define the most likely response 
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category for a specific person location value on the latent variable. The category threshold 
indicates a location on the latent variable where probability of selecting adjacent categories 
is equivalent (Linacre 1999).
2. Testing item and person fit to the model. This uses residuals obtained after fitting data to the 
model, calculating a fit residual statistic and the item trait interaction chi-statistic. 
The residual statistic for items is calculated as the squared summation of the standardized 
residuals of the responses of all persons to an item (Andrich et al. 2012b). Fit residuals 
exceeding |± 2.5| indicating poor fit (Andrich et al. 2012b). As the RM does not distinguish 
between items and persons (Bond, 2007), the residual fit statistic for persons is calculated 
and interpreted in a similar way. 
3. The item trait interaction test of fit, assesses the discrepancy between actual and model 
scores of class intervals (which group patients according to ability), visually reflected by 
discrepancy between the ICC and empirical counterpart. An item chi-value is generated by 
adding all standardized differences for class intervals (Andrich et al. 2012b, p.21) (Andrich 
et al.). 
4. Testing of overall model fit. Mean fit residual value of 0 and standard deviation of 1 reflect 
overall model fit (Shea et al. 2009). The item-trait interaction statistics for all items are 
summed up into total item-trait interaction statistic. Optimal fit is reflected in a non-
significant statistic (Chi-squared statistic, p-value > 0.05). Good fit to the RM implies that 
the hierarchical ordering of the items remains invariant across the different levels of severity 
assessed by the construct.
5. How well the instrument can differentiate persons according to severity should be assessed.  
This is reflected in the Personal Separation Index (PSI) which reflects the proportion of 
variance explained by the model out of the total person variability (Wright and Masters 1982; 
Bond and Fox 2007). A PSI of 0.8 reflects capability to reliably distinguish patients into at 
least 2 groups of severity e.g. high and low severity.
6. Assessing targeting of items. The item-person map is visually examined for adequacy in 
spread of the items along the breadth of the latent variable, ideally there should not be be 
large gaps in between items (Wright and Masters 1982, p.90);  mean location of persons 
should be close to 0 to match the item mean location centred at 0 logits. (Gorecki et al. 2011). 
7. Assessing unidimensionality. First, a principal component analysis is carried out on residuals 
after fitting the RM. Unidimensionality is supported if the first component accounts for no 
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more than 30% of the variance in the data and has eigenvalue of 3 or less (Linacre 1998). A 
more stringent assessment of unidimensionality has been suggested by (Smith 2002). Items 
are grouped according to their loading on the first residual factor, comprised of high positive 
and high negative loading items, respectively. Pairs of person estimates generated from the 
two item sets are compared using a series of t-tests. If the proportion of significant tests (or 
the lower bound of its confidence interval) exceeds 5% unidimensionality is ruled out
(Tennant and Pallant 2006).  
8. The assumption of local independence will be assessed by examining the correlation matrix 
of the item residuals. Residual correlation exceeding 0.2 – 0.3 reflect a violation of this 
assumption. The magnitude of the response dependence is calculated as the shift in the latent 
variable range representing a given response choice on the dependent item, induced by a 
particular response choice on the independent item (Andrich et al. 2012a). 
9. Assessing for invariance across demographic factors. DIF can be assessed for key 
demographic factors using a two way ANOVA test. A significant main effect (demographic 
variable) at 0.05 level of significance, with Bonferroni adjustment, indicates presence of 
uniform DIF. On the other hand a significant interaction effect (demographic variable X class 
interval representing ability groups along the latent trait), after Bonferroni adjustment, 
indicates non-uniform DIF (Andrich et al. 2012b). Identification of DIF requires a pure set 
of items, upon which the scale is anchored (Teresi and Fleishman 2007). 
Any action on DIF requires an understanding of its magnitude and impact. Magnitude 
indicates the difference between item difficulty estimates based on all patients and 
comparable estimates specific for each demographic group (Linacre 2009). The impact of 
the DIF on estimation of person estimates is assessed by comparing person estimates 
generated from the DIF-free items against estimates based on all items including those with 
DIF (Tennant and Pallant 2007). Using a t-test, significant results, at 0.05 level of 
significance, indicate that DIF has an impact. The Item Characteristic Curve (ICC) of the 
two series may also be useful in assessing whether the pairs of person ability estimates agree. 
Impact of DIF can also be explored by assessing whether the Test Characteristic Curves 
(TCCs) from different demographic groups are comparable i.e. whether the relationship 
between the raw score and the underlying latent variable varies across the demographic 
groups. Identical TCCs indicate the absence of impact of  DIF on the total score (Edelen et 
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al. 2006). The criterion for magnitude of DIF is also relevant for differential scale 
functioning
Missing Data
Situations where a question or an entire questionnaire has not been completed are common during 
data collection in QoL research. The reason behind the missing data has an influence on choice of 
tools for dealing with the consequent problems in data analysis, for example, whether an item is 
skipped by mistake or due to its irrelevant. There are three main classifications of patterns of 
missing data, missing completely at random (MCAR), missing at random (MAR) and missing not 
at random (MNAR) (Fayers and Machin 2007). MCAR arises where the probability of having a 
missing item (questionnaire) is independent of previous or unobserved current and future scores. 
MAR occurs where missingness is dependent on known covariates and scores of previous items, 
but not on the unobserved scores. The third case, relates to where the unobserved HRQoL 
influences the missingness. The presence of MAR and MCAR is not worrisome, as their impact 
on accurate measurement of HRQoL is minimal (Leidy et al. 1999).  MNAR causes the greatest 
concern as its presence may lead to an over or underestimation of HRQoL, highlighting the need
for transparent approaches in addressing its presence. 
There are no clear guidelines on the number of missing items to warrant the exclusion of an entire 
respondent’s questionnaire although Streiner and Norman (2008) have mentioned a ceiling of 5% 
of items. However, it’s worth noting that where Rasch scoring is applied, a higher number of 
missing items may be tolerated without much bias in measurement(Fayers and Machin 2007).  On 
the other hand, in some situations (e.g. during instrument development work) data imputation to 
replace the missing data offers a viable alternative. This is done in various ways including using 
the last observed value carried forward; by calculating a simple mean; or using regression methods 
(Fairclough 2010). Other more sophisticated imputation approaches such as hot-deck and markov-
chain are capable of preserving variability in the data.
To prevent the problem from arising in the first place, respondents will be instructed to cross-check 
their questionnaires to make sure they have completed all items for the paper-and-pencil version 
of the instrument in this study. 
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SUMMARY
 This chapter has provided the justification for a new instrument for evaluating QoL in 
hyperhidrosis, by elucidating on the role and need for HRQoL assessment in hyperhidrosis 
and the inadequacies in the existing instruments. The attributes of a measurement 
instrument necessary for the credibility of HRQoL information were highlighted. On that 
basis, the steps necessary to produce such evidence were outlined  reflecting the design of 
this study, to develop and validate a new instrument for measuring HRQoL in 
hyperhidrosis, for application both in the clinic and in research settings 
 An overview of the study is presented in Figure 2.4
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Figure 2.4: Flow chart of study
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CHAPTER 3
Development of a Hyperhidrosis-Specific Patient-Reported 
Outcome Measure: Qualitative Study
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INTRODUCTION
Skin disorders are unique in that the subjective experiences of patients tend to be a more powerful 
determinant of the patient’s quality of life (QoL) as well as the overall burden of the disease, in 
comparison to the degree of objective severity for instance (Russo et al. 2004; Jobling and Naldi 
2006). Patients care less about specific symptoms of skin for instance redness; flacking; or being 
wet; rather of more importance to them is the actual physical discomfort experienced; change in 
the patients self-image and; the wider implications for the patient’s psychological functioning and 
social life (Grob 2007). On a practical level, evaluating symptoms may not be as straightforward, 
in spite of their alluring objectivity. For example in hyperhidrosis, the amount of sweat considered 
pathologic is unclear; on the other hand, and the tools for quantifying amount of sweating are 
impractical for the routine clinic (Wörle et al. 2007).
Patients with hyperhidrosis have reported various impacts on their QoL, for instance physical 
discomfort associated with the continuous dampness; feelings of embarrassment and anxiety; and 
difficulties in meeting strangers; limitations in everyday life activities and in occupational 
activities (Strutton et al. 2004; Hamm et al. 2006; Solish et al. 2008). This current understanding 
is based on survey instruments and quantitative methods; a fuller picture of the extent and nature 
of the impacts for instance the complex interrelations among disease severity, individual adaptation 
and public response may require methods that can unveil patient thoughts, beliefs and 
interpretations of their experiences (Jobling and Naldi 2006). Further, other issues with possible 
implications on the QoL of patients such as patient’s information need; self-management 
strategies; experiences in obtaining care are not well understood. Thus a study rooted in qualitative 
research methods would be very useful in exploring and elucidating on these issues.
This, therefore, means that QoL impacts ought to be a key consideration in the diagnosis and 
management of hyperhidrosis in routine clinical practice and the  evaluation of treatments; a point 
also recognised in existing treatment guidelines (Tan and Solish 2002; Solish et al. 2008). This 
would require a credible way of capturing and evaluating such QoL impacts. Such a measure needs 
to be appropriate and relevant for assessing QoL impacts in hyperhidrosis and should at least have 
demonstrated evidence of its precision, reliability, validity, sensitivity to change and practicality.   
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OBJECTIVES
The objectives of this study were to:
 To explore the experiences of patients with hyperhidrosis in order to obtain an in-depth 
understanding of the extent and nature of QoL impacts
 To develop a disease-specific instrument for evaluating QoL impacts in hyperhidrosis 
based on the experiences of patients.
METHODS
Ethics
Ethics-approval for this study was obtained from the University Hospital of Greifswald Ethics
Committee in Germany on 31st July 2011, where the data collection was based.  Prior to this, 
guidance had been obtained from the South Wales NHS Research Ethic committee considered the 
study to lie outside their remits as data collection was not based within the UK.
Written informed consent was obtained from participants before their participation in the study.
Recruitment 
Materials, including the background to the study, information sheet and an invitation to patients 
were placed on the study’s Facebook page and other online social networking communities for 
patients with hyperhidrosis. Patients interested in the study contacted the research team by E-mail 
to participate in FGD or interviews. 
Study participants
The study included participants fulfilling the following inclusion criteria:
 With self-reported sweating problems.
 Seeking for treatment;
 18 years or older;
 Able to speak, understand and write in English.
 18 years or older;
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 Sweating linked to other underlying health problems or treatments
Sample size
In qualitative research, unlike in quantitative data collection, it is not feasible to objectively predict 
optimal sample size prior to data collection. Thus, we continued with data collection up until no 
new themes were emerging i.e. a point where ‘saturation’ of the content had been reached. 
Data collection
This study utilised qualitative research methods including semi-structured interviews, focus group 
discussions (FGD) and a survey with open ended questions for data collection. Interviews and 
focus groups are especially useful in facilitating detailed and deep understanding of social 
phenomena (Gill et al. 2008). Both allow the framework of understanding, thoughts, feelings, 
perceptions and emotions of study participants to be aptly explored (Bowling 2005).  Focus groups 
bring together a group of respondents to meet and discuss a particular topic or issue and; they 
involve a moderator, who is usually also the researcher, facilitating the sessions (Fayers and 
Machin 2007). The interaction among respondents adds to the richness of the data 
collected(Bowling 2005). Interviews on the other hand provide an appropriate setting for exploring 
sensitive topics (Gill et al. 2008).
Procedures
 Two FGD sessions were conducted in the form of online text-based discussions, each over 
a period of two weeks and were moderated by a member of the research team (P.K.) who 
posted topics, probes and prompts on the board. Participants were encouraged to read 
postings from the moderator and the responses of the others as well as make their own 
contribution to ongoing discussions. Access to the online discussion board (based on php) 
required a password and username which were given to each participant. 
 Interviews were carried out by telephone and internet instant chat facility e.g. Skype. Each 
interview began with inviting the patient to share their experience of the effects of the 
disease condition in general, through the following question: “In what ways does 
hyperhidrosis affects your life?” Each of the areas mentioned by the patient was probed 
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further. The interviewer also raised questions in relation to specific areas of life previously 
known to be heavily impacted by hyperhidrosis overlooked by the patient.
 Based on the topic guide, results from the FGD and interviews an online survey with 
open ended questions was developed according to Zoomerang survey platform. This was 
then posted on various online social networking communities for patients with 
hyperhidrosis.
Data Processing And Analysis
Interviews were tape recorded then transcribed verbatim. The focus group discussions and open 
surveys were already in text format. Content analysis of transcripts was carried out using NVIVO 
9. This form of qualitative analysis is focused on both the context and content of source material, 
with the aim of identifying major themes, their frequency and their relationship to external factors 
such as demographic characteristics of study subjects (Robson 2011). As an atheoretical approach, 
the analytical framework i.e. the thematic structure is data driven and not imposed from known 
theories or previous studies (Braun and Clarke 2006). Analysis of data started as soon as data 
collection started, and was continued during the data collection process. Transcripts were 
thoroughly studied in order to gain an understanding of the data and to build an initial overview of 
topics. This process was repeated with further data collection. The transcripts were indexed and 
sorted by assigning common labels to chunks of the transcript considered to be about the same 
topic, a process referred to as topic (Saldana 2009). During the early stages of analysis, the coding 
was aimed at indexing all data. In later stages, the initial coding was revised, not only to reflect 
subsequent data collected, but also to combine a number of codes addressing a similar topic, to 
enhance meaning and understanding of data. The higher level coding produced major themes from 
the data. Grouping themes addressing a common topic identified major domains in the data, 
representing areas important to patients. Further analysis aimed at identifying the number of 
subject contributing to a particular theme. The inter-relations between themes was also analysed 
by exploring the themes coding common material i.e. overlap in reference material. Throughout 
the study a clear audit trail of decisions taken was kept including a codebook and a saturation 
matrix. In order to provide clear examples of what each identified theme covered, quotations based 
on transcripts of what the patient actually said were included.
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RESULTS
Sociodemographic Characteristics Of The Study Participants
Out of 13 potential participants recruited for the FGD, 9 (69%) patients participated; out of 41 
recruited for the interviews, 32 took part; and out of 46 who started filling the survey 30 completed 
(65%) (Figure 3.1). In total 100 patients were recruited and 71 took part in the study. The mean
age of the study participants (males = 21, female = 50) was 34.9 years (range 16 - 67) and the 
mean duration of the condition was 23 years (3 – 60 years). The study participants experienced 
sweating in different areas: axillary plus other (n = 24), generalised (n = 19), palms and feet (n = 
13) (Table 3.1)
Data saturation and Qualitative themes
Saturation of data was achieved at the 33rd study participant. Because of the novelty of the patient 
recruitment strategy employed, further interviews were conducted as well as data collection using 
another mode of data collection. The data analysis identified 103 HRQoL issues, grouped under 
26 themes. These reflected seven main areas of QoL impact including daily life (mentioned by 
95.8% of patients), psychological life (91.5%), social life (90.1%), professional life (74.6%), 
dealing with the condition (74.6%), unmet health care needs (64.8%) and physical impact (53.5%) 
(Table 3.2). Mean number of themes reported per person was 11 (2-23 themes). 
No statistically significant differences (based on χ-test) were observed in number of themes 
reported by females and males, or among participants reporting different affected body areas. 
For the purpose of clarity, the study findings will be reported under two sections, Part 1, 
concentrating on the experiences of hyperhidrosis patients, covering the issues that impact on their 
QoL. Part 2, reports on the development of the Hyperhidrosis Quality of Life Index (HidroQoL) 
based on the data collected from the qualitative data collected from patients.
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Figure 3.1: Overview of data collection process
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Table 3.1: Sociodemographic characteristics of study participants
Gender, n (%)
Male 21 (30%)
Female 50 (70%)
Age (years)
Mean (SD) 34.9 (13.2)
Median 31
Range 16 - 67
Duration of disease (years)
Mean (SD) 23.3 (13.6)
Median 21
Range 3 - 60
Body site affected (n)*
Armpits only 3
Palms only 2
Feet only 3
Armpits plus other sites 24
Palms and feet 13
General (whole body) 19
Face 3
Trunk & lower body 7
Country
UK 41
U.S.A 14
Canada 2
Netherlands 2
Other 12
Part I: HRQoL Issues In Hyperhidrosis
Qualitative analysis of data collected from patients through interviews, focus groups and the open-
ended survey questions identified seven main areas of HRQoL affected by hyperhidrosis: daily life 
activities, psychological functioning, social life, managing the condition, professional life, 
physical discomfort, and unmet medical needs. The thematic analysis identified a total of 104 
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issues (sub-themes) which were subsequently organised under 29 themes grouping together similar 
issues. 
Daily Life Activities
Life Style
As a long term condition that patients live with on a daily basis immediate impacts on the patient’s 
way of life were reported. Nearly three-quarters of study participants reported lifestyle impacts 
making this the most prevalent theme.
Table 3.2: Issues considered under each HRQoL themes
HRQoL area Theme % Issues (subthemes)
Daily life (96%)
Touch 
technologies
21.1 Touch technologies
Hobbies 40.8 Sports
Recreational activities
Limitations –
general activities
39.4 Transacting with money (notes & coins)
Sitting for long periods
Light movements (e.g. dressing up)
Holding objects
Driving
Doing physical activities
Activities involving barefoot
Lifestyle 76.1 Travel & holidays
Choice of clothing
Choice of footwear
Appearance e.g. hairstyle & make-up
Food choices
Limitations –
home
32.4
Daily household chores (cooking, 
cleaning)
Shopping
Caring for children
Handling pets
Summer-activities 32.3 Activities typical for summer months 
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Table 3.2 (continued)
HRQoL area Theme % Issues (subthemes)
Psychological-
functioning 
(92%)
Self-image 49.3 Think about sweating all time
Low self-esteem
Low self-confidence
Looking untidy
Feeling less attractive
Self-conscious
People's 
judgement
64.8 Feel stigmatised
Fear reactions of others to my sweating
Worry about leaving sweat marks on 
things
Fear that sweating will be noticeable 
(e.g. avoid raising arms)
negative emotions 69 Feeling nervous
Feeling embarrassed
Feeling depressed
Feeling sad
Feeling lonely
Feeling hopeless
Feeling frustrated
Feeling angry
health concerns 15.5 Fear that condition is worsening
Worried that something is medically 
wrong
Worried of passing condition to offspring
Restricted life 50.7 Sweating greatly hinders my life
Inconvenience
Taken over my life
Negatively affects my satisfaction with 
life
Controls my thoughts
Influences all my decisions
Fear of doing new things
More passive – laid back
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Table 3.2 (continued)
HRQoL area Theme % Issues (subthemes)
Social functioning 
(90%)
Relationships 39.4 Am a virtual recluse
Stops one from having friends, partner
Negatively affects personal relationships
Interferes with communication
Physical contact 66.2 Avoid holding or shaking hands
being near others e.g. sitting, queuing, 
dancing
physically expressing affection e.g. 
hugging and cuddling
Interacting with 
people
57.7 meeting new people
Not able to socialise with others.
Being in public 29.6 Being in public e.g. going out
Travel on public transport
Professional Life 
(75%)
Career 32.4
major career decisions e.g. choosing a 
career or retiring
Work-tasks 63.4 Reduced performance at work
Dealing with the 
condition (75%)
Special chores 60.6 Wearing additional layers of clothing
Controlling the sweating or keeping dry
Aides to assist in carrying out daily 
activities
Carrying spare clothing and towel (e.g. 
handkerchief, kitchen towels)
Actively disguise sweat
Personal 
hygiene
16.9 Shower several times a day
Change clothes several times a day
Financial 
burden
12.7 Financial burden
Time concerns 29.6 Take things at a slower pace
Spend more time in daily body hygiene
Can't do things spontaneously (i.e. need 
to plan in advance for everything)
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Table 3.2 (continued)
HRQoL area Theme % Issues (subthemes)
Unmet health care 
needs (65%)
Poor 
management of 
condition
57.7 Treatments not working
Unhappy with how doctors treat 
condition
Disappointed with poor access to 
treatment
Information 
needs
32.4
Knowledge of health care professionals 
about condition
Patient information not adequate
Lack of public awareness
Physical impact 
(54%)
Skin problems 16.9 Sore and cracked skin
Painful skin due to soreness
Skin infections e.g. athletes feet, 
dermatitis.
physical 
discomfort
36.6 Cold sweating
Constantly sweating
Constantly feeling hot
Sweat dripping into eyes
body and clothes wet
Slide in and out of shoes
Body odour 14.1 Feet
Body & clothes
Patients (61%) frequently mentioned effect on their choices of fabric, colour and design of their 
clothing. Many reported avoiding colours as ‘red’ or ‘blue’, favouring ‘black’ or ‘white’. Others 
would stick to cottons, staying away from fabrics like polyester, which do not allow good aeration.
 “You decide your whole wardrobe of clothes around that one thing...rather than thinking 
oh that’s a nice fashionable type of thing you know...so you end up wearing black a lot” 
 “…I have to wear black ...if I wear white it’s going to show up and it’s the most 
embarrassing thing ever”
 “I never wear a skirt. I would wear either short trousers or linen trousers coz the top of my 
legs and the middle of my legs rub as well...and I get blisters” 
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 Take care not to wear clothes that are too thick, try to wear thinner layers so that they be 
removed easily.
Several explanations were offered for these effects including: physical discomfort and; because of 
concerns over whether other people would notice the sweating. Thus, choice of clothing was 
among the various strategies employed in managing the sweating.
 “You have to watch what clothes you wear...obviously to try and hide the perspiration coz 
no matter what you did...you clothes were marked...it was really restricting as far as where 
going out socially was concerned...and you are always aware...it could be a smell..” 
Choice of shoes was also affected: particularly in patients with sweating of the feet. One patient 
said: “every time I wear flip-flops it is impossible for me to walk without slipping”. A small number 
of respondents (12.7%) reported effects on their food choices, they avoided spicy or hot foods, 
drinks containing alcohol or caffeine. Other less prevalent issues, included interferences with 
holiday decisions (choice of activities or destination); effects on appearance, a number of female 
participants reported ‘make-up melting away’ or ‘hair getting messy’.
Hobbies
Forty-one percent of participants reported effects on their hobbies. Frequently mentioned activities 
included sports and recreational activities like playing musical instruments. One participant talked 
of their ‘pastime reading’ being affected because they can’t hold a book. In as much as these 
primarily relate to the physical challenges of sweating for instance wet hands, there was still an 
element of concern about what others thought of the sweating.
 ... I don’t like exercising on the street or anything like that...like going for a walk people 
tend to look at me if am really sweaty ...and that makes me really nervous...
 “..Cycling I used to enjoy...walking I will do...but I’ll only do short distances...if I get too 
hot and bothered I sort of give up...coz it pushes my boundaries...I used to like ice 
skating...can’t do that anymore...swimming is the only one probably am comfortable 
with...because its wet...I can’t go in Saunas...any Gymn activities....unfortunately I put on 
weight in the last 6 years... I want to lose it...I don’t want to go to the Gymn for people to 
comment...so I find it a struggle...to do those sort of things” (Female, 27yrs)
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General activities
Forty percent of the subjects reported difficulties with everyday life activities. The most 
commonly mentioned included trouble with holding objects, turning door knobs, opening jars, 
working with hand tools and driving, which were linked to sweating of the palms. Doing manual 
work, dressing up, and activities involving being barefoot were reported as being uncomfortable.  
A few participants mentioned avoiding making payments using cash or notes as they tend to stick 
to the palms which resulted in embarrassment.
 “…when the temperature rises above about 22 degrees [celcius] I cannot do anything 
except sit still indoors with a fan running, this helps but does not stop it completely. I can't 
go outside, walking or do gardening, in fact anything that involves movement of my body, 
even moving my arms like using a whisk when cooking, or sewing affects the complaint, 
even in the winter if I am active, like walking. This all means that I cannot participate in 
anything physical as perspiration just pours from my head and neck and runs down my 
face and soaks my clothes, my hair looks like I have just washed it as it is wet all over” 
(Female, 67yrs)
 “ I don’t drive because of hyperhidrosis....with the steering wheel,...that has been a huge 
effect...not so much living in London...where...I doubt I would drive anyway...but living in 
Australia, New Zealand, you need to drive I’d make any excuses not to drive...because it 
just seems so difficult”
 “Simple everyday tasks become nonstop worries – holding an object, opening a jar or 
writing with a pen. I even found driving a car a test, my hands would leave the steering 
wheel soaking wet, making it very slippery, and subsequently dangerous” (Male, 24)
Activities at home
Nearly a third of the study participants reported challenges in their life at home. Tasks such as 
cleaning, cooking, ironing and other household chores were affected. Two mothers mentioned 
challenges with caring for young children.
 “The minute I start to do anything the least strenuous I stream with sweat, so housework 
is a nightmare. I have to change all my soaked clothes if I hoover one room. Have to tie 
strips of towel around my forehead and neck when I do anything that involves movement, 
and have to keep changing them as they get soaked’.
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Summer activities
The respondents reported that their sweating worsens during the summer months (in the US & 
Western Europe), activities that tend to be done during this season were affected. Nearly a third 
of the study participants experienced trouble with such activities, for instance, outdoor activities 
tending their gardening and mowing; or going to open air concerts. For some the mere approach 
of the summer season make them worried.
 “ I have a son who I’d love to take out in the summer, but sometimes we don’t because I’ve 
had so many years of fearing summer” (Male, 32 yrs)
Touch technologies
Constantly having hands that are wet, was reported to cause difficulties in using technologies 
that rely on touch. This was a problem in nearly a fifth of the subjects. Mostly, difficulties were 
experienced in the ‘use of computer keyboards’, ‘laptop mouse’, texting and sending short 
messages or general use of mobile phone, and using touch-screen interfaces. Two patients 
mentioned damaging their cell phones and keyboards because of the humidity from their hands.
Psychological Functioning
Emotions
Study subjects experienced various emotions as a result of their condition. This was mentioned by 
69% of the participants and was the most prevalent psychological impact of hyperhidrosis. The 
sweating made the majority of subjects feel embarrassed; while a slightly lesser number reported 
feeling anxious about their sweating, and that others would notice it. Other participants said they 
were frustrated with life because of the condition. A handful reported feeling depressed. Less 
frequent emotions included sadness, anger, and hopelessness
A female participant shared her experiences as follows:
 “...little things... when you are wearing a ring on your finger and people want to have a 
look so they grab your hand and you feel all embarrassed cause they are sweaty. Having 
your nails done, they are constantly working with your half and once again you feel 
embarrassed because you are sweating” (Female)
 “...the biggest problem is that it is horrendously embarrassing particularly if its problems 
with the hands, am quite an easy going type of person so if I meet someone for the first 
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time or even if I meet someone whom I know I would like to shake their hand but I am very 
reluctant to do so, the first thing that goes through my head is...are my hands sweating..” 
(Male, 37 yrs)
Although negative emotions resulted from the sweating, the reverse was also seen, certain negative 
emotions lead to sweating. 
 “I'm on an antidepressant. I feel like I sweat because I'm nervous and I'm nervous because 
I sweat. It's a vicious cycle. I feel like an antidepressant helps to relieve that nervousness 
and helps to relieve a tiny percentage of my sweating” 
 “It's like a catch 22 or what came first, "The chicken or the egg?" Kind of like what comes 
first with us, the sweat or the anxiety? They both go hand in hand”
People’s judgement 
Concerns over how other people would react to the sweating was reported by nearly 64% of the 
study participants, making it the third most prevalent theme. A feeling that others misunderstood 
led to fears over how people would react. As such, participants often worried over how noticeable 
their sweating looked. Many feared leaving behind sweat marks on objects they came into contact 
with e.g. chairs, door knobs. On the most extreme, participants felt stigmatized, although this was 
not commonly reported. 
Concerns over people’s reactions emerged as a key underlying theme behind other impacts 
experienced. For instance, impacts on hobbies; summer activities; feeling anxious and; 
embarrassed; impacts on social life were all linked to the perception of the judgment of others.
 I can’t raise my hand all the way without showing my huge puddle of sweat...I can’t tell you 
how many times I heard “your back’s wet” from the person behind me. Just pure 
embarrassment” 
 “if you are giving something to someone and you have sweat marks all over it... its 
nasty...and it’s not something that you can control...” 
 “I remember at school when I would win a certificate in a subject, I knew I would have to 
go up on stage and collect it, just the thought of standing there with everyone looking, 
thinking that they might see me sweating, it was so upsetting!” 
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 “Sitting on a plastic chair or a leather one is a no-no in hot weather, or I would leave a 
sweat mark (sometimes it doesn’t even have to be a hot day, it can be any day). And you 
can’t see if your back sweat is showing through, so leads you constantly thinking that it is 
and everyone is laughing at you behind you, when you hear a laugh”. 
Self-image
Hyperhidrosis also had an impact on the way participants viewed themselves, with nearly half of 
them reporting issues related to this theme. Many mentioned being preoccupied by their sweating 
condition. A heightened self-consciousness was commonly experienced; while some thought of 
themselves as being less attractive; or as dirty. On the extreme the participant’s sense of self-worth 
was diminished leading to low self-esteem; and reduced feeling of self confidence.
 “I am disgusted in myself for it and so it massively eats away at my self confidence, it 
makes me feel awful and dirty and gives me low self esteem - this has certainly been the 
route cause of my severe lack of confidence in everything I do or I am”
 “it makes me feel quite dirty even though I’ve had quite a few showers per day, even though 
I’ve changed my clothes three times a day....it makes me feel very depressed...and very 
alone”  
 .well...it takes over what you have to think about before you leave home...whether you take 
extra clothing...whether you are wearing a black shirt...or t-shirt.....it constantly doesn’t 
leave you...it affects your life all the time....it makes you feel very uncomfortable...and very 
aware... (Male, 42 yrs)
 Socially it made me very insecure...its embarrassing shaking hands and sweating through 
your clothes, when you’re a girl its even worse.
Restricted life
Half the study participants expressed feeling hindered by their sweating. Patients extensively 
described feeling their whole life is being held back, one patient said ‘there has been countless 
things I haven’t done because you first sort of thought ohh God that’s going to place me in an 
uncomfortable position’. Some patients talked of how they avoided any form of new challenges in 
their life. A handful of patients considered their life taken over by their sweating condition. One 
participant said ‘everything you do in life you have to think the sweating will become a problem. 
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Even for a handful who said they considered their sweating as something they can get on with, 
they nonetheless called it an inconvenience. This suggests that patients with hyperhidrosis perceive 
some degree of loss of control over their life.
 “My life revolves around how sweaty I am that day. If I'm really sweaty, I stay inside and 
to myself. If I'm not too sweaty, I will more than likely go do something.
 I have to make sacrifices over this disorder (Female, 18yrs)
 I can’t take subway after April, because its too hot on the platforms, so it takes twice as 
long to get anywhere. I don’t own a car in NYC its more of a hindrance than a help .
 “I just don’t want to go out...I wan be in the background I don’t want anyone coming near 
me...its quite inhibiting” (Female, 26 yrs)
Health concerns
The sweating resulted in concerns over their health for sixteen percent of the participants. 
Participants were worried that their condition was worsening.
Social Functioning
Participants mentioned experiencing disruption in their social life. To a large extent this reflected 
behavioural avoidance of activities or circumstances where embarrassment, anxiety feelings, self 
consciousness or other negative emotions might be experienced. This was also related to a 
diminished self-image in other cases.
Physical contact
Driven by concerns over how others would react to the sweat and fears of rejection, the majority 
of participants (57.7%) mentioned feeling uncomfortable with being in close proximity to others. 
For instance, touching others; holding or shaking hands; was avoided by many. Some participants 
avoided being close to others for instance when seated, queuing and; dancing. A smaller number 
had trouble with hugging, cuddling or any other forms of expressing affection.
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 “you distance yourself away from people. So they probably think I am a cold person... you 
cant expose yourself to the rest of them knowing that I’ve got this condition” (Female, 36 
yrs)
 “was always too scared to dance with anybody because my back was always soaking 
wet...and the hotter I got the worse I got” (Female, 58 yrs)
 I am unable to touch my husband, daughters and grandchildren, without first thinking 
about how to do it without them actually having contact with my skin
 “You were very aware of it...when people would get close to you...it was really 
embarrassing...I didn’t really like that...you were afraid that they would notice...that you 
were sweating..(Female, 55 yrs).
 “I suppose you don’t really wanna get too close to someone if you are constantly 
sweating...they might feel very uncomfortable...you are so aware of your sweating and its 
not nice to be that close to someone”...(Male, 42 yrs)
Interacting with people
The participants described how the condition inhibits their social interaction with other people, as 
expressed by 57% of the participants. A high self-consciousness; reduced self confidence and the 
fear of being judged by others made interacting with people in various social situations for instance 
weddings, seminars or when visiting friends, a challenging task. This also presented when meeting 
people for the first time, with a third struggling with this.
 “[the sweating] affects my social competence because it is difficult focusing on a 
conversation when trying to hide sweating or thinking about how disgusting it feels against 
the body and having wet clothes”.
 “when meeting new people I have a constant worry and fear of shaking hands. Do I shake 
their hand? Do I pretend I didn’t see them offering the hand? Do I tell them I have sweaty 
hands? endless excuses echo around your head”
 “I sweat more if in social gatherings. Visiting, depending on whom, if my family then I'm 
comfortable and ask to put the fan on or drink my tea or coffee cold or iced.  If with friends 
or people who do not know about my sweating disease then I will sweat more and flush 
badly”
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 “The thought of meeting new people and having to shake their hand is terrifying! You just 
know it will be stone cold and sweating, then they look at you with a funny look!” 
Being in public
Furthermore, a third of the study participants described various situations in public for instance 
going out to a party, restaurant, cinema which made them uncomfortable. Some subjects had 
trouble using public transport. As with the other themes related to social life, self-image impacts 
and concerns over the reactions of other people was the underlying issue.
 ‘there have been times where I’ve been very nervous about going to a party or work 
gathering fearing the sweating’.
 “travelling to and from work is mortifying. Sitting or standing in sodden clothes for 8 hours 
and travelling on public transport is horrendous” (Male, 32 yrs)
 “I can’t go out... to like parties....or anything coz when I do...like... when I fix my hair or 
anything it will ... I would literary be blow drying my hair and I would be sweating all 
over” (Female, 18yrs)
Relationships
The study participants mentioned finding support through friends and family who were 
understanding of their condition. Nonetheless, a much larger number (40%) reported that their 
condition had impacted their personal relationships. Avoiding going out and being in public meant 
that they would not be able to mix and interact with friends which is an ingredient to sustaining 
such relationships, loosing touch in the end. Low self-esteem also resulted in communication 
problems.
 “I have not been in a relationship, as I feel too embarrassed to explain, I lost touch with 
most of my friends after school, because by this time, the sweating had got worse and they 
were wanting to go out, I would  feel too anxious about it and would make an excuse”. 
(Female, 24 yrs).
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Dealing with Hyperhidrosis
Special chores
The majority of participants (63%) employed various strategies in managing their condition. The 
burden of mitigating the symptoms and impacts of sweating presents an additional burden on the 
patients in their daily life. These were thought of as ‘little rituals’ by one patient, and included 
carrying a towel, tissue or handkerchief or; a pair of extra clothes for changing. Some patients said 
they needed to have a fan or air-conditioning running when at home or at the office; carry around 
a small hand-fan. Two participants mentioned drying up in the rest rooms when in public facilities.
 One woman said ‘we become masters of disguise... I used to hide under layers of clothing 
even in the hot summers. Just to hide the sweat!’ while others reported putting on gloves in 
summer to hide the sweat.
Personal hygiene
Staying clean and maintaining body hygiene required extra effort, as indicated by some 
participants (17%).  To stay fresh participants took several showers, changed clothes or shoes 
several times in a day.
 “it makes you feel very unclean some times...you are constantly bathing three, four or five 
times a day”.  
For those working or studying; this can be particularly challenging .as they have be out for the 
whole day.
 ‘I have to wash my uniform each night and sometimes take spare set to work to change 
during the day’ (Female Nurse, 23 yrs)
 'the fear that the sweat will start to smell...I tried to avoid long days at school as much as 
possible or at least have two shirts with me to school so I could change’ (Female Student, 
17 yrs)
Time concerns
Dealing with the condition was time-consuming for the study participants. They required 
additional time mostly for various activities in managing the sweating including personal hygiene. 
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Moreover performing daily life activities (walking; dressing up) would usually require more time, 
as they took things at a slower pace to avoid the sweating from breaking out. Moreover, managing 
the sweating in and out of the home involved advanced planning, on things like clothing, which 
meant some loss of spontaneity.
 One patient said ‘I try not to be short of time to get to any appointment as rushing will 
cause a problem. (Female, 50 yrs)
 ‘You know like when I do take a shower I have to wait... for an hour to completely dry ...or 
relax...not to do anything... It’s not nice at all’. (Female, 18 yrs)
 “it makes me feel quite dirty even though I’ve had quite a few showers per day, even though 
I’ve changed my clothes three times a day....it makes me feel very very depressed...and very 
alone (Male, 28 yrs)”
Physical Impact
Physical discomfort
Some level of physical discomfort was associated with the condition; as reported by 40% of the 
study participants. Being in wet clothes day in day out was a concern. Further discomfort was 
associated with having wet feet, particularly in those with plantar hyperhidrosis. Those with facial 
sweating were annoyed with sweat dripping into their eyes.  
 One subject said putting on shoes ‘feels like paddling’.
 ‘my legs sweat, every inch of my body...it is so uncomfortable living in wet clothing. I have 
to some times change several times a day as it ends up smelling like a vinegar sweaty smell’

Skin problems
Constant dampness made the skin vulnerable to other problems, as reported by 17% of participants. 
The commonly reported skin problems were soreness and cracked skin. Skin conditions such as 
hand eczema, Athletes feet, were also reported. A handful of patients experienced excessive 
sweating concomitantly with facial blushing.
 I moved 150 miles away to a cooler part of the country. My skin often becomes so sore that 
it cracks and bleeds. I have constant chafing.
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Body odour
Fourteen percent of the subjects voiced concerns over body odour. This theme was directly related 
to being in public view and how the participants perceived other people's reactions to their 
condition; or body odour. Thus, they were more worried about the smell in situations where they 
were in close proximity to others or were in a enclosed public space for instance in a bus.
 “The worst is the effect of unpleasant odour of my feet. I remember taking a bus ride and 
everybody noticed the offending smell. I try to avoid enclosed places like elevators, 
conference room, airport lounge”. (Male, 41 years)
 “I find, perhaps because I am Asian, spicy food affect the sweating, that there is a horrible 
smell. Even when I cut back on problem foods my sweat has very distinct smell, acidic even. 
Its both the wet patch and the smell I worry about” (Female, 27 yrs)
Unmet Medical Needs
Clinical management
How the study participants viewed the care they received was also an important theme for them, 
with 58% feeling that their condition had been poorly managed. Patients raised concerns related 
to their relationship with their doctor; the effectiveness of the treatments they received and; the 
side-effects associated with them. For many, obtaining a correct diagnosis of the condition was not 
easy; others felt their doctors neither gave them adequate attention nor showed any understanding. 
Further concerns were mentioned in relation to access to treatments: subjects frequently mentioned 
not findings a treatment that worked for them, this was particularly a problem in post-surgery 
treated patients. Respondents reported experiencing dry-mouth after oral treatment; compensatory 
sweating following surgery, with secondary impacts on their feelings and heart functioning; a bitter 
taste following iontophoresis.
 ‘my GP [primary care doctor] didn’t diagnose that I had hyperhidrosis or identify that it 
was a condition...even though I took a magazine article along...he sort of acted like it was 
rubbish... told me to apply more anti-perspirants...told me to get a stronger anti-
perspirants...it was quite humiliating...’.(Male, 32 yrs)
 “what I would like to see over time are doctors who do understand, ..., who show 
compassion and do understand, and give us the time of day. this alone would take away 
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from us that awful feeling of being alone and that no one understands. we all have come 
out feeling worse than walking in as they do not understand the whole of how we feel and 
how this affects us in our daily lives.”
 “getting treatment can be as bad as pulling a tooth with no Novocaine! Topicals burn and 
irritate your skin making it red raw...oral meds dry you out to the point you can't spit or 
pee and leave you in a dozy daze all day. Botox is like liquid gold, the one thing that does 
give us a break is the most hardest to get because of the greed of the Doctors costs and 
each vial. The iontophoresis machines are so expensive if not covered through heath care 
or insurance. ETS has left people worse than before with horrific side effects, the Dr's who 
did not tell the truth about how the surgery is really preformed!!!...Yet all the organizations 
claim how easy it is if you go to see a Dermatologist...It has taken me 12 years to finally 
get where I am and the frustration of not being understood, heard or fobbed off with 
another medicine because the side effect is less sweating but can cause you to overheat 
and be hospitalized is just in my opinion not bloody good enough!” (Female, 42 yrs)
Information needs
Lack of information was also highlighted as an aspect of care that was reported as a concern to 
patients. Nearly a third of the study participants found currently available information inadequate. 
Patients pointed out their need for more information about their condition. During the data 
collection several participants wanted to find out what causes it. Worry was expressed over the 
level of knowledge of healthcare practitioners about hyperhidrosis. Others considered the lack of 
awareness about the condition in the general public was responsible for the lack of public sympathy 
for the condition.
 ‘The lack of knowledge about hyperhidrosis among the medical community is also 
frustrating... I feel that it is difficult to find a provider that is knowledgeable about this 
condition because it is not a "sexy" diagnosis, there is so little funding that goes into research 
for hyperhidrosis. I am very thankful for research such as this that allows for any insight 
into living with hyperhidrosis’.
 Even though the family doctor knew from an early age...likes 13/15...when I had gone to 
see him... he said I would grow out of it. ...felt really let down by the family 
doctor...ignorance probably (Male, 42 yrs)
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 “[it is] a very difficult thing to explain to someone that...you’re not just sweating because 
you are nervous or sweating because you have bad personal hygiene...or sweating because 
you’re weird...but you’ve actually got a condition...you’ve actually got something that 
causes you to do that because its not a very publicly known condition...its not like you’re 
saying to someone you’ve got cancer coz everybody knows what ...that is or you’ve got MS 
which everyone knows its sort of seen as something weird.”
Professional Life
Work-tasks
The study participants reported difficulties in their occupational life as a result of the excessive 
sweating. Performance of tasks at work or school was affected in 63.4% of the subjects, the 
majority of whom regarded this as the most important impact of the condition. Having wet palms 
presented a challenge in the performance of certain tasks: for instance any manual work requiring 
the hands; operating machinery; writing; and using a computer. For example, a participant working 
as a nurse found it hard to put on latex gloves or administer an IV. Some limitations were also 
attributable to concerns over how clients or co-workers would react. For example a pharmacist 
found it difficult to dispense medication which had sweat marks all over, due to her sweating.
 “Jobs are difficult as you can imagine handing someone’s change back wet, as they look at 
the beads of sweat on your hands reflecting under the light. or when your writing the paper 
sticks to your hand and smudges the ink”.
 “ I am a nurse, but I no longer perform patient care.  When I was performing patient care, 
my hyperhidrosis interfered with numerous work tasks- simple things such as putting on 
sterile gloves, connecting IV tubing, examining a patient, etc.  I was always able to work 
though the hand sweat, but it did cause me stress.  Also, the constant hand sweat inside of 
gloves caused irritation and dermatitis on my hands.  My hands were always red and raw.  
Since leaving patient care, I still have to be conscious of the hand sweat when filling out 
forms on paper, typing on the computer”.
 “In recent months, in between my two Botox treatments, my arms were red raw for 4 days, 
the first two I couldn’t lift my arms without being in excruciating pain. I was miserable at 
work and barely did any lifting e.t.c. and just said I had pulled a muscle. This prompted me 
to pay for the 2nd botox as i just could not continue like that. I smothered creams on for a 
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few days and barely went out and then went for my Botox treatment. I had it 3 weeks ago 
now and i am back to being very confident and not having to worry about sweat marks, 
smells, i can put a little bit of deo on for a nice smell but not worry about it irritating my 
arms either
Career
Participants reported being influenced by their condition in making major career decisions. As 
mentioned by a third of the participants, they had chosen their career, then, just to accommodate 
their sweating. Some participants believed that they had not progressed in their careers due to the 
condition, while others had opted for early retirement because of their sweating condition. One 
participant said she had let go of an opportunity to become a policeman, which was her career of 
choice, settling for a ‘really boring office job’, because of her condition.  One patient had opted 
for an early retirement due to the condition.
 if I am to be absolutely honest...when I was at school I would have applied to do 
medicine...but because I knew I would have to examine people with my hands which I could 
never do...I opted to do pharmacy because I knew I would be able to do that’ (Female, 40 
yrs).
Part II: Development of the Preliminary HidroQoL
Conceptual framework
An important first step in the development of HRQoL instruments involves the development of a 
conceptual framework. This clearly defines the concept being measured; the rationale for 
undertaking the measurement; the target population; as well as the context of measurement 
(DeVellis 2011, pp.73-75). Skipping this critical step, has consequences for the clarity of the 
dimensional structure; may complicate subsequent data analysis and; may ultimately obscure 
interpretation of scale scores (Rothman et al. 2007). The conceptual framework of the new 
instrument presented in Figure 3.2 was based on results from the qualitative study undertaken in 
hyperhidrosis patients, reported in the previous section:
 The new instrument was developed for assessing hyperhidrosis-specific QoL. The main 
impacts of hyperhidrosis on QoL included physical discomfort, daily life impacts, 
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psychological impacts, social life impacts, impacts on professional life, and the burden 
associated with managing the condition.
Figure 3.2: Conceptual framework for the new QoL impact questionnaire for hyperhidrosis
Note: The core impacts of hyperhidrosis on QoL are enclosed in the dashed red box. Unmet needs 
considered outside the core QoL impacts is a results of the interaction between impacts of 
hyperhidrosis and available care given to patients.
 The target patient population for the new measure included persons with primary 
hyperhidrosis, including patients with different body areas affected. 
 The new measure was to be used for evaluative purposes: evaluating the HRQoL of 
individual patients with hyperhidrosis, both in routine clinical practice and in research 
settings.
Initial item pool
Following content analysis of the data collected through interviews, focus groups and open surveys 
with hyperhidrosis patients, major QoL issues were identified. These were subsequently used to 
create the preliminary version of the instrument following the criteria listed below:
 Issues with a prevalence of 5% or more in the qualitative sample were included.
 Age or gender specific issues, regardless of being mentioned by less than 5% of the sample, 
were also included.
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 Language considerations were made in crafting each item: 
− The wording of the item was meant to follow and reflect the language used by 
patients, technical jargons were to be avoided; 
− Readability was to be such that a 12-year old would understand;
− The items were to be written in concise and simple sentences, aiming for six words 
or less;
− Each item was to represent a single concept; not be double barrelled; and not use 
ambiguous words;
− Items were to correspond to response formats (DeVellis 2011; Patrick et al. 2011b).
Response format
Once the items were drafted an appropriate response categorisation fitting the item stem, the 
concept under measurement, recall period and the mode of administration was chosen. This 
decision would involved deciding on type of scaling to use for responses, the corresponding 
number of categories, and their labels. While visual analogue scales may seem attractive for the 
range over which respondents can distinguish their condition; this very advantage may make the 
response task burdensome; and may also result in variation unrelated to the underlying condition 
of the patients. Seven, plus or minus two, has been recommended as maximum number of 
categories that people are capable of distinguishing (Streiner and Norman 2008, pp.48-49). On the 
other hand, caution ought to be exercised as offering people less choices than their capability to 
discriminate may lead to a loss of information (Streiner and Norman 2008, pp.48-49). Initially a 
7-point Likert scale was used for the first prototype questionnaire with descriptors unique for each 
item. This was revised during the developmental process, to a 5-point Likert scale, with an option 
for ‘not relevant’; with common descriptors used for all items. This was seen to strike a balance 
between applicability as well as need to offer sufficient choices and precision.
Frame of reference
Further, the period of time respondents needed to consider in producing answers, the recall period, 
was set. In turn, the wording of the items and responses and instructions would reflect this decision. 
The suitability of the recall period depends on measurement goals, for instance long-term impacts 
versus efficacy of intervention; the nature of the construct, symptoms or HRQoL impacts; 
frequency of assessments and; ultimately the target population (Norquist et al. 2011). The shortest 
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recall period feasible is recommended,  a recall period that is too short may unnecessarily 
overburden the respondent; on the other hand exceeding one month may be associated with 
increased recall bias (Frost et al. 2007b). ‘At present’ was chosen as recall period for the new 
instrument. Responses based on the condition of the respondents during the time of assessment 
would be subject to minimal recall bias as the respondents would produce answers spontaneously, 
minimising noise in the measurement process.
Mode of Administration
The choice of how the instrument will be applied during data collection, whether in-person 
interview; telephone; paper and pencil; electronic; web-based tends to have an influence on data 
obtained (Frost et al. 2007b). Suitability of the mode depends on a number of factors: the 
preferences of the target participants and the construct under assessment; the content of the 
instrument for instance recall period; number and frequency of assessments among others 
(DeVellis 2011, p.189). Paper and pencil administration was chosen for the new instrument 
because of its ease of administration, making it easy and practical for routine clinical practice while 
avoiding ‘social desirability’ issues salient in modes such as in-person interview. Furthermore, to 
reach patient populations outside the clinic, it would also be administered via the internet, which 
may allow coverage of patients outside the clinic; besides other advantages for instance a stronger 
sense of anonymity for respondents.
Layout and structure
The structure of the instrument including its formatting is an important element of the instrument, 
with impacts on the accuracy and reliability of data collected (Haynes et al. 1995). For example 
formatting has potential implications, on navigational errors (such as item non-response and 
misinterpretation) and; respondent and administrative burden (Mullin et al. 2000). In order to 
ensure a simple, clear, consistent and natural design, the following decisions were taken:
 Items containing similar content were grouped together
 A light grey shading of 0.4 cm thickness was used to separate items, in order to reflect the 
responses that related to a particular item; grid lines were avoided.
 Tick boxes were provided for giving responses
 Responses categories followed a natural ordering from ‘no, not at all’ on the extreme left 
to ‘very much’ on the extreme right.
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 Instructions were provided on what was being measured and the relevant recall period for 
participants to use in recalling their answers and how to choose responses. Instructions 
presented on the first page were circumscribed in a border to enhance their visibility. 
Instructions were also included on each page throughout the instrument. 
The earliest proto-type of the new questionnaire contained a total of 75 QoL issues (Table 3.3). 
Subsequently this was re-organised to form the 47 item HidroQoL mostly by combining similar 
issues (Table 3.3) Its items were scored on a 5 point Likert scale with an additional ‘not applicable’ 
option.
DISCUSSION
Recognising patients as the experts in their personal experiences with their disease (Rothman et 
al. 2009), this study utilised a mix of qualitative methods to dig into the thoughts, perceptions and 
beliefs of patients with hyperhidrosis in relation to their experience of living with the condition, 
particularly to understand the extent and nature of QoL impacts. An additional aim of the study 
was to use the information collected from patients to develop a new instrument for assessing QoL 
impacts in hyperhidrosis. The findings obtained in this study are in accordance with previous 
published studies on the impacts of hyperhidrosis on patients HRQoL (Tan et al; Hamm et al; 
Solish et al.; Neumann et al.).  The QoL impacts of hyperhidrosis were cross-cutting. Patients have 
previously also reported feeling that their life is taken over by hyperhidrosis (Thomas et al. 2006). 
For example, aspects of daily living including choice of clothing and relationships with family and 
friends have been reported to be affected (Thomas et al., 2006). In a study by (Solish 2006), 
respondents reported limitations when in public places (74%); meeting people for the first time 
(70.2%); developing personal relationships (58.5%). Patients mentioned feeling less confident 
than they would like (69.8%); frustration with some daily activities (58.2%); changing (41.6%) or 
reducing time spent (34.6%) on leisure and reducing time spent working. Patients reported being 
emotionally impaired (74%), having less confidence (74%), reduced work performance (63%), 
influences on career choice (42%); while a comparative control group registered no impairment in 
a study based at German University clinic (Hamm et al. 2006). 
The HRQoL impacts of hyperhidrosis are comparable to those experienced in other chronic 
conditions. For instance, the condition had an influence on major life changing decisions (e.g. 
career choice) and location, which have been previously observed in psoriasis, cystic fibrosis or 
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diabetes (Bhatti et al. 2011). Impairment in dermatology-QoL was comparable to other skin 
conditions: the DLQI scores from patients with axillary (17 – 11.6) or palmar (18 – 9.1) 
hyperhidrosis were comparable to, or worse than those from patients with dermatitis (inpatient) 
(16.2) or psoriasis (13.9). Cina and Clase (Cinà and Clase 1999) found the lifestyle intrusiveness 
associated with hyperhidrosis to be worse than in other known chronic conditions, such as end-
stage renal disease, rheumatoid arthritis or multiple sclerosis.
The use of qualitative methods in this study provided further insights beyond merely identifying 
QoL effects, but also the main factors influencing those issues were explored. This was highly 
useful for two main reasons, first in supporting the understanding of the interconnection between 
various impacts. For example, the fear of others noticing and judging the person lead to feelings 
of ‘embarrassment’, which in turn result in avoiding situations in which others would notice the 
sweating or they would feel the negative emotions, which essentially reflects the daily life and 
social life impacts. The same can be said about feelings of anxiety, experienced whenever the 
person sweats in the presence of others or; whenever they think their sweating is noticeable. 
Consequently, such situations are avoided. Furthermore, as in psoriasis (Magin et al. 2009), 
Table 3.3: List of issues forming the initial 75-item instrument proto-type
1 Sweating influences my choice of clothing (e.g. design, colour or material)
2 I avoid exposing soaked clothing around the armpits area sweating (e.g. I avoid raising my arms)
3 I do activities at a slower pace due to the sweating (e.g. physical activities such as walking)
4 Sweating influences my choice of footwear
5 Holidays are less enjoyable because of sweating
6 I have trouble handling money with my hands because of the sweating 
7 I have trouble giving care to  children because of my sweating
8 I avoid certain foods  e.g. spicy foods because they make me sweat (gustatory sweating)
9 I find it difficult to do hobbies that involve physical activities (e.g. walking, cycling, exercising, playing musical 
instruments)
10 Doing work-related activities is difficult (e.g. dealing with clients, caring for patients, working with tools)
11 Sweating restricts my life (e.g. stops me from travelling)
12 Sweating influences my career decisions (e.g. choice of work)
13 Handling paper documents and writing is difficult because of my sweating
14 I avoid outdoor activities (sun-basking or gardening)
15 I have trouble using hand operated electronics due to my sweating (e.g. computer keyboards, cell-phone, touch-screens)
16 My sweating makes shopping difficult
17 Activities involving walking barefoot are difficult because of my sweating
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Table 3.3 (continued)
18 I dread holding or shaking hands with others
19 Sweating interferes with my personal relationships (e.g. with friends or partner)
20 I feel embarrassed because of the sweating
21 I can’t socialize as much as I would like to
22 I am afraid of meeting new people
23 I fear speaking to groups of people because of my sweating (e.g. doing presentations, meetings, interviews)
24 I avoid going out (e.g. to parties, eating in restaurants)
25 I am a virtual recluse because of my sweating
26 I can't find a treatment that works for me
27 My doctor does not understand my condition
28 Adapting to the sweating is difficult (e.g. maintaining body hygiene, need to keep fan or air condition on)
29 I disguise my sweating (e.g. wear gloves, jacket, socks)
30 I carry spare clothes or towel with me because of my sweating
31 I fear that my sweating will be noticed by others
32 I look untidy 
33 I change clothes... 
34 I shower…
35 I feel less attractive
36 I can't wear a hairstyle or make-up of my choice 
37 Sweating makes me feel nervous
38 Sweating has taken over my life
39 I fear doing new things because of my sweating
40 I feel hopeless 
41 My sweating makes me feel sad
42 I feel miserable because of my sweating
43 I dread summers because of the sweating
44 I fear that my sweating is worsening
45 I think about sweating ...
46 My self-esteem is low because of my sweating
47 I feel less confident because of my sweating
48 I am emotionally drained because of the sweating
49 I feel more self-conscious because of my sweating
50 Sweating makes my sexual life less enjoyable 
51 I fear leaving sweat marks on objects
52 I have trouble being in crowded spaces because of my sweating (e.g. in bus or train)
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Table 3.3 (continued)
53 I am drenched in sweat (e.g. my clothes are wet)
54 My sweating is physically uncomfortable
55 Light movements make me sweat (e.g. getting dressed)
56 I slide in and out of my shoes 
57 Sweat gets into my eyes 
58 My feet give an unpleasant odour
59 It is difficult to grip objects in my hands because of my sweating (e.g. tools, door knobs)
60 I am afraid to physically express affection because of my sweating (hugging and cuddling)
61 I avoid getting close to people (when sitting, queing, dancing)
62 I feel that others judge me because of my sweating 
63 I feel depressed because of my sweating
64 I fear rejection from others because of my sweating
65 My sweating makes housework difficult (e.g. cleaning, cooking)
66 My sweating exerts a financial burden on my life
67 Casual walking makes me sweat
68 My skin is sore and cracked because of my sweating
69 I can’t do things spontaneously
70 Sweating makes driving difficult
71 Doing physical activities is difficult because of my sweating (e.g. manual work)
72 My body (or clothes) gives a bad odour because of the sweating
73 I sweat even in winter
74 I get other skin problems as a result of my sweating
75 I feel hot even in winter
126
Figure 3.3: The 47-item developmental version of the new instrument
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avoidance of activities that would put the patient on the spot light, making the sweat more 
noticeable and; situations where self-consciousness, embarrassment and anxiety might be 
experienced explained most social life and life style impacts. For multi-factorial skin disorders, 
the psychological stress of living with the condition tends to exacerbate the condition 
(Beltraminelli and Itin 2008), which seems to be the case in hyperhidrosis. (Park et al. 2010) found 
that anxiety, stress and social relationships to be more influential aggravating factors for 
hyperhidrosis ahead of heat or summer season based on a Korean sample attending a university 
hospital centre. On the other hand, heighted concerns over how people would react to the sweat at 
the core of most impacts of the condition seems strongly rooted in a ‘perfect body image’ 
perpetuated in modern society (Beltraminelli and Itin 2008).
For the first time the findings of this study revealed perceptions of the patients on the management 
of hyperhidrosis. The patients perceived general practitioners as lacking knowledge on the 
condition; not showing empathy and understanding in their interaction with the patients. Such 
experiences were reported across the entire continuum of care, from diagnosis to treatment 
decision-making. Similar observations have been made in other skin conditions (Nelson et al. 
2012). Further concerns of the patients such as the need for quality information on the condition; 
the lack of public awareness, leading to a lack of public sympathy have been previously reported  
(Golics et al. 2009) Managing excessive sweating and its impacts can be quite demanding in terms 
of time, effort and money. Patients spend 15 to 60 minutes in managing symptoms of the condition, 
50 – 70% of patients change their clothes more than twice a day (Hamm et al. 2006), while slightly 
more than a fifth of patients have been noted to use some aides to make it possible to carry out 
their daily life as normal (Strutton et al. 2004). In this study patients reported carrying around 
towels, handkerchiefs for drying up; having a fan or air conditioner on when at home or at work;
or carrying around a handheld fan or even using hand-dryers in public restrooms when on the go. 
Still, a good part of dealing with the condition involves disguising or concealing the sweating.
The complexity of QoL impacts of hyperhidrosis, particularly their interrelations and strong social 
rooting, has implications for their measurement. First, instruments that focus on severity of 
physical symptoms may underestimate the impact.  Moreover, subjective experience of patients 
may be more relevant and important in determining QoL than the degree of objective severity 
(Russo et al. 2004; Jobling and Naldi 2006) such that even mild severity may still result in major 
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QoL impacts. On the other hand, use of a generic HRQoL instrument, in spite of their broadness 
might miss out on some issues specific to hyperhidrosis patients, while including some irrelevant 
materials. This calls for a measure that would reflect the appropriate emphasis on issues most 
important for hyperhidrosis patients while concurrently excluding irrelevant materials. 
The second part of this study involved developing a new instrument for assessing the QoL impacts 
of hyperhidrosis, based on the information reflecting the experiences and perception of the 
patients. The implications of the approach taken were multi-fold: first, this ensured that the 
instrument being developed had high applicability for the intended measurement purpose and 
acceptability in the target patient population (patients with hyperhidrosis). Second, the 
involvement of the target patient population in item elicitation was essential to the content validity 
of the new measure (Rothman et al. 2009).  Ultimately, this reflects the essence and nature of  
measures of QoL-impact as a vehicle for patients to express their voice in relation to the impacts 
of their condition on all aspects of daily life (Basra and Shahrukh 2009).
Drug regulatory authorities such as the FDA require documentation on the process followed in the 
development of PRO instruments used in making labeling claims, as evidence for content validity 
(US-F.D.A. 2009). This points towards the need for an organized and well thought out 
development process. The development of the new instrument, therefore, involved: first, defining 
measurement aims, the target population, the construct and level of specificity with which it would 
be measured; second, setting criteria to guide the selection of issues and drafting of content; and 
finally the actual drafting of the questionnaire. 
The new instrument was intended for assessing impacts of QoL on individual patients in routine 
clinical practice and in clinical research. The target patient population includes all forms of 
hyperhidrosis, based on body-area affected. The construct was being measured at a level generic 
enough for the items to have relevance to all forms of hyperhidrosis. The items reflected aspects 
of QoL affected by hyperhidrosis based on the personal feelings and perceptions of the patients. 
Response categorization was chosen to reflect different levels of impairment in the concepts 
addressed in each item. Instructions were written to be clear, highly visible and offer useful guide 
to the patients in the questionnaire completion process. Frame of reference was chosen to minimise 
recall bias and match the aspects of hyperhidrosis-QoL. Formatting decisions were made to realize 
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a simple, natural and organized design ensuring easy navigation, minimal respondent burden and 
an attractive questionnaire.
The data collection in this study benefited from triangulation of several qualitative data collection 
methods including focus groups, semi-structured interviews and online open surveys. During the 
FGD, interactions among participants helped with stimulating new aspects or topics of discussion, 
generating additional data otherwise not realisable (Patrick et al. 2011b). The interviews, on the 
other hand, provided in-depth and detailed information about an individual’s experience besides 
the relative ease of arranging appointments with the patients (Patrick et al. 2011b). The surveys 
with open ended questions were the low-hanging fruit, as they could be implemented with relative 
ease, while providing a good balance between ability to reach large numbers of patients relatively 
easily while still allowing respondents to give detailed description of their opinions (Bowling 
2009), however, lack of opportunity for probing as is the case in FGD or interviews my limit the 
depth of information provided.
SUMMARY
 This study has provided deep insights into the major issues influencing the HRQoL of 
patients with hyperhidrosis. Further, the unmet health care needs of relevance to the 
patients HRQoL were also identified, including treatment and information related issues.
 The HRQoL issues identified from the qualitative study, which are based on the patient’s 
own words provided a rich source for developing the content of a novel hyperhidrosis-
specific QoL questionnaire for assessing QoL impacts of hyperhidrosis, ensuring that the 
new measure was indeed appropriate and had the right emphasis for the target patient 
population.
 The structured process followed in the development of the new instrument, including the 
development of a conceptual framework; having a clear criteria for the content; and 
subsequently drafting the content of the instrument in line with the criteria, further 
enhanced the appropriateness and suitability of the new measure for hyperhidrosis patients. 
Enhancing the new measure’s content validity, acceptability and practicality 
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CHAPTER 4
Development of a Hyperhidrosis-Specific Health-Related 
Quality of Life Instrument: Content Validation
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INTRODUCTION
Evidence supporting a particular interpretation of scores reflects claims that a PRO instrument 
measures what it purports to measure i.e. that it has construct validity (Lohr 2002). Crucially, such 
evidence is based on the presumption that the observable indicators are related to the underlying 
construct being assessed which ought to be established through content validation. Formally, the 
content validity of an instrument reflects the extent to which it represents the most relevant and 
important aspects of a concept in the context of a given measurement application (Magasi et al. 
2012). Ensuring content validity, therefore, requires that the content domain is adequately sampled 
suggesting a rigorous instrument development process (Nunnally and Bernstein 1994, p.102). 
Similar to other psychometric properties, content validity relates to particular measurement aims, 
usage, construct being assessed and target population, hence the need for their clear articulation 
(Terwee et al. 2007). In particular, experts judge the appropriateness and relevance of the content 
in relation to the construct being measured and the considerations listed above (Streiner and 
Norman 2008, p.252). This process, then, is the first ‘proof of concept’ that the instrument’s content 
is connected to the construct being measured. Without such evidence, construct validity and the 
meaning attached to the instrument’s scores (interpretability) may not be established (Haynes et 
al. 1995). On the other hand an instrument demonstrating content validity is more likely to reflect 
strong construct validity, interpretability besides superior acceptability and practicality as it would 
tap into the most relevant issues for both the construct and patients, also rendering the measure 
more interesting to patients. The qualitative study in the previous chapter (chapter 3) reported on 
how QoL issues were collected from patients; the conceptualisation of HRQoL in hyperhidrosis; 
the subsequent transformation of QoL issues into content of the instrument providing initial 
evidence of content validity. In this study, content validity was formally assessed. 
OBJECTIVES
The objectives of this study were to:
 Assess whether the content of the new instrument was relevant to patients with 
hyperhidrosis and the concept of quality of life in hyperhidrosis.
 Assess the adequacy with which the new instrument represents the concept of 
hyperhidrosis quality of life.
 Assess the appropriateness of the layout, recall period and technical quality of the new 
instrument for assessing hyperhidrosis quality of life.
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METHODS
The scope of an instrument’s content considered during content validation studies extends beyond 
just items and their responses. All elements of the instrument that would influence the data 
collected are included (Haynes et al. 1995). Responses and collected data may be influenced for 
example by the structure of the instrument (the instructions, response formats, frame of 
references), technical quality of the measure, apart from the relevance of the content to a given 
patient population (Patrick et al. 2011b).  This study, therefore, considered the following aspects:
 The Layout: the graphical structure and design must lend themselves to a natural flow 
through the questionnaire (Mullin et al. 2000) including pagination, font size and font 
styles.
 Instructions provide important orientation to the patient regarding what is being measured, 
the frame of reference to apply when providing responses, and how to choose between 
response categories (Patrick et al. 2011b). Thus, the need that they are adequate, clear and 
appropriately located.
 Frame of reference: this defines the period of time patients need to refer to when providing 
their responses, the recall period (Norquist et al. 2011).  It has to be suitable for the 
construct being measured (HRQoL impact), the characteristics of the disease, the treatment 
and duration of treatment-effect, the intended number of assessments and the target 
population (Norquist et al. 2011).
In addition, individual items were evaluated on the following criteria:
 Language-clarity: The sentence and wording of each item should be clear, understandable, 
straightforward and simple. Phrases and wording should be unambiguous and jargon free 
and should be understood by someone with a reading ability of a 12-year old (Streiner and 
Norman 2008).
 Completeness: The sentences should be complete, not broken and should end 
appropriately, comprehensively addressing the idea they are covering (Guyatt et al. 1993)
 Relevance: Each item should reflect an aspect of HRQoL of importance to the target 
patient population, thus also relevant to the construct being measured (Leidy et al. 1999)
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 Scaling: This represents how the actual responses of the patients will be measured. The 
choice of the response format, number and labelling of response categories must fit the 
items and be appropriate to the construct being measured (DeVellis 2011). 
Panels
Five dermatologists located at various centres in Germany, were invited to participate in the 
content validation of the hyperhidrosis. They were all multi-lingual, and were leading experts in 
hyperhidrosis. Two were heads of dermatology departments at University clinics. The other two 
were active in clinical research related to hyperhidrosis. An invitation was also made to seven 
patients who had lived with the condition for at least 10 years and who were English native 
speakers through the International Hyperhidrosis Society (IHHS). A minimum of 3 experts is 
accepted for such panels, although having five or more reduces chance agreement (Lynn 1986). 
Two separate panels were conducted for the dermatologists and the patients. 
Three experts in outcomes research were invited to participate in the review process following 
content validation. This included a professor in health outcomes measurement, two clinical 
researchers with experience in hyperhidrosis, one with a medical degree, and the other with a 
pharmacy degree. Both panels were chaired by the principal investigator (P.K.).
Materials
Each panel member was provided a copy of the developmental HidroQoL and the content 
validation questionnaire. The developmental HidroQoL was conceptualised as an instrument for 
assessing the impacts of hyperhidrosis on the quality of life of patients. The instrument included 
47 items addressing all aspects of quality of life considered important to patients solicited during 
previous qualitative work in hyperhidrosis patients (chapter 3) and six response options were 
provided: ‘No, not at all’; ‘A little’; ‘Somewhat’; ‘Quite a bit’; ‘Very much’; and ‘Not relevant’. 
The content validation questionnaire evaluated each of the 47 items of the HidroQoL on four 
aspects: language clarity, completeness, relevance, scaling, previously defined. Each of these 
aspects were rated on a 4 point-Likert scale as 1 = strongly disagree, 2 = disagree, 3 = agree, 4 = 
strongly agree, for all items. Additional space was provided for open-ended feedback or 
suggestions for each item as well as the entire questionnaire.
Procedure 
An invitation to participate in the content validation study was sent to the experts by email. 
Subsequently, a copy of the HidroQoL and the content validation questionnaire were sent. The 
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purpose and intention of the study including guidance on how the experts were to assess the 
HidroQoL were included in the email communications and were also contained on the content 
validation form. Appointment dates for the panel session were also agreed after a number of email 
exchanges. Two sessions, for the dermatologists and the patients, were conducted in the form of a 
panel discussion, assessing the adequacy of all aspects of the HidroQoL. Decision-making during 
the panels was based on the consensus and agreement of all panel members. Completed content 
validation questionnaires were returned by the experts either before or at the beginning of the panel 
sessions. Decisions required the agreement of all panel members.
Data Processing and Analysis 
Panel sessions were tape recorded and later transcribed. Transcripts were analysed for the major 
issues and decisions relating to each aspect of content assessed. Open ended feedback and 
suggestions on the content validation questionnaire were handled in the same way. Item ratings 
from the questionnaire were coded and then analysed using SAS Software, version 9.2 and MS 
Excel 2007.
Multiple approaches were used for quantifying and interpreting the ratings:
i) Mean item score was calculated for language clarity, completeness, relevance and 
scaling. A mean value of at least 3 is required for adequacy of an item, following 
previous work (Davidson 2003).
ii) Average deviation mean index calculated as standard deviation (SD) of individual item 
ratings was estimated to capture extent of disagreement on item ratings (Burke and 
Dunlap 2002). SD greater than 0.75 indicated disagreement (Davidson 2003).
iii) Content Validity Index (CVI) was calculated for each individual item and for the scale 
as a whole, for language clarity, completeness, relevance and scaling. An item CVI (I-
CVI) is computed as the proportion of individuals giving an item a rating of 3 (agree) 
or 4 (strongly agree), while a scale CVI based on universal agreement (S-CVI/UA) is 
given by proportion of items receiving a rating of 3 or 4 from all raters (Polit and Beck 
2006). Attaining endorsement requires a minimum I-CVI of 1 for a panel of 5 members 
or less and 0.78 where there are six or more (Lynn 1986; Polit and Beck 2006). 
Minimum threshold for S-CVI/UA of 0.8 was applied in judging validity at the scale 
level (Polit and Beck 2006)
iv) Finally, inter-rater agreement of the expert ratings was assessed at the scale level, using 
the Gwet’s coefficient of agreement statistic, which is effective and free of the 
vulnerabilities of the multi-rater kappa coefficient (Gwet 2002). The Gwet coefficient 
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is interpreted in a similar way as the kappa coefficient: < .00 is considered poor; .00 –
0.2 is slight; .21 - .4 is fair; .41 - .6 is moderate; .61 - .8 is substantial, .81 – 1 is almost 
perfect (Landis and Koch 1977).
RESULTS
The results are presented under three sections. The first includes findings from the patient-expert 
panel, the second covers the dermatologist-expert panel and the third includes review panel which 
carried out the final revisions.
Part I: Patients-Expert Panel
Panel session
All aspects including the design and organisation of the instrument were thoroughly discussed 
during the panel session, in some instances, varied conclusions would be reached as 
recommendations. The general layout of the instrument, including the font-type, font-size and 
organisation of the instrument were considered appropriate and adequate. Instructions were 
thought to be understandable and helpful in completing the questionnaire. Suggestions were made 
on the questions related to patient demographics: i) to allow respondents to choose more than one 
dominant area affected ii) to add a question on previous treatments iii) to provide examples of 
activities patients needed to consider in addressing the question on additional money or time spent 
on hyperhidrosis, iv) to provide space where respondents would describe how the disease had 
impacted them, in addition to responding to the general impact question.
The panel had diverse views in relation to the frame of reference used as the recall period. They 
stated that ‘at the moment’ did not reflect their experiences. Members argued that their condition 
tends to fluctuate on longer time horizon than day to day. On the other hand, they said, the relief 
from treatments such as oral medications or iontopheresis tend to last over a couple of days to 
weeks. The panel suggested either not specifying time frame or to use ‘at peak when sweating is 
at its worst’ as recall period. In relation to response formatting the panel suggested reversing the 
initially proposed format (‘no, not at all’, ‘a little, somewhat’, ‘quite a bit’, ‘very much’, ‘not 
relevant’). One panel member argued that it seemed logical to have ‘no, not at all’ next to ‘not 
applicable’, than as initially arranged where ‘very much’ was placed next to ‘not applicable’. The 
suggested format was ‘very much’, ‘quite a bit’, ‘somewhat’, ‘a little’ ‘no, not at all’, ‘not relevant’.
In order to assess whether the construct of hyperhidrosis-QoL was adequately covered by the 
developmental instrument, the panel was asked whether there were any gaps in the content or 
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whether they would make any additions on the items. They considered the HidroQoL to cover all 
important HRQoL issues for patients with hyperhidrosis, thus they suggested no additions.
Content Validation Questionnaire
All forty-seven items had mean scores of at least 3 for language clarity, completeness, relevance, 
scaling (Table 4.1). According to the Average Mean Deviation Index, item-level disagreement in 
the ratings was noted. The SD for language clarity ratings in 16 items exceeded 0.75 including for 
I worry about being in places close to other people (SD = 1.41), I feel that I need more time for 
hygiene (1.1), I have problems speaking with groups of people (1.1). Similarly, SD for 
completeness ratings for I feel more self-conscious (1.34), I worry about people’s reactions (1.34) 
and I worry being in places close to other people (1.1) and an additional sixteen items were above 
threshold. Ratings for relevance and scaling had high SD in eight and two items, respectively. Six 
items had language-clarity I-CVI below 0.8, including ‘my holiday is affected (I-CVI=0.6)’, ‘I
have problems speaking with groups of people (I-CVI=0.6)’, ‘I worry being in places close to other 
people’, and ‘I slide in and out of my shoes (I-CVI=0.6)’. I-CVI was below 0.8 for three items for 
completeness including my holiday is affected, I worry being in places close to other people, I 
slide in and out of my shoes, while only 1 item (my eating habits are affected) had relevance I-CVI 
below threshold. All items were endorsed for scaling. At the scale level, all aspects (language 
clarity, completeness, relevance and completeness) achieved content validity (S-CVI = 87% to 
100%) (Table 4.2). Agreement on ratings at the scale level was also strong on all the four aspects 
assessed, the coefficient of agreement ranged from 0.7 to 1.
Suggestions
In addition to the individual item ratings, the experts also provided comments and suggestions 
pertaining to specific items as well as the whole questionnaire. Comments were given on 34 items 
(Table 4.3). For example respondents commented that they were not sure whether the item ‘My 
holiday is affected was asking about the actual holidays or its planning. One expert thought the 
item ‘my self esteem is affected’ duplicates my self confidence is affected. In reference to the item 
“I feel my skin is hot all the time”, one panel member commented that sweating would still occur 
even when they felt cold. Another comment made in relation to the same item was that it was not 
the skin was necessarily hot, but rather damp/wet. 
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Part II: Dermatologists panel
Panel session
The dermatologists’ panel found the general layout of the instrument including the font-style, font-
size and organisation of the instrument was appropriate and adequate. The panel found the font-
size and font-type to be suitable and appropriate. The instruction If a statement does not apply to 
you please mark ‘not relevant’ on the first/cover page of the draft HidroQoL (Appendix  A4.1) 
were considered inappropriately placed on the first page. Concerns were raised that patients might 
also apply this instruction to the demographics question following immediately after on same page,
resulting in confusion or mistakes in the completion of the demographic questions. The panel’s
recommendation was to remove this instruction from the first page, but to retain it on the rest of 
the pages. It was suggested that the instructions on the rest of the pages of the instrument be 
enclosed in a border. An additional change was suggested to the instruction The statements in this 
questionnaire relate to how your life is being affected by your excessive sweating condition 
(hyperhidrosis) at the moment. Instead of emphasising the words ‘your’ only, emphasis was to be 
placed on the entire clause ‘your life is being affected by your excessive sweating’. 
The recall period ‘at the moment’ was considered to be too short and impractical. It was argued 
that when patients are asked about how they feel at the moment, they relate to events of the 
preceding days. They further stated that if the instrument were to be used for monitoring of 
response to treatments, a day may not be long enough to observe any meaningful changes. A recall 
period of 1 – 2 weeks was suggested instead. Several issues were raised regarding the response
scaling: for the general impact question, ‘in general, how would you rate the effect of excessive 
sweating on your life’ with response options: ‘no effect at all’, ‘slight’, ‘moderate’, ‘quite a bit’
and ‘extreme’, the panel considered these to not appropriately reflect equal interval of increasing 
intensity. They suggested changing ‘slight’ to ‘mild’; ‘quite a bit’ to ‘strong’ and extreme to ‘very 
strong’. Furthermore, in relation to the response scaling used for the individual items, ‘no, not at 
all’, ‘a little’, ‘somewhat’, quite a bit’ ‘very much’, ‘not applicable’, the panel made a number of 
points. They considered ‘a little’ and ‘somewhat’ to lack a clear demarcation; ‘quite a bit’ was 
seen as not reflecting midway between ‘somewhat’ and ‘very much’. A strong case was made 
against including ‘not relevant’.
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Table 4.1: Patient-panel ratings of language clarity, completeness, relevance, scaling of the 
HidroQoL
I-CVI
Instrument Item LanguageComplete-
ness
Relevance Scaling
Mean SD Mean SD Mean SD Mean SD Lan ComRel Scal
1 My choice of clothing is affected 4 0 4 0 4 0 4 0 1 1 1 1
2 My choice of footwear is affected 4 0 4 0 4 0 4 0 1 1 1 1
3 My holiday is affected 3.2 1.1 3.2 1.1 3.8 0.45 4 0 0.6 0.6 1 1
4 I have difficulties gripping objects 3.6 0.89 3.6 0.89 4 0 4 0 0.8 0.8 1 1
5 I have difficulties handling money 4 0 4 0 4 0 4 0 1 1 1 1
6 I have difficulties with physical 
contact with others
3.6 0.89 4 0 4 0 4 0 0.8 1 1 1
7 My hobbies are affected 3.8 0.45 4 0 4 0 4 0 1 1 1 1
8 I have problems speaking with 
groups of people
3.2 1.1 3.6 0.89 3.6 0.89 4 0 0.6 0.8 0.8 1
9 My physical activities are affected 3.8 0.45 4 0 4 0 4 0 1 1 1 1
10 My outdoor activities are affected 3.8 0.45 4 0 4 0 4 0 1 1 1 1
11 My everyday housework is affected 4 0 4 0 4 0 4 0 1 1 1 1
12 I find it hard to handle paper 4 0 4 0 4 0 4 0 1 1 1 1
13 My career decisions are affected 3.6 0.89 4 0 4 0 4 0 0.8 1 1 1
14 My work is affected 3.6 0.89 4 0 4 0 4 0 0.8 1 1 1
15 I have difficulties with using touch-
technologies
4 0 4 0 4 0 4 0 1 1 1 1
16 My relationships with others are 
affected
3.6 0.89 4 0 4 0 4 0 0.8 1 1 1
17 I feel embarrassed 3.6 0.89 4 0 4 0 3.6 0.89 0.8 1 1 0.8
18 I do not socialize as much as I 
would like to
4 0 4 0 4 0 4 0 1 1 1 1
19 I avoid meeting people 4 0 4 0 4 0 4 0 1 1 1 1
20 I avoid going out 4 0 4 0 4 0 4 0 1 1 1 1
21 I feel nervous 4 0 3.6 0.89 3.6 0.89 4 0 1 0.8 0.8 1
22 I feel hopeless 4 0 3.6 0.89 3.6 0.89 4 0 1 0.8 0.8 1
23 I feel sad 4 0 3.6 0.89 3.6 0.89 4 0 1 0.8 0.8 1
24 I feel depressed 4 0 3.6 0.89 3.6 0.89 4 0 1 0.8 0.8 1
25 I feel frustrated 4 0 3.6 0.89 3.6 0.89 4 0 1 0.8 0.8 1
26 My confidence is affected 4 0 4 0 4 0 4 0 1 1 1 1
Note: Lan, Language clarity; Com, completeness; Rel, Relevance; Scal, Scaling.
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Table 4.1 (continued)
I-CVI
Instrument Item Language Complete-
ness
Relevance Scaling
Mean SD Mean SD Mean SD Mean SD Lan ComRel Scal
27 My self-esteem is affected 4 0 4 0 4 0 4 0 1 1 1 1
28 My whole life is affected 4 0 4 0 4 0 4 0 1 1 1 1
29 Sweating is constantly on my mind 4 0 4 0 4 0 4 0 1 1 1 1
30 I avoid taking on new challenges 3.8 0.45 4 0 4 0 4 0 1 1 1 1
31 My summer activities are affected 3.6 0.89 4 0 4 0 4 0 0.8 1 1 1
32 I feel more self conscious 3.8 0.45 3.4 1.34 4 0 4 0 1 0.8 1 1
33 My appearance is affected 3.8 0.45 3.6 0.89 4 0 4 0 1 0.8 1 1
34 I feel uncomfortable physically 
expressing affection
3.4 0.89 3.6 0.89 4 0 4 0 0.8 0.8 1 1
35 I worry about people's reactions 3.8 0.45 3.4 1.34 4 0 4 0 1 0.8 1 1
36 My sex life is affected 4 0 4 0 4 0 4 0 1 1 1 1
37 I worry about leaving sweat marks in 
public places
4 0 4 0 4 0 4 0 1 1 1 1
38 I worry being in places close to other 
people
3 1.41 3.2 1.1 4 0 4 0 0.6 0.6 1 1
39 My eating habits are affected 3.2 1.1 3.4 0.89 3.2 1.1 4 0 0.6 0.8 0.6 1
40 I slide in and out of my shoes 3 1 3.2 1.1 3.6 0.89 3.6 0.89 0.6 0.6 0.8 0.8
41 I have problems with being barefoot 3.8 0.45 3.8 0.45 4 0 4 0 1 1 1 1
42 My eyes get irritated 3.4 0.89 3.4 0.89 3.8 0.45 4 0 0.8 0.8 1 1
43 I feel my skin is hot all the time 3.4 0.89 3.6 0.89 3.6 0.55 4 0 0.8 0.8 1 1
44 I worry about the extra demands on 
my finances
3.8 0.45 3.6 0.89 4 0 4 0 1 0.8 1 1
45 I find it difficult to cope with my 
condition
4 0 4 0 4 0 4 0 1 1 1 1
46 I find it difficult to do things without 
planning in advance
3.8 0.45 4 0 4 0 4 0 1 1 1 1
47 I feel that I need more time for 
hygiene chores
3.2 1.1 3.4 0.89 4 0 4 0 0.6 0.8 1 1
Note: Lan, Language clarity; Com, completeness; Rel, Relevance; Scal, Scaling.
Table 4.2: Level of agreement and content validity index for the panel of patients
CVI* AC1, r**
Language clarity 87% 0.7
Completeness 94% 0.8
Relevance 98% 0.9
Scaling 100% 1
*Content Validity Index
** Gwet’s AC1 Coefficient of agreement
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Table 4.3: Comments from patients
Item Suggestions
1 My choice of clothing is affected Add ‘by my excessive sweating’ 
2 My choice of footwear is affected Add ‘by my excessive sweating’ 
3 My holiday is affected I wasn’t sure whether this is asking if the holiday itself is affected, 
or if I plan my holidays to suit my hyperhidrosis. 
Would be better if this read ‘my choice of holiday is affected’ 
4 I have difficulties gripping objects ..Would be better if read ‘ have difficulty holding onto objects’ 
Its more than objects – hand rails on tube, steering wheel in care 
6 I have difficulties with physical 
contact with others
.I understood this as: “I have difficulties in situations which involve 
physical contact with others”. Not sure if that was correct?
7 My hobbies are affected Is this asking “My choice of hobbies is affected”? 
Would be better if read ‘my choice of hobbies are affected’.
My choice of hobbies are affected 
8 I have problems speaking with 
groups of people
-I wasn’t sure what this was asking 
9 My physical activities are affected I took this to mean everyday physical activities, rather than sporting 
/ recreational. .
Maybe better if this read ‘I avoid certain physical activities which 
would exacerbate/highlight my condition’
10 My outdoor activities are affected Maybe better if this read ‘I avoid certain physical activities which 
would exacerbate/highlight my condition’
12 I find it hard to handle paper Could also add ‘hard/embarrassing’
13 My career decisions are affected I wasn’t sure if this meant my choice of career.
Could read ‘my career choice has been affected by my condition’ 
Mine have been affected in the past 
14 My work is affected Work = career? 
16 My relationships with others are 
affected
Does this mean personal relationships / work relationships / intimate 
relationships / etc? 
Ok, although may want to distinguish between close/family 
relationships and friends/work colleagues
17 I feel embarrassed Embarrassed all the time, or under certain conditions? 
18 I do not socialize as much as I 
would like to
Could read ‘my condition  inhibits my social activities’
19 I avoid meeting people Could read ‘ I avoid meeting people in circumstances where my 
condition may be obvious’
20 I avoid going out as in Q19. Also, this may be worse at certain times of the year, so 
perhaps ‘I avoid going out when my condition is at its worse’ 
21 I feel nervous Could read ‘I feel nervous that my condition will appear obvious to 
others’ …
144
Table 4.3 (continued)
23 I feel sad leave out 
27 My self-esteem is affected leave out, duplicates confidence question 
30 I avoid taking on new challenges Bit vague. ‘I avoid taking on new challenges where my condition 
would be evident’ 
31 My summer activities are affected leave out  
Ok although this underestimates the impact that warm weather has. 
‘summer is unbearable’ springs to mind 
32 I feel more self-conscious leave out More than what? ‘more’ should be taken out 
34 I feel uncomfortable physically 
expressing affection
leave out
10 My outdoor activities are affected Maybe better if this read ‘I avoid certain physical activities which 
would exacerbate/highlight my condition’
12 I find it hard to handle paper Could also add ‘hard/embarrassing’
13 My career decisions are affected I wasn’t sure if this meant my choice of career.
Could read ‘my career choice has been affected by my condition’ 
Mine have been affected in the past 
14 My work is affected Work = career? 
16 My relationships with others are 
affected
Does this mean personal relationships / work relationships / intimate 
relationships / etc? 
Ok, although may want to distinguish between close/family 
relationships and friends/work colleagues
17 I feel embarrassed Embarrassed all the time, or under certain conditions? 
18 I do not socialize as much as I 
would like to
Could read ‘my condition  inhibits my social activities’
19 I avoid meeting people Could read ‘ I avoid meeting people in circumstances where my 
condition may be obvious’
20 I avoid going out as in Q19. Also, this may be worse at certain times of the year, so 
perhaps ‘I avoid going out when my condition is at its worse’ 
21 I feel nervous Could read ‘I feel nervous that my condition will appear obvious to 
others’ …
23 I feel sad leave out 
27 My self-esteem is affected leave out, duplicates confidence question 
30 I avoid taking on new challenges Bit vague. ‘I avoid taking on new challenges where my condition 
would be evident’ 
31 My summer activities are affected leave out  
Ok although this underestimates the impact that warm weather has. 
‘summer is unbearable’ springs to mind 
32 I feel more self-conscious leave out More than what? ‘more’ should be taken out 
34 I feel uncomfortable physically 
expressing affection
leave out
35 I worry about people's reactions Reactions to what? 
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Table 4.3 (continued)
Item Suggestion
37 I worry about leaving 
sweat marks in
public places
reword hyperhidrosis, eating habits 
‘that my sweating will be visible to members of the public ’
38 I worry being in places 
close to other people
reword crowded places
39 My eating habits are 
affected
This isn’t relevant to me, but could say: My eating habits are 
affected, i.e. avoid public places to eat. OR does this mean you 
eat certain foods that cause less sweating or something?
40 I slide in and out of my 
shoes
reword 
I’m generally uncomfortable in shoes 
41 I have problems with 
being barefoot
add hyperhidrosis 
42 My eyes get irritated Could add ‘by facial sweating’ 
43 I feel my skin is hot all 
the time
leave out 
Not necessarily ‘hot’ but ‘damp/wet’ 
Can be cold and still sweating though 
44 I worry about the extra 
demands on my 
finances
I’m not sure about this. Personally, I haven’t been worried about 
this 
47 I feel that I need more 
time for hygiene 
chores
Reword
Instead of ‘hygiene chores’, should read ‘personal hygiene’
The panel raised concerns about ambiguity between the option ‘no, no at all’ and ‘not relevant’. 
An example given was of the item ‘my hobbies are affected’. Although the expectation is that only 
those without hobbies would choose the ‘not relevant’ option while those with hobbies but not 
affected choosing ‘no, not at all’, respondents may easily confuse the two.
Content validation questionnaire
The panel also assessed language clarity, completeness, relevance and scaling of each of the 47 
individual items. Mean language clarity rating was below 3 in five items including I feel 
uncomfortable physically expressing affection (mean = 2.25), I find it difficult to cope with my 
condition (2.5), I feel more self-conscious (2.25). SD for sixteen items exceeded the minimum 
threshold (SD > 0.75), including ‘I feel my skin is hot all the time’ (SD = 1.5), ‘my career decisions 
are affected’ (1.15), ‘my summer activities are affected’’ (1.15) reflecting disagreement in the 
ratings. Mean relevance rating was below 3 for sixteen items. The same items also had a mean
language clarity or completeness rating below 3. SD of relevance rating for 20 items was above 
the threshold, including my choice of footwear (SD 0 1.5), my hobbies are affected (SD = 1.15), 
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this also included all items showing mean score exceeding 3. All items had mean scaling rating of 
3 or 4, there were no disagreements on any item. Further, ratings were analysed using content 
validity index. Sixteen items had I-CVI below 1 for language clarity, including ‘I feel more self-
conscious’ (CVI = 0.25), ‘I find it difficult to cope with my condition’ (0.25) and ‘I feel 
uncomfortable physically expressing affection’ (0.25). For completeness, 12 items were below the 
threshold (CVI => 1), eight of these had also been identified with language clarity problems.
Twenty items did not achieve content validity for relevance, fifteen of which had shown problems 
for language clarity and completeness.
Table 4.4: Level of agreement and content validity index for the panel of dermatologists
*Content Validity Index
** Gwet’s AC1 Coefficient of agreement
The items with optimal language clarity and completeness but lacking in relevance included 'my 
choice of footwear is affected', 'i have difficulties with physical contact with others, ' I worry about 
the addition demands on my finances’ were endorsed for language clarity and completeness. Only 
one item ‘I feel my skin is hot all the time’ had I-CVI less than 1 for scaling.
Content validity indices were also estimated at the scale level (S-CVI/UA), for language clarity, 
completeness, relevance and scaling.  S-CVI/UA for language clarity (66%) and completeness 
(74%) was below minimum threshold, while relevance and scaling aspects were above the content 
validity threshold. Inter-rater agreement was moderate for completeness (r = 0.5) and poor for 
relevance (r = 0.2) (Table 4.4). This hints on a number of challenges associated with ascertaining 
the relevance quality of life issues based merely based on observation as opposed to first hand 
experience from patients. 
Suggestions 
A rich set of comments were provided by the panel on 29 items. Suggestions were made to delete 
five items including I feel my skin is hot all the time, I feel that I need more time for hygiene chores, 
I find it difficult to cope with my condition, My summer activities are affected. In the case of the 
item I find it difficult to cope with my condition, it was argued that although the concept of coping 
CVI* AC1, r**
Language clarity 66% 0.5
Completeness 74% 0.6
Relevance 89% 0.2
Scaling 98% 1
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is closely related to QoL it relates to a different construct. The panel feared that the item ‘My 
summer activities are affected’ would not reflect much sensitivity to change in clinical settings. A 
similar comment was made with regard to My holidays are affected. The item ‘I have problems 
with speaking with groups of people’ was also thought to cause ambiguities in the sense that it was 
unclear what sort of group, whether it was the ‘group factor’ or the ‘speaking’. More general 
comments were also made in relation to the level at which quality of life was being measured. 
Whether the instrument would focus on specific types of hyperhidrosis and the issues specific to 
each; or would assess HRQoL at a higher hierarchical level of the construct, common to all types 
of hyperhidrosis. The choice would have implications for the content, crafting of the items, 
structure of the measure and ultimately, its practicality. For example, if the instrument will aim to 
measure hyperhidrosis-QoL at a high level, then all items must be of relevance for all forms of 
hyperhidrosis. Paying no attention to this intricate decision risks development of a measure that 
would be biased against patients with one type of hyperhidrosis over another. The panel 
recommended assessing hyperhidrosis at a higher level where all items would apply to all forms 
of hyperhidrosis.
A consideration of the overall representativeness of the HidroQoL for quality of life in 
hyperhidrosis was also made by the panel. The panel identified various areas as being under-
represented in the content: i) concerns related to bad odour ii) the burden related to extra effort 
involved in managing hyperhidrosis (e.g. carrying second bags, towel, air conditioning, washing 
clothes, treatment, personal-hygiene) iii) physical discomfort associated with hyperhidrosis (e.g. 
being wet, cracked skin, dampness, hot). Although these issues were not included in the 47-item 
version of the instrument, they were nonetheless, mentioned during qualitative study.
Part III: Review panel
The data collected during the content validation panels provided a wealth of information on the 
HidroQoL covering all aspects of the HidroQoL, for instance recommendations related to ‘frame 
of reference’, ‘instructions’, suggested items to be added and the ratings of the items of the 
HidroQoL. The review panel examined this data and made decisions based on the developmental 
goals of the HidroQoL. There was consensus to maintain the instrument’s structure, the graphical 
design, font style and font size, presentation of the items, as originally intentioned, moreover no 
changes had been suggested by the expert panels. The review panel agreed to maintain the second 
instruction on the front page considering its relevance to the organisation of the entire instrument, 
with the argument that instructions on the first page relate to the entire instrument. Instructions 
were maintained on every page and were placed in borders. The recommendation maintained to 
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not specify recall period or to use ‘at peak’ was considered as not reflecting the intended use of the 
instrument, the assessment of impacts on quality of life in routine clinical practice or for research. 
This includes the assessment of change over time or making comparisons across patients. The 
review panel considered two other alternatives, ‘in recent times’, which was considered as lacking 
the necessary precision and containing some ambiguity; and ‘over the last two weeks’ which was 
thought to be too long. There were strong arguments for maintaining the initial proposal of ‘at the 
moment’, including the precision in assessing the patient’s condition at the time of measurement. 
An additional consideration was the nature of the impacts of hyperhidrosis which may be felt on a 
longer time horizon. Than at the moment the review panel therefore agreed on ‘in the last 7 days 
including today’ as frame of reference. 
Table 4.5: Dermatologists-panel ratings of language clarity, completeness, relevance, 
scaling of the HidroQoL
Instrument Item Language Complete-
ness
Relevance Scaling CVI
Mean SD Mean SD Mean SD Mean SD Lan Com Rel Scal
1 My choice of clothing is affected 4 0 4 0 3.75 0.5 4 0 1 1 1 1
2 My choice of footwear is affected 3.75 0.5 4 0 3.25 1.5 4 0 1 1 0.75 1
3 My holiday is affected 2.75 1.5 3 1.41 2.75 1.5 4 0 0.5 0.75 0.5 1
4 I have difficulties gripping objects 4 0 4 0 4 0 4 0 1 1 1 1
5 I have difficulties handling money 4 0 4 0 3.5 1 4 0 1 1 0.75 1
6 I have difficulties with physical 
contact with others
3.5 0.58 3.75 0.5 4 0 4 0 1 1 1 1
7 My hobbies are affected 3.25 0.96 3.5 1 3 1.15 4 0 0.75 0.75 0.5 1
8 I have problems speaking with 
groups of people
3.25 0.96 3.5 1 3.5 1 4 0 0.75 0.75 0.75 1
9 My physical activities are affected 3.75 0.5 3.75 0.5 3.5 0.58 4 0 1 1 1 1
10 My outdoor activities are affected 3.5 0.58 3.75 0.5 3.25 0.96 4 0 1 1 0.75 1
11 My everyday housework is affected 4 0 4 0 3.5 1 4 0 1 1 0.75 1
12 I find it hard to handle paper 4 0 4 0 3.75 0.5 4 0 1 1 1 1
13 My career decisions are affected 3 1.15 3.5 1 3.75 0.5 4 0 0.5 0.75 1 1
14 My work is affected 4 0 4 0 4 0 4 0 1 1 1 1
15 I have difficulties with using touch-
technologies
4 0 4 0 3.75 0.5 4 0 1 1 1 1
16 My relationships with others are 
affected
3.75 0.5 4 0 4 0 4 0 1 1 1 1
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Table 4.5 (continued)
Instrument item LanguageComplete-
ness
Relevance Scaling CVI
Mean SD Mean SD Mean SD MeanSDLanCom Rel Scal
17I feel embarrassed 4 0 4 0 4 0 4 0 1 1 1 1
18I do not socialize as much as I would 
like to
4 0 4 0 4 0 4 0 1 1 1 1
19I avoid meeting people 3.75 0.5 3.75 0.5 3.75 0.5 4 0 1 1 1 1
20I avoid going out 4 0 4 0 3.75 0.5 4 0 1 1 1 1
21I feel nervous 4 0 4 0 3.75 0.5 4 0 1 1 1 1
22I feel hopeless 4 0 4 0 4 0 4 0 1 1 1 1
23I feel sad 3.5 1 3.5 1 2.75 0.96 4 0 0.75 0.75 0.5 1
24I feel depressed 4 0 4 0 3.75 0.5 4 0 1 1 1 1
25I feel frustrated 3.75 0.5 4 0 3.75 0.5 4 0 1 1 1 1
26My confidence is affected 4 0 4 0 3.75 0.5 4 0 1 1 1 1
27My self-esteem is affected 3 1.15 4 0 3.25 0.96 4 0 0.5 1 0.75 1
28My whole life is affected 4 0 4 0 3.75 0.5 4 0 1 1 1 1
29Sweating is constantly on my mind 4 0 4 0 3.75 0.5 4 0 1 1 1 1
30I avoid taking on new challenges 3.75 0.5 4 0 3.75 0.5 4 0 1 1 1 1
31My summer activities are affected 3 1.15 3.5 1 3.25 0.96 4 0 0.5 0.75 0.75 1
32I feel more self-conscious 2.25 1.26 2.25 1.26 2.5 1 4 0 0.25 0.25 0.25 1
33 My appearance is affected 3.75 0.5 3.75 0.5 3.75 0.5 4 0 1 1 1 1
34 I feel uncomfortable physically 
expressing affection
2.25 1.26 3.5 1 3 1.15 4 0 0.25 0.75 0.5 1
35 I worry about people's reactions 3.75 0.5 3.75 0.5 3.75 0.5 4 0 1 1 1 1
36 My sex life is affected 4 0 4 0 3.75 0.5 4 0 1 1 1 1
37 I worry about leaving sweat marks in 
public places
3.5 0.58 3.75 0.5 3.75 0.5 4 0 1 1 1 1
38 I worry being in places close to other 
people
3.5 1 3.5 1 3.25 0.96 4 0 0.75 0.75 0.75 1
39 My eating habits are affected 3.25 0.96 3.75 0.5 3.25 0.96 4 0 0.75 1 0.75 1
40 I slide in and out of my shoes 3.25 0.96 3.75 0.5 3.5 0.58 4 0 0.75 1 1 1
41 I have problems with being barefoot 3.5 0.58 3.75 0.5 3.25 0.96 4 0 1 1 0.75 1
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Table 4.5 (continued)
LanguageComplete-
ness
Relevance Scaling CVI
Mean SD Mean SD Mean SD MeanSD LanCom Rel Scal
42 My eyes get irritated 3.75 0.5 3.75 0.5 3.25 0.96 4 0 1 1 0.75 1
43 I feel my skin is hot all the time 2.75 1.5 3.5 1 2.25 1.26 3.5 1 0.5 0.750.250.75
44 I worry about the extra demands on 
my finances
4 0 4 0 3.5 1 4 0 1 1 0.75 1
45 I find it difficult to cope with my 
condition
2.5 1.29 3.25 0.96 2.75 0.96 3.75 0.5 0.5 0.75 0.5 1
46 I find it difficult to do things without 
planning in advance
3.25 0.96 3.25 0.96 2.75 0.96 4 0 0.750.75 0.5 1
47 I feel that I need more time for 
hygiene chores
3.25 0.96 4 0 3.75 0.5 4 0 0.75 1 1 1
Additionally, as recommended by the dermatologist-panel the ‘not relevant’ response category was 
removed to minimise the risk of satisficing and measurement errors. In order to address the 
ambiguities surrounding the demarcation between ‘Quite a bit’ and ‘very much’ as pointed out by 
the experts, further consultations were made. Two experts on patient reported outcome instrument 
development were consulted on whether the response options were clear and represented equal 
intervals of increasing intensity. They considered the response categorisation to be appropriate and 
reflecting widely used response categorisation. On this basis, the review panel maintained the 
response categorisation.
The review panel agreed to delete one item ‘I find it difficult to cope with my condition’, given the 
possibility that it might be tapping into a related yet different construct than quality of life (Table 
4.7). Three new items were added i) I worry about my body odour ii) I worry about my condition 
in the future iii) I worry about people’s reaction to improve coverage of the hyperhidrosis quality 
of life. A further seventeen items were revised, for instance: the item ‘my holidays are affected’
was changed to ‘my holidays are affected (e.g. planning, activities)’; ‘I have problems speaking 
with groups of people’ was amended to ‘I avoid public speaking (e.g. doing presentations). With 
a developmental goal that the HidroQoL would be relevant for patients with hyperhidrosis of all 
forms (e.g. palmar, feet, axillary, facial) and with considerations of practicality and applicability, 
it was decided that the measure will assess hyperhidrosis-QoL at a higher hierarchical level, with 
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the implication that i) the items included would need to have relevance for all hyperhidrosis forms 
and ii) the actual crafting of the items would have to reflect the same.
Naming of the new disease-specific hyperhidrosis QoL instrument
Deciding on the name for the new instrument took a number of factors into consideration: to be 
capable of hinting on the underlying concept being measured by the instrument; the way that the 
construct was going to be measured; and ultimately to be easy to remember. It was agreed to 
include ‘Quality of Life’ in the name to reflect that the measure purports to measure this construct.
It was agreed further to include ‘hyperhidrosis’ in the name to emphasise the focus of the 
instrument i.e. disease-specific quality of life of hyperhidrosis patients. Finally, the team debated 
on whether to use profile or index as a suffix. Index was chosen to reflect the intended 
measurement model, to hint on the availability of a single score that sums up the patients quality 
of life. Therefore the full name chosen for the new instrument was ‘Hyperhidrosis Quality of Life 
Index’. The acronym HidroQoL was chosen as a combination of ‘Hidro’ reflecting water and ‘QoL’ 
reflecting quality of life. It was thought that this would also be easy to remember as a measure of 
HRQoL in hyperhidrosis. Following thorough consideration of the findings from the expert panels, 
the revisions decided by the review panel led to the developmental version of the new instrument, 
the HidroQoL (Table 4.1). This included 49 items scored on a common 5 point Likert scale. Field 
testing and further validation studies carried out later, used this version
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Table 4.6: Suggestions made by the panel of dermatologists
Item Suggestion
2 My choice of footwear is affected
− Either should be removed or item 1 should be changed to mention that "footwear" is included
− Footwear is also clothing 
3 My holiday is affected
− What exactly is affected? Choice of destination, what would happen if I holiday at the Antarctica
− Would this question be expected to reflect change in a clinical trial setting; Should be removed - it is 
ambiguous
4 I have difficulties gripping objects − For a subgroup of patients very important 
6 I have difficulties with physical contact 
with others
− initially not understood "with others" can be dropped without loss of meaning; alternatively 
"touching others" can be used.
− Most relevant for the majority o f patients 
8 I have problems speaking with groups 
of people
− initially not understood; does this capture if you are asked to participate in a conference but when 
you are not the speaker - the current wording may narrow it down unnecessarily; must change to "I 
have problems interacting with groups of people" OR "I have problems with participating in 
gatherings "; "I avoid  presenting in front of groups of people"
10 My outdoor activities are affected − Indoor is more a problem
12 I find it hard to handle paper − Only for one subgroup of patients 
13 My career decisions are affected
− active or passive? Are you failing to rise up the career ladder because of others? Or because you 
don't want to be? Career decisions is more active - e.g. "I don’t want to be the boss". Solution: "My 
career is affected"
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Table 4.6 (continued)
Item Suggestion
16 My relationships with others are affected − suggestion: my relationships are affected
19 I avoid meeting people
− duplicates "i have problems speaking with groups of people"; Q.8 must be refined; 
for someone repairing cars Q.8 might be understood as involving something 
outside his working hours
23 I feel sad
− delete; sad, depressed, frustrated are similar ! - hyperhidrosis cannot make 
someone sad
24 I feel depressed
− Can someone be depressed without being sad? Is not frustration a mild form of 
depression
26 My confidence is affected
− add the words "self-" to confidence. For the majority of hyperhidrosis patients they 
might not see a difference with self-esteem.
27 My self-esteem is affected − delete; patients will not distinguish this from "confidence"
28 My whole life is affected
− see how changing the place of this question affects the response - but this has been 
generally already covered; consistency check…can be correlated to the first 
question…
31 My summer activities are affected
− likely to not be sensitive to change; delete…same recommendation applies to 
holidays…not sensitive to therapy
32 I feel more self-conscious
− more than what ? How do you explain ? Remove "more". This is duplicate for self-
confidence
34
I feel uncomfortable physically 
expressing affection
− how do you physically express affection without contact?
37 I worry about leaving sweat marks in 
public places
− "in public places" should be deleted; this makes it more inclusive…"I worry to 
disturb other people by leaving sweat marks"
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Table 4.6 (continued)
Item Suggestion
38 I worry being in places close to other 
people
− remove "in places", it should be clear "close" is referring to physical contact and 
not "emotional closeness"…may be examples are necessary…only use examples 
if best expressions cannot be found…
39 My eating habits are affected − My eating and drinking habits are affected…"hyperhidrosis limits my eating and 
drinking habits"
40 I slide in and out of my shoes − change as I see fit
41 I have problems with being barefoot − add because of hyperhidrosis…
42 My eyes get irritated − discuss how items specific to particular hyperhidrosis are included.
43 I feel my skin is hot all the time − delete
44 I worry about the extra demands on 
my finances
− Perhaps interesting, too: “I worry about the side effects of the hyperhidrosis 
treatment” OR “I would pay 3000 € for a surgery if this would stop sweating.(JN)
45 I find it difficult to cope with my 
condition
− Delete ‘I am worried about the extra effort dealing with my hyperhidrosis takes !’
because coping as a construct is broad and means alot of things cannot be assessed 
just based on this item e.g. active coping, resignation, e.t.c.
− I don’t think patients know the meaning cope (JN)
46 I find it difficult to do things without 
planning in advance
− too general
47 I feel that I need more time for 
hygiene chores
− should be changed to I feel that I need more time for personal hygiene
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Table 4.7: Revision to the items of the HidroQoL
Before content validation After content validation
1 My choice of clothing is affected My choice of clothing is affected
2 My choice of footwear is affected My choice of footwear is affected
3 My holiday is affected My holidays are affected (e.g. planning, 
activities)
4 I have difficulties gripping objects I have difficulties holding objects
5 I have difficulties handling money I have difficulties handling money
6 I have difficulties with physical 
contact with others
I find it hard to touch other people
7 My hobbies are affected My hobbies are affected
8 I have problems speaking with groups 
of people
I avoid public speaking (e.g. during 
presentations)
9 My physical activities are affected My physical activities are affected
10 My outdoor activities are affected My outdoor activities are affected
11 My everyday housework is affected My everyday housework is affected
12 I find it hard to handle paper I find it hard to handle paper
13 My career decisions are affected My career decisions are affected (e.g. career 
choice)
14 My work is affected My work is affected
15 I have difficulties with using touch-
technologies
I have difficulties using touch-technologies (e.g. 
computer keyboard, smart-phones)
16 My relationships with others are 
affected
My personal relationships are affected
17 I feel embarrassed I feel embarrassed
18 I do not socialize as much as I would 
like to
I do not socialise as much as I would like to
19 I avoid meeting people I avoid meeting new people
20 I avoid going out I avoid going out
21 I feel nervous I feel nervous
22 I feel hopeless I feel hopeless
23 I feel sad I feel sad
24 I feel depressed I feel depressed
25 I feel frustrated I feel frustrated
26 My confidence is affected My self-confidence is affected
27 My self-esteem is affected My self-esteem is affected
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Table 4.7 (continued)
Before content validation After content validation
28 My whole life is affected My whole life is affected
29 Sweating is constantly on my mind Sweating is constantly on my mind
30 I avoid taking on new challenges I avoid taking on new challenges
31 My summer activities are affected My summer activities are affected
32 I feel more self-conscous I feel self-conscious
33 My appearance is affected My appearance is affected
34 I feel uncomfortable physically 
expressing affection
I feel uncomfortable physically expressing 
affection (e.g. hugging and cuddling)
35 I worry about people's reactions I worry about people's reactions
36 My sex life is affected My sex life is affected
37 I worry about leaving sweat marks 
in public places
I worry about leaving sweating marks on 
things
38 I worry being in places close to 
other people
I find it hard to be near other people
39 My eating habits are affected My choice of food and drinks is affected
40 I slide in and out of my shoes I feel uncomfortable in my shoes
41 I have problems with being 
barefoot
I have problems with being  barefooted
42 My eyes get irritated My eyes feel irritated
43 I feel my skin is hot all the time My skin feels uncomfortable
44 I worry about the extra demands on 
my finances
I worry about the additional money spent in 
dealing with my condition
45 I find it difficult to cope with my 
condition
[item deleted ]
46 I find it difficult to do things 
without planning in advance
I find it hard to do things without planning in 
advance
47 I feel that I need more time for 
hygiene chores
I worry about the additional time spend in 
dealing with my condition
I worry about my body odour
I worry about my condition in the future
I worry about the additional chores in dealing 
with my condition
DISCUSSION
Psychometric properties of PRO instruments such as validity and interpretability rely on the 
hypothesis that scores of an instrument reflect the ‘status’ of the underlying construct. This 
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assumes a link between the content of an instrument and the underlying construct (Wynd et al. 
2003). Evidence of content validity, underpins this assumption by demonstrating the relevance of 
an instrument’s content and how adequately it represents of the underlying construct (Rothman et 
al. 2009). Without such evidence, inferences drawn from the scores are not supported, as it is 
unclear what is actually being assessed, thus the definition of actual construct being measured 
becomes ambiguous (Haynes et al. 1995). This study, therefore, examined whether the HidroQoL 
adequately addressed important aspects of quality of life relevant to hyperhidrosis patients and 
whether the other aspects of content’s structure and technical quality support this.
Content validation of the HidroQoL employed expert panels who evaluated all aspects of the 
HidroQoL. Panel discussions and a content validation questionnaire were used for collecting data. 
The latter enabled the systematic assessment of each item, enhancing the structure, objectivity and 
credibility of the process (Lynn 1986). The panel discussions provided further information on the
structure and organisation of the instrument and other general issues, while permitting the 
collection of valuable insights. Focused discussions tend to generate rich and unique data as 
discussion members contribute and respond to each other’s comments (Krueger 1994). In addition 
to the therapeutic expert’s panel, a separate second panel was comprised of patients with 
hyperhidrosis. Apart from items and their corresponding response options, the structural aspects 
of the HidroQoL such as frame of reference, instructions and formatting were subjected to content 
validation. Not only are these aspects important in facilitating the definition -and understanding of 
the construct under measurement (Patrick et al. 2011b), but they also have a bearing on the 
acceptability and applicability of the instrument. Moreover, their role in the response generation 
process suggests that these have potential to cause substantial biases in the measurement process. 
For instance, a recall period that is too short may lead to understatement of impact being measured 
while the extreme opposite (too long recall period) may be associated with under- or 
overestimation of burden due to recall biases (Norquist et al. 2011). On recommendation of the 
experts, instructions were revised, for instance, changing the emphasis on particular phrases and; 
including instructions on each page throughout the instrument. A further recommendation was to 
change the frame of reference. The proposed ‘at the moment’, was thought to be too short and not 
a reflection of the nature of the impact of hyperhidrosis or its treatment. It was further argued that 
patients tend to think about the recent past even when asked about today. Recall period was, 
therefore, revised to ‘in the last seven days including today’. Each of the 47 individual items was 
assessed on language clarity, completeness, relevance and scaling. 
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Figure 4.1: The developmental version of the HidroQoL with 49 items
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The two methods of analysing the items, based on mean scores versus estimating an item-content 
validity index, yielded slightly differing results. The latter was more stringent and led to the 
endorsement of less items relative to the former across all aspects. On the other hand, the CVI 
offers a systematic approach for estimating the scale level validity (Polit and Beck 2006). 
The HidroQoL met content validity criteria for language clarity, completeness, relevance and 
scaling based on the judgement of the patient-panel. Relevance and scaling were also endorsed in 
the dermatologist-panel, while language clarity and completeness were not supported in this panel. 
Language clarity and completeness were closely related: items identified as having completeness 
issues in the dermatologists panel (12-items) and the patient’s panel (1-item) also had language 
clarity problems. Free comments provided by the experts may elucidate on this issue. For instance 
the comments i) I wasn’t sure whether this is asking if the holiday itself is affected or if I plan my 
holidays to suit my hyperhidrosis (for: my holiday is affected’), ii) reword crowded place; remove 
‘in places’...maybe examples are necessary (for: I worry being in places close to other people)
points towards ambiguities surrounding certain word, rendering the sentences unclear and 
incomplete. 
The two-panels rated relevance differently, the patient’s panel endorsed all items except ‘my 
holiday is affected’, while the dermatologists endorsed 27 out of the 47 items. Differences in how 
medical practitioners and patients with skin disease evaluate their own quality of life have been 
observed before (Jemec 1996). An additional and important consideration stems from the fact that 
the physician makes judgements based on observations while the patients relate to first hand 
experiences. Moreover, as observations cannot be divorced from the observer they tend to be liable 
to observer biases (Streiner and Norman 2008). This to a great extent reflects the poor inter-rater 
agreement related to the rating of relevance in the dermatologists’ panel. In view of this, there is a 
strong case for involving patients in the content validation process, especially in considerations of 
the relevance of content. Out of the twenty items not endorsed for relevance by the panel of
dermatologists, fourteen had language clarity problems. The single item considered lacking 
relevance by the patient-panel (my holidays are affected) also had language problems. This 
highlights the importance of making serious consideration of technical quality issues during 
instrument development (Hambleton and Rogers 1991). 
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SUMMARY
 The format (e.g. font size and font style) and design of the HidroQoL was appropriate and 
facilitated natural flow through the questionnaire.
 Instructions were revised to enhance their clarity and visibility in the instrument.
 The recall period of the HidroQoL was revised to ‘in the last 7 days including today’ to 
reflect the characteristics of the conditions and its treatment as well as the experiences of 
patients.
 Items of the HidroQoL were judged to be relevant to patients with hyperhidrosis and the 
concept of quality of life as it relates to them. 
 Sixteen items had language clarity issues, twelve of which were also considered lacking 
completeness. At the scale level content validity of language clarity and completeness were 
not supported.
 Seventeen items were revised, which involved replacement of words or addition of 
examples.
 One item was deleted and four were added in order to adequately cover the construct of 
quality of life as it relates to hyperhidrosis.
 Methodological decisions such as involvement of patients, whether the study includes a 
qualitative component and the choice of quantitative method for evaluating the ratings has 
a bearing on findings of content validation. 
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CHAPTER 5
Development of a Hyperhidrosis-Specific Quality of Life 
Instrument (HidroQoL): Factor Analysis
Item reduction and construct validation using classical test theory
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INTRODUCTION
Demonstrating that an instrument measures what it intends to measure involves providing 
“evidence for, as well as potential consequences of, score interpretation (Messick 1995).  This 
presumes the existence of a robust vehicle for assigning scores to the construct being measured 
i.e. a measurement model. Ascertaining construct validity in a newly developed instrument 
requires initially developing and testing a measurement model. This interprets the conceptual 
framework of an instrument in measurement terms providing a basis for subsequent hypothesis 
testing based on the instrument’s scores e.g. correlations with other existing instruments. 
Reflecting the central role of the measurement model, scientific advisory committee on medical 
outcome trust regarded it as one of the eight key attributes of a measurement instrument(Lohr 
2002).
Various multivariate analyses, including inter-item and item-total score correlations, step-wise 
regression analysis and factor analysis are typically utilised for developing and validating 
measurement models (Frost et al. 2007b).  This technique seeks to identify the least number of 
variables accounting for covariation among items, which then allows a large number of items to 
be simplified into a few variables (Kline 1994). Utilising inter-item correlations, factors group 
together items sharing more correlation. On the other hand less correlation is expected between 
items in different factors. In turn, this method allows the development of scales comprised of items 
that tap into the intended construct and share homogeneity. Such scales are likely to exhibit strong 
internal consistency. The usefulness of FA during instrument development also relates to the 
process of item reduction. The grouping together of variables that share a greater correlation also 
allows the identification of items that share a weak relationship with the construct being measured 
which can be candidates for review. This can also identify aspects of the construct that are 
underrepresented. Factor analysis is useful for evaluating other properties of instruments, 
including testing hypotheses regarding factorial structure of existing instruments, measurement 
invariance, and testing for response shift (Visser et al. 2005; Meredith and Teresi 2006). In view 
of the perennial nature of the instrument validation process, FA seems versatile to support 
hypothesis tests of different forms carried out in an instrument’s life cycle.
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OBJECTIVES
The objectives of this study were to:
 Explore the general functioning of the HidroQoL in the intended target population.
 Explore and test the factorial structure of the HidroQoL
 Identify poor items and perform an item reduction on the HidroQoL
 Evaluate the internal consistency of the revised version of the HidroQoL
 Evaluate the replicability of the factorial structure of the HidroQoL 
METHODS
Study design
Field-testing studies require the involvement of a large heterogeneous group of patients that 
represents the full range of the target population in terms of demographic and disease 
characteristics (Fayers and Machin 2007). For the intended methods of analysis, rooted in 
correlation analysis, the sample used needs to provide responses covering the entire response 
range(Gorsuch 1997). This study, therefore, followed a cross-sectional design where respondents 
completed the developmental HidroQoL questionnaire on a single time period. A large sample of
patients (n > 250) representing all types and severity levels of hyperhidrosis was targeted.
Rules of thumb on sample size requirements for correlation analysis and factor analysis vary in 
their guidance, ranging from  5 to 20 observations per variable with more suggestion above and 
below this ratio (Costello and Osborne 2005). However, the minimum sample size required for 
accurate recovery of population factor pattern matrix is influenced by many factors including the 
distribution and reliability of the variables,  degree of association among variables, communalities, 
degree to which factors are over identified (Reise et al. 2000; Schmitt 2011). Thus power and 
precision ought to be core consideration in parametric estimation  based factor methods (Schmitt 
2011), while in non-parametric approaches when communalities are high, sample size of 100 may 
be adequate (Reise et al. 2000). 
Study population
This analysis included patients with self-reported hyperhidrosis, fulfilling the following criteria:
 Aged 18 years or above.
 With a score of 2 or higher on the HDSS
 With onset of hyperhidrosis in teenage years or early adult years.
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Patients meeting the following criteria were excluded from the study:
 Below the age of 18
 With onset of hyperhidrosis after age of 30 and reporting a co-morbidity (hypertension, 
diabetes, pm hormonal disorders, psychological disorders)
 With HDSS score of 1.
Patients were recruited through hyperhidrosis online social networking communities, mainly the 
International Hyperhidrosis Society (IHHS) and the UK Hyperhidrosis support group, from May 
to September 2012. A detailed description of the study population and procedures is available in 
chapter 2.
Outcome measures
The developmental Hyperhidrosis Quality of Life instrument (HidroQoL) was used for collecting 
data on the QoL impact of hyperhidrosis. The instrument has 49 items, each scored on a 5 point 
scale, including ‘no, not at all’, ‘a little’, ‘somewhat’, ‘quite a bit’ and ‘very much’ (
Figure 4.1). Disease severity was assessed using the Hyperhidrosis Disease Severity Scale, scored 
as follows: 1. My sweating is never noticeable and never interferes with my daily activities 2. My 
sweating is tolerable but sometimes interferes with my daily activities 3. My sweating is barely 
tolerable and frequently interferes with my daily activities 4. My sweating is  intolerable and 
always interferes with my daily activities. Additional questions related to patient demographics, 
characteristics of disease and treatment related characteristics were also included.
Data Processing And Analysis
Data analysis was carried out using MPLUS 6 and STATA.  First, the data was explored using 
frequencies, for categorical variables; and mean, standard deviation and median for continuous 
variables. Further, the distribution of the responses to the HidroQoL were established calculating 
the proportion of endorsement for each item. Correlation analysis, based on polychorric 
correlations, was carried out to identify items that were multi-collinear. Correlation > .08 indicates 
multi-collinearity (Fayers and Machin, 2007). Exploratory factor analysis (EFA) was carried out
to explore the factorial structure of the HidroQoL as follows:
 Optimal number of factors was determined by parallel analysis and confirmed using scree 
plots and goodness of fit statistics.
168
The following criteria were used for identifying poor items during EFA:
 Items with highest loading below 0.4;
 Items with more than one loading above  0.4, with none above 0.5;
 Items with residual variance (uniqueness) of 0.7 or more; and
 Items whose content does not match their factor (Lackey et al. 2003; Costello and Osborne 
2005; Nijsten et al. 2006a)
Hypothesis testing of factorial structure used confirmatory factor analysis (CFA). Goodness of fit 
statistics were applied in determining how well the data fit to the model:
 Chi-square test of model fit: p-value < 0.05 indicates lack of fit;
 Tucker Lewis Index, Comparative Fit Index: Values greater than >.90 show acceptable fit, 
while >.95 indicate good fit;
 Root Mean Square Error of Approximation (RMSEA): Values > .1 show poor fit, 0.08 -
.1 shows moderate fit; < 0.05 shows good fit;
 Standardised Root Mean Square Residual (SRMR): < 0.06 show good fit;
 Weighted Root Mean Squared Residual (WRMR): < 0.95 shows good fit  (Hays et al. 
2005; Byrne 2011)
RESULTS
In the purpose of clarity the results will be presented in three parts. Part I, reports on the correlation 
analysis carried out to identify redundant items; Part II, addresses exploratory analysis of the 
factorial structure of the HidroQoL; and Part III, covers the CFA analysis carried out to test the 
replicability of the proposed structure 
Sociodemographic characteristics of study participants
A total of 674 patients with hyperhidrosis were recruited for the study, through the online patient 
communities of the IHHS and the UK hyperhidrosis support group. Out of the total, 559 patients
were from the U.S. and 115 were from the UK. The subsample including patients from the USA 
was employed in the correlation analysis and subsequent exploratory factor analyses. The group 
including patients from the UK, was utilised in the hypothesis testing of the proposed factorial 
structure. 
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US subsample - ‘sample 1’
Sample 1 comprised of a total of 559 patients with hyperhidrosis from the U.S. This included 106 
males (19%) and 453 females (81%), with a mean age of 41 (±14years) (Table 5.1). Those aged 
50 to 59 (n = 156, 28%) made up the largest age group (Figure 5.1). For the majority of the patients, 
the condition affects multiple areas. Patients whom the hands, feet and axillary were all affected 
made up twenty seven per cent of the sample. Thirty five patients had lived with condition for less 
than 10 years. Forty-six per cent of the patients reported ‘their sweating as intolerable and always 
interfering with daily activities’, the highest level of severity (Figure 5.3) Forty-nine percent
reported the impact of the sweating on their life to be extreme (Figure 5.4). The majority of patients 
(89%) had seen a doctor for their condition, and sixty-six per cent reported receiving treatment 
within the last 6 months while those receiving treatment currently were thirty-per cent (Table 5.2)
UK subsample -‘Sample 2’
Sample 2 comprised of a total of 115 patients with hyperhidrosis from the UK Thirty-seven (32%) 
were male and 78 (81%) were female (Table 5.1). The mean age was 40.2 years, with those aged 
between 30 and 39 making up the largest age group (n = 36). Similar to the US group, participants 
reported multiple areas in 36 participants whose sweating was generalized. Forty-five percent of 
the patients reported no co-morbidity. The proportion of patients reporting currently receiving 
treatment was 36%, while those who had previously received surgical treatment was 17%, in both 
instances, greater than the proportion in the U.S. sample.
Distribution of item responses
As an initial step, the distribution of the responses was assessed. For all items there was no 
response category accounting for more than 80% of responses, showing reasonable variability 
(Table 5.3) Nevertheless, the items showed a negative skew reflecting some ceiling effects. In 
forty-four items the highest response category ‘very much’ was chosen by 20% of participants. 
The ceiling effects were worse in seventeen items where 50% of participants chose ‘very much’. 
Item Q1, Q21, Q31 and Q35 showed excessively large kurtosis. Thus the data shows some minor 
departure from normality. Nine items showed very low use (below 5%) of the lowest response 
category, ‘no, not at all’, this includes Q1, Q10, Q21, Q25, Q27, Q9, Q31, Q35 and Q49. This 
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raises questions related to the utility of this category for these items. Missing data occurred at 
random, and for the items affected (Q18 – Q49), was not more than 2% of responses.
The incidence of missing data increased with successive items, starting from item Q18, reflecting 
drop-outs, people who started responding to the questionnaire but stopped along the way. 
Withstanding the ceiling effects and the underuse of response category ‘no, not at all’ the 
distribution of responses was encouraging.
Table 5.1: Sociodemographic characteristics of study participants
Sample 1 (n = 559) Sample 2 (n =115)
Gender, n (%)
Male 106 (19%) 37 (33%)
Female 453 (81%) 78 (67%)
Age (years)
Mean (SD) 40.7(14.19) 40.2(13.3)
Median 39 39
Range 18 -74 18-74
Age (years), n
18 to 29 143 27
30 to 39 142 36
40 to 49 112 24
50 to 59 156 16
≥ 60 5 12
Duration of condition, years
Mean (SD) 27.7 (14.1) 24.1 (13)
Median 25 21
Range 2 to 69 2 to 60
Duration of condition (years), n
< 10 35 12
10 to 19 134 36
20 to 29 149 26
30 to 39 109 25
40 to 49 75 10
≥ 50 57 6
Body area affected, n (%)
Head* 123 (22%) 32
Axilla* 51 (9%) 14
General 121 (22%) 36
Axilla, Palms, Feet 150 (27%) 15
Palms and Feet 114 (20%) 19
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Table 5.1 (continued)
Sample 1 (n = 559) Sample 2 (n =115)
Severity of disease (HDSS score), n
1 0 0
2 73 16
3 227 46
4 259 53
Global impact of hyperhidrosis
(GQ score), n
No, none at all 0 0
Slight 2 2
Moderate 46 11
Quite a bit 214 39
Extreme 276 58
Co-morbidity, n (%)
None 307 (55%) 52 (45%)
Menopausal complaints 58 (10%) 8 (7%)
Diabetes 29 (5%) 4 (3%)
Hypertension 48 (9%) 10 (9%)
Neurological disorders 57(10%) 9 (8%)
Thyroid disorders 60 (11%) 23 (20%)
Employment status, n (%)
Employed 360 (64%) 74(64%)
Unemployed 98 (18%) 24(21%)
Retired 67 (12%) 11(10%)
Full-time student 34 (6%) 6(5%)
Variability in the data was maintained, reflecting the usefulness of the HidroQoL’s response 
categories as well as the relevance of the items in discriminating among patients. Thirty item pairs 
had a correlation of 0.8 or greater reflecting multicollinearity problems (Table 5.4, Table 5.5, Table 
5.6, Table 5.7). This included, I feel embarrassed (Q21) against I feel nervous (Q22) and I feel self-
conscious (Q31); My self-confidence is affected (Q27) against My self-esteem is affected (Q28) 
and I feel self-conscious (Q31); and I have difficulties holding objects (Q4) against I have 
difficulties handling money (Q5), I find it hard to touch other people (Q6), I find it hard to handle 
paper (Q13) and I have difficulties using touch-technologies (e.g. computer-keyboard, smart 
phones) (Q16).
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Figure 5.1: Age distribution of the study participants
Figure 5.2: Duration of disease 
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Figure 5.3: Patient’s self-reported disease severity 
Figure 5.4: General impact of disease on patient’s life
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Table 5.2: Access to and use of treatment
Sample 1- USA Sample 2 – UK 
n % n %
Seen a doctor in relation to hyperhidrosis 485 87% 103 90%
Treated within last 6 months 368 66% 73 63%
Has received Botox within last 6 months 47 8% 7 6%
Surgical treatment 61 11% 19 17%
Currently being treated 169 30% 41 36%
Table 5.3: Frequency of endorsement to the HidroQoL
Number of participants
with each score
Proportion of participants 
(%) with each score
Mean Med Skw. Kurt
1 2 3 4 5 M 1 2 3 4 5 M
Q1 16 28 51 103 361 0 3% 5% 9% 18% 65% 0% 4.37 5 -1.69 5.07
Q2 98 36 62 66 297 0 18% 6% 11% 12% 53% 0% 3.77 5 -0.83 2.07
Q3 69 59 137 112 182 0 12% 11% 25% 20% 33% 0% 3.5 4 -0.47 2.05
Q4 185 68 89 104 113 0 33% 12% 16% 19% 20% 0% 2.81 3 0.12 1.5
Q5 244 69 94 72 80 0 44% 12% 17% 13% 14% 0% 2.42 2 0.52 1.8
Q5 91 39 61 87 281 0 16% 7% 11% 16% 50% 0% 3.77 5 -0.84 2.15
Q7 50 43 93 141 232 0 9% 8% 17% 25% 42% 0% 3.83 4 -0.89 2.68
Q8 29 48 73 121 288 0 5% 9% 13% 22% 52% 0% 4.06 5 -1.12 3.15
Q9 30 49 75 102 303 0 5% 9% 13% 18% 54% 0% 4.07 5 -1.12 3.08
Q10 20 37 62 86 354 0 4% 7% 11% 15% 63% 0% 4.28 5 -1.47 4.1
Q11 100 83 119 115 142 0 18% 15% 21% 21% 25% 0% 3.21 3 -0.21 1.74
Q12 80 72 69 86 252 0 14% 13% 12% 15% 45% 0% 3.64 4 -0.62 1.87
Q13 178 46 66 82 187 0 32% 8% 12% 15% 33% 0% 3.1 3 -0.13 1.34
Q14 61 57 122 140 179 0 11% 10% 22% 25% 32% 0% 3.57 4 -0.58 2.22
Q15 102 48 63 104 242 0 18% 9% 11% 19% 43% 0% 3.6 4 -0.65 1.88
Q15 184 43 85 101 146 0 33% 8% 15% 18% 26% 0% 2.97 3 -0.04 1.41
Q17 57 66 90 105 241 0 10% 12% 16% 19% 43% 0% 3.73 4 -0.7 2.16
Q18 112 70 105 127 142 3 20% 13% 19% 23% 25% 1% 3.21 3 -0.26 1.7
Q19 130 81 111 124 110 3 23% 14% 20% 22% 20% 1% 3.01 3 -0.08 1.66
Q20 83 85 130 110 148 3 15% 15% 23% 20% 26% 1% 3.28 3 -0.25 1.82
Q21 9 14 40 85 408 3 2% 3% 7% 15% 73% 1% 4.56 5 -2.22 7.71
Q22 29 33 65 119 310 3 5% 6% 12% 21% 55% 1% 4.17 5 -1.35 3.83
Q23 105 68 87 74 222 3 19% 12% 16% 13% 40% 1% 3.43 4 -0.4 1.63
Q24 110 104 94 72 176 3 20% 19% 17% 13% 31% 1% 3.18 3 -0.11 1.52
Notes: M, missing; Med., median; Skw., Skewness; Kurt., Kurtosis.
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Table 5.3 (continued)
Number of participants with each 
score
Proportion of participants (%) with 
each score
Mean Med Skw. Kurt
1 2 3 4 5 M 1 2 3 4 5 M
Q25 147 104 95 62 148 3 26% 19% 17% 11% 26% 1% 2.93 3 0.12 1.52
Q26 20 40 54 95 346 4 4% 7% 10% 17% 62% 1% 4.27 5 -1.47 4.1
Q27 27 50 75 112 291 4 5% 9% 13% 20% 52% 1% 4.06 5 -1.1 3.07
Q28 46 49 72 103 285 4 8% 9% 13% 18% 51% 1% 3.96 5 -1.02 2.76
Q29 17 43 66 137 292 4 3% 8% 12% 25% 52% 1% 4.16 5 -1.23 3.6
Q30 89 72 123 110 161 4 16% 13% 22% 20% 29% 1% 3.33 3 -0.32 1.82
Q31 9 24 47 106 369 4 2% 4% 8% 19% 66% 1% 4.45 5 -1.79 5.64
Q32 30 52 85 109 279 4 5% 9% 15% 19% 50% 1% 4 5 -1 2.84
Q33 95 92 100 98 170 4 17% 16% 18% 18% 30% 1% 3.28 3 -0.24 1.65
Q34 29 32 47 77 370 4 5% 6% 8% 14% 66% 1% 4.31 5 -1.63 4.52
Q35 7 24 56 118 348 6 1% 4% 10% 21% 62% 1% 4.4 5 -1.59 4.95
Q35 74 66 119 130 164 6 13% 12% 21% 23% 29% 1% 3.44 4 -0.45 1.99
Q37 48 53 93 129 229 7 9% 9% 17% 23% 41% 1% 3.79 4 -0.81 2.48
Q38 164 89 114 61 121 10 29% 16% 20% 11% 22% 2% 2.79 3 0.22 1.62
Q39 246 86 96 55 67 9 44% 15% 17% 10% 12% 2% 2.29 2 0.69 2.1
Q40 130 66 60 84 211 8 23% 12% 11% 15% 38% 1% 3.33 4 -0.33 1.48
Q41 178 47 35 55 237 7 32% 8% 6% 10% 42% 1% 3.23 4 -0.23 1.26
Q42 80 62 91 107 210 9 14% 11% 16% 19% 38% 2% 3.55 4 -0.56 1.92
Q43 285 69 82 59 54 10 51% 12% 15% 11% 10% 2% 2.14 1 0.84 2.29
Q44 162 121 100 68 98 10 29% 22% 18% 12% 18% 2% 2.67 2 0.36 1.76
Q45 147 118 97 103 88 6 26% 21% 17% 18% 16% 1% 2.76 3 0.21 1.7
Q45 112 103 108 103 124 9 20% 18% 19% 18% 22% 2% 3.04 3 -0.03 1.66
Q47 56 57 73 134 232 7 10% 10% 13% 24% 42% 1% 3.78 4 -0.83 2.41
Q48 87 57 103 115 190 7 16% 10% 18% 21% 34% 1% 3.48 4 -0.5 1.9
Q49 21 48 68 110 303 9 4% 9% 12% 20% 54% 2% 4.14 5 -1.19 3.32
Out of the thirty pairs showing multi-collinearity (correlation > 0.8), thirteen items were removed. 
Items my outdoor activities are affected (Q9) and my summer activities are affected (Q10) were 
dealing with similar issues. An aspect of both of these was addressed in my physical activities are 
affected (Q8). The social elements of the items can be argued to have been taken care of by items 
on ‘going out’ and ‘socializing’. 
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Table 5.4: Polychoric correlations between items of the HidroQoL (part 1)
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14
Q2 0.17
Q3 0.45 0.03
Q4 0.16 0.78 0.20
Q5 0.13 0.76 0.24 0.92
Q6 0.12 0.67 0.18 0.84 0.83
Q7 0.36 0.40 0.50 0.58 0.59 0.54
Q8 0.45 0.07 0.68 0.27 0.32 0.22 0.73
Q9 0.43 0.02 0.68 0.20 0.24 0.16 0.66 0.92
Q10 0.41 0.07 0.69 0.19 0.24 0.17 0.65 0.87 0.95
Q11 0.36 0.02 0.59 0.22 0.28 0.13 0.48 0.70 0.74 0.72
Q12 0.38 0.07 0.53 0.30 0.34 0.29 0.44 0.44 0.41 0.38 0.30
Q13 0.03 0.79 0.09 0.91 0.91 0.85 0.52 0.16 0.08 0.08 0.15 0.26
Q14 0.33 0.26 0.48 0.44 0.49 0.44 0.54 0.54 0.45 0.43 0.39 0.48 0.44
Q15 0.35 0.27 0.48 0.41 0.50 0.45 0.53 0.49 0.38 0.36 0.25 0.60 0.42 0.75
Q16 0.10 0.80 0.15 0.88 0.87 0.81 0.54 0.19 0.14 0.13 0.16 0.27 0.90 0.42
Q17 0.37 0.02 0.63 0.26 0.31 0.36 0.47 0.50 0.48 0.47 0.36 0.66 0.20 0.53
Q18 0.27 0.10 0.55 0.31 0.36 0.42 0.41 0.41 0.38 0.36 0.29 0.68 0.29 0.49
Q19 0.38 -0.09 0.64 0.14 0.15 0.18 0.42 0.54 0.54 0.53 0.46 0.59 0.06 0.50
Q20 0.33 0.09 0.55 0.21 0.22 0.30 0.44 0.48 0.44 0.45 0.33 0.50 0.17 0.51
Q21 0.38 0.05 0.57 0.21 0.22 0.36 0.48 0.54 0.53 0.53 0.41 0.57 0.17 0.47
Q22 0.30 0.16 0.50 0.32 0.37 0.44 0.46 0.47 0.40 0.38 0.26 0.63 0.30 0.49
Q23 0.32 0.07 0.58 0.28 0.34 0.36 0.43 0.50 0.49 0.52 0.36 0.52 0.22 0.46
Q24 0.34 0.09 0.56 0.24 0.31 0.31 0.41 0.50 0.48 0.50 0.35 0.52 0.19 0.46
Q25 0.33 0.06 0.54 0.21 0.26 0.26 0.37 0.48 0.48 0.46 0.39 0.46 0.15 0.44
Q26 0.35 0.06 0.51 0.24 0.32 0.35 0.45 0.50 0.50 0.50 0.36 0.48 0.19 0.41
Q27 0.33 0.02 0.53 0.23 0.30 0.33 0.45 0.50 0.44 0.43 0.31 0.60 0.20 0.48
Q28 0.34 0.05 0.54 0.25 0.30 0.34 0.43 0.50 0.45 0.44 0.33 0.58 0.21 0.48
Q29 0.49 0.06 0.59 0.23 0.25 0.31 0.47 0.52 0.51 0.51 0.41 0.54 0.17 0.45
Q30 0.41 0.06 0.61 0.29 0.33 0.31 0.50 0.56 0.53 0.48 0.40 0.65 0.22 0.55
Q31 0.44 0.04 0.53 0.22 0.26 0.31 0.48 0.51 0.50 0.49 0.37 0.57 0.16 0.45
Q32 0.53 -0.16 0.63 0.02 0.04 0.05 0.43 0.59 0.60 0.58 0.50 0.49 -0.09 0.41
Q33 0.43 0.14 0.38 0.18 0.20 0.18 0.28 0.32 0.32 0.33 0.25 0.33 0.11 0.26
Q34 0.39 0.42 0.31 0.57 0.58 0.60 0.53 0.34 0.31 0.32 0.24 0.33 0.55 0.43
Q35 0.32 0.14 0.43 0.29 0.31 0.46 0.43 0.40 0.33 0.33 0.21 0.50 0.26 0.52
Q36 0.34 0.10 0.57 0.32 0.36 0.41 0.43 0.52 0.47 0.46 0.34 0.59 0.28 0.53
Q37 0.35 0.13 0.47 0.40 0.40 0.57 0.46 0.47 0.44 0.43 0.36 0.48 0.34 0.48
Q38 0.34 0.14 0.48 0.21 0.26 0.31 0.40 0.45 0.40 0.42 0.32 0.43 0.21 0.42
Q39 0.30 0.08 0.44 0.13 0.18 0.14 0.29 0.42 0.45 0.45 0.42 0.30 0.07 0.34
Q40 0.08 0.90 0.06 0.77 0.74 0.68 0.41 0.12 0.05 0.10 0.04 0.13 0.77 0.32
Q41 -0.03 0.89 -0.01 0.77 0.74 0.72 0.40 0.03 -0.04 0.01 -0.02 0.14 0.81 0.35
Q42 0.22 0.47 0.36 0.47 0.50 0.50 0.49 0.43 0.36 0.43 0.33 0.29 0.44 0.39
Q43 0.23 -0.07 0.42 0.07 0.08 0.04 0.24 0.41 0.44 0.43 0.51 0.25 -0.01 0.15
Q44 0.36 0.16 0.50 0.28 0.32 0.24 0.36 0.35 0.33 0.34 0.31 0.42 0.24 0.43
Q45 0.34 0.16 0.56 0.27 0.30 0.25 0.43 0.45 0.46 0.46 0.50 0.41 0.21 0.46
Q46 0.33 0.13 0.53 0.23 0.27 0.24 0.44 0.46 0.43 0.42 0.42 0.40 0.17 0.44
Q47 0.28 0.06 0.45 0.17 0.17 0.26 0.36 0.39 0.39 0.37 0.33 0.40 0.16 0.39
Q48 0.46 0.04 0.65 0.17 0.18 0.22 0.45 0.55 0.56 0.55 0.46 0.50 0.10 0.43
Q49 0.46 0.08 0.63 0.25 0.31 0.32 0.52 0.59 0.56 0.54 0.47 0.50 0.21 0.59
177
Table 5.5: Polychoric correlations between the items of the HidroQoL (part 2)
Q15 Q16 Q17 Q18 Q19 Q20 Q21 Q22 Q23 Q24 Q25 Q26 Q27 Q28
Q16 0.43
Q17 0.63 0.26
Q18 0.63 0.33 0.85
Q19 0.53 0.09 0.85 0.81
Q20 0.53 0.22 0.72 0.72 0.75
Q21 0.51 0.13 0.64 0.6 0.63 0.61
Q22 0.55 0.26 0.64 0.65 0.6 0.59 0.8
Q23 0.51 0.24 0.63 0.6 0.64 0.62 0.76 0.76
Q24 0.53 0.24 0.66 0.63 0.66 0.65 0.76 0.76 0.9
Q25 0.51 0.20 0.63 0.61 0.66 0.66 0.71 0.71 0.84 0.93
Q26 0.45 0.26 0.56 0.53 0.55 0.54 0.72 0.66 0.78 0.79 0.75
Q27 0.58 0.20 0.71 0.7 0.68 0.66 0.78 0.79 0.76 0.78 0.75 0.76
Q28 0.57 0.22 0.71 0.72 0.67 0.67 0.77 0.78 0.76 0.78 0.77 0.74 0.98
Q29 0.47 0.18 0.56 0.51 0.57 0.53 0.73 0.62 0.67 0.66 0.6 0.71 0.69 0.68
Q30 0.66 0.24 0.76 0.73 0.73 0.63 0.71 0.68 0.67 0.71 0.71 0.64 0.73 0.73
Q31 0.51 0.19 0.63 0.59 0.63 0.59 0.83 0.73 0.74 0.74 0.69 0.78 0.83 0.82
Q32 0.36 -0.02 0.57 0.46 0.64 0.54 0.62 0.5 0.6 0.6 0.59 0.59 0.63 0.64
Q33 0.25 0.15 0.36 0.3 0.35 0.37 0.43 0.42 0.45 0.43 0.41 0.41 0.44 0.45
Q34 0.43 0.58 0.4 0.4 0.32 0.42 0.51 0.51 0.45 0.44 0.41 0.47 0.47 0.47
Q35 0.53 0.27 0.62 0.61 0.5 0.6 0.77 0.73 0.7 0.68 0.61 0.67 0.75 0.74
Q36 0.56 0.28 0.73 0.74 0.72 0.72 0.68 0.72 0.74 0.72 0.71 0.63 0.73 0.74
Q37 0.45 0.34 0.62 0.63 0.63 0.63 0.65 0.61 0.68 0.64 0.62 0.63 0.65 0.65
Q38 0.47 0.24 0.53 0.49 0.52 0.7 0.52 0.47 0.53 0.55 0.57 0.52 0.57 0.59
Q39 0.31 0.15 0.45 0.38 0.45 0.46 0.34 0.29 0.36 0.42 0.43 0.36 0.37 0.4
Q40 0.38 0.77 0.09 0.18 -0 0.14 0.13 0.24 0.21 0.2 0.17 0.22 0.2 0.21
Q41 0.35 0.80 0.09 0.17 -0.1 0.14 0.07 0.24 0.16 0.16 0.12 0.11 0.11 0.11
Q42 0.35 0.46 0.33 0.35 0.29 0.39 0.41 0.41 0.45 0.44 0.43 0.43 0.4 0.4
Q43 0.11 0.02 0.3 0.25 0.39 0.23 0.3 0.19 0.26 0.31 0.38 0.25 0.27 0.28
Q44 0.45 0.23 0.43 0.4 0.44 0.48 0.45 0.46 0.44 0.48 0.45 0.4 0.45 0.47
Q45 0.45 0.23 0.51 0.46 0.53 0.56 0.5 0.5 0.55 0.55 0.56 0.46 0.54 0.53
Q46 0.45 0.19 0.52 0.42 0.53 0.55 0.46 0.51 0.53 0.55 0.57 0.46 0.53 0.52
Q47 0.45 0.14 0.48 0.44 0.48 0.53 0.54 0.55 0.63 0.64 0.62 0.6 0.57 0.57
Q48 0.51 0.13 0.64 0.53 0.64 0.57 0.58 0.58 0.61 0.64 0.63 0.55 0.59 0.6
Q49 0.59 0.21 0.64 0.6 0.66 0.65 0.64 0.61 0.7 0.71 0.68 0.66 0.7 0.71
178
Table 5.6: Polychoric correlations between items of HidroQoL (part 3)
Q29 Q30 Q31 Q32 Q33 Q34 Q35 Q36 Q37 Q38 Q39 Q40 Q41 Q42 Q43 Q44 Q45 Q46 Q47 Q48
Q30 0.66
Q31 0.77 0.75
Q32 0.62 0.61 0.71
Q33 0.45 0.46 0.47 0.51
Q34 0.57 0.43 0.56 0.32 0.48
Q35 0.66 0.62 0.77 0.51 0.37 0.54
Q36 0.62 0.72 0.72 0.57 0.44 0.5 0.75
Q37 0.63 0.61 0.66 0.55 0.44 0.54 0.7 0.78
Q38 0.45 0.54 0.5 0.49 0.42 0.43 0.44 0.54 0.53
Q39 0.34 0.43 0.32 0.42 0.36 0.22 0.25 0.42 0.34 0.56
Q40 0.22 0.15 0.16 -0 0.2 0.5 0.22 0.2 0.25 0.26 0.17
Q41 0.12 0.15 0.11 -0.2 0.08 0.52 0.23 0.18 0.21 0.23 0.09 0.88
Q42 0.43 0.41 0.41 0.34 0.35 0.48 0.4 0.46 0.44 0.38 0.25 0.53 0.55
Q43 0.25 0.35 0.31 0.44 0.23 0.05 0.14 0.29 0.24 0.24 0.39 -0.04 -0.10 0.31
Q44 0.47 0.45 0.44 0.37 0.39 0.35 0.43 0.5 0.44 0.49 0.39 0.20 0.22 0.37 0.30
Q45 0.5 0.51 0.49 0.46 0.46 0.44 0.45 0.57 0.46 0.52 0.44 0.22 0.22 0.43 0.34 0.73
Q46 0.5 0.53 0.47 0.45 0.45 0.4 0.47 0.54 0.47 0.53 0.39 0.18 0.19 0.41 0.30 0.71 0.87
Q47 0.57 0.5 0.53 0.43 0.41 0.38 0.57 0.58 0.53 0.48 0.35 0.16 0.13 0.38 0.28 0.59 0.66 0.73
Q48 0.62 0.67 0.62 0.59 0.45 0.35 0.53 0.63 0.55 0.49 0.45 0.10 0.03 0.38 0.37 0.55 0.63 0.64 0.72
Q49 0.73 0.69 0.68 0.62 0.39 0.46 0.64 0.67 0.63 0.56 0.40 0.20 0.12 0.44 0.31 0.58 0.62 0.63 0.66 0.76
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Therefore Q9 and Q10 were removed. In the case of the collinearity between item I have difficulties 
using touch technologies (e.g. computer-keyboard, smart-phones) (Q16) and items I have 
difficulties holding objects (Q4) and I find it hard to handle paper (Q13), item Q16 was removed. 
This was based on its lesser prevalence during qualitative research (chapter 3) and the narrower 
conceptual breadth. The item My whole life is affected (Q49) was unique, as a general impact 
question it reflected a general view of respondents condition summing up all aspects already 
addressed by the rest of the items. This suggests that it was overlapping with the rest of the 
instrument’s items. Therefore, item Q49 was also removed, despite showing no correlation above 
0.8 with any of the remaining items. This stage led to a 36-item version of the developmental 
HidroQoL (HidroQoL-36). The final version of the HidoroQoL following the first item reduction 
contained 36 items.
Table 5.7: Multicollinear items (correlations of at least 0.8)
Item Related item
Q2   Q40 Q 41
Q4   Q5 Q6 Q13 Q16
Q5  Q6 Q13 Q16
Q6  Q13 Q16
Q8 Q9 Q10
Q9 Q10
Q13 Q16 Q41
Q16 Q41
Q17 Q18 Q19
Q18 Q19
Q21 Q22 Q31
Q23 Q24 Q25
Q24 Q25
Q27 Q28 Q31
Q28 Q31
Q40 Q41
Q45 Q46
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Part II: Exploratory Factor Analysis of The Hidroqol-36
Following correlation analysis, exploratory factor analysis was carried out on the HidroQoL to 
explore its dimensional structure as well as to perform item reduction. First, the optimal number 
of factors to be extracted was determined, then the factors were estimated. The factor solution was 
rotated to yield interpretable results (DeVellis 2011). The poorly performing items were dropped 
in subsequent iterations, until a ‘simple structure was achieved’. According to Thurstone’s criteria 
a simple structure is characterised by a few high loadings on each factor with the rest of the 
loadings being zero or close to zero with variables having significant multiple loadings being at a 
minimum (Kline 1994). Three factors were extracted from the EFA of the HidroQoL-36, based on 
Horn’s parallel analysis criterion (Table 5.9). This is supported by the scree-plot criterion (Figure 
5.5). Three factors lied to the left side of the elbow on the plot, the rest of the factors from the 4th
going to the right were rubble, the fourth factor also marked a change in the slope of the curve.
Goodness of fit indices criterion showed mixed results. Although the Chi-square test of model fit 
was significant (chi-square = 2316.34, d.f. = 525, p = 0) indicating poor fit of the 3 factor solution, 
practical fit indices suggested otherwise (RMSEA = .078, SRMR = 0.51, CFI = 0.934, TLI = .921) 
(Analysis 1, Table 5.10). The factor pattern matrix was analysed to determine the performance of 
the individual items. Twenty-eight items had a clear strong loading on at least one factor; two items 
showed poor loadings, below 0.4, on all factors; five items showed crossed loadings (the highest 
loading on these items was at least 0.4 but below 0.5, and the difference with the smaller loading 
was less than 0.2) (Table 5.11). A single item had strong loadings on two factors. Three of the five 
items loading onto the first factor, I find it hard to handle paper (Q13), I have difficulties holding 
objects (Q5), and I find it hard to touch other people (Q6) and my hobbies are affected (Q7)
reflected limitations associated with palmar sweating. 
The item My choice of footwear (Q2) seemed misplaced under this factor. The second factor had 
strong loadings from eight items, including my everyday housework is affected (Q11), my holidays 
are affected (Q3), my choice of clothing is affected (Q1), I worry about the additional chores in 
dealing with my condition (Q45). This factor captured an array of effects experienced in everyday
life activities. Nonetheless, one item, My eyes feel irritated (Q43) did not fit the conceptual focus 
of the factor. Sixteen items loaded into the third factor. This was comprised of items focusing on 
the emotional impacts of hyperhidrosis including I feel embarrassed (Q21), I feel nervous (Q22) I 
feel sad (Q24), Sweating is constantly on my mind (Q29). This factor also included items 
addressing more of the social aspect of life, I avoid public speaking (Q12), I avoid meeting new 
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people (Q18), I find it difficult to be near other people (Q36). Nevertheless, items such as I worry 
about people’s reactions (Q35) demonstrate the strong connection between the two aspects. Taken 
together the two aspects of this factor were assessing the psychosocial impacts of hyperhidrosis.
Table 5.8: Item review based on correlation matrix (addressing multicollinearity)
Item removed Justification
I feel uncomfortable in my shoes (Q40)
I have problems with being barefoot (Q41)
Adequately captured in: my choice of footwear is 
affected (Q2). 
Q2 had higher prevalence than Q40; Q41 in 
qualitative study (QS).
I worry about the additional time spent in 
dealing with my condition (Q46)
Amount of time may be a reflection of activities 
involved in: I worry about additional chores in 
dealing with my condition (Q45). Q45 has higher 
prevalence in Q46.
I feel self-conscious (Q 31) May raise ambiguity issues
Less prevalently reported than Q21, Q27, Q28, which 
are more straight forward
My self-esteem is affected (Q28) Respondents not able to distinguish from: my self-
confidence is affected (Q27); Q28 less prevalent 
than Q27 in QS.
My whole life is affected (Q49) Seen as duplicating the entire instrument.
Was included for consistency purposes
I feel hopeless (Q23) Seen as ambiguous in comparison to Q24 and Q25, 
both of which adequately address issues in Q23.
I feel depressed (Q25) Is a complex construct compared to “feeling sad 
(Q24)”
I avoid going out (Q19) Content overlap with Q17
I have difficulties handling money (Q5) Content overlap with: I have difficulties holding 
objects (Q4) 
I have difficulties using touch technologies 
(e.g. computer-keyboard, smart-phones
(Q16)
Content overlap with Q4. 
Predictable with Q13
Less prevalent than Q4 or Q13.
My outdoor activities are affected (Q9) 
My summer activities are affected (Q10)
Both Q9 & Q10 ask for an overlapping set of 
activities; My physical activities are affected (Q8) 
seems to be capturing some of that. 
Social aspects of summer/outdoor activities is 
addressed items on ‘social’ life.
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Table 5.9: Eigen values for all 36 items*
Factor Based on 
WLSMV 
Based on Principal 
Factoring
Observed Adj.fact Unadj Bias
1 16.88 13.33 13.88 0.54
2 3.76 2.55 3.04 0.49
3 2.05 1.05 1.52 0.47
4 1.40 0.60 1.01 0.41
5 1.26 0.51 0.91 0.40
6 1.04 0.16 0.53 0.37
7 0.95 0.13 0.49 0.35
8 0.80 0.10 0.39 0.29
9 0.64 0.03 0.30 0.27
10 0.57 0.00 0.24 0.24
* observed and Horn’s parallel analysis
Figure 5.5 Scree-plot based on the Eigenvalues from the WLSMV for all 36 items
The two items with poor loadings were I worry about my body odour (Q33) and my work is affected 
(Q14), while the items showing weak-moderate loading on multiple factors included My skin feels 
uncomfortable (Q42), My appearance is affected (Q32), I worry about leaving sweat marks on 
objects (Q34), I worry about my condition in future (Q47). These results seem to suggest that 
issues related to the physical aspects of the sweating play a minimal role in the overall quality of 
life in hyperhidrosis.
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Table 5.10: Steps during EFA analysis: removal of poorly performing items
Analysis Poor-load Cross-load
Res_var
>0.7
Factor#
-K's rule
Factor#
-Paral
Factor#
extract RMSEA SRMR CFI TLI Chi-1 Chi-2
1, All 36 items Q33, Q14
Q42, Q32, Q47, Q34, 
Q48, Q7 _ 6 3 3
.078
(.075, .081)
p=0.000 .051 .934 .921
2316.34 
df=525
p=0
27716.08
df=630
p=0
2, remove Q33 Q14
Q42, Q32, Q47, Q34, 
Q48, Q7 Q1 6 3 3
.079
(.076, .083)
p=0 .051 0.933 0.922
2233.99
df=493
p=0
27396.52
595
p=0
3, remove Q14 _
Q42, Q32, Q47, Q34, 
Q48, Q7 Q1 5 3 3
.078
(.075, .082)
p=0 .05 .94 .93
2039.42
df=462
p=0
26958.234
df=561
p=0
4, remove Q32 and 
Q42 _ Q47, Q34, Q48, Q7 Q43, Q1 5 3 3
0.82
(.078, .085)
p=0 .05 .942 .928
1908.4
df=403
p=0
26319.9
df=496
p=0
5, remove Q34 _ Q47, Q48, Q7 Q43, Q1 5 3 3
.084
(.08, .088)
p=0 0.05 .942 .929
1859.1
df=375
p=0
26230.1
df=465
p=0
6, remove Q47, Q48 _ Q38, Q7 Q43*, Q1 5 3 3
.086
(.082, .090)
P=0 .049 .945 .931
1646.39
df = 322
p = 0
24607.0
df = 406
p = 0
7,  remove Q38, Q1 Q7 - 5 2 3
.089
(.085, .094)
P=0 0.48 .948 .933
1491.1
P = 273
P = 0
23804.98
df =351
p = 0
8, remove Q2, Q4, 
Q13 _ Q43, Q6 4 2 2
.099
(.094, .104)
P=0 .059 .937 .924
1490.17
df = 229
p=0
20221.98
df = 276
p = 0
9, remove Q43, Q6 _ _ Q39 (=0.7) 4 1 2
.102
(.096, .107)
p=0 .055 .944 .932
1273.01
df=188
p=0
19726.8
df=231
p=0
10, remove Q39 _ _ _ 3 1 2
.106
(.101, .112)
p=0 .056 .944 .93
1239.92
df=169
p=0
19305.35
df=210
p=0
184
Table 5.11: Factor pattern and factor structure matrices for the 36 items of the HidroQoL
Factor pattern Factor structure
F1 SE F2 SE F3 SE Res.Var Issue F1 F2 F3
Q13 0.98 0.02 -0.12 0.05 -0.02 0.02 0.07 0.96 0.04 0.27
Q4 0.96 0.02 0.02 0.04 -0.04 0.04 0.10 0.95 0.15 0.32
Q2 0.88 0.03 0.00 0.01 -0.22 0.06 0.31 0.80 0.01 0.10
Q6 0.82 0.03 -0.21 0.05 0.27 0.05 0.17 0.89 0.10 0.44
Q7 0.53 0.04 0.51 0.04 0.02 0.03 0.35 0.62 0.61 0.52
Q11 0.11 0.05 0.84 0.05 -0.17 0.06 0.42 0.19 0.75 0.38
Q8 0.20 0.05 0.79 0.03 0.00 0.02 0.28 0.34 0.83 0.56
Q3 -0.02 0.03 0.58 0.04 0.31 0.05 0.37 0.19 0.76 0.65
Q45 0.12 0.04 0.58 0.05 0.23 0.07 0.40 0.30 0.74 0.62
Q43 -0.07 0.06 0.58 0.06 -0.03 0.07 0.69 0.02 0.55 0.30
Q44 0.14 0.05 0.50 0.05 0.20 0.06 0.52 0.30 0.65 0.56
Q39 -0.01 0.04 0.45 0.05 0.19 0.06 0.66 0.14 0.57 0.46
Q1 0.04 0.06 0.44 0.06 0.15 0.07 0.69 0.17 0.54 0.44
Q18 0.01 0.02 -0.18 0.05 0.96 0.03 0.25 0.33 0.41 0.85
Q27 -0.08 0.04 -0.04 0.05 0.94 0.03 0.22 0.26 0.52 0.88
Q35 0.06 0.05 -0.18 0.05 0.91 0.04 0.29 0.36 0.39 0.83
Q17 -0.04 0.03 -0.03 0.04 0.90 0.03 0.25 0.28 0.52 0.87
Q22 0.06 0.04 -0.11 0.05 0.89 0.04 0.28 0.36 0.45 0.84
Q21 -0.05 0.05 0.01 0.05 0.88 0.04 0.25 0.28 0.54 0.86
Q36 0.06 0.03 0.00 0.03 0.85 0.03 0.25 0.36 0.53 0.87
Q24 -0.06 0.04 0.07 0.05 0.83 0.04 0.28 0.25 0.57 0.85
Q26 -0.04 0.04 0.07 0.05 0.77 0.04 0.36 0.25 0.53 0.80
Q30 0.01 0.03 0.14 0.05 0.75 0.04 0.29 0.30 0.60 0.84
Q20 -0.01 0.03 0.11 0.05 0.73 0.04 0.37 0.27 0.55 0.79
Q37 0.17 0.04 0.00 0.03 0.72 0.03 0.36 0.43 0.47 0.79
Further, the interconnection among the various aspects of quality of life being assessed was quite 
apparent. The first factor ‘limitations related to palms’ shared weak correlation with the second 
factor (rho = .171), a moderate correlation (rho = 0.364)  with the second factor. On the other hand, 
the second factor had a rather strong correlation with the third factor, psychosocial impact.
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Table 5.11 (continued)
Factor pattern Factor structure
F1 SE F2 SE F3 SE Res.Var Issue F1 F2 F3
Q12 0.05 0.04 0.04 0.06 0.66 0.05 0.50 0.30 0.46 0.71
Q29 0.01 0.04 0.21 0.05 0.63 0.04 0.39 0.28 0.60 0.76
Q15 0.33 0.04 0.08 0.05 0.53 0.05 0.42 0.53 0.46 0.70
Q38 0.06 0.04 0.27 0.05 0.47 0.05 0.53 0.28 0.56 0.65
Q42 0.43 0.04 0.26 0.05 0.16 0.06 0.59 CL 0.53 0.43 0.48
Q32 -0.22 0.05 0.47 0.05 0.47 0.05 0.36 CL 0.03 0.71 0.67
Q47 -0.01 0.04 0.33 0.05 0.47 0.06 0.48 CL 0.22 0.62 0.67
Q34 0.47 0.04 0.05 0.06 0.36 0.06 0.49 CL 0.61 0.35 0.56
Q48 -0.06 0.04 0.45 0.05 0.47 0.05 0.34 CL 0.19 0.73 0.72
Q33 0.04 0.05 0.29 0.06 0.31 0.06 0.70 LL 0.20 0.49 0.50
Q14 0.37 0.04 0.21 0.05 0.35 0.05 0.48 LL 0.54 0.49 0.61
Note: CL, crossloading; LL, low-loading 
This raises questions whether the two can be combined as one factor.
Item reduction process
A further step following EFA of the 36-item set involved removing items that showed poor 
performance, to enhance the structure of the instrument. By examining the relationship between 
the individual items and their related constructs, the best items could be identified and selected 
(Gorsuch 1997). Poorly performing items were iteratively removed, in total this included fourteen 
items (Table 5.10). Initially (Analysis 2 – 3) two items I worry about my body odour (Q33) and 
my work is affected (Q14) showing weak loading on all factors were removed. This did not seem 
to affect the factor loadings of the remaining items, although overall fit of the 3 factor solution was 
enhanced according to the practical fit statistics.
Next, an additional five items including My appearance is affected (Q32), my skin feels 
uncomfortable (Q42), I worry about leaving sweat marks on things (Q34), I worry about my 
condition in future (Q47) and I find it hard to do things in advance (Q48) which showed cross-
loading and lacked strong loading on any factor were sequentially removed. The items my sex life 
is affected (Q38) and my choice of clothing is affected (Q1) were subsequently removed due to 
cross loading and high singularity, respectively. At each step of the EFA the optimal number of 
factors to be extracted was assessed, during the initial steps three factors were extracted. After the 
removal of the 9th item, Q1, two factors were extracted.
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In view of the hierarchical level at which the construct of hyperhidrosis quality of life was being 
measured and the intended target population of the instrument, all hyperhidrosis patients, the first 
factor was considered to be a group-specific domain, with relevance only to patients with palmar 
sweating. Measuring quality of life impacts at the hyperhidrosis-type hierarchical level would have 
required items specific to the different areas affected. Ultimately such an approach would results 
in a much longer instrument, likely to have unfavourable applicability in a routine busy clinic. 
Thus items I have difficulties holding objects (Q4) and I find it hard to handle paper (Q13) were 
removed. Additionally My choice of footwear is affected (Q2) also loading onto the first factor was 
removed. Subsequently, items my eyes feel irritated (Q43), I find hard to touch other people (Q6) 
and My choice of food and drinks is affected (Q39) due to excessive uniqueness i.e. these items 
shared too little co-variation with the rest of the items. 
Revised HidroQoL: 21 item set
Ultimately, the iterative item reduction process yielded a set of twenty one items which fitted to a 
two-factor solution (Table 5.10, Analysis 10; Table 5.12). Six items loading onto the first factor, 
were related to ‘daily life activities’, for example My physical activities are affected (Q8), My 
everyday housework is affected (Q11), I worry about the additional chores in dealing with my 
condition (Q45). Fifteen items loaded onto the second factor, these were related to psycho-social 
impact and included I worry about people’s reactions (Q35), I feel embarrassed (Q21), I feel 
nervous (Q22), I feel sad (Q24), I avoid public speaking (Q12), and I do not socialise as much as 
I would like to (Q17). The two factors correlated strongly (rho = 0.645), suggesting that a single 
factor solution might fit the data. Moreover, the Horn’s parallel analysis and scree-plot were in 
support of a single factor solution (Table 5.13, Figure 5.6) However, the two-factor solution 
showed much better fit based on goodness of fit statistics.
On the other hand, this would be indicative of the amount of measurement error with which the 
instrument was measuring the intended constructs (Lackey et al. 2003, p.162). The item-test 
correlation for the ‘daily life activities impact’ factor ranged from 0.68 (Q44) to 0.78 (Q3), for the
psychosocial impacts this ranged from 0.7 (Q12) to 0.83 (Q36) (Table 5.14). The coefficient alpha 
for the two factors was 0.83 and 0.94, respectively.
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Table 5.12: Factor pattern matrix and residual variances for the 21 items of the HidroQoL
Item Factor pattern Factor structure
F1 SE F2 SE Res.Var F1 F2
Q8 0.89 0.019 0.004 0.003 0.204 0.892 0.578
Q11 0.832 0.043 -0.144 0.053 0.441 0.74 0.393
Q7 0.632 0.04 0.133 0.046 0.475 0.718 0.541
Q45 0.593 0.052 0.235 0.061 0.414 0.744 0.618
Q3 0.563 0.037 0.292 0.042 0.385 0.752 0.655
Q44 0.529 0.051 0.215 0.059 0.527 0.668 0.556
Q29 0.176 0.048 0.645 0.041 0.406 0.592 0.759
Q15 0.168 0.048 0.578 0.044 0.513 0.541 0.686
Q30 0.129 0.04 0.756 0.034 0.286 0.616 0.839
Q12 0.082 0.052 0.66 0.045 0.489 0.507 0.712
Q20 0.079 0.042 0.729 0.035 0.388 0.55 0.78
Q26 0.027 0.051 0.782 0.04 0.362 0.531 0.799
Q37 0.015 0.045 0.773 0.037 0.387 0.513 0.783
Q24 0.011 0.04 0.838 0.032 0.285 0.552 0.845
Q21 0.004 0.046 0.864 0.034 0.249 0.561 0.866
Q36 0.001 0.03 0.87 0.024 0.242 0.562 0.871
Q17 0 0.033 0.867 0.026 0.248 0.56 0.867
Q27 -0.069 0.038 0.926 0.027 0.22 0.528 0.882
Q22 -0.083 0.041 0.898 0.029 0.283 0.497 0.845
Q18 -0.115 0.041 0.933 0.03 0.254 0.487 0.859
Q35 -0.171 0.049 0.935 0.034 0.303 0.432 0.825
Table 5.13: Eigenvalues for all 21 items: observed and Horn’s parallel analysis
Factor Observed Adjusted Unadjusted
Estimated 
bias
1 12.292 9.700 10.137 0.437
2 1.604 0.814 1.130 0.316
3 1.045 0.503 0.799 0.295
4 0.986 0.333 0.571 0.238
5 0.71 0.144 0.342 0.197
6 0.628 0.086 0.252 0.166
7 0.466 -0.020 0.128 0.148
8 0.404 -0.020 0.103 0.123
9 0.361 -0.003 0.073 0.076
10 0.343 -0.054 -0.001 0.053
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Figure 5.6: Scree-plot based on the Eigen-values from the WLSMV for all 21 items
Part III: Confirmatory Factor Analysis of the 21 item HidroQoL
Confirmatory factor analysis technique was used to test the factorial structure of the HidroQoL 
obtained from the analysis in the previous section (the exploratory factor analysis results). The 
following hypotheses were tested:
 The HidroQoL has two factors, ‘impact on daily life activities’ and ‘psychosocial impacts’. 
Six items, Q3, Q7, Q8, Q11, Q44, Q45 load on the first, and 15 items on the second, 
including Q12, Q15, Q17, Q18, Q20, Q21, Q24, Q26, Q27, Q29, Q35, Q37. There is no 
cross-loading of the items, although the two factors are hypothesised to be correlated.
 A single factor , into which all items have a loading, underlies the HidroQoL
First, the distribution of the item responses was explored, given that departures from multivariate 
normality distort goodness of fit indices (Ozer et al. 2009). There was no response category with 
more than 70% of the responses, among all items (Table 5.15). In eighteen out of the 21 items the 
upper-extreme response tended to have the highest frequency of endorsement. Nonetheless 
normality assumptions were not violated, skewness ranged from -1.75 to 0.82, while kurtosis 
ranged from 1.5 to 5.5 (six items had kurtosis exceeding 3). Item ‘I worry about the additional 
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money in dealing with my condition (Q44) had missing data on 2% of the responses, thirteen items 
had missing data on 1% of responses, the other 7 items had no missing responses
Two factor model
The two-factor CFA model was statistically rejected based on a significant Chi-test (Chi-statistic 
= 316.18, df=188, p < 0.001) (Table 5.16). Practical fit indices were also considered, these reflected 
contrary findings. The RMSEA was 0.077 (.064, .092) indicating acceptable fit. The CFI and TLI 
at 0.98 and 0.977, respectively, both reflected excellent fit, further supported by the WRMR (.897). 
The item loadings for both factors were all significant, large, and had the expected signs. 
Table 5.14: Correlation measures of internal consistency for the 21-item HidroQoL
Item
Item-test 
correlation
Item-rest 
correlation
ave. inter-item 
covariance alpha
Daily life activities impact
q8 0.76 0.65 0.84 0.79
q11 0.74 0.59 0.81 0.80
q7 0.69 0.55 0.88 0.81
q45 0.77 0.63 0.79 0.79
q3 0.78 0.66 0.79 0.79
q44 0.68 0.51 0.86 0.82
scale 0.83 0.83
Psychosocial impacts
q29 0.71 0.67 0.93 0.94
q15 0.67 0.60 0.90 0.94
q30 0.82 0.79 0.88 0.94
q12 0.70 0.64 0.90 0.94
q20 0.75 0.70 0.90 0.94
q26 0.70 0.66 0.93 0.94
q37 0.75 0.70 0.91 0.94
q24 0.79 0.75 0.87 0.94
q21 0.71 0.68 0.95 0.94
q36 0.83 0.80 0.88 0.94
q17 0.81 0.78 0.88 0.94
q27 0.83 0.80 0.90 0.94
q22 0.77 0.73 0.91 0.94
q18 0.80 0.76 0.88 0.94
q35 0.74 0.71 0.94 0.94
scale 0.9 0.94
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Table 5.15: Distribution of responses to the HidroQoL in Sample 2
Number of patients Proportion of patients
Items 1 2 3 4 5 M 1 2 3 4 5 M Mean Med Skew Kurt
Q3 12 12 17 28 46 0 10% 10% 15% 24% 40% 0% 3.73 4 -0.77 2.33
Q7 7 14 20 34 40 0 6% 12% 17% 30% 35% 0% 3.75 4 -0.71 2.48
Q8 6 8 15 29 57 0 5% 7% 13% 25% 50% 0% 4.07 4 -1.18 3.44
Q11 23 19 19 27 27 0 20% 17% 17% 23% 23% 0% 3.14 3 -0.17 1.65
Q12 16 19 12 21 47 0 14% 17% 10% 18% 41% 0% 3.56 4 -0.52 1.75
Q15 24 11 14 11 55 0 21% 10% 12% 10% 48% 0% 3.54 4 -0.53 1.63
Q17 23 13 11 15 53 0 20% 11% 10% 13% 46% 0% 3.54 4 -0.54 1.64
Q18 24 18 11 23 38 1 21% 16% 10% 20% 33% 1% 3.29 4 -0.29 1.52
Q20 13 20 20 25 36 1 11% 17% 17% 22% 31% 1% 3.45 4 -0.38 1.84
Q21 0 3 8 24 79 1 0% 3% 7% 21% 69% 1% 4.57 5 -1.75 5.49
Q22 4 15 14 21 60 1 3% 13% 12% 18% 52% 1% 4.04 5 -0.96 2.63
Q24 18 17 20 13 46 1 16% 15% 17% 11% 40% 1% 3.46 4 -0.38 1.65
Q26 2 8 14 17 73 1 2% 7% 12% 15% 63% 1% 4.32 5 -1.41 3.91
Q27 4 7 15 22 66 1 3% 6% 13% 19% 57% 1% 4.22 5 -1.33 3.85
Q29 5 9 5 30 65 1 4% 8% 4% 26% 57% 1% 4.24 5 -1.54 4.41
Q30 17 13 20 27 37 1 15% 11% 17% 23% 32% 1% 3.47 4 -0.51 1.94
Q35 2 6 12 17 77 1 2% 5% 10% 15% 67% 1% 4.41 5 -1.66 4.87
Q36 18 16 20 25 35 1 16% 14% 17% 22% 30% 1% 3.38 4 -0.38 1.79
Q37 12 12 17 28 45 1 10% 10% 15% 24% 39% 1% 3.72 4 -0.75 2.31
Q44 54 20 13 10 16 2 47% 17% 11% 9% 14% 2% 2.24 2 0.82 2.19
Q45 39 23 17 13 22 1 34% 20% 15% 11% 19% 1% 2.61 2 0.41 1.7
The standardised loadings ranged from .63 for item Q3, to .87 for Q8 (Figure 5.7, Arrows from 
the boxes ‘indicator variables’ to the two eclipses ‘factors’). The item residuals ranged from .075 
(Q3) to .014 (Q8) for Q3 and Q8, reflecting optimal fit. Based on the r-squared values, the ‘daily 
life activities impact’ factor explains from 40% (Q3) to 78% (Q8) of variance in its related items
(Table 5.17). The psycho-social impact factor on the other hand explains from 53% (Q15) to 87% 
(Q36) of variance in its related items.
DISCUSSION
It is pertinent that new HRQoL instruments are tested in the target population and under the 
conditions in which they will ultimately be applied prior to being brought into use. This permits 
the evaluation of how well the items function and an assessment of the adequacy with which the 
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conceptual framework has been translated into a measurement model. Further validation work and 
application of an HRQoL measure makes the implicit assumption that the instrument is internally 
valid. This study, therefore, set out to explore the general functioning of the HidroQoL in patients 
with hyperhidrosis. In addition, the measurement model of the HidroQoL was explored and tested. 
Also, item reduction was carried out. The initial item reduction was carried out using correlation 
analysis to remove multicollinear items. This often reflects redundancy in content suggesting the 
little contribution in measurement that such items actually make. The decision to remove items 
took into account the importance of the issue reflected in an item based on previous qualitative 
research (reported in Chapter 3). Thirteen items were removed at this stage. 
Further item reduction was carried out based on EFA, leading to the removal of fifteen items. The 
process proceeded systematically, where removal of underperforming items was followed by 
further iterations of EFA, until a set of optimally performing items was achieved. Physical 
discomfort related issues, seemed nominal to the hyperhidrosis-quality of life, for instance ‘my 
skin feels uncomfortable’ (Q42), and ‘my eyes feel irritated’ (Q3). 
Table 5.16: Goodness of fit of the CFA models estimated
Goodness of fit test Threshold 2-factor 1-factor Difference
Chi-square Test of Model fit
Value
DF
P-value > 0.05
316.167
188
0.0000
489.52
189
0.0000
44.7
1
0.000
Root Mean Square Error of Approximation
Estimate
90 Percent C.I.
Probability RMSEA <= 0.05
< 0.05 0.077
(0.064 0.092)
0.002
.118
(0.105, 0.130) 
0.000
CFI > 0.95 0.980 0.952
TLI > 0.95 0.977 0.947
Chi-square Test of Model Fit for the Baseline Model
Value 
DF 
P-value > 0.05
6487.1
210
0.0000
6487.996
210
0.0000
Weighted Root Mean Square 
Residual
< 0.90 0.897 1.216
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Table 5.17: Correlation between variables and construct (r-squared) and uniqueness 
(residual variance)
Item 2-factor model 1-factor model
R-squared Residual Variance R-squared Residual Variance
Q8 0.78 0.22 0.55 0.45
Q11 0.47 0.53 0.33 0.67
Q7 0.57 0.43 0.42 0.59
Q45 0.74 0.26 0.54 0.46
Q3 0.40 0.61 0.27 0.73
Q44 0.75 0.25 0.57 0.43
Q35 0.61 0.39 0.59 0.41
Q18 0.90 0.10 0.90 0.11
Q27 0.82 0.18 0.81 0.19
Q22 0.62 0.38 0.60 0.40
Q36 0.76 0.24 0.75 0.26
Q17 0.83 0.17 0.82 0.18
Q21 0.74 0.26 0.73 0.27
Q24 0.82 0.18 0.81 0.19
Q26 0.71 0.29 0.70 0.30
Q37 0.66 0.34 0.65 0.36
Q30 0.87 0.13 0.86 0.14
Q20 0.54 0.46 0.52 0.48
Q12 0.59 0.42 0.57 0.43
Q29 0.56 0.44 0.55 0.45
Q15 0.53 0.47 0.52 0.48
The item on ‘clothing choices’ (Q1), among the most prevalent issues in a previous qualitative 
work, surprisingly performed poorly. This might be an artefact of the reliance of EFA on 
covariance matrices such that, in lowly endorsed and highly endorsed items, the item will exhibit 
minimal variation in its score. Although the item reduction process presents an opportunity for 
reducing respondent burden and enhancing a scale’s measurement attributes, caution is needed on 
how and when items can be removed. Coste et al. (1997) notes a lack of conceptualisation of the 
process and an overreliance on statistical approaches as common pitfalls during item reduction.
Reise et al. (2000) emphasises the need for sound planning of the process, clarity on the construct 
being measured and a clear rationale reasons for removing any items during item reduction.
. 
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Figure 5.7: Path-diagram of the CFA Model with two correlated factors.
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Figure 5.8: Path-diagram for CFA model with 1 –factor
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Juniper et al. (1997) compared application of FA against ‘patient importance ratings’ in performing 
item reduction. They found the instruments to share much content although there were difference 
in some items. The FA method left out some items considered of highest importance to patients.
Similarly, some items with very strong measurement attributes were not important to patients. This 
indicates that ultimately optimal measurement of HRQoL requires a clear method for reconciling 
such frictions, marrying statistical objectives with clinical sensibility. An EFA of the final 21 item 
set showed a two-factor solution, where six items loaded onto the first factor, ‘impact on daily life 
activities’ and fifteen items loaded onto the second factor ‘psychosocial impact’. Both the factor 
pattern and factor structure matrices, reflecting the partial and non-adjusted correlations of the 
items with the factors showed that the final set of items were tapped strongly into their respective 
factors. There is some debate surrounding the factor loadings to be interpreted. Kline (Kline 1994)
recommends the factor pattern matrix, citing that they best reflect the relationship between an item 
and the construct, given that the effects of other variables are accounted for, while Gorsuch 
(Gorsuch 1997) based on the same reasons argues that this undervalues the correlations which 
should be considered when evaluating such relationships. Given that both matrixes provide 
important information, Pat (Pat 2004) recommends considering both.
The two factors showed strong correlation, raising the question whether the two could have been 
combined into one factor. How large correlations ought to be before combining them into a single 
factor does not lend itself to a simple or clear cut answer (DeVellis 2011, p.146). Some suggestions 
indicate thresholds of 0.6 (Lackey et al. 2003). In this case, the researcher is left to his own devices. 
Still, this issues reflects a potent issue in PRO measurement, that of unidimensionality. First, a 
parallel analysis of the 21 items supported a single factor solution, although this was not followed 
on consideration of the goodness of fit indices, which were poor with a single factor. Second, the 
ratio of the eigenvalues of the first and second factors exceeded the minimum threshold of 4 (Hattie 
1985; Basra et al. 2006). Third, the single factor model of the CFA showed fit on practical indices. 
Finally, in spite of the clear better fit that the 2 factor model had over the 1-factor model, the 
residuals when the single factor model was implemented were not inflated. These findings suggest 
that unidimensionality property is tenable for hyperhidrosis-QoL as a construct and the HidroQoL 
as an instrument for its measurement.
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Dimensional structure has been tested and reported on one hyperhidrosis quality of life measure, 
the ‘Hyperhidrosis Scale’. Kuo et al. (Kuo et al. 2004) based on a Korean population of patients 
awaiting surgery obtained 5 factors from an EFA of their newly developed 29-item questionnaire 
for hyperhidrosis-quality of life, which included: ‘functional domain’, ‘psychological domain’, 
‘social domain’, ‘affective domain’ and a ‘physical domain’. Reliance on eigenvalues for factor 
extraction in their study implies that over-extraction was quite likely. Moreover, the Kuo et al 
measure contains severity and symptom related questions which might be causal rather than 
indicator variables. Moreover in the current study these were found to make little contribution to 
the measurement of hyperhidrosis-related QoL and to lack fit in the dimensional structure of the 
HidroQoL, respectively.
SUMMARY
 A total of 559 patients from the USA completed the 49-item HidroQoL.
 In all items no response category accounted for more than 80% of responses, although 17
items had more than 50% of participants on the extreme category (“very much”).
 Correlation analysis showed 30 pairs of items to be multi-collinear. Thirteen items were 
removed to resolve the content redundancy, leading to a 36-item version of the HidroQoL.
 Exploratory factor analysis on the 36-item measure showed that 3 factors best captured 
variability in scores; 28 items showed optimal fit, based on their factor loadings. Two items 
had poor fit (no loading >= 0.4), five items were cross-loading.
 Poorly performing items were sequentially removed, through iterations of EFA. An optimal 
“simple” factor structure was realised after eliminating 15 items. Two alternative 
interpretations were permitted by the results, a 1 factor solution and a two factor solution. 
The 2 factors in the latter were interpretable as ‘impact on daily life activities’ and 
‘psychosocial impacts’.
 The two alternative factor solutions for the HidroQoL were tested on a new group of 
patients (UK sample, N = 115) using confirmatory factor analysis.
 Although both solutions performed poorly on absolute goodness of fit tests, practical fit 
indices indicated good fit for both of them. Nonetheless the two factor solution provided a 
significantly better fit to the data.
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CHAPTER 6
Development of a Hyperhidrosis-specific quality of life 
instrument (HidroQoL): Rasch analysis
Item reduction and construct validation using 
Item Response Theory (IRT)
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INTRODUCTION
In skin disease, the assessment of HRQoL plays a particularly central role, due to, among other 
factors, skin’s high visibility and the strong connection between impacts on social life and self-
perception, and severity of disease (Grob et al. 2005). This suggests a key role for HRQoL 
measures in skin disease, with the implication for the need to ensure their rigor in order to 
guarantee accurate, efficient and reliable assessment of HRQoL impact. For this, a clear conceptual 
model reflected in a robust measurement model are essential ingredients. The latter has been 
traditionally achieved through classical test theory (CTT) based methods such as item-total 
correlation analysis, stepwise regression and factor analysis (Coste et al. 1997). An increasingly 
applied method is based on Rasch model, a variation of the IRT. This is regarded by some as setting 
new rules in measurement and thus creating a new ‘gold standard’ in HRQoL instrument 
development (Reise and Henson 2003; Nijsten 2012).The Rasch model generates a linear metric 
scaled in logit-units, representing the construct being measured, on which both the items and 
persons are located hierarchically reflecting their levels on the construct (Prieto et al. 2003). 
Further, the probability of a particular response on an item by an individual is then given by a 
logistic function of the difference between the item location and person location and nothing else 
(Twiss et al. 2011).Then, following a prescriptive approach, items and persons are assessed for 
conformity to the model applying fit statistic (Nijsten et al. 2006a). Ultimately, demonstrating 
conformity to the Rasch model gives an instrument a number of advantages. First, ordinal scores 
into interval level scores, a requisite property for the calculation of effect sizes and other statistics 
in clinical research  usually taken for granted (Reise and Haviland 2005). Second, by 
conceptualizing measurement error as an item level property, high reliability can be attained even 
with a shorter questionnaire, making it possible to minimize patient burden without compromising 
precision (Reeve et al. 2007). Additionally, the property of invariance of the item and person 
parameters facilitates a variety of highly useful analyses and validation hypotheses including, 
equating of measures, the testing for differential item functioning, among others (DeMars 2010). 
Whether an instrument based on the Rasch Model (RM) is significantly better than another based 
on CTT is still a hot topic. Nonetheless, for the practitioner the range of tools accessible for 
understanding the psychometric properties of an instrument and its items seems enough 
justification for the application to scale development, testing for properties otherwise taken for 
granted in CTT (Reise and Henson 2003).
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OBJECTIVES
The objectives of this study were to:
 Evaluate the extent to which the new instrument (HidroQoL-36 version) conforms to the 
RM, assessing whether:
− the scale was unidimensional
− targeting of the items to the population of hyperhidrosis patients was optimal
− response categories were functioning optimally
− the items were invariant across groups according to gender, age, site of hyperhidrosis, 
severity of disease i.e. whether DIF was present.
− item estimates remained invariant across patient populations, comparing UK and 
North-America.
 Identify and remove from the HidroQoL poorly performing items based on the RM.
 Evaluate the construct validity of the final version of the HidroQoL.
METHODS
Study design
This study followed a prospective cross-section design. The major design consideration in Rasch 
analysis study is ensuring that respondents reflect the entire continuum of the construct, from the 
highest possible quality of life impairment and to the minimum possible impairment (Bond 2004). 
To ensure this, a large and heterogeneous patient population reflecting varying levels of disease 
severity and different types of hyperhidrosis was targeted. The RM analyses can be carried on a 
sample as small as 100, nevertheless a sample size of at least 243 is large enough to achieve 
precision of ± 0.5 logits within at 99% level of confidence even in heavily skewed data (Linacre 
1999). For stable estimation of category thresholds, at least 10 observations are needed in each 
response category of an instrument. In view of this, the recruitment targeted 400 patients, 
representing the full range of disease severity according to the Hyperhidrosis Disease Severity 
Scale (HDSS).
Study population
Inclusion criteria:
 Self-reported hyperhidrosis.
 Aged 18 years or above.
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 With a score of 2 or higher on the HDSS
 With onset of hyperhidrosis in teenage years or early adult years.
Exclusion criteria:
 Below the age of 18
 With onset of hyperhidrosis after age of 30 and reporting a co-morbidity (hypertension, 
diabetes, pm hormonal disorders, psychological disorders)
 With HDSS score of 1.
Recruitment and data collection procedure
Patients were recruited through hyperhidrosis online social networking communities, mainly the 
International Hyperhidrosis Society (IHHS) and the UK Hyperhidrosis support group, from May 
to September 2012. A detailed description of the study population and procedures is provided in 
Chapter 2.
Data processing and analysis
Data analysis based on the Rasch model was carried out using RUMM 2030. Factor analysis was 
carried out using MPLUS-6 and STATA 11. A detailed description of the Rasch model and its 
application in scale development is available in Chapter 2.
RESULTS
For purposes of clarity the results will be presented in three parts. Part I: calibration of the 
HidroQoL, Part II: item reduction and refinement, and Part III: cross-validation of the refined 
HidroQoL. Patients recruited for this study were grouped as follows: sample 1 comprised of study 
participants from the U.S and Canada, and sample 2 which included respondents from the UK
Analysis reported in Part I and Part II utilized sample 1, while part III employed sample 2. 
Part I: Calibration of the HidroQoL using the Rasch Model
Sociodemographic characteristics of study participants (sample 1)
A total of 595 patients with hyperhidrosis were recruited for this study. Of the total, 113 (19%) 
were male and 482 (81%) were female (Table 6.1). The mean age was 25 years, with those aged 
between 18 and 39 making up 52% of the sample (Figure 6.1). Forty patients reported living with 
hyperhidrosis for a period of less than 10 years, on the other hand those with duration of disease 
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from 20 to 29 years comprised the largest number (Figure 6.2). For most patients, hyperhidrosis 
affected multiple areas: for example in 27% of the participants hyperhidrosis affected the hands, 
feet and axillar. Forty-six percent of the patients (N = 274) had sweating that was intolerable and 
always interfered with daily activities (HDSS score = 4) (Figure 6.3).
Forty-nine percent of the patients (N = 294) perceived their sweating to have an extreme negative 
impact on their overall life (Figure 6.4). Eighty-six percent of the patients (n=513) reported 
previously visiting their doctor in relation to their sweating condition, while 14% had not (Table 
6.2). A lesser number (n = 324) reported getting treatment within the last 6 months. An even 
smaller number (n = 176) reported receiving treatment currently. Forty-eight patients had received 
a Botox injection within the last 6 months.
HidroQoL affirmation responses
Further exploratory analysis of the data involved analyzing the distribution of responses for each 
item. The items showed a positive skew towards the higher response categories (Table 6.3). All 
items except Q4, Q5, Q39, Q43 and Q45 had ceiling effects. In contrast, 13 items (Q4, Q5, Q13, 
Q16, Q19, Q25, Q38 – Q41, and Q43 – Q45) showed floor effects. Floor or ceiling effects are seen 
if either of the items extremities has at least 20% of responses (Both et al. 2007). Nevertheless, 
this did not compromise meaningful variability in the data, with 80% considered as the upper limit 
of endorsement for categories (Streiner and Norman 2008, p.84). Noteworthy is the connection 
between ceiling and floor effects in the response data, all items without ceiling effects show floor-
effects. The influence of the severity of disease and its impact, as reported in this sample, on the 
response pattern should not be ignored. The majority of patients had severe HH. On the other hand, 
questions of appropriateness of the response categorisation and the level of difficulty of the items 
can still be raised.
For example in relation the former, items Q21, Q31 and Q35 show less than 10 observations in the 
response category “no, not at all”. This can be a problem in the context of Rasch modeling, 
particularly in estimating stable threshold values (Bond and Fox 2007, p.222). A general 
recommendation is to have a minimum of 10 observations per category (Linacre 1999). There was 
no pattern to the missing data, thus data is missing at random. Nevertheless the rates of missing 
data increase towards the end of the questionnaire, for instance before Q18, no item has missing 
information. Further, missing data only reaches 2% at Q38. This item deals with a very personal 
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aspect of life, which some respondents may not be willing to talk about. On the other hand, the 
higher rates of missing data notable among items with floor effect might also be a reflection of 
their relevance. Moreover, there was no choice provided for responses that were not applicable.
Table 6.1: Sociodemographic characteristics of study participants
Gender, n (%)
Male 113 (19%)
Female 482(81%)
Age (years)
Mean (SD) 40.5 (14.2)
Median 39
Range 18 - 74
Age (years), n
18 to 29 154
30 to 39 155
40 to 49 117
50 to 59 95
≥ 60 74
Duration of condition (years)
Mean (SD) 27.5 (14.1)
Median 25
Range 2 - 69
Duration of condition (years), n
< 10 40
10 to 19 144
20 to 29 156
30 to 39 116
40 to 49 79
50 to 59 49
60 to 69 11
Body are affected
Head* 129 (22%)
Axilla* 54 (9%)
General 130 (22%)
Axilla, Palms, Feet 158 (27%)
Palms and Feet 124 (21%)
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Table 6.1 (continued)
Severity of disease (HDSS score), n
1 0
2 79
3 242
4 274
Global impact of hyperhidrosis (GQ 
score), n 
No, none at all 0
Slight 3
Moderate 50
Quite a bit 230
Extreme 290
Co-morbidity
None 327 (55%)
Menopausal complaints 61(10%)
Diabetes 30 (5%)
Hypertension 47 (8%)
Neurological disorders 64 (11%)
Thyroid disorders 66 (11%)
Employment status
Employed 380(64%)
Unemployed 107 (18%)
Retired 70(12%)
Full-time student 30(6%)
* This category included patients reporting other areas, the indicated area thus reflects the 
predominant body area affected.
Calibrating the HidroQoL on the Rasch model
Rasch analysis was carried out on the HidroQOL-36, a version of the HidroQoL containing 36 
items, developed in the previous chapter following resolution of item redundancy in the initial 
developmental HidroQoL (HidroQoL-49). The Likelihood ratio test for choice of appropriate RM 
supported the use of the partial credit model, the Chi-statistic was 529.47 (degrees of freedom = 
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1.04) and was significant (p < 0.001). Partial credit model allows the differences between category 
thresholds of items to vary across items (Masters and Wright 1997). In this case, restricting such 
differences to be equal as is assumed in the Rating Scale model would lead to a loss of information 
(Tennant and Conaghan 2007).
Figure 6.1: Age distribution of study participants
Figure 6.2: Duration of disease of the study participants
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HidroQoL-36
Overall fit of the HidroQOL-36 to the RM was assessed using the Item Trait Interaction Chi-
Squared Statistic (ITICS) and the mean fit residuals. The former was 1642.32 (df = 324) and was 
significant (p < 0.001), indicating a lack of fit of HidroQoL-36 to the RM (Table 6.4, Analysis 1).
Figure 6.3: Patient reported disease severity based on the HDSS
Figure 6.4: Patient reported general impact of disease
The item and person residual mean values reflected same conclusion (items, residual mean = 0.22, 
SD = 3.96; and persons, residual mean = -0.00, SD = 1.48). Thus, although the items showed poor 
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fit, the sample largely responded in conformity to the RM. Furthermore, model fit was also 
explored at the individual item and person level, using fit residuals and ITICS. The fit residuals 
for 15 items fell between -2.5 and 2.5, indicating optimal fit (Table 6.5). Eleven items had fit 
residuals exceeding 2.5 and an additional ten had fit residuals below -2.5, indicating underfit and 
overfit. The under-fitting group (fit residuals > 2.5) largely included items relevant to effects 
related to particular body areas.The over-fitting group (fit residuals < -2.5) primarily included 
items relating to negative emotions and the social impacts of hyperhidrosis, giving hints on the 
sources of the poor fit. Suboptimal response categorization is one cause of poor item fit to the RM 
(Linacre 1999). For an optimally functioning response categorisation, the choice of categories is 
expected to conform to the rasch probabilistic pattern. Thus, functioning of the response 
categorisation for the HidroQoL was tested. Three items (Q8, Q29 and Q35) showed appropriately 
ordered category thresholds, where consecutive category thresholds increased with increasing 
levels of the latent variable (quality of life impact) (Figure 6.5). The rest of the items had 
disordered thresholds, where the monotonicity of the thresholds was violated.  This implies that 
for these items response categories was used inconsistently for example respondents struggling to 
distinguishing between response categories. Measures applied in clinical practice need to be 
optimally targeted for the intended population (Pallant and Tennant 2007). The mean location 
parameters for persons and items were, therefore, compared. Furthermore, the spread of the items 
along the latent variable was also analysed. The mean person location was 0.5 (± 0.82) in 
comparison to that of 0 (± 0.6) for items.
Table 6.2: Access to and utilization of treatment
Number of 
patients (%)
Seen a doctor in relation to hyperhidrosis 513 (86%)
Treated within last 6 months 201 (34%)
Has received Botox within last 6 months 48 (8%)
Surgical treatment 64 (11%)
Currently being treated 176 (30%)
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Table 6.3: Patients responses to the HidroQoL
Item Descriptor
No, not at 
all
A little Somewhat Quite a 
bit
Very 
much
Missing
n % n % n % n % n % n %
Q1 My choice of clothing is affected 18 3% 30 5% 51 9% 110 18% 386 65% 0 0%
Q2 My choice of footwear is affected 106 18% 38 6% 66 11% 72 12% 313 53% 0 0%
Q3
My holidays are affected (e.g. 
planning, activities)
70 12% 67 11% 143 24% 121 20% 194 33% 0 0%
Q4 I have difficulties holding objects 201 34% 71 12% 96 16% 112 19% 115 19% 0 0%
Q5 I have difficulties handling money 262 44% 71 12% 102 17% 79 13% 81 14% 0 0%
Q6 I find it hard to touch other people 98 16% 43 7% 67 11% 89 15% 298 50% 0 0%
Q7 My hobbies are affected 52 9% 51 9% 95 16% 153 26% 244 41% 0 0%
Q8 My physical activities are affected 29 5% 52 9% 77 13% 129 22% 308 52% 0 0%
Q9 My outdoor activities are affected 30 5% 52 9% 81 14% 110 18% 322 54% 0 0%
Q10 My summer activities are affected 21 4% 37 6% 67 11% 96 16% 374 63% 0 0%
Q11 My everyday housework is affected 107 18% 89 15% 127 21% 124 21% 148 25% 0 0%
Q12
I avoid public speaking (e.g. 
presentations)
84 14% 75 13% 72 12% 96 16% 268 45% 0 0%
Q13 I find it hard to handle paper 193 32% 49 8% 69 12% 91 15% 193 32% 0 0%
Q14 My work is affected 65 11% 60 10% 132 22% 149 25% 189 32% 0 0%
Q15
My career decisions are affected (e.g. 
career choice)
107 18% 49 8% 69 12% 111 19% 259 44% 0 0%
Q16
I have difficulties using touch-
technologies (e.g. computer-
keyboard, smart phones)
198 33% 47 8% 90 15% 105 18% 155 26% 0 0%
Q17
I do not socialise as much as I would 
like to
60 10% 69 12% 98 16% 113 19% 255 43% 0 0%
Q18 I avoid meeting new people 117 20% 75 13% 114 19% 138 23% 148 25% 3 1%
Q19 I avoid going out 135 23% 88 15% 118 20% 133 22% 118 20% 3 1%
Q20 My personal relationships are affected 89 15% 87 15% 139 23% 120 20% 157 26% 3 1%
Q21 I feel embarrassed 9 2% 15 3% 44 7% 89 15% 435 73% 3 1%
Q22 I feel nervous 30 5% 35 6% 70 12% 126 21% 331 56% 3 1%
Q23 I feel hopeless 110 18% 73 12% 95 16% 79 13% 235 39% 3 1%
Q24 I feel sad 117 20% 109 18% 99 17% 79 13% 188 32% 3 1%
Q25 I feel depressed 152 26% 115 19% 102 17% 66 11% 157 26% 3 1%
Q26 I feel frustrated 22 4% 42 7% 61 10% 99 17% 367 62% 4 1%
Q27 My self-confidence is affected 28 5% 51 9% 81 14% 117 20% 314 53% 4 1%
Q28 My self-esteem is affected 47 8% 51 9% 78 13% 110 18% 305 51% 4 1%
Q29 Sweating is constantly on my mind 17 3% 47 8% 70 12% 146 25% 311 52% 4 1%
Q30 I avoid taking on new challenges 93 16% 77 13% 131 22% 118 20% 172 29% 4 1%
208
Table 6.3 (continued)
Item No, not 
at all
A little Somewhat Quite a 
bit
Very 
much
Missing
n % n % n % n % n % n %
Q31 I feel self-conscious 9 2% 27 5% 50 8% 108 18% 397 67% 4 1%
Q32 My appearance is affected 33 6% 52 9% 95 16% 113 19% 298 50% 4 1%
Q33 I worry about my body odour 102 17% 98 16% 105 18% 105 18% 181 30% 4 1%
Q34 I worry about leaving sweat 
marks on things
30 5% 35 6% 49 8% 82 14% 395 66% 4 1%
Q35 I worry about people's reactions 7 1% 27 5% 58 10% 126 21% 370 62% 7 1%
Q36 I find it hard to be near other 
people
79 13% 69 12% 129 22% 136 23% 175 29% 7 1%
Q37 I feel uncomfortable physically 
expressing affection (e.g. 
hugging others)
49 8% 57 10% 103 17% 135 23% 243 41% 8 1%
Q38 My sex life is affected 172 29% 92 15% 128 22% 67 11% 125 21% 11 2%
Q39 My choice of food and drinks is 
affected
260 44% 88 15% 108 18% 58 10% 71 12% 10 2%
Q40 I feel uncomfortable in my 
shoes
138 23% 70 12% 66 11% 89 15% 223 37% 9 2%
Q41 I have problems with being 
barefooted
188 32% 49 8% 38 6% 61 10% 251 42% 8 1%
Q42 My skin feels uncomfortable 83 14% 69 12% 99 17% 113 19% 221 37% 10 2%
Q43 My eyes feel irritated 305 51% 72 12% 87 15% 61 10% 59 10% 11 2%
Q44 I worry about the additional 
money spent in dealing with 
my condition
173 29% 130 22% 105 18% 75 13% 101 17% 11 2%
Q45 I worry about the additional 
chores in dealing with my 
condition
155 26% 126 21% 103 17% 110 18% 94 16% 7 1%
Q46 I worry about the additional 
time spent in dealing with 
my condition
119 20% 108 18% 116 19% 111 19% 131 22% 10 2%
Q47 I worry about my condition in 
future
61 10% 61 10% 77 13% 144 24% 244 41% 8 1%
Q48 I find it hard to do things 
without planning in advance
90 15% 64 11% 112 19% 117 20% 204 34% 8 1%
Q49 My whole life is affected 23 4% 52 9% 71 12% 118 20% 321 54% 10 2%
This indicates that the HidroQoL was at a slightly lower level of HRQoL impairment in 
comparison to the sample. The item-person distribution map, shows an even distribution of the 
items across the latent variable (Figure 5.6). Reliability was assessed using the PSI. The 
HidroQOL-36 showed a PSI of 0.94, reflecting capability to distinguish up to 4 levels of QOL 
impairment patient groups. This is way ahead of the minimum levels needed for individual level 
use. 
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Part II: Item Reduction and Refinement
Following the initial calibration of the HidroQoL-36 which showed poor fit both for the overall 
model as well as for the individual items and persons, revisions were made to the instrument, based 
on the RM (Pallant and Tennant 2007). First, the category threshold disordering was addressed and 
then the misfit in the items. Subsequently, unidimensionality and local independence assumptions 
and the invariance property were tested.
Revision of response categorisation
One way of addressing disordered response category thresholds is to combine adjacent categories 
(Bond and Fox 2007). Thus, for the HidroQoL-36, first, categories ‘somewhat’ and ‘a little’ were 
combined; leading to a rescoring of the categories as 0-1-1-2-3. This resolved disordering in six 
items. Overall fit to the model showed a slight improvement, although the total-ITICS statistic was 
still significant (Table 6.4, Analysis 2). Further, the response category ‘quite a bit’ was combined 
with ‘a little’ and “somewhat’, leading to a 3 point scaling, score as 0-1-1-1-2. This resolved the 
disordering of thresholds in the rest of the items as well as improving overall fit to the RM (Figure 
6.7, Figure 6.8). The total ITICS statistic declined from 1642.64 (df = 324) before any rescoring 
to 1087.4 (df = 324) post collapsing to 3 categories. This had minimal consequences on reliability 
(PSI = 0.94). Seven items (Q44, Q6, Q1, Q21, Q37, Q48, Q18) showed improved fit. Thus in total 
twenty-one items showed optimal RM fit, while the remaining fifteen lacked fit.
Removal of misfitting items 
The last resort for items not fitting the RM is to remove them from an instrument. Such items may 
lead to biased estimates of latent variables as well as item parameters in case of overfitting or 
worse still, ability to accurately measure may be degraded in the case of overfits (Baghaei 2008b; 
Smith et al. 2008). Still, removal of items ought to consider impact on the entire scale. Therefore, 
misfitting items were sequentially removed from the HidroQoL-36, iteratively assessing their 
impact on overall model fit as well as the remainder of the items. Four underfitting items, Q2- My 
choice of footwear is affected; Q4- I have difficulties holding objects; Q13- I find it hard to handle 
paper; Q43- My eyes feel irritated relevant only to hyperhidrosis affecting particular body areas 
were the first candidates for removal. The ITICS statistic declined to 768.26 (df = 288), reflecting 
improvement in fit (Table 6.6, Analysis 4). The item fit residual mean (SD), at -0.12(3.35) was still 
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suboptimal. The person fit residual (SD), -0.31(1.59) had slightly improved, though still out of 
optimal range. The PSI of 0.94 reflected that reliability remained strong. 
Other items were impacted: specifically, fit of Q1 and Q6 deteriorated, while fit of Q26 improved.
Such unexpected/unwanted consequences reflect a shift in the instrument’s frame of reference. In 
the subsequent nine steps, 14 items were removed sequentially as shown in Table 5.6 (Analysis 5 
– 12). At each stage, the impact of removing misfitting items on overall fit, including total ITICS 
statistic, the mean item and person residual fit statistics, reliability (according to the PSI) as well 
as the individual item fit of the remaining items was evaluated. Overall fit showed a steady 
improvement: the total ITICS statistic decreased to 194 (df=162) although it remained significant 
(p = 0.04). The mean fit residual and its SD for items and persons both fell to acceptable ranges, 
at -0.12 (1.22) and -0.31(1.37), respectively. Reliability was still adequate for individual level 
analyses despite declining to 0.89. Fit of item Q22 showed changes in both ways during 2 iteration 
stages: improving when Q39, Q6 and Q11 were removed (at stage 5), worsening at stage 6, when 
Q36, Q27 and Q30 were removed, then improving again when Q33 and Q42 were removed. In the 
end, 18 eighteen items showing good fit to the RM were achieved (Table 6.7).
Table 6.4: Overall model fit statistics for the 36 items HidroQoL and subsequent versions 
after rescoring
Action Overall Model Fit Item Fit 
Residuals
Person Fit 
Residuals
Dimension-
ality
PSI
Chi df p Mean SD Mean SD Sign. t-test(%)
1. All 36 items included 1642.64 324 0.00 0.22 3.96 -0.01 1.5 26.39%1 0.94
2. Revise scoring to 01123 1404.5 324 0.00 0.00 3.9 -0.089 1.55 33.28%2 0.94
3. Revise scoring to 01113 1087.4 324 0.001 -0.05 3.48 -0.234 1.64 28.57% 0.94
Note: 
1. Items 13, 4, 2, 6, 7, 42, 34 had positive loadings of 0.3 and above. Items 29, 18, 26, 20, 48, 36, 32, 30, 17, 21, 24 
and 27 had negative loadings. 
2. Items 13, 4, 2, 6, 7, 42, 34 had positive loadings of 0.3 and above. Items 26, 35, 18, 29, 22, 48, 32, 20, 17, 36, 21, 
30, 24, 36 and 27 had negative loadings below – 0.3.
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Table 6.5: Rasch model item parameters for the 36-items of the HidroQoL
Fitting items Location SE Fit 
Resid
ChiSq. Prob Thresholds
1 2 3 4
I36 I find it hard to be near others 0.28 0.07 ­4.95 48.65 0.00 ­0.33 ­0.62 0.25 0.70
I30 I avoid taking on new challenges 0.41 0.07 -4.12 33.99 0.00 -0.27 -0.58 0.37 0.49
I27 My self-confidence is affected -0.76 0.07 -4.10 30.05 0.00 -0.72 -0.01 0.37 0.35
I37 I feel uncomfortable physically expressing affection -0.28 0.07 -3.27 30.11 0.00 -0.34 -0.40 0.23 0.51
I20 My personal relationships are affected 0.52 0.07 -3.17 31.20 0.00 -0.45 -0.50 0.33 0.61
I17 I do not socialize as much as I would like to -0.17 0.07 -3.10 19.20 0.02 -0.38 -0.17 0.33 0.22
I24 I feel sad 0.58 0.06 -3.04 25.97 0.00 -0.37 0.08 0.43 -0.13
I22 I feel nervous -0.94 0.08 -3.02 33.21 0.00 -0.16 -0.27 0.10 0.33
I18 I avoid meeting new people 0.64 0.07 -2.76 22.36 0.01 -0.09 -0.54 -0.07 0.70
I21 I feel embarrassed -2.08 0.09 -2.62 28.34 0.00 -0.38 -0.28 0.45 0.20
I29 Sweating is constantly on my mind -0.90 0.08 -2.37 24.52 0.00 -0.95 0.12 0.14 0.70
I48 I find it hard to do things without planning in 
advance
0.17 0.07 -2.37 19.89 0.02 -0.01 -0.51 0.24 0.28
I26 I feel frustrated -1.05 0.08 -1.92 16.08 0.07 -0.47 0.16 0.28 0.03
I03 My holidays are affected (e.g. planning, activities) 0.12 0.07 -1.74 12.81 0.17 -0.29 -0.66 0.51 0.44
I14 My work is affected 0.08 0.07 -1.41 12.32 0.20 -0.17 -0.72 0.19 0.70
I35 I worry about people’s reactions -1.59 0.09 -1.40 22.01 0.01 -1.47 0.10 0.54 0.84
I07 My hobbies are affected -0.29 0.07 -1.29 13.99 0.12 -0.14 -0.40 0.01 0.54
I08 My physical activities are affected -0.67 0.07 -1.07 8.68 0.47 -0.60 0.07 0.17 0.36
Note: SE., Standard error; FitResid., Fit Residual from the Rasch model; ChiSq., Chi-squared; Prob., p-value of the Chi-squared statistic.
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Table 6.5: (continued)
No
Fitting Items Location SE Fit 
Resid
ChiSq Prob Threshold
I15 My career decisions are affected (e.g. career choice) -0.02 0.06 -0.76 7.75 0.56 0.56 -0.27 -0.22 -0.07
I45 I worry about the additional chores in dealing with 
my condition
1.28 0.07 -0.72 8.27 0.51 -0.49 -0.06 -0.16 0.71
I38 My sex life is affected 0.99 0.07 ­0.33 6.23 0.72 0.06 ­0.53 0.59 ­0.12
I32 My appearance is affected -0.60 0.07 -0.22 3.32 0.95 -0.45 -0.23 0.49 0.20
I34 I worry about leaving sweat marks on things -1.05 0.08 -0.18 16.68 0.05 0.05 0.18 0.19 -0.41
I12 I avoid public speaking (presentations) -0.03 0.06 0.32 8.93 0.44 -0.07 0.23 0.05 -0.21
I42 My skin feels uncomfortable 0.09 0.07 0.53 11.23 0.26 0.01 -0.27 0.15 0.11
I47 I worry about my condition in the future -0.16 0.07 0.67 5.31 0.81 -0.18 -0.03 -0.21 0.42
I04 I have difficulties holding objects 1.01 0.07 2.66 28.31 0.00 0.52 -0.58 -0.29 0.35
I01 My choice of clothing is affected -1.14 0.08 3.09 25.03 0.00 -0.13 0.13 0.05 -0.05
I44
I worry about the additional money in dealing with 
my condition
1.23 0.07 3.38 6.93 0.64 -0.33 -0.02 0.25 0.10
I06 I find it hard to handle paper -0.21 0.06 3.44 40.61 0.00 0.74 -0.23 0.00 -0.51
I33 I worry about my body odour 0.46 0.06 3.63 25.46 0.00 -0.23 -0.02 0.18 0.07
I11 My everyday housework is affected 0.57 0.07 4.13 45.41 0.00 -0.18 -0.40 0.20 0.38
I43 My eyes feel irritated 1.63 0.07 4.22 83.73 0.00 0.71 -0.69 -0.07 0.06
I39 My choice of food and drinks is affected 1.52 0.07 4.94 35.83 0.00 0.35 -0.66 0.35 -0.05
I13 I find it hard to handle paper 0.51 0.06 5.97 105.73 0.00 1.09 -0.45 -0.25 -0.39
I02 My choice of footwear is affected -0.18 0.06 9.69 256.28 0.00 1.11 -0.30 0.14 -0.95
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Figure 6.5: Category Probability Curves of the original 5-category HidroQoL
a. Item 35 (I worry about people’s reactions) had appropriately ordered category thresholds: 
the curve for each response category shows a unique peak.
b. Item 7 (My hobbies are affected) shows disordered category thresholds: response category 
curve for score ‘1’ reflecting the option ‘a little’ does not have a unique peak.
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Figure 6.6:Person-item distribution map of the 36-items of the HidroQoL showing an even 
spread of the items across the latent variable.
The impact of removing items on the targeting of the HidroQoL against the sample was also 
assessed. The difference between the person mean location and item mean location had increased
(Figure 5.9). From a person mean location of 0.87(±1.35) for the HidroQOL-36, person mean
location had shifted to 1.25 (±1.6) following item reduction (estimates related to Analysis 12, Table 
6.6, Figure 6.9). This is also reflected in number of person’s with extreme scores which had 
increased to 19 persons from 4 prior to item reduction. This suggests a shift in the scale. 
Testing the assumption of unidimensionality
A key underlying assumption of the Rasch model is that the latent variable is unidimensional. This 
was therefore formally tested on the HidroQoL-18. A principal component analysis (PCA) was 
carried out on the residuals after extraction of the Rasch component. The first PC had an eigenvalue 
of 2 and accounted for 11.1 % of variance in the residuals. Both demonstrate a clear single 
dimension of the data. 
Further, a more stringent test of unidimensionality (Smith 2002) was used. Person estimates 
generated from two pairs of item subsets, with the highest positive and negative loading above 
|±0.3| on the first principal component, respectively, were compared using a t-test. Items with high 
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positive loadings included Q8, Q7, Q14, Q3, and Q15, while those with the highest negative 
loadings included Q29, Q22, Q37, Q47, Q35 and Q26. The proportion of significant t-tests was 
5.3% [4.8%, 5.7%] confirming unidimensionality of the instrument. 
Figure 6.7: Item threshold map of the HidroQoL-36 after rescoring to 3 point response 
categories
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Figure 6.8: An illustration of the impact of rescoring on category probability curves
a. Item 12 (I avoid public speaking) showing disordered category probability curves, prior 
to rescoring
b. Item 12 (I avoid public speaking) showing appropriately ordered category probability 
curves after rescoring from 5 to 3 categories.
Misfitting persons
Considering that the RM treats persons in a similar way to items, lack of overall fit may be a 
consequence of a few misfitting persons (Pallant and Tennant 2007). Given that all items in the 
HidroQOL-18 were fitting the model, misfitting persons were suspected to be behind the lack of 
overall model fit. Sequentially removing 6 respondents showing the largest fit residuals led to a 
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good overall model fit (ITICS = 178.49, df = 162, p = 0.18). Item and person fit residuals both fell 
to acceptable ranges, at -0.25 (1.14) and -0.31 (1.3), respectively (Table 6.6, Analysis 13). 
Analysis of Differential Item Functioning (DIF)
Once an instrument demonstrates fit the RM item calibrations should remain invariant across 
populations and testing situations (Reeve and Mâsse 2004). This means that when people with 
different demographic characteristic, for example, females and males, complete an instrument 
scores obtained should not differ, holding underlying variable constant. This assumption was 
explored by testing for differential item functioning for country, gender, age, body are affected, 
disease severity and co-morbidity. Items Q3, Q7, Q8, Q15, Q32 and Q34 showed uniform DIF for 
body area affected. Item Q3 showed uniform DIF for disease severity; and item Q8 showed DIF 
for co-morbidity. In the second step, the purification phase, all items with DIF were removed, in 
order to remain with a set of ‘pure’ items showing no DIF, as means of addressing the issue of 
compensatory DIF (Teresi 2006). This proceeded sequentially by removing one item at a time and 
iteratively assessing for DIF. Two items (Q26 and Q35) showing no DIF during the initial 
assessment had DIF for body area affected. In contrast, two items (Q47 and Q7) previously 
showing DIF no longer showed DIF. This on one hand, implies that, not all DIF observed is real, 
and on the other, that DIF could also be induced in items due to its presence in others (Tennant and 
Pallant 2007).
In the end a set of 8 pure items without DIF for any of the patient characteristics considered were 
realised. In the final step, DIF was reassessed while anchoring the scale on the ‘pure’ set of items 
(Table 6.8). There were no differences in the resultant items identified as showing DIF following 
the -purification process.
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Table 6.6: Impact of item reduction steps on overall fit of the RM and individual items.
Action Overall Model Fit Item Fit 
Residuals
Person Fit 
Residuals
PSI Fit Resid > 2.5 Fit Resid < -2.5
Chi df p Mean SD Mean SD
3. Revise scoring to 01113 1087.40 324.00 0.001 ­0.05 3.48 ­0.23 1.64 0.94 39, 2, 13, 43, 33, 11, 
4
26, 20, 22, 17, 30, 24, 
27, 36
4. Q2, Q4, Q13 and Q43 
removed
768.26 288.00 0.001 -0.12 3.35 -0.31 1.59 0.94 39, 6, 11, 33, 42, 1, 
44
22, 20, 24, 17, 30, 27, 
36
5. Q39, Q6 and Q11 removed 612.89 261.00 0.001 -0.29 2.69 -0.35 1.55 0.93 33, 42, 1, 44 20, 24, 17, 30, 27, 36
6. Q36, Q27 and Q30 453.34 234.00 0.001 -0.22 2.26 -0.34 1.48 0.92 33, 42, 1, 44 22, 20, 24, 17
7. Q33 and Q42 removed 346.51 216.00 0.001 -0.23 1.96 -0.34 1.43 0.92 44, 1 24, 20, 17
8.Q17 and Q20 removed 290.29 198.00 0.001 -0.21 1.78 -0.33 1.37 0.91 44, 1 21, 24
9. Item 1 deleted 277.60 189.00 0.001 -0.23 1.68 -0.34 1.37 0.91 44 21, 24
10. Q24 deleted 233.68 180.00 0.001 -0.19 1.54 -0.34 1.35 0.90 44 -
11. Q44 deleted 239.49 171.00 0.001 -0.27 1.39 -0.34 1.33 0.89 - 21
12. Q21 deleted 194.00 162.00 0.04 -0.25 1.22 -0.33 1.37 0.89
13. 6 respondents removed 178.49 162.00 0.18 -0.25 1.16
14. 6 respondents removed 169.57 162.00 0.33 -0.25 1.14 -0.31 1.30 0.89
15. 2 respondents removed 171.47 162.00 -0.25 -0.25 1.13 -0.31 1.29 0.89
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Table 6.7: Parameter estimates for the final 18 items fitting the Rasch model following item 
reduction
Fitting Item Loca-
tion
SE FitRes. Chi-Sq p-value THreshold
1 2
Q3 My holidays are affected 0.47 0.09 ­1.10 7.64 0.57 ­1.70 1.70
Q7 My hobbies are affected -0.01 0.09 0.83 5.31 0.81 -1.56 1.56
Q8 My physical activities are affected -0.67 0.09 -1.30 4.41 0.88 -1.64 1.64
Q12 I avoid public speaking (e.g.
presentations)
0.33 0.08 1.28 14.09 0.12 -0.97 0.97
Q14 My work is affected 0.51 0.09 -0.20 16.18 0.06 -1.74 1.74
Q15 My career decisions are affected (e.g. 
career choice)
0.49 0.08 -0.26 3.23 0.95 -0.81 0.81
Q18 I avoid meeting new people 1.16 0.08 0.07 3.03 0.96 -1.59 1.59
Q22 I feel nervous -0.76 0.09 -1.80 16.52 0.06 -1.53 1.53
Q26 I feel frustrated -1.08 0.09 -1.93 10.16 0.34 -1.42 1.42
Q29 Sweating is constantly on my mind -1.04 0.09 -0.92 5.89 0.75 -2.00 2.00
Q32 My appearance is affected -0.45 0.09 0.91 4.90 0.84 -1.55 1.55
Q34 I worry about leaving sweat marks on 
things
-1.07 0.09 1.40 9.02 0.44 -0.87 0.87
Q35 I worry about people’s reactions -2.05 0.10 -0.29 16.66 0.05 -2.40 2.40
Q37 I feel uncomfortable physically 
expressing affection (e.g. hugging 
others)
-0.03 0.09 -0.50 13.66 0.13 -1.65 1.65
Q38 My sex life is affected 1.60 0.08 1.19 14.60 0.10 -1.22 1.22
Q45 I worry about the additional chores in 
dealing with my condition
1.80 0.09 0.08 5.10 0.83 -1.74 1.74
Q47 I worry about my condition in future 0.17 0.08 0.38 8.12 0.52 -1.42 1.42
Q48 I find it hard to do things without planning 
in advance
0.63 0.08 -2.24 12.96 0.16 -1.43 1.43
DIF was still seen in all items which previously showed problems (Table 6.9, Figure 6.10). 
Nonetheless, the purification process gave useful hints on items whose DIF was likely to be 
compensatory rather than real.
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Figure 6.9: Person-item distribution showing targeting of the HidroQoL following item 
reduction
Magnitude of DIF
Showing statistically significant DIF, only rules out the possibility that such observation is a result 
of chance (Linacre 2009). Of practical relevance for measurement is the actual size of the observed 
DIF. This was, thus, evaluated by measuring the differences between the general and group 
specific-item difficulty estimates across each patient characteristic. The magnitude of differences 
across all DIF items exceeded 0.5 logits indicating non-trivial DIF. For example, item Q32 (my 
appearance is affected) was 3.3. logits easier for patients with generalised hyperhidrosis in 
comparison with the estimate based on all patients. This item was 2.06 logits more difficult for 
patients with palmar and plantar hyperhidrosis (Table 6.10). DIF by age was most severe in  item 
Q34: respondents the age group 40 to 49 found this item 2.9 logits easier than the average patient. 
Impact of DIF
Having established that the DIF was not due to chance and was not trivial, the ultimate question 
was whether it indeed mattered, in the actual evaluation of persons (Tennant and Pallant 2007). 
This was assessed by looking at the impact of the item level DIF on the final scale scores. First, 
the direction of the DIF for the groups was assessed to see whether the DIF cancelled out, where 
some items favoured one group and the other items favoured the other groups. 
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Table 6.8: Pure set of items showing no DIF following the purification
Location Threshold_1 Threshold_2
Q7 -0.498 -1.554 1.554
Q14 -0.010 -1.700 1.700
Q18 0.607 -1.536 1.536
Q29 -1.513 -1.983 1.983
Q37 -0.511 -1.634 1.634
Q38 1.061 -1.226 1.226
Q45 1.222 -1.750 1.750
Q47 -0.359 -1.417 1.417
Table 6.9: DIF in items according to patient characteristics
Item Age Body area affected Disease severity Co-morbidity
F-Stat. p F-Stat p F-Stat. p F-
tat.
p
Q3 16.16 0.00002 12.7 0 7.48 0.000629 ns
Q7 1.55 ns 5.9 0.000571 ns ns
Q8 14.5 0.00005 12.7 0.000001 ns 4.8 0.000265
Q12 1.67 ns ns ns ns
Q14 0.41 ns ns ns ns
Q15 1.15 ns 5.9 0.000584 ns ns
Q18 ns ns ns ns
Q22 ns ns ns ns
Q26 ns ns ns ns
Q29 ns ns ns ns
Q32 10.29 0.000001 28.21 0 ns ns
Q34 11.74 0.00001 14.79 0.00001 ns ns
Q35 ns ns ns ns
Q37 ns ns ns ns
Q38 ns ns ns ns
Q45 ns ns ns ns
Q47 6.25 0.000365 ns ns ns
Q48 ns ns ns ns
Notes: F, F-statistic; P, p-value; ns, not significant.
For DIF according to age, two sets of items seemed to cancel out: Q47 against Q3 and; Q34 against
Q32. However, DIF according to body area does not show clear balancing out.  Person estimates 
obtained from the eight ‘pure’ items during the purification stage were compared with person 
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estimates from the full item set with the DIF-free items anchored at their values obtained during 
the purification phase. The two sets of person estimates correlated highly (Pearson correlation = 
0.94), 83.2% of sets of person estimates showed a difference of below 0.5 logits [comparison with 
standard deviation]; 97.3% of person estimate sets had a difference below 1 logit. Based on a 
paired t-test the person estimates from the two measures were not statistically different (p=0.29). 
This indicates that the DIF in the different items simultaneously had no impact on the scale scores.
Further, the DIF impact at the scale level was also assessed graphically using Test Characteristic 
Curves. Group specific test characteristic curves (TCC) were estimated for each patient 
characteristic to assess whether the relationship between raw score and latent variable remained 
invariant across groups. TCCs were estimated for groups across age, body area affected and 
disease severity. The results showed largely invariant TCCs across all patient characteristics (age, 
severity of disease, co-morbidity), nonetheless, the TCC for site of hyperhidrosis showed marginal
variance (≤ 0.5 logits) (Figure 6.11). The findings indicate that the DIF observed at the item level 
did not affect the optimal functioning of the overall scale.
Local Independence
Rasch model’s assumption of local independence requires that any set of items should not share 
any meaningful correlation, once the Rasch component is accounted for (Baghaei 2008a). This 
assumption was evaluated for the HidroQOL-18 by examining the residual correlations between 
items. Four item pairs showed a correlation greater than 0.2: Q15 and Q32; Q3 and Q34; Q14 and 
Q15; and Q7 and Q8. Similar to DIF analysis the size and practical implications of local 
dependence are not clear based on correlations alone. Thus the size of the local dependence was 
measured. The locally dependent items (Q15, Q8, and Q3) were split according to responses on 
the corresponding independent items (Q32, Q7 and Q34). Overall fit to the RM was poor following 
the split, the ITICS statistic was 267.93 and was significant (Table 6.11, Analysis 1). Two items
showed poor fit (Q48; and Q7- 0, for those who had a score of zero on item 8). The PSI was not 
affected by splitting. The magnitude of response dependence was calculated using the category 
thresholds of the new set of split items.
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Figure 6.10: An illustration of DIF as reflected in empirical group-specific Item 
characteristics curves
a. Item 8, ICC showing expected score for each level of the latent variable traced for each age 
group.
b. Item 34, ICC showing expected score for each level of the latent variable traced for the body 
area involved in the hyperhidrosis
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Table 6.10: Magnitude of DIF
Note: Size of DIF for each item is [item difficulty estimate, whole sample (Qxx_original) – groupspecific item estimate]. 
The largest dependence was seen between item Q7 and Q8 at 1.18 logits, while that between Q14 
and Q15 was 0.826. On the other hand the dependence between Q4 and Q34 was trivial, at 0.182.
Using the magnitude of response dependence as a basis for decision-making regarding how to 
address the dependence, items Q15, Q8, and Q48 were sequentially removed (Table 6.11, Analysis 
Items split according to body area 
affected
Items split according to age-
group
Items split according to 
comorbidity
Item Difficulty
Estimate
DIF 
Size
Item Difficulty 
Estimate
DIF 
Size
Item Difficulty 
Estimate
DIF 
Size
Q3_original ­0.06
Q3_head 0.00 -0.06 Q3_18to29 1.60 ­1.66
Q3_axilar 1.31 -1.36 Q3_30to39 0.95 -1.01
Q3_generic 0.22 -0.28 Q3_40to49 0.73 -0.78
Q3_p&f 1.23 -1.29 Q3_50+ -0.06 0.01
Q8_Original -1.13
Q8_head -0.79 -0.34 Q8_18to29 -0.13 -1.00 Q8_none 0.07 ­1.20
Q8_axilar 0.22 -1.35 Q8_30to39 0.26 -1.39 Q8_men -4.51 3.38
Q8_generic -0.70 -0.43 Q8_40to49 -0.24 -0.89 Q8_diab -1.21 0.08
Q8_p&f -0.38 -0.75 Q8_50to59 -1.36 0.23 Q8_hyper -1.28 0.15
Q12_original -0.21
Q12_head 0.64 -0.84
Q12_axilar 0.24 -0.44
Q12_generic 0.36 -0.57
Q12_p&f 1.21 -1.42
Q32 Original -0.97
Q32_head -1.76 0.79 Q32_18to29 0.60 -1.57
Q32_axilar -0.28 -0.69 Q32_30to39 -0.50 -0.47
Q32_generic -4.25 3.28 Q32_40to49 -0.11 -0.86
Q32_p&f 1.09 -2.06 Q32_50+ -0.67 -0.30
Q34_Original -1.53
Q34_head 0.14 -1.67 Q34_18to29 -1.86 0.33
Q34_axilar -1.14 -0.38 Q34_18to29 -0.79 -0.74
Q34_generic -0.88 -0.65 Q34_40to49 -4.42 2.89
Q34_p&f -4.49 2.96 Q34_50to59 -0.12 -1.40
Q48_original 0.09
Q48_head 0.68 -0.59
Q48_axilar 1.20 -1.10
Q48_generic 0.31 -0.22
Q48_p&f 1.42 -1.32
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2- 4). The HidroQoL showed lack of overall fit to the RM after the removal of the three items, 
although the remaining items fitted the RM. The HidroQoL also failed the formal test of 
unidimensionality, the proportion of significant t-tests of person estimates for subtests of the 
instrument, exceeded 5%. Following the removal of misfitting respondents (n = 22), fit of the 
HidroQoL to the RM was improved. Unidimensionality was also achieved (Analysis 5).
Figure 6.11: Test Characteristic Curves for the HidroQoL-18
TCCs by age
TCCs by body area affected
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TCCs by severity of disease
TCCs by co-morbidity
Applying classical exploratory factor analysis to the Rasch calibrated HidroQoL
Following the calibration of the HidroQoL as a unidimensional measure using Rasch analysis, 
classical exploratory factor analysis (EFA) was employed to cross-validate the calibration; and to 
further confirm unidimensionality. The number of factors to be extracted was determined based on 
multiple criteria. According to the Kaiser’s rule, a single factor achieved an eigenvalue greater 
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than 1, for both the 15 and 18 item HidroQoL versions (Table 6.12). This was supported by scree 
plots: only a single factor lay to the left of the elbow in the plots for both the 15 and 18 item 
versions (Figure 6.12). 
This means that variance in the HidroQoL scores can be effectively captured using a single latent 
variable. All items of the HidroQoL also showed strong loading onto the single factor (range 0.592 
to 0.782) (Figure 6.13). The HidroQoL’s items also showed a high level of shared variance, the 
highest item residual was 0.65 and 0.62, for the 18-item and 15-item versions. These results 
strongly suggest that the HidroQoL (both 18-item and 15-item versions) is unidimensional, 
supporting the results of the Rasch analysis.
Part III: Testing the Invariance Of The Hidroqol
Rasch calibrated measures are expected to show invariance in item parameters across different 
sub-populations (Bond and Fox 2007). Thus, the HidroQoL was recalibrated on a new sample to 
determine if it would replicate original calibration. 
Table 6.11: Impact of adjusting for response dependence on overall model fit.
Action
Overall 
Model Fit
Item Fit 
Residuals
Person Fit 
Residuals
Person 
Location
Unid PSI
Chi df p Mean SD Mean SD Mean SD sig 
1. Splitting Q7, Q15 
and Q3 
267.93 188 <.001 -0.29 1.29 -0.3 1.18 1.1 1.66 0.872
2 Removing item 15, 
from HidroQoL-
18
168.94 153 0.179 -0.27 -0.3 1.24 1.3 1.67 0.882
3. Removing Q8 from 
HidroQoL
187.96 144 < 
0.001
-.23 1.33 -.3 1.2 1.31 1.68 0.88
4. Removing Q48 165.72 135 0.039 -0.2 1.21 -0.3 1.18 1.34 1.66 7.09
5. Removing 22 
persons 
159.64 135 0.07 -0.09 1.19 -0.24 1.05 1.365 1.65 3.42 0.869
Note: Chi: Chi-squared; df: degrees of freedom;
Table 6.12: Eigen values of the HidroQoL
Instrument
Factors Adjusted
Eigen value
observed
Eigen value
Estimated
Bias
18-items 1 6.536 6.834 0.298
15-items 1 5.244 5.544 0.300
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Figure 6.12: Scree plots of the HidroQoL
a. scree plot of 18 item version of the HidroQoL
b. scree plot of  the 15-item version of the HidroQoL
Specifically the following hypothesis were tested: 
 the HidroQoL (18-item and 15-item versions) fits the RM; 
 the hierarchical ordering of the items would not change; and 
 the item parameters remained invariant within linear transformation across the two 
populations (US/Canada versus UK). 
Moreover, these aspects entail assessing the cross cultural validity of the instrument, an 
increasingly demanded property especially in instruments applied in international clinical trials 
(Nijsten et al. 2007).
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Table 6.13: Factor loadings and residual variances of the HidroQoL
18- item version 15-item version
Item Loading S.E. Res. Var Loading S.E Res. Var
Q3 0.724 0.023 0.476 0.694 0.026 0.518
Q7 0.696 0.027 0.516 0.619 0.033 0.617
Q8 0.77 0.022 0.407
Q12 0.658 0.027 0.568 0.663 0.028 0.561
Q14 0.684 0.026 0.532 0.612 0.033 0.626
Q15 0.736 0.024 0.459
Q18 0.715 0.025 0.488 0.724 0.025 0.475
Q22 0.793 0.023 0.372 0.808 0.023 0.347
Q26 0.768 0.025 0.41 0.799 0.024 0.361
Q29 0.739 0.025 0.454 0.758 0.025 0.426
Q32 0.682 0.028 0.535 0.682 0.029 0.535
Q34 0.592 0.036 0.649 0.615 0.035 0.622
Q35 0.759 0.027 0.424 0.79 0.026 0.376
Q37 0.729 0.024 0.469 0.756 0.024 0.428
Q38 0.636 0.03 0.596 0.648 0.03 0.579
Q45 0.699 0.027 0.511 0.693 0.029 0.52
Q47 0.72 0.025 0.481 0.691 0.028 0.522
Q48 0.782 0.021 0.389
Sociodemographic characteristics of the study participants (sample 2)
A total of 115 patients with hyperhidrosis were included for analysis of part III of the results. 
Thirty-seven  participants (32%) were male and 78 (68%) were male (Table 6.14) The mean age 
was 40.2 years, with 36 patients being aged between 30 and 39, making up the largest age group. 
Patients reporting generalised hyperhidrosis made up the largest group, with 36 participants. Forty-
five percent of the patients reported no co-morbidity (n = 54).
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HIdroQoL-18
All eighteen items showed good fit to the RM with fit residuals lying between -2.5 and 2.5. The 
average mean person location estimate of 1.26 (1.57) indicated that the HidroQoL was at a lower 
QoL impact, relative to this patient population. This is similar to estimates obtained during initial 
calibration. The PSI (0.889) replicated the strong reliability obtained earlier (Table 6.15). 
Table 6.14: Sociodemographic characteristics of study participants
Gender , N (%)
Male 37(33%)
Female 78 (67%)
Age (years)
Mean (SD) 40.2 (13.3)
Median 39
Range 18-74
Duration of condition (years)
Mean (SD) 24.1
Median 21
Range 2 to 60
Body area affected, n
Head* 28
Axilla* 14
General 36
Axilla, Palms, Feet 15
Palms and Feet 19
Co-morbidity
None 52 (45%)
Menopausal complaints 8 (7%)
Diabetes 4 (3%)
Hypertension 10 (9%)
Neurological disorders 9 (8%)
Thyroid disorders 23 (20%)
Employment status
Employed 74 (64%)
Unemployed 24 (21%)
Retired 11 (10%)
Full-time student 6 (5%)
*This only indicates this site as a predominant site affected.
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Table 6.15: Overall model fit statistics for the HidroQoL on participants from UK
Action
Overall Model 
Fit
Item Fit 
Residuals
Person Fit 
Residuals
Unid. test PSI
Chi df p Mean SD Mean SD Sign. t-test (%)
1. 18 items* 49.47 36 0.07 -0.02 1.1 -0.2 1.18 7.14% 0.889
2. Q8 and Q15 
removed
40.32 32 0.15 -0.014 1.17 -0.22 1.12 5.36% 0.876
3. Q48 removed 45.05 30 0.04 0.03 1.12 -0.21 1.08 2.68% 0.864
The three level categorization seemed to function well, all items had appropriately ordered 
thresholds, increasing monotonically along the latent variable. Unidimensionality was tested using 
multiple approaches, based on the residuals. A principal component analysis (PCA) of the residuals 
showed that the first component explained 12% of variation in the residuals and had an eigen-
value of 2, supporting unidimensionality. Strict unidimensionality was assessed by comparing 
person estimates from a subset of items with positive loading to the first residual PC (Q48, Q8, 
Q26, Q47) against a subset of items with negative loading (Q38, Q37, Q15, Q14). 7.14% (CI: 
2.9%, 12.7%) of person estimates showed statistically significant differences, indicating 
unidimensionality. To test the assumption of local independence a correlation analysis of the 
residuals was carried out. This showed a number of item pairs exceeding the average: Q8 and Q7; 
Q48 against Q14; Q48 and Q38. The next step was to examine the magnitude of the observed 
response dependence. The response dependence between Q8 against Q7 was of magnitude of 2.23 
logits; that between Q48 and Q14 was -.33 logits while that between Q48 and Q38 was -0.69. The 
response dependence between Q8 and Q7 was similarly observed during original calibration; 
moreover item Q48 also showed worse fit following the resolution of the response dependence 
during the original calibration. This suggests that the composition of the HidroQoL as a 
unidimensional metric for measuring hyperhidrosis-specific QoL is invariant. 
Comparison of model fit: HidroQOL-15
During the initial/original calibration of the HidroQoL three items (Q8, Q15 and Q48) were 
removed from the HidroQOL-18 (18 item set of the instrument) to resolve local dependence 
problems, resulting into HidroQOL-15. The 15-item HidroQOL was also assessed for its fit to the 
RM based on the new patient population (UK, N = 115). The ITICS statistic decreased to 45.05 
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(df=32) and indicated poor fit to the RM (p=0.04). The mean fit residuals for persons and items 
showed no change from the HidroQoL-18 (persons, -0.21±1.08; items, 0.03±1.12). Reliability had 
declined (PSI = 0.86). The targeting of the instrument also showed no change from the HidroQoL-
18. According to the Smith’s t-test the HidroQoL’s 15-item version was also unidimensional: 
2.68% (CI: 1.2%, 9.3%) of person estimates derived from two subsets of the HidroQoL showed
significant t-tests. This suggests that although the individual items remain optimal and comprise a 
unidimensional scale, its functioning across (the ordering of items) across levels of impairment is 
not invariant. 
Testing for invariance
Further, the hierarchical ordering of the items of the HidroQoL was compared, between the patient 
populations. The item maps for the 18-item version of the HidroQoL was generated and compared 
with the one generated from the US and Canadian sample (Figure 6.13). The hierarchy of the items 
had changed on account of items Q37, Q35, Q34, Q29 and Q26 which had shifted their order. 
Items Q37, Q35, Q34, Q29 seemed more difficult for the UK sample, while Q26 was regarded 
easier than as originally calibrated.
Next, the invariance of the actual item difficulty estimates of the HidroQoL was assessed using a 
scatter plot of item estimates from the original calibration against those from the U.K sample 
(Figure 6.14). The imprecision of each estimate was taken account of by overlaying 95% control 
lines based on standard errors for each set of item-difficulty as suggested by (Bond and Fox 2007). 
The graph shows that one out of the eighteen items fell outside the control lines.  With 94.5% of 
the estimates falling within the control lines, the argument for invariance is, therefore, supported.
Revision of the HidroQoL
Following the item reduction process reported in this and the previous chapter the developmental 
HidroQoL was revised to 18 items, loosing 31 items (Figure 6.15). The response scoring was 
revised to a 3 point scale. Fifteen of the 18 items are based on the results of the Rasch item 
reduction process (in this chapter). The other three are retained for their importance to patients 
(according to results of the qualitative study in chapter 3). This was the final version taken for 
reliability, validity and responsiveness assessment, reported in the subsequent three chapters.
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Figure 6.13: Comparison of item hierarchical order between original calibration of the HidroQoL and from the UK sample
a) Original item hierarchical order based on US and Canada 
participants
b) Item hierarchical order based on calibration on participants 
from the UK.
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Figure 6.14: Scatter plot of item difficulty estimates of the HidroQoL, plotting estimates 
from the original calibration against those from the UK samples
a) 18-item set
b) 15-item set
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Figure 6.15: The final version of the HidroQoL with 18-items
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Figure 6.15 (continued)
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DISCUSSION
Before a QOL instrument is considered ready for use, it is imperative to undertake field testing, 
similar to the large “phase III” trials in clinical trial language, in order to determine whether its 
measurement model is functioning as envisaged and if necessary to undertake any revisions. This 
constitutes an important aspect of Messick’s substantive aspect of validity, that theoretical 
rationales relating to both item content and processing models explain observed consistencies 
among items (Wolfe and Smith 2007a). On the other hand this demonstrates the internal validity 
of the instrument, the organization of items into scales and subscales and how they relate to each 
other. Among other approaches for developing and testing the scaling of an instrument, the 
unidimensional Rasch model offers a number of advantages. It allows the hierarchical ordering of 
the items based on the level of the underlying construct (QOL impairment) they assess (Prieto et 
al. 2003). In addition, the model is consistent with requirements of conjoint measurement 
permitting the transformation of raw scores into interval scaled measures once fit to the model is 
confirmed (Bond 2004).  Therefore, the aim of this study was to assess the extent to which the 
HidroQoL conforms to the RM. In addition, to use the RM and its properties as a basis for the item 
reduction process and construct validation of the HidroQoL. This is based on the consideration of 
the RM as a template for an instrument satisfying fundamental axioms of measurement.
The version of the HidroQoL used in this study, the HidroQoL-36, contained 36-items and was a 
result of earlier item reduction steps reported in the previous chapter. The HidroQOL-36 lacked 
overall fit to the RM, which means that the hierarchical ordering of the items was not invariant 
across different levels of QOL impairment along the latent variable continuum (Pallant and 
Tennant 2007). This may be a consequence of any number of problems including dysfunctional 
response categories, items or person whose response patterns are inconsistent with the RM’s 
probabilistic structure, violations of model assumptions such as local independence, presence of 
additional dimensions or differential item functioning (Tesio 2003). Further analysis explored each 
of these elements. 
An analysis of the individual items showed that 21 items had poor fit to the RM.  Underfitting 
items (fit residuals < 2.5) by and large included items specific to types of hyperhidrosis (body area 
affected). For example, the following items, I have difficulties holding objects (Q4), I find it hard 
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to handle paper (Q13), I find it hard to touch other people (Q6) are all linked to palmar 
hyperhidrosis. Items my choice of footwear is affected (Q2) and My eyes feel irritated (Q43), are 
linked to plantar hyperhidrosis and craniofacial hyperhidrosis, respectively. The lack of fit suggests 
these items were considered to be measuring a different construct, other than the one captured by 
the Rasch model, indicating multidimensionality problems. On the other hand, nearly all items that 
overfit the model (with fit residuals < -2.5) were related to psychosocial QOL impacts: I feel 
uncomfortable physically expressing affection (e.g. hugging others) (Q37), I find it hard to be near 
others (Q36), I worry about people’s reactions (Q35), I feel frustrated (Q29), My self-confidence 
is affected (Q27),  I feel sad (Q24), I feel nervous (Q22) and I feel embarrassed (Q21). The overlap 
and interrelation in the content among this set of items meant that a response on one item predicted 
a choice of a particular response on another. Overfit presents a challenge to the assumption of local 
independence (Whalley et al. 2004). In addition, the functioning of the response categories was 
assessed. Optimally functioning response categorization is not only ideal in the context of attaining 
good fit to the RM at the item level, but also lends support to the substantive aspect of validity, 
that the response categorization is understood as intended (Wolfe and Smith 2007b). Three items, 
My physical activities are affected (Q8), Sweating is constantly on my mind (Q29) and I worry 
about people’s reactions (Q35) had optimally functioning response categories, with category 
thresholds increasing monotonically. The rest of the items (N = 33) had disordered category
thresholds, reflecting inconsistencies in how the sample used the response categories.  This was 
most seen among the categories ‘a little’ ‘somewhat’ and ‘quite a bit’, which may stem from the 
wide range of overlapping degrees of mildness to which they all relate to. Consequently, subjects 
might have been unable to distinguish between categories (Pallant and Tennant 2007).
The assumption of unidimensionality was not supported on the HidroQOL-36, based on both PCA 
analysis of residuals and based on Smith’s t-test (Smith 2002). This was already hinted in the 
misfitting of hyperhidrosis-specific items. In the Rasch framework, multidimensionality may also 
result from persons whose pattern of response departed from the RM probabilistic prediction.
Revision of the HidroQOL-36 based on Rasch analysis, first addressed the issue of dysfunctional 
response categories. Combining categories ‘a little’ and ‘somewhat’ resolved response 
categorization problem in 6 items, 27 items still had disordered thresholds. Collapsing the three 
categories, ‘a little’, ‘somewhat’ and ‘quite a bit’ achieved optimally ordered response category 
thresholds in all items. This sheds light on where most of the inconsistent use of response 
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categorization occurred, i.e. between ‘somewhat’ and ‘quite a bit’. This indicates the importance 
of descriptors for options on the utility of scales. 
Further, misfitting items were removed from the HidroQoL with the intention of achieving greater 
conformity to the Rasch model (Nijsten et al. 2006a). Relying on statistical considerations for 
decision-making regarding which items to include and which ones not to, has its own drawbacks, 
for example the elimination of items important to patients. Nonetheless maintaining items which 
add little to the measurement aims, either because they are assessing a different construct other 
than the intended construct or because they provide redundant information (2008a) would not 
ensure adequate and efficient measurement of the underlying construct. Therefore, eighteen 
misfitting items were sequentially removed from the HidroQoL. Fit to the RM was enhanced, 
while reliability and targeting slightly worsened. Nonetheless, reliability remained adequate for 
individual level comparisons (above 0.85), the difference between item mean location and person 
mean location increased by more than 0.5 logits. The number of persons with extreme scores 
increased. The removal of the items had an impact on the scope and range of the continuum of the 
latent variable in turn affecting reliability and leading to increase in extreme scores (Hagquist et 
al. 2009). In addition, the removal of misfitting items affected how the remaining items fit the 
model for example, some overfitting saw an improved fit (Bond and Fox 2007, p.240). This 
highlights the importance of a sequential approach in the item-reduction process, to allow careful 
assessment of the impacts of removing items on the scale as a whole and on other individual items. 
Thus, the sequential process followed in the item reduction of the HidroQoL safeguarded against 
adversely affecting the goals of development and measurement for the HidroQoL.
During the Rasch analysis six misfitting persons were removed from the sample. Misfitting 
persons shows response patterns that are inconsistent with a person’s level of ability, representing 
departures from the Rasch probabilistic pattern (Tesio 2003). Underfit of persons can be a case of 
‘lucky guessing’ where people of low ability unexpectedly get a difficult question right, or 
‘carelessness’, where a person of high ability gets an item on a low ability level wrong. While such 
behaviors tell nothing of the actual person’s ability, the risk is that they might be mistakenly 
included in the calibration of person abilities leading to false conclusions (Bond and Fox 2007, 
p.64). On the other hand, there seems to be a real danger of removing persons misfitting person 
from the sample to the extent of compromising the generalisability of findings all in the name of 
RM (Pallant and Tennant 2007) ultimately rendering the instrument not usable in practice.
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An implication of the RM property of invariance of item parameters, is that conditioning on the 
latent trait, the items are expected to function in the same way in people belonging to different 
demographic groups (Reeve and Mâsse 2004, p.272). An assessment of DIF on the items of the 
HidroQoL found no DIF for patient’s gender or country.  Uniform DIF was detected with respect 
to disease severity, age, body area affected and co-morbidity.  Several items faced DIF across more 
than one demographic factor, for instance, My holidays are affected (Q3), My physical activities 
are affected (Q8), My appearance is affected (Q32) and I worry about leaving sweat marks on 
things (Q34), had DIF for age and body area affected. Items Q3 and Q8 also showed DIF for 
disease severity and co-morbidity, respectively.
Although removing items affected by DIF is seen as a solution, blindly doing so does not always 
yield intended results. In some situations this may make the DIF worse in the remaining items 
(Tennant and Pallant 2007). Moreover, removing items may also impact on the definition of the 
underlying construct (Bond and Fox 2007). This calls for a ‘cost-benefit’ analysis of the DIF in 
terms of its measurement implications. All DIF identified was of a moderate to large size, with 
items Q32 and Q34 showing the largest DIF for body area affected and age. DIF equal to or above 
0.64 is considered large, while that equal to or above 0.43 is considered to be slight or moderate 
(Tristan 2006). Further, an investigation into the effects of the item level DIF on the functioning 
of the scale as a whole was carried out using the Test Characteristic Curve. This showed that the 
DIF had minimal impact on the scale as whole. Therefore all items showing DIF were retained. 
These findings suggest that the HidroQoL can be used across patients with varying levels of 
disease severity, across different ages, hyperhidrosis affecting different body areas, patients with 
different co-morbidities, without worrying that the results will be biased against one group for 
each of the factors.  However, cross sectional comparisons of individual patients varying in body 
area affected using items Q3, Q7, Q32 and Q34 individually would be discouraged due to the non-
trivial DIF associated with these items (Edelen et al. 2006).  This recommendation extends to items 
showing DIF for age, disease severity, co-morbidity.
With these findings the HidroQoL is the first disease-specific QOL instrument in hyperhidrosis in 
which invariance across types of hyperhidrosis has been explicitly assessed. Other measures such 
as the Hyperhidrosis Scale use a modular approach, where sections of the instrument apply to a 
specific type of hyperhidrosis. Moreover, in addressing the issues of bias and unidimensionality 
concurrently, the substantive challenge associated with the optimal scoping of the construct 
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especially where the target population for the instrument has diverse characteristics is more 
effectively addressed. 
The DIF for body area affected observed on the HidroQoL reflects a fundamental challenge in the 
design and development of HRQoL measures for hyperhidrosis, that of developing a measure that 
would be relevant across the different types of hyperhidrosis. None of the previous measures has 
been assessed for DIF by body area affected, although the design of one measure, the 
Hyperhidrosis Scale, shows consideration of this aspect by containing subsections relevant to 
hyperhidrosis of different areas (Keller et al. 2001). 
Where an instrument achieves sufficient fit to the RM, item calibrations are expected to remain 
invariant across patient populations (Bond and Fox 2007).  This property was explicitly assessed 
for the HidroQOL, by comparing initial calibrations (based on a sample from the US & Canada) 
and a recalibration based on a fresh sample (UK). Hierarchical ordering of items changed for 5 
items, including I feel uncomfortable physically expressing affection (e.g. hugging others) (Q37), 
I worry about people’s reactions (Q35), I worry about leaving sweat marks on things (Q34). These 
items touch upon issues reflecting social norms core to self-image and public life that may differ 
across any two cultures. Nonetheless, the importance of these difference should not be 
overemphasized, as the hierarchical ordering is based on point estimates and does not into account 
measurement errors. Indeed, seventeen of the HidroQoL-18’s items and fourteen of the HidroQoL-
15’s items were invariant between the initial calibration and re-calibration samples, once 
measurement error was taken into account. This confirms the construct validity of the HidroQoL, 
by supporting the initial definition of the underlying construct in patient populations from the USA
and Canada. On the other hand, this provides compelling evidence for the crucial property of 
cultural equivalence of the HidroQoL, between the US & Canada and the UK. Ultimately, whether 
the impact of Rasch model is regarded as ‘evolutionary’ or ‘revolutionary’ cannot obviate the 
unique properties and advantages brought to the scale development and construct validation 
processes, particularly in achieving well defined constructs. In this respect, the RM allowed 
thorough understanding and evaluation of the items of HidroQoL finally leading to an optimally 
defined construct, otherwise not feasible in the CTT.
SUMMARY
 Field testing was carried out on the developmental version of the HidroQOL in patient with 
hyperhidrosis (N = 595) from the U.S.A, Canada and the UK
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 The measurement model of the HidroQOL (HidroQOL-36), following the resolution of 
item redundancy, was tested using the Rasch model. Further, item reduction and revision 
was performed on the HidroQOL to achieve conformity to the model. The desirability of 
this lies in that that the Rasch model fulfils the requirements of conjoint measurement, 
allowing transformation of the raw scores into interval scaled measures.
 The HidroQOL-36 had overall poor fit to the Rasch model, 10 items underfitted (fit-
residuals > 2.5), another 10 items showed overfit (fit-residuals < -2.5). Reliability was 
strong (PSI = 0.94). Three items had optimally functioning response categories, the 
remaining 33 items showed disordered category thresholds. The HidroQOL-36 showed 
lack of unidimensionality.
 Optimal functioning of response categories was achieved by collapsing the categories quite 
a bit, somewhat and a little as one. 
 Eighteen misfitting items were sequentially removed, resulting in a set of 18-items fitting 
the model (HidroQOL-18). The assumption of unidimensionality was also supported.
 DIF was assessed on the HidroQOL-18: 7 items showed uniform DIF for age, 6 items 
showed uniform DIF for body-area affected; 1 item showed DIF for disease-severity and
another items showed DIF for co-morbidity. DIF for age balanced out for two pairs of items 
(Q47 and Q3) and (Q34 and Q32), but not across any other factor. Although all DIF 
identified was non-trivial, its impact on the functioning of the scale as a whole was 
negligible.
 Non-trivial response dependence was detected in two item pairs Q7 and Q8 and Q14 and 
Q15 while one other pair (Q4 and Q34) showed trivial response dependence. Three items 
were removed to resolve this, Q15, Q8 and Q48, resulting in the HidroQOL-15.
 Results of factor analysis for both the 18-item and 15-item versions of the HidroQOL 
showed a single-factor solution supporting findings from the Rasch model.
 The item calibrations of HidroQOL-18 and HidroQOL-15 were tested for invariance by 
recalibration in a fresh patient population. For both versions one item, Q29, and Q26, 
respectively, showed lack of invariance, supporting that the instrument as a whole was 
largely invariant across patient populations.
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CHAPTER 7
Evaluation of the Reliability of the Hyperhidrosis Quality of 
Life Index (HidroQoL)
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INTRODUCTION
The centrality of HRQoL as the ultimate measure of disease impact and efficacy of drug therapies 
is clear. The current challenge, however, is in how to transform the process of measuring, collecting 
and applying HRQoL within the clinic, from guesswork into science (Finlay 2011). This is 
particularly relevant in skin disease where the impairment in HRQoL is profound (Finlay 1998)
and represents a key indicator of disease activity. Part of the task entails ensuring that measurement 
instruments produce valid and reliable results. The latter means that an instrument produces 
measurements that are free of measurement error (Lohr 2002). In multi-item scales measuring 
unidimensional concepts, where items are assumed to be indicators of a single underlying construct 
reliability is demonstrated in internal consistency. The degree to which the different items forming 
the scales are homogenous or whether they tap into different components of differing constructs 
(Fayers and Machin 2007). Overall, internal consistency shows that the instrument is capable of 
identifying variability in patients condition (Streiner and Norman 2008) and that each of the 
included items contributes to measuring the underlying concept. Where an instrument is used 
across time, reliability can be demonstrated by reproducibility of scores, test-retest reliability. This 
reflects the degree to which an instrument yields stable scores over time, with repeated 
administration, among respondents who are assumed not to have changed (Lohr 2002). This entails 
that test-retest reliability can only be determined in a longitudinal context and that it relies on the 
assumption that the patient’s condition has indeed not changed.
Reliability is central to the measurement process such that it has an impact on other attributes of 
an instrument. For example poor reliability may obscure correlation of a measure with other 
measures, in the assessment of convergence validity. On the other hand, an instrument’s ability to 
detect change over time, responsiveness, is equally affected by poor reliability. Fundamentally,
reliability not a property of an instrument, but only an indication of the degree of reliability related 
to the use of an instrument in specific target populations and in a specific setting (Streiner and 
Norman 2008). This means that reliability may vary with target population and application of an 
instrument, indicating the need for establishing reliability each time a measure is put to a new use.
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OBJECTIVES
The objectives of this study were to:
 Assess the internal consistency of the scores for the impact on daily life activities and 
psychosocial impact domains of the HidroQoL; and the overall scale score.
 Assess the test-retest reliability of the individual items of the HidroQoL; the scores for the 
impact on daily life activities and psychosocial impact domains; and the overall scale score. 
METHODS
Study design
This study followed a prospective longitudinal study design with patient’s assessed on two 
occasions, at baseline (assessment 1) and followed-up (assessment 2) at least 7 days after initial 
assessment. This interval has been recommended (Salek and Luscombe 1992) as offering a good 
balance between avoiding ‘learning effects’ in the second assessment and ‘ensuring that change in 
the construct being measured does not take place. In addition, even though patients may experience 
much variability in their sweating on a day to day basis the overall impacts on their life are 
relatively stable over a number of days. Moreover, effects of hyperhidrosis treatments such as oral 
systemic drugs or Iontophoresis last 5 – 14 days, during which time little change may be expected.
Patient population
The study population was recruited through the UK Hyperhidrosis support group and the 
International Hyperhidrosis Society (IHHS). These two organisations rely largely on social 
networking for communications with their members. Further details about the patient population 
are available in chapter 2. 
Inclusion criteria:
 Patients with self-reported excessive sweating problems;
 Experiencing some interference in their daily life (HDSS > 1);
 Onset of hyperhidrosis in teenage or early adulthood years;
 Aged 17 or above.
Exclusion criteria:
 Patients not experiencing excessive sweating problems;
 Experiencing no interference in their daily life (HDSS score = 1);
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 Onset of hyperhidrosis after age of 30; and reporting a co-morbidity (hypertension, 
diabetes, PM hormonal disorders, psychological disorders);
 Aged below 17. 
Outcome Measures
Apart from the HidroQoL questionnaire, patients were also asked to complete the HDSS, a 
validated single item scale for assessing the severity of sweating and its interference on patient’s 
daily life (Kowalski et al. 2004). This instrument has been reviewed in chapter 1. 
Procedures
Following completion of the first assessment, patients received communication regarding their 
follow-up assessment due in 7 days and were informed that they would subsequently receive 
appropriate communication containing the access details for the follow-up questionnaire. On the 
5th day following their initial assessment patients were sent an email with the link to the follow-up 
(second assessment) questionnaire (web-HidroQoL). Although the plan was for all patients to 
complete the questionnaire on the 7th day, once the email with the details to the second assessment 
was sent out patients could complete at any time, before or after the 7th day.
Data Processing And Analysis
Data entry was automated; information was directly gathered into a database as patients completed 
the web HidroQoL. Cleaning and coding of data was performed prior to analysis using statistical 
software which included SPSS for Windows version 20 (SPSS Inc., Illinois, U.S.A) and STATA 
Version 11. The analyses involved the estimation of reliability coefficients. Internal consistency of 
the HidroQoL was assessed using the Cronbach’s alpha coefficient, which gives the average inter-
item correlation (DeVellis 2011). Internal consistency was also assessed using inter-item and item-
total partial correlation, based on Spearman’s rank sum correlation. In an internally consistent scale 
a moderate correlation (r = 0.3) is expected between items; and correlation ranging of 0.2 – 0.8 is 
optimal for item-total partial correlation (Streiner and Norman 2008). A very high inter-item 
correlation may reflect content redundancy between items.
To assess reproducibility of the HidroQoL scores, the level of agreement between scores from the 
first (baseline) and second (follow-up) assessments was assessed using Intra Class Correlation 
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(ICC). This shows the absolute agreement between the two scores, after accounting for both 
systematic bias and measurement error and is based on a decomposition of the variance in scores 
using ANOVA (Terwee et al. 2007). Reliability coefficients of 0.7 are optimal for group analyses, 
while using in individual comparisons requires rates of 0.9 (Nunnally and Bernstein 1994; Lohr 
2002).
RESULTS
Socio-demographic Characteristics of Study Participants
A total of 260 participants completed the study questionnaires. One hundred and forty two 
patients (54.6%) were from the USA and 73 (28.1%) from the UK. The remaining participants 
(n =45, 17.3%) came from 20 other countries. The mean age of the patients from the US was 38 
(±15) with a range of 17 – 73, those from the UK had similar mean age and age range (Table 
7.1). The largest age group was those 17 to 30 for both the USA (n = 50, 35.2%) and the UK
patient populations (n = 101, 38.8%). Eighty five percent (N = 120) of US sample and sixty three 
percent (n = 72) of the UK sample were female. The majority of patients had an HDSS score of 
3 their sweating was barely tolerable and frequently interfered with their daily activities (USA, 
n = 63, 44%; UK, n = 32, 44) (Table 7.1).
The majority of patients had seen a doctor before in relation to their sweating (94%, USA; 88%, 
UK). A total of 65 patients (43%) from the USA and 33 patients (47%) from the UK had received 
some treatment for their sweating within the last six months, a smaller number ( n = 53, 37.5%, 
USA; n = 26, 35.6%, UK) were being treated currently (Table 7.2). The majority of the patients 
did not have co-morbidities, the most prevalent among those listed were psychiatric or 
neurologic disorders (N = 22, 16%, USA; n = 7, 9.6%, UK). The majority considered the effects 
of the condition on their life as ‘large’ (GQ score = 3) (USA sample, n = 53, 37.3%; UK Sample, 
n = 33, 45.2%, Pooled, N = 106, 40.8%). 
Part I: Internal Consistency
Internal consistency of the HidroQoL was assessed for the UK and the USA samples separately; 
and for the pooled patient population combining patients from all countries; using the baseline and 
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follow-up scores. In the pooled sample, the Cronbach’s alpha estimates of the HidroQoL overall 
scale were 0.89 and 0.93, for test 1 and test 2, respectively (Table 7.3).
Table 7.1: Sociodemographic characteristics of the study participants (during assessment 1)
Characteristic USA Sample
(N =142)
UK Sample 
(N =73)
Pooled Sample*
(N = 260)
Gender, n (%)
Male 22 (15.5%) 27 (37%) 65 (25%)
Female 120 (84.5%) 46 (63%) 195 (75%)
Age, years
Mean, SD 38, 15 38, 14 37, 14
Median 33 37 33
Mode 31 25 25
Range 57 44 57
Age groups
below 30 50 (35.2%) 26 (35.6%) 101 (38.8%)
31 - 40 33 (23.2%) 23 (31.5%) 69 (26.5%)
41 - 50 29 (20.4%) 10 (13.7%) 43 (16.5%)
51 - 60 17 (12 %) 4 (5.5%) 23 (8.8%)
61 plus 13 (9.2%) 10 (13.7%) 24 (9.2%)
Body site involved, 
n (%)
General 31 15 52
Palms, feet & 
armpits
50 11 73
Palms and feet 29 20 65
Armpits only 7 4 15
Armpits plus 
other
8 3 13
Head 11 11 24
Palms 3 3 8
Feet 3 2 6
Trunk/other 1 2 4
Employment, n 
(%)
Employed 91 (64.1%) 42 (57.5%) 160 (61.5%)
Unemployed 22 (15.5%) 9 (12.3%) 37 (14.2%)
Retired 10 (7%) 11 (15.1%) 21 (8.1%)
Full time student 19 (13.4%) 11 (15.1%) 42 (16.2%)
*Country, n (%)
USA 142 (54.6%)
UK 73 (28.1%)
Australia 11 (4.2%)
Canada 11 (4.2%)
other 23 (9%)
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Table 7.1 (continued)
USA sample UK sample Pooled* sample
HDSS Score, n (%)
1 0 0 0
2 28 (19.7%) 17 (23.3%) 51 (19.6%)
3 63 (44.4%) 32 (43.8%) 120 (46.2%)
4 51 (35.9%) 24 (32.9%) 89 (34.2%)
GQ Score, n (%)
0 2 (2.74%) 2 (0.77%)
1 9 (6.34%) 5 (6.85%) 18 (6.92%)
2 37 (26.06%) 17 (23.29%) 65 (25%)
3 53 (37.32%) 33 (45.21%) 106 (40.77%)
4 43 (30.28%) 16 (21.92%) 69 (26.54%)
Table 7.2: Disease-related characteristics of study participants
Characteristic
USA Sample UK Sample Pooled Sample*
(n = 142) (n = 73) (n = 260)
Treated by a medical practitioner 
regarding hyperhidrosis
133 93.7% 64 87% 233 89.6%
Have received Surgical treatment 19 13.4% 8 11% 33 12.7%
Received Botox within last 6 months 19 13.4% 5 6.8% 27 10.4%
Received treatment within last 6
months
65 45.8% 33 45.2% 114 43.8%
Currently receiving treatment 53 37.5% 26 35.6% 89 34.2%
Oral-systemic drugs (pill-form) 31 21.8% 13 17.8% 47 18.1%
Iontophoresis 10 7% 13 17.8% 25 9.6%
Aluminium Chloride Topical 
treatment
15 10.6% 4 5.5% 22 8.5%
Non-prescription/cosmetic 
preparations
17 12% 7 9.6% 27 10.4%
Co-morbidities, n (%)
Thyroid disorders 10 7% 3 4.1% 13 5%
Psychiatric or neurologic disorders 22 15.5% 7 9.6% 30 11.5%
Menopausal related complaints 13 9.2% 2 2.7% 16 6.2%
Diabetes 10 7% 1 1.4% 11 4.2%
Hypertension 20 14.1% 5 6.8% 29 11.2%
Other 25 17.6% 15 20.5% 47 18%
Note: * The pooled sample includes patients from 11 other countries in addition to the USA 
and the UK
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Coefficient estimates for the impact on daily life activities domain (H-DA) were 0.76 and 0.86;
and for the psychosocial impact domain (H-PS) they were 0.86 and 0.90, for test 1 and test 2, 
respectively. Estimates obtained from the US sample were larger, while those from the UK sample 
were the smallest, although all within a percentage point margin of difference. Optimal 
homogeneity is reflected in moderate inter-item correlation and moderate-to-strong corrected item-
total correlations (Streiner and Norman 2008). This was, therefore, also examined for each of the 
HidroQoL’s items. In the pooled sample, corrected item-total correlation ranged from 0.376 to 
0.618 (Table 7.4). The lowest correlation was seen on item 1 (My choice of clothing is affected, rs 
= 0.376), while that for item 15, rs = 0.618, was the highest. In the US sample corrected item-total 
correlations ranged from 0.410 to 0.664. Item ‘I feel frustrated’ (item 9) had the highest correlation 
while the lowest was seen on ‘my sex life is affected’ (item 18). In the UK group the values of 
item-total correlation ranged from 0.24 to 0.739 (Table 7.5). The item ‘I avoid meeting new people’ 
(item 15) had the highest item-correlation value, while the lowest value was seen on item ‘my 
choice of clothing is affected’ (item # 1). This indicates that the HidroQoL is well balanced, as no 
item carried too much weight; each of the included items tapped an aspect of the underlying 
construct (hyperhidrosis QoL), including the item ‘my choice of clothing is affected’. On the other 
hand, the items ‘I feel frustrated’ and ‘I avoid meeting new people’ seem to highlight the 
experiences of having hyperhidrosis, in summing up the emotional and social responses of the 
disease by the patient.
Inter-item correlations
In classical test theory a core assumption is that items of the instrument reflect a sampling from 
the universe of indicators of a given underlying construct (Nunnally and Bernstein 1994). As all 
items are expected to be tapping into the underlying construct, items are expected to at least share 
a moderate correlation with each other. Therefore, the correlation among the items of the 
HidroQoL was assessed.
Table 7.3: Internal Consistency* of the HidroQoL
HidroQoL score US Sample UK Sample Pooled Sample
Test 1 Test 2 Test 1 Test 2 Test 1 Test 2
Total scale, 18 items 0.89 0.94 0.89 0.92 0.89 0.93
Impact on daily life activities 0.78 0.89 0.72 0.78 0.76 0.86
Psychosocial impact 0.87 0.91 0.85 0.89 0.86 0.90
Note: *Cronbach alpha coefficient
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Table 7.4: Item-total scale correlations, for the HidroQoL, pooled/international, test 1 (n = 
260)
SVID CITC CAID
My choice of clothing is affected 42.71 .376 .885
My physical activities are affected 40.93 .493 .882
My hobbies are affected 41.18 .483 .882
My work is affected 41.0 .535 .881
I worry about the additional activities in dealing with my 
condition
41.0 .574 .879
My holidays are affected (e.g. planning, activities) 40.5 .496 .882
I feel nervous 40.7 .588 .879
I feel embarrassed 42.1 .578 .881
I feel frustrated 42.2 .571 .881
I feel uncomfortable physically expressing affection (e.g. 
hugging)
40.9 .550 .880
I think about sweating 42.1 .566 .881
I worry about my future health 40.0 .535 .881
I worry about people’s reactions 42.4 .526 .882
I worry about leaving sweat marks on things 42.5 .450 .883
I avoid meeting new people 38.9 .618 .877
I avoid public speaking (e.g. presentations) 39.2 .592 .879
My appearance is affected 39.8 .574 .879
My sex life is affected 40.7 .417 .886
Note: CAID, Cronbach’s alpha if item is deleted; CITC, Corrected Item-Total Correlation; SVID, Scale Variance 
if Item Deleted
In the pooled patient population, item 1 (my choice of clothing is affected) had correlations greater 
than 0.3 with two out of the 17 other items. The remaining items belonging to the impact on daily 
life activities domain (item 2 to item 6) showed an inter-item correlation ranging from 0.27 to 0.48 
(Table 7.7). The lowest correlation was between my My holidays are affected e.g. planning, 
activities and My work is affected (r = 0.27). Item 18 showed correlations greater than 0.3 with 
three other items in the full HidroQoL scale. The remaining items in the psychosocial domain 
(items 7 to 17), showed correlations ranging from 0.20 to 0.63, with six item pairs below 0.3. Item 
17 (my appearance is affected) showed moderate to strong correlation with all items in the impact 
on daily life activities domain and seven items in the psychosocial impact domain. This suggests
that ‘effects on appearance’ might be an underlying issue in understanding impact on daily life 
activities resulting from HH. 
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Table 7.5: Item-total scale correlations, for the HidroQoL, U.S. Sample, test 1 (n = 142)
SVID CITC CAID
My choice of clothing is affected 42.428 .426 .888
My physical activities are affected 41.177 .475 .886
My hobbies are affected 41.607 .484 .886
My work is affected 41.208 .536 .884
I worry about the additional activities in dealing with my 
condition
41.003 .568 .883
My holidays are affected (e.g. planning, activities) 40.696 .480 .887
I feel nervous 40.204 .636 .881
I feel embarrassed 42.055 .583 .884
I feel frustrated 41.608 .664 .882
I feel uncomfortable physically expressing affection (e.g. 
hugging)
40.407 .606 .882
I think about sweating 41.869 .621 .883
I worry about my future health 40.051 .542 .884
I worry about people’s reactions 41.941 .560 .884
I worry about leaving sweat marks on things 42.340 .446 .887
I avoid meeting new people 39.284 .580 .883
I avoid public speaking (e.g. presentations)
39.669 .541 .885
My appearance is affected 40.180 .546 .884
My sex life is affected 40.850 .410 .890
Note: CAID, Cronbach’s alpha if item is deleted; CITC, Corrected Item-Total Correlation; SVID, Scale Variance 
if Item Deleted
On the other hand, item 5 (I worry about the additional activities in dealing with my condition) 
showed moderate to strong correlation with 10 of the 12 items in the psycho-social domain. Thus, 
chores in dealing with hyperhidrosis, may not only represent a challenge to daily life activities but 
may also be taxing on patient’s psycho-social life.
Inter-item correlations were also explored for the US patient population. Correlations of item 1 
with item 3 and item 4 were 0.28 and 0.27, otherwise the rest of the items in domain 1 had 
correlation ranging from 0.31 to 0.41. Items 17 and 18 had a pattern noted previously in the pooled 
patient population. Item 17 had moderate correlations with all items in domain 1 (items 1 to 6) but 
only four of the domain 2 items. On the other hand, item 18 had correlations of at least 0.3 with 2 
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items only in the whole scale. The correlation of item 7 (I feel nervous) with eight items in the 
psychosocial impact was greater than 0.4, hinting that across the different psychosocial impacts 
experienced by the patients ‘feeling nervous’ was a cross-cutting impact. The highest correlation 
across the items was seen between item 8 and item 9 (r = 0.675). In the UK group, item 1 had a 
correlation of a moderate magnitude with only two other items in the instrument (item 9 and item
17). On the other hand, 4 items had a correlation of at least moderate magnitude with item #18. 
The rest of the items in domain 1 had a correlation ranging from 0.12 to 0.57, among each other. 
On the other hand, inter-item correlation of items in domain 2 ranged from 0.168 to 0.648. Item 
#5 showed a moderate strong correlation with 9 items in the psychosocial domain, as previously 
noted in the US patient population.
Table 7.6: Item-total scale correlations, for the HidroQoL, UK Sample, test 1 (n = 73)
SVID CITC CAID
My choice of clothing is affected 46.618 .240 .889
My physical activities are affected 42.651 .587 .879
My hobbies are affected 42.981 .566 .879
My work is affected 42.818 .568 .879
I worry about the additional activities in dealing with my 
condition
43.709 .575 .879
My holidays are affected (e.g. planning, activities) 43.541 .478 .883
I feel nervous 43.898 .497 .882
I feel embarrassed 45.527 .553 .882
I feel frustrated 46.166 .434 .884
I feel uncomfortable physically expressing affection (e.g. 
hugging)
43.454 .553 .880
I think about sweating 45.097 .522 .882
I worry about my future health 43.139 .480 .883
I worry about people’s reactions 45.301 .520 .882
I worry about leaving sweat marks on things 44.784 .521 .881
I avoid meeting new people 40.581 .739 .872
I avoid public speaking (e.g. presentations) 41.965 .595 .878
My appearance is affected 42.136 .604 .878
My sex life is affected 43.427 .423 .886
Note: CAID, Cronbach’s alpha if item is deleted; CITC, Corrected Item-Total Correlation; SVID, Scale Variance 
if Item Deleted
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Pattern noted for item 7 and 17 was not maintained. The results from the different samples 
consistently show strong reliability for the HidroQoL. The small differences were likely a 
consequence of differences in sample sizes.
Part II: Inter-temporal stability of the HidroQoL Scores
The reproducibility of the HidroQoL scores in repeated administration was tested. Patients 
completed the HidroQoL on two occasions, at baseline (test 1) and follow up assessment (test 2). 
A central issue in the reliability relates to ensuring that the patients condition has not indeed 
changed. One approach is to use a reasonably short time frame, to ensure that the underlying 
condition of the patient does not change but not too short to risk the patients recalling the prior 
responses. In this study patients took the follow-up assessment 5 to 7 days after initial assessment. 
On the other hand, patients also completed the HDSS scale, a self-assessment disease severity 
scale. Test-retest reliability of the HidroQoL was assessed only in patients whose underlying 
disease severity had not changed. 
A total of 144 patients (pooled population) completed the second assessment out of the 260 patients 
completing the initial assessment, 104 patients showed no change on their HDSS score between 
the first and second assessments, therefore only these were considered in the analysis (Figure 7.1). 
The level of agreement between the baseline (test 1) and follow-up scores (test 2) was assessed 
using ICC. In the pooled sample, the level of agreement in the HidroQoL scores was strong (ICC: 
Overall scale score, 0.92; H-DA, 0.8; H-PS, 0.91) (Table 7.10). 
The individual items scores also showed a strong reproducibility (ICC range, 0.74 – 0-88). The 
ICC for item 5 (I worry about additional activities in dealing with my condition) was the lowest 
(ICC = 0.59). In the USA sample, similar results were observed (ICC: Overall scale scores, 0.92; 
H-DA, 0.89; H-PS, 0.90) (Table 7.11). The ICC of the individual item scores ranged from 0.654 
to 0.88. Item 5 (I worry about the additional activities in dealing with my condition) showed the 
lowest ICC (0.456). The UK patient population was small (n = 22) thus the obtained estimates may 
be considered only as preliminary. The HidroQoL showed strong test-retest reliability in the UK
patient population. The HidroQoL total score had an ICC of 0.93 (Table 7.12). 
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Figure 7.1: Patients included in the test-retest reliability study
On the other hand, the ICC values for the domain scores were 0.87 for impact on daily life activities
domain and 0.92 for the psychosocial impact domain. At the individual item level, the item I worry 
about the additional activities in dealing with my condition also showed the lowest ICC (0.59). 
The rest of the items had an ICC ranging from 0.65 to 0.93.
DISCUSSION
The broader impacts of disease on the individual patient’s life, particularly the impairment in daily 
life and limitations associated with psychosocial functioning, need to be addressed in patient 
management as well as clinical studies as a corner-stone to a truly patient centred care. Moreover, 
in skin conditions such as hyperhidrosis, symptoms alone might be insufficient to provide an 
accurate picture of disease activity. In such situations QoL impairment functions as an important 
predictor of disease activity (Chren 2005). This means that the measurement of HRQoL including 
the related processes of collecting, analysing and using such information ought to proceed 
scientifically to ensure that measures are free from any measurement-error (Guyatt et al. 1993). 
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Table 7.7: Correlations§ among HidroQoL’s items, test 1, pooled sample (n = 260)
Item 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
1 My choice of clothing is affected 1
2 My physical activities are affected .282 1
3 My hobbies are affected .245 .479 1
4 My work is affected .207 .328 .450 1
5 I worry about the additional activities 
in dealing with my condition
.293 .355 .354 .447 1
6 My holidays are affected (e.g. 
planning, activities)
.266 .419 .359 .266 .368 1
7 I feel nervous .100 .214 .314 .398 .379 .219 1
8 I feel embarrassed .218 .188 .213 .234 .305 .325 .507 1
9 I feel frustrated .377 .182 .194 .243 .348 .265 .449 .627 1
10 I feel uncomfortable physically 
expressing affection (e.g. hugging)
.261 .331 .276 .342 .349 .220 .495 .424 .382 1
11 I think about sweating .143 .262 .189 .358 .363 .263 .481 .549 .482 .340 1
12 I worry about my future health .279 .266 .167 .246 .361 .361 .355 .312 .370 .249 .350 1
13 I worry about people’s reactions .078 .216 .152 .305 .313 .146 .495 .522 .399 .402 .437 .307 1
14 I worry about leaving sweat marks on 
things
.202 .114 .182 .227 .260 .112 .377 .419 .426 .331 .424 .232 .605 1
15 I avoid meeting new people .165 .281 .268 .362 .359 .287 .480 .360 .309 .383 .385 .457 .408 .377 1
16 I avoid public speaking (e.g. 
presentations)
.159 .284 .348 .413 .384 .331 .438 .353 .375 .322 .331 .372 .304 .231 .619 1
17 My appearance is affected .373 .399 .329 .311 .325 .513 .233 .375 .353 .315 .332 .376 .267 .205 .343 .328 1
18 My sex life is affected .195 .274 .271 .249 .230 .209 .185 .178 .227 .271 .231 .321 .212 .172 .313 .284 .350 1
§ Spearman’s rank correlations
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Table 7.8: Correlations§ among HidroQoL’s items, test 1, USA Sample (n = 142)
Item 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
1. My choice of clothing is affected 1
2. My physical activities are affected .389 1
3. My hobbies are affected .281 .512 1
4. My work is affected .269 .354 .410 1
5. I worry about the additional activities in 
dealing with my condition
.382 .345 .334 .398 1
6. My holidays are affected (e.g. planning, 
activities)
.313 .433 .339 .394 .432 1
7. I feel nervous .167 .241 .244 .303 .379 .256 1
8. I feel embarrassed .243 .169 .260 .250 .309 .299 .522 1
9. I feel frustrated .396 .208 .306 .321 .386 .315 .566 .675 1
10. I feel uncomfortable physically 
expressing affection (e.g. hugging)
.307 .293 .187 .358 .424 .246 .589 .453 .501 1
11. I think about sweating .201 .272 .274 .392 .387 .267 .513 .522 .500 .501 1
12. I worry about my future health .310 .227 .204 .252 .410 .346 .419 .364 .387 .266 .368 1
13. I worry about people's reactions .098 .221 .147 .233 .278 .133 .583 .543 .490 .480 .470 .323 1
14. I worry about leaving sweat marks on 
things
.208 .113 .192 .159 .246 .053 .398 .433 .472 .347 .394 .206 .606 1
15. I avoid meeting new people .158 .233 .241 .272 .306 .216 .481 .329 .334 .416 .380 .490 .464 .375 1
16. I avoid public speaking (e.g. 
presentations)
.106 .231 .299 .352 .297 .276 .476 .280 .437 .372 .359 .389 .321 .215 .638 1
17. My appearance is affected .382 .393 .397 .376 .301 .446 .277 .346 .415 .265 .356 .333 .298 .225 .248 .230 1
18. My sex life is affected .212 .219 .294 .349 .218 .154 .209 .209 .244 .328 .299 .239 .222 .218 .287 .209 .350 1
§ Spearman’s rank correlations
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Table 7.9: Correlations§ among HidroQoL’s items, test 1, UK (n = 72)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
1 My choice of clothing is affected 1
2 My physical activities are affected .156 1
3 My hobbies are affected .112 .380 1
4 My work is affected .052 .263 .569 1
5 I worry about the additional activities in 
dealing with my condition
.046 .401 .306 .526 1
6 My holidays are affected (e.g. planning, 
activities)
.245 .511 .450 .122 .226 1
7 I feel nervous -.031 .174 .533 .575 .393 .111 1
8 I feel embarrassed .187 .293 .220 .293 .253 .304 .437 1
9 I feel frustrated .310 .246 .172 .199 .309 .120 .182 .501 1
10 I feel uncomfortable physically expressing 
affection (e.g. hugging)
.181 .506 .426 .276 .257 .251 .420 .455 .302 1
11 I think about sweating .073 .332 .198 .411 .406 .213 .338 .503 .364 .205 1
12 I worry about my future health .127 .347 .184 .177 .313 .385 .168 .194 .323 .257 .300 1
13 I worry about people's reactions .076 .296 .235 .462 .434 .178 .339 .420 .273 .274 .417 .283 1
14 I worry about leaving sweat marks on 
things
.226 .193 .291 .374 .300 .260 .309 .443 .378 .353 .518 .274 .648 1
15 I avoid meeting new people .199 .476 .464 .524 .518 .254 .518 .411 .284 .422 .484 .395 .400 .444 1
16 I avoid public speaking (e.g. presentations) .081 .382 .474 .550 .413 .240 .372 .417 .204 .282 .299 .197 .280 .231 .624 1
17 My appearance is affected .432 .524 .290 .250 .362 .549 .118 .359 .270 .452 .291 .436 .227 .257 .378 .389 1
18 My sex life is affected .063 .274 .198 .136 .283 .293 .135 .125 .206 .261 .131 .451 .201 .105 .451 .392 .374 1
§ Spearman’s rank correlations
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Table 7.10: Test-retest reliability for individual items of the HidroQoL, international 
Sample (n = 104)
ICC 95% CI
Lower Upper Sig
1 My choice of clothing is affected .741 .620 .824 .0001
2 My physical activities are affected .799 .704 .863 .0001
3 My hobbies are affected .831 .747 .886 .0001
4 My work is affected .740 .619 .823 .0001
5 I worry about the additional activities in 
dealing with my condition
.592 .402 .722 .0001
6 My holidays are affected (e.g. planning, 
activities)
.768 .660 .842 .0001
7 I feel nervous .860 .793 .904 .0001
8 I feel embarrassed .874 .816 .914 .0001
9 I feel frustrated .760 .648 .836 .0001
10 I feel uncomfortable physically expressing 
affection (e.g. hugging)
.770 .663 .843 .0001
11 I think about sweating .718 .587 .808 .0001
12 I worry about my future health .822 .739 .879 .0001
13 I worry about people’s reactions .741 .610 .826 .0001
14 I worry about leaving sweat marks on 
things
.779 .673 .850 .0001
15 I avoid meeting new people .879 .823 .918 .0001
16 I avoid public speaking (e.g. 
presentations)
.798 .702 .863 .0001
17 My appearance is affected .848 .777 .897 .0001
18 My sex life is affected .876 .814 .916 .0001
HidroQoL - Daily life activities .883 .828 .921 .0001
HidroQoL - Psychosocial domain .914 .868 .943 .0001
HidroQoL-total .926 .885 .952 .0001
Otherwise, distinguishing patients with different levels of impairment or assessing change in the 
patients’ condition may be obscured (Terwee et al. 2003). This study, therefore, was aimed at 
assessing the reliability of the HidroQoL in patients with hyperhidrosis. Reliability was assessed 
for the total scale as well as for the two domains, impact on daily life activities and psychosocial 
domains of the HidroQoL. The results showed adequate internal consistency according to 
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Cronbach’s alpha for the HidroQoL total score, as well as for the two domains, daily life activities 
domain and for the psychosocial domain. This suggests that the domains (sub-scales) and the 
overall scale are homogeneous. The observed moderate-strong corrected item-total correlations 
provide further evidence that the items optimally tap into the same construct. This means that each 
of the scales have been optimally defined and that each of the items reflect a different aspect of 
the core construct.
Table 7.11: Test-retest reliability for individual items of the HidroQoL, USA Sample (n = 
64)
Item ICC
95% CI
Lower Upper P-value
1 My choice of clothing is affected .759 0.604 0.853 .0001
2 My physical activities are affected .806 0.682 0.882 .0001
3 My hobbies are affected .844 0.74 0.906 .0001
4 My work is affected .769 0.622 0.859 .0001
5 I worry about the additional activities in 
dealing with my condition
.456 0.105 0.669 0.008
6 My holidays are affected (e.g. planning, 
activities)
.806 0.681 0.882 0.000
7 I feel nervous .845 0.746 0.905 0.000
8 I feel embarrassed .889 0.819 0.932 0.000
9 I feel frustrated .798 0.668 0.877 0.000
10 I feel uncomfortable physically expressing 
affection (e.g. hugging)
.750 0.59 0.848 0.000
11 I think about sweating .709 0.523 0.823 .0001
12 I worry about my future health .857c 0.766 0.913 .0001
13 I worry about people’s reactions .697 0.505 0.814 .0001
14 I worry about leaving sweat marks on 
things
.654 0.437 0.789 .0001
15 I avoid meeting new people .864 0.776 0.917 .0001
16 I avoid public speaking (e.g.
presentations)
.761 0.607 0.854 .0001
17 My appearance is affected .771 0.624 0.861 .0001
18 My sex life is affected .868 0.783 0.919 .0001
HidroQoL - Daily life activities .892 0.824 0.934 .0001
HidroQoL - Psychosocial domain .904 0.843 0.941 .0001
HidroQoL-total .919 0.868 0.951 .0001
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Table 7.12: Test-retest reliability for individual items of the HidroQoL, UK Sample (N = 22)
Item
ICC
95% CI
Lower Upper
p-
value
1 My choice of clothing is affected .784 .485 .909 .000
2 My physical activities are affected .779 .471 .907 .001
3 My hobbies are affected .814 .559 .922 .000
4 My work is affected .826 .597 .926 .000
5 I worry about the additional activities in 
dealing with my condition
.593 .084 .824 .016
6 My holidays are affected (e.g. planning, 
activities)
.645 .177 .848 .009
7 I feel nervous .885 .732 .951 .000
8 I feel embarrassed .878 .713 .948 .000
9 I feel frustrated .738 .398 .888 .001
10 I feel uncomfortable physically expressing
affection (e.g. hugging)
.809 .504 .922 .000
11 I think about sweating .721 .342 .881 .001
12 I worry about my future health .744 .395 .892 .001
13 I worry about people’s reactions .820 .542 .926 .000
14 I worry about leaving sweat marks on 
things
.917 .801 .965 .000
15 I avoid meeting new people .927 .829 .969 .000
16 I avoid public speaking (e.g. presentations) .749 .350 .898 .000
17 My appearance is affected .901 .768 .958 .000
18 My sex life is affected .870 .596 .951 .000
HidroQoL - Daily life activities .866 .689 .943 .000
HidroQoL - Psychosocial domain .919 .649 .973 .000
HidroQoL-total .932 .740 .976 .000
Although the general guide in scale development is to delete those items that contribute little to 
variance of the scale i.e. items which when deleted do not result in a major change in scale variance 
(Fayers and Machin 2007), the fact that all items of the HidroQoL affected total variance of the 
scale within comparable magnitudes reflects balance in the instrument, that all items made a 
largely similar contribution to the scale.
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The correlation of the item ‘my choice of clothing is affected’ with the rest of the items was low, 
particularly in the UK population and for the pooled sample. This mirrors results from the Rasch 
analysis reported in the previous chapter, where this item also performed sub-optimally. This 
represents a friction given that this was one of the most prevalent items during the qualitative 
research done during the content development of the measure. Elimination of such an item might 
compromise the content validity and clinical relevance of the instrument. Similarly the item ‘My 
sex life is affected’ while showing a low correlation with the rest of the instrument’s items, was 
placed on the upper end of the impairment continuum during Rasch analysis. Omitting this item 
might compromise the instrument’s ability to measure patients experiencing extreme effects.
Together, these results show that the HidroQoL is indeed sensitive to variability in the patient’s 
condition, with minimal measurement error. 
The reproducibility of the HidroQoL has been established. This involved repeated administration 
of the instrument, 5 to 7 days following baseline (first) assessment.  This period was considered 
long enough to ensure patients do not recall their initial answers but short enough for the condition 
to have remained stable (Salek and Luscombe 1992). To ensure this, a disease severity scale (the 
HDSS) was administered. Only patients with stable disease severity were included during the 
analysis.
The results showed a strong level of agreement between the baseline and follow-up scores in 
patients whose condition had not changed, for the HidroQoL total score as well as for the two 
domain scores, impact on daily life activities and psychosocial impacts. This indicates that the 
HidroQoL appropriately distinguishes clinically relevant change from measurement error. 
Moreover, the magnitude of observed ICC would support use of the measure for QoL measurement 
in individual patients. 
SUMMARY
 The internal consistency and reproducibility of the HidroQoL were established in differing 
patient populations, including a group from the UK and U.S.A and a pooled international 
patient population.
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 The internal consistency Cronbach’s alpha was estimated for the HidroQoL scale and for 
the two domains (impact on daily life activities and psychosocial domain) in the pooled 
patient population as well as for the UK and USA patient populations, separately.
 Reproducibility of the HidroQoL was assessed for HidroQoL total score, the two domain 
scores (impact on daily life activities impact and psychosocial impact domain) and the 
individual items by estimating the level of agreement between scores from the baseline and 
the follow-up assessments using ICC. 
 Cronbach’s alpha values ranged from 0.89 to 0.94 for the HidroQoL total score, 0.72 – 0.88 
for the impact on daily life activities domain and 0.87 – 0.9 for the psychosocial domain. 
 Therefore, scales of the HidroQoL (overall scale, impact on daily life activities domain and 
psychosocial impact domain) showed optimal homogeneity, reflecting clear definition of 
the scales as well as the inclusion of relevant items.
 The ICC between the baseline and follow scores were, 0.88 – 0.87 for the daily life 
activities, 0.90 – 0.92 for the psychosocial domain and 0.92 – 0.93 for the HidroQoL total 
scores. This provides strong support for the application of the measure in evaluating QoL 
in individual patients 
 The results obtained support the longitudinal as well as cross-sectional application of the 
HidroQoL scores in USA and UK patient populations as well as in international patient 
population.
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CHAPTER 8
Evaluation of the Validity of the Hyperhidrosis Quality of Life 
Index (HidroQoL)
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INTRODUCTION
Validity encompasses the evaluative judgement of the degree to which empirical evidence and 
theoretical rationales support the trustworthiness of interpretations and actions based on scale 
scores (Messick 1988). This indicates a focus on the participants and their responses; and the 
inferences that can be drawn about them, based on their scale scores (responses). Although a 
delineation is made among different types of validity (content validity, criterion validity and 
construct validity) a unified perspective of validity considers all forms of validity to be 
encompassed by construct validity (Streiner and Norman 2008). Construct validity relates to the 
extent to which theoretically derived hypothesis relating to the construct being measured by an 
instrument are supported by empirical evidence (Terwee et al. 2007). Although there is no 
prescription regarding type, form and nature of such empirical evidence, the need to demonstrate 
construct validity, arises each time a measure is used in a new situation or where different inference 
will be drawn, reflecting on the continuous nature of the validation process (Streiner and Norman 
2008). For this reason, there is an even greater imperative to generate such evidence for new 
instruments. Evidence demonstrating the adequacy with which the content of the new instrument, 
the HidroQoL, covers and represents the full content domain of HRQoL issues in HH was 
presented in chapter four. Additional construct validation data based on the internal structure of 
the new measure, applying both the EFA and CFA as well as modern test theory’s Rasch model
were presented in chapter’s five and six. In the current study further construct validation of the 
HidroQoL was undertaken including: testing for group differences in the scores of the HidroQoL
across gender, age groups and disease severity; and testing the relationship between scores of the 
HidroQoL and those of other established instruments i.e. convergent and divergent validities.
OBJECTIVES
The objectives of this study were to:
 Explore for differences in HidroQoL scores in patients with different characteristics with 
respect to; demographic factors; level of disease severity; overall impact of disease; daily 
time spent in managing symptoms of the condition and their impacts; values of Willingness 
to Pay (WTP) for cure of condition.
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 Assess the relationship between the scores of the HidroQoL and other measures of disease 
impact, including: EQ-5D score, Skindex-17 score, DLQI score, HDSS score, GQ score, 
WTP values, daily time spent managing condition.
METHODS
Study design
This study followed a cross-sectional design where a heterogeneous group of patients from the 
USA and the UK were assessed on a single occasion. The absence of a recommended design for 
validation studies means that the choice of study design is dependent on the hypotheses assessed. 
The study population was recruited through the UK Hyperhidrosis support group and the 
International Hyperhidrosis Society (IHHS). Further details regarding the patient population and 
recruitment process are available in Chapter 2.
Inclusion criteria:
 Patients with self-reported excessive sweating problems;
 Experiencing some interference in daily life (HDSS > 1);
 With onset of hyperhidrosis in teenage or early adulthood years;
 Aged 17 or above.
Exclusion criteria:
 Patients not experiencing any excessive sweating problems;
 Experiencing no interference in daily life (HDSS = 1);
 With onset of hyperhidrosis after age of 30 and reporting a co-morbidity (hypertension, 
diabetes, PM hormonal disorders, psychological disorders);
 Aged below 17. 
Outcome Measures
Apart from the HidroQoL, data were also collected on: patient’s disease severity using the HDSS; 
dermatology-specific QoL using the DLQI and the Skindex-17; and generic HRQoL using the EQ-
5D. In addition, the following questions were administered: 
− Global question (GQ) on overall impact of hyperhidrosis, scored on a 5 point Likert scale; 
− Patient’s willingness to pay for a complete cure in hyperhidrosis; 
− Time spent daily in dealing with HH; and
− Additional monthly expenditures arising from hyperhidrosis.
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The HRQoL instruments have been reviewed and presented in more detail in Chapters 1 and 2 
(Table 8.1).
Data Processing And Analysis
The use of a web-system for the data collection made it possible to have the data directly entered 
into a database automatically during completion, eliminating the need for manual data entry thus 
avoiding potential errors (Dillman 2006). All data analyses were carried out using STATA 11.2 and 
SPSS. Further, descriptive analysis was carried out to explore the distribution of variables. 
Hypothesis testing used a conventional level of significance of 0.05 (Munro 2005). Specifically 
the following tests were carried out: 
 the Mann-Whitney U test and K-Wallis were utilised to test for group differences in 
HidroQoL scores (for instance across patient’s socio-demographic characteristics and 
disease characteristics; HDSS scores; GQ scores).
 Spearman’s Rank correlation analysis was to assess the relationship between the scores of 
the HidroQoL and other measures. A correlation coefficient greater than 0.3 – 0-4 supports 
convergence validity (Fayers and Machin 2007).
 Univariate OLS regression was used to assess the relationship between the HidroQoL 
scores and the scores of the HDSS; Skindex-17; DLQI; and EQ-5D. The coefficient of 
determination, R2, provided a measure of how much variance in the independent variable  
was being explained by the predictor variable (Norman and Streiner 2007).
 Multivariate OLS regression was used to determine the predictors of HRQoL in 
hyperhidrosis patients, HidroQoL score was the independent variable; and patient’s socio-
demographic and disease characteristics were dependent variables. Post-hoc diagnostic 
tests were carried out to assess model fit and assumptions, including tests for normality of 
residuals (Shapiro Wilk Test; Kernel density Plots); heteroskedasticity (Breuch Pagan and 
White’s tests; scatter plot of fitted vs. residuals) and multi-colinearity (Gujarati 2003)
RESULTS
Sociodemographic Characteristics Of Study Participants
A total of 163 participants completed the HidroQoL questionnaire, out of 204 initially enrolled for 
the study, representing 80% completion rate. One hundred and twenty seven patients (78%) were 
from the USA and thirty six (22%) the UK (Table 8.2).
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Table 8.1: Attributes of outcome measures used in data collection
DLQI Skindex - 17 HDSS EQ_5D
Concept 
measured 
Impact of skin disease 
on patient's QoL  (based 
on intensity of effects)
effects of skin-disease 
on HRQoL: (based on 
frequency of effects)
hyperhidrosis 
severity and degree 
of interference in 
daily life 
Generic QoL (health status) 
Target 
population
Adults with skin 
disease
Adults with skin 
disease
Adults with 
hyperhidrosis
Adults
Number of 
items
10 17 1 5 domains plus a VAS scale
Number of 
domains
8: Symptoms, Daily 
activities, Leisure
Work/school, Personal 
relationships, Treatment
2: Symptom, 
Psychosocial
Na 5 (for descriptive part):
mobility, self-care, usual activities, 
pain/discomfort, anxiety 
Scoring 
format
A total score is 
calculated by summing 
the item scores
Total score and 
domain scores
calculated by 
summing individual 
scores. 
Na Descriptive part: analysis at 
individual item level only; item 
scores forming a 5-digit number can 
be read off a reference values to 
obtain health status preference 
values
Total score 
range
0 (no impact) - 30 
(maximum impact on 
QoL)
0 (no impact) - 34 
(maximum impact on 
QoL)
0 (lowest severity) 
- 4 (highest 
severity)
Descriptive part:for individual 
items, 1 (no problems) - 5
(maximum problems).
VAS scale: 0  (worst health 
imaginable) - 100 (best health
imaginable)
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The mean age of the patients from the USA was 38.8 (14.1) with a range of 17 – 73, while those 
from the UK had a mean of 42.8 (16.13), ranging from 20 to 74. The age group 17 to 29 was the 
largest (n = 37, 29%) in the USA sample, while the age group 30 to 39 was the largest in the UK 
sample (n = 12, 33.3%) (Figure 8.1). One hundred and twenty patients (84%) from the US and 
seventy two patients (72%) from the UK sample were female. The majority of USA patients (N = 
57) had an HDSS score of 3, their sweating was barely tolerable and frequently interfered with 
their daily activities; while the majority in the UK sample (n=13) had the most extreme HDSS 
score (representing a score of 4 out of 4), their sweating was intolerable and always interfered with 
daily activities (Figure 8.2). The majority (n = 46, USA sample; n = 15, UK sample) considered 
the effects of the condition on their life as ‘large’ (representing a score 4 out of 5) (Figure 8.3). 
The majority of patients in both samples had seen a doctor before in relation to their sweating 
(94%, USA; 97%, UK) for their sweating (Table 8.3).  43% of those from the USA and 47% of 
the UK sample had received treatment for their sweating within the last six months while; 36% 
(USA) and 39% (UK) were currently receiving treatment. Patients on average spent 121.9 
minutes (USA) and 42.6 minutes (UK) per day in managing their condition and they incurred an 
additional monthly expenditure of £ 55 GBP and £ 22 GBP, respectively (Table 8.4). The most 
prevalent range of sum of money patients are willing to pay for a complete cure was 50 - 99 GBP 
for USA patients (n = 37) and 1- 49 GBP (N = 12) for the UK patients (Figure 8.4).
Items of the HidroQoL receiving affirmation 
An item was affirmed if an answer other than No, not at all was chosen and; was considered 
missing if patients did not provide a response. Item mean scores are presented in Figure 8.5. The 
item ‘thinking about sweating’ received the highest affirmation from US patients (99%), while 
the ‘choice of clothing’ item was the most affirmed in the UK sample (97%) (Table 8.5). In both 
groups the item ‘my sex life is affected’ was the least affirmed, suggesting that this issue might 
not be important for most patients. Otherwise, the sensitivity associated with issues pertaining 
to sex cannot be ruled out as an influence. No data were missing.
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Table 8.2: Sociodemographic characteristics of the patients
USA Sample (n = 127) UK Sample (n = 36)
Gender, n (%)
Male 20 (16%) 10 (28%)
Female 107 (84%) 26 (72%)
Age, years
Mean, SD 38.8 (14.1) 42.8
Median 37 39.5
Mode, n 25 24
Range 17 – 73 20 - 74
Age (years), n
≤29 37 6
30 to 39 34 12
40 to 49 28 7
50 to 59 14 2
≥ 60 14 9
Body site involved, n (%)
Generalised 28 (22%) 10 (28%)
Palms, feet & axilla 48 (38%) 6 (17%)
Palms and feet 26 (20%) 5 (14%)
Head, Face 14 (11%) 7 (19%)
Axilla 8 (6%) 4 (11%)
Palms 2 (2%) 2 (6%)
Feet 1 (1%) 1 (3%)
Other 1 (3%)
Disease severity (HDSS score), n
1 0 0
2 25 11
3 57 12
4 45 13
Global impact of hyperhidrosis 
(GQ score), n
No effect 0 2
Small effect 9 5
Moderate effect 34 7
Large effect 46 15
Extremely large effect 38 7
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Table 8.2 (continued)
USA Sample (n = 127) UK Sample (n = 36)
Co-morbidities, n (%)
Thyroid disorders 10 (8%) 2 (6%)
Psychiatric of neurologic disorders 21(17%) 4(11%)
Menopausal related complaints 13 (10%) 1(3%)
Diabetes 10 (8%) 1(3%)
Hypertension 20 (16%) 5 (14%)
Other 22 (18%) 10 (28%)
Employment, n (%)
Employed 84 (66%) 22(61%)
Unemployed 18 (14%) 3 (8%)
Retired 10 (8%) 9 (25%)
Full time student 15 (12%) 2 (6%)
Table 8.3: Patients’ treatment history
Characteristic USA UK sample
Seen doctor in relation to sweating 119 (94%) 35 (97%)
Received treatment in last 6 months 55 (43%) 17 (47%)
Have received surgical treatment before 18 (14%) 6 (17%)
Received Botox Injection in last 6 months 17 (13%) 4 (11%)
Currently receiving Treatment 46 (36%) 14 (39%)
Current treatments, n (% of sample)
Aluminium Chloride (topical cream) 14 (11%) 2 (6%)
Systemic oral medication 26 (20%) 8 (22%)
Iontopheresis 9 (7%) 10 (19%)
Cosmetic preparations 16 (13%) 5 (14%)
Scores of the HidroQoL
The mean HidroQoL total score was 25.64 (±6.95) for the USA and 26.96 (±7.52) for the UK
sample (Figure 8.5). The mean scale item scores are presented in Figure 8.6. The range for the 
HidroQoL total score was 2 to 36, in the USA group and 1 to 33, in the UK group. Five patients 
(4%) in the USA group and none of the patients in the UK sample achieved the maximum 
HidroQoL overall scale (36). 
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Part I: Comparison of HidroQoL scores along socio-demographic characteristics of patients 
The first step in evaluating the validity of the HidroQoL involved making comparisons of the 
scores of the HidroQoL across important patient characteristics. 
Gender
Mann Whitney (MW) test was used to compare HidroQoL scores across males and female patients.
There were no significant gender differences in HidroQoL score (p = 0.53)  in the US sample 
(Table 8.7) Analysis of the domain scores also indicated non-significant gender differences for the 
impact on daily life activities domain (H-DA) (p = 0.08) as well as the psychosocial impact domain 
(H-PS) (p = 0.808).
Table 8.4: Patient’s level of disease burden: timea and moneyb spent in managing the 
condition and willingness to payc
USA Sample UK Sample
Time spent in managing the sweating, Minutes
Mean 121.9 42.64
Median 45 37.5
Mode 60 60
Range 0 - 1440 0 - 120
IQR 15 - 90 20-60
Money spent in managing the sweating per month, GBP (£)
Mean 55.4 22
Median 25 15.5
Mode 0 0
Range 0 – 1000 0-100
IQR 0 - 50 0-30
Willingness To Pay (GBP - £), n
£0 4 6
£1 - £49 36 12
£50 - £99 37 9
£100 - £199 19 2
£200 - £299 6 1
≥ £300 25 6
a. For example extra time spent on personal hygiene and treatment due to disease.
b. For example extra money spent on personal hygiene, treatment or new clothes.
c. Willingness to pay for a treatment that would provide complete cure of the hyperhidrosis
in British Pounds (£).
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Figure 8.1: Patients’ age distribution
Figure 8.2: Patients’ disease severity based on HDSS score
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Figure 8.3: Overall health related quality of life impairment
Figure 8.4: Amount of money patients are willing to pay (WTP) for a permanent cure for 
their condition.
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Table 8.5: Items of the HidroQoL receiving affirmation and missing responses
Item USA Sample UK Sample
Affirmative 
responses 
Missing 
Affirmative 
responses 
Missing 
Impact on daily life activities
My choice of clothing is affected 119(94%) 0 (%) 35(97%) 0(0%)
My physical activities are affected 113(89%) 0 (%) 32(89%) 0(0%)
My hobbies are affected 119(94%) 0 (%) 30(83%) 0(0%)
My work is affected 119(94%) 0 (%) 28(78%) 0(0%)
I worry about the additional activities 
in dealing with my condition
118(93%) 0 (%) 32(89%) 0(0%)
My holidays are affected (e.g. 
planning, activities)
106(83%) 0 (%) 32(89%) 0(0%)
Impact on psychosocial impact
I feel nervous 117(92%) 0 (%) 31(86%) 0(0%)
I feel embarrassed 123(97%) 0 (%) 35(97%) 0(0%)
I feel frustrated 124(98%) 0 (%) 35(97%) 0(0%)
I feel uncomfortable physically 
expressing affection (e.g. hugging)
116(91%) 0 (%) 32(89%) 0(0%)
I think about sweating 126(99%) 0 (%) 34(94%) 0(0%)
I worry about my future health 91(72%) 0 (%) 23(64%) 0(0%)
I worry about people’s reactions 123(97%) 0 (%) 34(94%) 0(0%)
I worry about leaving sweat marks on 
things
120(94%) 0 (%) 33(92%) 0(0%)
I avoid meeting new people 90(71%) 0 (%) 22(61%) 0(0%)
I avoid public speaking (e.g. 
presentations)
101(80%) 0 (%) 26(72%) 0(0%)
My appearance is affected 109(86%) 0 (%) 30(83%) 0(0%)
My sex life is affected 79(62%) 0 (%) 18(50%) 0(0%)
At the individual level, one item (my hobbies are affected) showed significant gender differences 
(p < 0.01, Females, Median score = 2; Male, Median score = 1). In the UK group, the total 
HidroQoL score also showed non-significant differences between males and females (p = 0.31)
(Table 8.8). Comparisons involving the two domains also showed non-significant differences (H-
DA, p = 0.91, H-PS, p = 0.16).
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Table 8.6: Frequency of the HidroQoL Scores
HidroQoL
total score
USA Sample UK Sample
Freq. % Cum. Freq. % Cum.
1 1 2.78 2.78
2 1 0.79 0.79
6 1 0.79 1.57
7 1 0.79 2.36
8 1 2.78 5.56
12 1 0.79 3.15
14 2 1.57 4.72
15 4 3.15 7.87
16 1 0.79 8.66 1 2.78 8.33
17 3 2.36 11.02 1 2.78 11.11
18 1 0.79 11.81
19 3 2.36 14.17 1 2.78 13.89
20 4 3.15 17.32 3 8.33 22.22
21 6 4.72 22.05 1 2.78 25
22 5 3.94 25.98 3 8.33 33.33
23 5 3.94 29.92 1 2.78 36.11
24 3 2.36 32.28 2 5.56 41.67
25 1 0.79 33.07 2 5.56 47.22
26 7 5.51 38.58
27 7 5.51 44.09 1 2.78 50
28 6 4.72 48.82
29 7 5.51 54.33 3 8.33 58.33
30 8 6.3 60.63 2 5.56 63.89
31 11 8.66 69.29 5 13.89 77.78
32 9 7.09 76.38 3 8.33 86.11
33 9 7.09 83.46 3 8.33 94.44
34 9 7.09 90.55
35 7 5.51 96.06 2 5.56 100
36 5 3.94 100
Total 127 100 36 100
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Figure 8.5: Distribution of the HidroQoL total Scores using box and whisker plot (USA, n = 
127; UK, n = 36).
Only two items showed significant gender differences (I avoid public speaking e.g. presentations,
median score: M = 1, F = 2; my appearance is affected, median score: M = 1, F = 2). This indicates 
that the effects of hyperhidrosis patients are largely similar between males and females, although 
females seemed to suffer greater impairment in those aspects related to the public; reflecting 
women’s greater concern for their ‘looks’ especially in social life.
Age
HidroQoL scores of patients belonging to different age groups were compared, using the Kruskall 
Wallis (KW) test. Patients were divided into five age groups: 17 to 29; 30 to 39; 40 to 49; 50 to 59 
and; above 60. No statistically significant differences in the overall HidroQoL score across the 
age-groups were seen in the USA group (p = 0.7). The median HidroQoL score of the 17 to 29 
age-group was the highest (30) while that of the 40-49 group, was the lowest (26) (Table 8.9). A 
comparison of the scores for the daily life activities and psychosocial domain scores also turned 
no significant differences (H-DA, p = 0.95, H-PS, p = 0.55). None of the individual items showed 
a statistically significant difference across the age-groups. Similar analysis in the UK sample also 
showed non-significant age-group differences in the overall HidroQoL score (p = 0.98) and in the 
domain scores (H-DA, p = 0.75, H-PS, p = 0.96) (Table 8.10). At the individual item level, only 
one item (I feel nervous) showed statistically significant differences across the age groups. The
age groups 17 – 29 and 30 to 39 had the highest item median score (2). The relationship between 
age and the HidroQoL score was further explored using regression analysis of HidroQoL total 
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score on age (measured in years) and by drawing a scatter plot of the two variables. This analysis 
was carried out on the sample only, due to the small size of the UK sample The results support 
the finding obtained earlier, there was no significant relationship between age and HidroQoL 
scores (model F-statistic = 2.9, p = 0.09, B-coefficient = 0.008 ) (Table 8.11). The scatter plot 
showed no clear pattern of association (Figure 8.7)
Figure 8.6: Mean scores for the HidroQOL’s individual items
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Table 8.7: Comparison of HidroQoL scores by patient’s gender (USA sample)
Item Median MW
Male
(n=20)
Female
(n= 107)
z-
score
p-
value
Impact on daily life activities
My choice of clothing is affected 2 2 -0.93 0.35
My physical activities are affected 2 2 -1.61 0.108
My hobbies are affected 1 2 -2.64 0.008
My work is affected 2 2 -0.32 0.75
I worry about the additional activities in dealing with 
my condition
2 2 -0.76 0.45
My holidays are affected (e.g. planning, activities) 1 1 -1.40 0.16
Psychosocial impact
I feel nervous 2 2 -0.38 0.7
I feel embarrassed 2 2 -1.74 0.082
I feel frustrated 2 2 -0.08 0.938
I feel uncomfortable physically expressing affection 
(e.g. hugging)
2 2 0.84 0.401
I think about sweating 2 2 0.76 0.45
I worry about my future health 1 1 -0.97 0.334
I worry about people’s reactions 2 2 -0.97 0.426
I worry about leaving sweat marks on things 2 2 0.07 0.947
I avoid meeting new people 1 1 1.42 0.156
I avoid public speaking (e.g. presentations) 2 1 1.18 0.239
My appearance is affected 2 2 -0.26 0.797
My sex life is affected 1 1 0.74 0.459
Impact on daily life activities 9 10 -1.75 0.08
Psychosocial impact 19 19 0.25 0.803
Overall scale 27 29 -0.63 0.529
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Table 8.8: Comparison of HidroQoL scores by patient’s gender (UK sample)
Item Median MW
Male
(n=10)
Female
(n= 26)
z-
score
p-
value
Impact on daily life activities
My choice of clothing is affected 2 2 -1.17 0.24
My physical activities are affected 2 2 -0.39 0.69
My hobbies are affected 2 2 0.3 0.76
My work is affected 1 1 -0.13 0.89
I worry about the additional activities in dealing with 
my condition
2 2 1.19 0.23
My holidays are affected (e.g. planning, activities) 1.5 2 -0.8 0.42
Psychosocial impact
I feel nervous 1 1 -0.5 0.62
I feel embarrassed 2 2 -1.8 0.07
I feel frustrated 2 2 -0.97 0.33
I feel uncomfortable physically expressing affection 
(e.g. hugging)
2 2 -0.87 0.38
I think about sweating 2 2 -1.04 0.3
I worry about my future health 1 1 0.57 0.57
I worry about people’s reactions 2 2 0.05 0.96
I worry about leaving sweat marks on things 1.5 2 -1.69 0.09
I avoid meeting new people 1 1 -1.2 0.23
I avoid public speaking (e.g. presentations) 1 2 -1.73 0.04
My appearance is affected 1 2 -2.52 0.01
My sex life is affected 1 0 0.81 0.42
Impact on daily life activities 9.5 9 -0.11 0.91
Psychosocial impact 16 18.5 -1.42 0.16
Overall scale 24 29 -1.01 0.31
Notes: z, z-score; p, p-value
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Table 8.9: Comparison HidroQoL scores by patient’s age (USA sample)
Median KW 
Test
p-value
Group 1
(n = 37)
Group 2 
(n = 34)
Group 3 
(n = 28)
Group 4 
(n = 14)
Group 5 
(n = 14)
Impact on daily life activities
My choice of clothing is affected 2 2 2 2 2 0.17
My physical activities are affected 2 2 2 2 2 0.53
My hobbies are affected 2 2 2 2 1.5 0.36
My work is affected 2 1 2 2 2 0.62
I worry about the additional activities in dealing with my condition 2 2 2 2 1.5 0.1
My holidays are affected (e.g. planning, activities) 1 1 1 1 2 0.5
Psychosocial Impact
I feel nervous 2 2 2 2 2 0.39
I feel embarrassed 2 2 2 2 2 0.6
I feel frustrated 2 2 2 2 2 0.45
I feel uncomfortable physically expressing affection (e.g. hugging) 2 2 2 2 2 0.23
I think about sweating 2 2 2 2 2 0.84
I worry about my future health 1 1 1 1 1 0.11
I worry about people’s reactions 2 2 2 2 2 0.63
I worry about leaving sweat marks on things 2 2 2 2 2 0.11
I avoid meeting new people 1 1 1 1 1 0.99
I avoid public speaking (e.g. presentations) 2 1 2 1 1 0.68
My appearance is affected 1 2 1 1.5 2 0.28
My sex life is affected 1 1 1 1 0.5 0.91
Impact on daily life activities 10 9 9 10 10 0.95
Psychosocial impact 19 19 17.5 18.5 18.5 0.55
Overall scale 30 29 26 27.5 28 0.7
282
Table 8.10: Comparison of individual item and total HidroQoL scores by patient’s age (UK Sample)
Item Median KW
Group 1
(n = 6)
Group 2
(n= 12)
Group 3
(n= 7)
Group 4
(n= 2)
Group5 
(n= 9)
p-
value
Impact on daily life activities
My choice of clothing is affected 2 2 2 2 2 0.69
My physical activities are affected 2 2 2 2 2 0.4
My hobbies are affected 2 2 2 1 1 0.28
My work is affected 2 2 1 2 0 0.21
I worry about the additional activities in dealing with my 
condition
2 2 2 2 2 0.67
My holidays are affected (e.g. planning, activities) 2 2 2 2 2 1
Psychosocial impact
I feel nervous 2 2 1 1 1 0.04
I feel embarrassed 2 2 2 2 2 0.45
I feel frustrated 2 2 2 2 2 0.5
I feel uncomfortable physically expressing affection (e.g. 
hugging)
2 2 1 2 2 0.17
I think about sweating 2 2 2 2 2 0.38
I worry about my future health 1 1 1 2 1 0.65
I worry about people’s reactions 2 2 2 2 2 0.17
I worry about leaving sweat marks on things 2 2 2 2 1 0.08
I avoid meeting new people 1 1 1 1 0 0.78
I avoid public speaking (e.g. presentations) 1 2 2 1 2 0.95
My appearance is affected 1 1 1 2 2 0.17
My sex life is affected 0 1 1 0 0 0.31
Impact on daily life activities 11 9.5 9 9 9 0.75
Psychosocial impact 17.5 19 18 18 16 0.96
Overall scale 29 30 27 27 24 0.98
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Table 8.11: Univariate regression analyses of HidroQoL score against patient’s age
Ind. Var N F( df) p R2 Adj R2 Dep Var ß SE t p Beta
HidroQoL 
Score 
127 2.9 (1, 125) 0.091 0.023 0.015 Age -0.074 0.044 -1.7 0.1 -0.151
C 29.836 1.796 16.61 0
Note:  
M: model; Ind. Var.: Independent Variable; p: p-value; Adj. R2: Adjusted r-squared; Dep. Var.: dependent 
variable; ß: Coefficient for dependent variable; DMT: Daily time spent dealing with hyperhidrosis; AME: 
Additional monthly expenditures due to hyperhidrosis; C: constant.
Figure 8.7: Scatter plot showing relationship between HidroQoL Score and age.
HDSS score
A comparison of HidroQoL scores across patients with different levels of disease severity, 
according to the HDSS score, was carried out using the KW test. Patients were grouped according 
to their HDSS score: group 1, HDSS = 2; group 2, HDSS = 3; group 3, HDSS = 4. Patient with
HDSS = 1 were excluded from the study. In the USA sample statistically significant differences 
(p < 0.001) were observed in the HidroQoL overall score across the disease-severity groups (Table 
8.12). The median overall score increased with HDSS score from 21 (group 1), 27 (group 2) to 33
(group 3). Domain scores also showed statistically significant differences (p < 0.001 for both 
impact on daily life activities and psychosocial impact domains). The item scores also showed 
statistically significant differences across the severity groups (p < 0.01). 
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Table 8.12: Comparison of individual items and total HidroQoL scores by HDSS score 
(level of disease severity): USA sample
HidroQoL Score Median KW
HDSS 2
(n = 25)
HDSS 3 
(n = 57)
HDSS 4 
(n = 45) p
Impact on daily life activities
My choice of clothing is affected 1 2 2 0
My physical activities are affected 1 2 2 0
My hobbies are affected 1 2 2 0
My work is affected 1 2 2 0
I worry about the additional activities in 
dealing with my condition
1 2 2 0
My holidays are affected (e.g. planning, 
activities)
1 1 2 0
Psychosocial impact
I feel nervous 1 2 2 0
I feel embarrassed 2 2 2 0
I feel frustrated 2 2 2 0
I feel uncomfortable physically expressing 
affection (e.g. hugging)
1 2 2 0
I think about sweating 1 2 2 0
I worry about my future health 1 1 1 0
I worry about people’s reactions 2 2 2 0
I worry about leaving sweat marks on things 2 2 2 0.01
I avoid meeting new people 0 1 2 0
I avoid public speaking (e.g. presentations) 1 1 2 0
My appearance is affected 1 1 2 0
My sex life is affected 1 1 1 0.01
Impact on daily life activities 8 9 12 0
Psychosocial impact 14 18 22 0
Overall scale 21 27 33 0
Similar analyses were carried out on the UK sample. Overall HidroQoL score and the scores for 
the two domains showed statistically significant differences across the disease severity groups (p 
< 0.01 for all scores) (Table 8.13). Further, significant differences were seen in six out the eighteen 
items of the HidroQoL including my holidays are affected (e.g. planning, activities) (p = 0.02), my 
work is affected (p = 0.01), I worry about the additional activities in dealing with my condition (p 
= 0.03), I feel frustrated (p = 0.01), I think about sweating (p < 0.001) and I avoid meeting new 
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people (p < 0.001). These results show that the HidroQoL is capable of distinguishing between 
patients experiencing different levels of self-reported disease severity, based on the HDSS scores. 
Patients with higher disease severity showed greater impairment in HRQoL.
Table 8.13: Comparison of individual items and total HidroQoL scores by HDSS score (level 
of disease severity) (UK sample)
Median KW 
p-valueHDSS 2
(n=11)
HDSS 3
(n=12)
HDSS4
(n=13)
Impact on daily life activities
My choice of clothing is affected 2 2 2 0.45
My physical activities are affected 1 2 2 0.02
My hobbies are affected 1 2 2 0.13
My work is affected 1 1 2 0.01
I worry about the additional activities in 
dealing with my condition
1 2 2 0.03
My holidays are affected (e.g. planning, 
activities)
1 2 2 0.1
Psychosocial impact
I feel nervous 1 1 2 0.1
I feel embarrassed 2 2 2 0.19
I feel frustrated 2 2 2 0.01
I feel uncomfortable physically expressing 
affection (e.g. hugging)
2 2 2 0.68
I think about sweating 1 2 2 0
I worry about my future health 0 1 1 0.09
I worry about people’s reactions 2 2 2 0.08
I worry about leaving sweat marks on things 2 2 2 0.08
I avoid meeting new people 0 1 1 0
I avoid public speaking (e.g. presentations) 1 2 2 0.12
My appearance is affected 1 2 2 0.17
My sex life is affected 0 1 1 0.38
Impact on daily life activities 7 9 12 0.01
Psychosocial impact 13 17 20 0
Overall scale 21 26 31 0
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Site of Hyperhidrosis
The site of hyperhidrosis varied across patients, for instance, the armpits, the feet, the palms and 
the head. HidroQoL scores of patients with different sites of hyperhidrosis were compared using 
the KW test. As there were numerous combinations of affected sites among the patients. Five 
groups were created as follows: generalised sweating (group 1); palms, feet and axillary (group 
2); palms or/and feet (group 3); face or/and head (group 4) and; axillary (or plus other) (group 
5) (Table 8.14). In the USA sample, significant differences were observed in the total HidroQoL 
score across the different groups of patients based on body site (p < 0.01). Patients with 
generalised sweating (group 1) suffered the greatest impairment (median overall score = 32); 
while those with hyperhidrosis affecting the palms and feet (group 3) had the lowest impairment 
(median overall score = 26). Significant differences were also observed in the domain scores (p 
< 0.01, for both impact on daily life activities domain and the psychosocial impact domain). An 
analysis at the individual item level showed significant differences in twelve items. The 
remaining six showing non-significant differences included my hobbies are affected, my work is 
affected, I feel nervous, I feel embarrassed, I feel frustrated, I worry about leaving sweat marks 
on things. This suggests that aspects of psychosocial impairment resulting from hyperhidrosis 
might be common across patients with different types of hyperhidrosis.
Similar analyses were carried out on the UK sample. The KW test showed non-significant
differences in the overall HidroQoL score and the scores for the two domain scores (overall 
HidroQoL score, p = 0.13; H-DA, p = 0.17; H-PS, p = 0.2) (Table 8.15). At the individual item 
level, two items, my physical activities are affected and my appearance is affected showed 
significant differences.
Global impact Score
HidroQoL scores of patients experiencing different levels of overall impact were compared using 
the KW test. Patients were divided into four groups according to their level of overall impact 
(based on their GQ score): Group 1, GQ=1, small effect; Group 2, GQ=3, moderate effect; Group 
3, GQ=4, large effect; Group 4, GQ=5, extremely large effect. No patient in either the US or the 
UK samples reported GQ = 1 (no effect at all). The overall scale score showed statistically 
significantly differences across the four patient groups (p < 0.001) (Table 8.16). 
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Table 8.14: Comparison of individual items and total HidroQoL scores by site of hyperhidrosis (USA sample)
Median KW
Group1
(n=28)
Group2
(n= 48)
Group3
(n=29)
Group 4
(n=14)
Group 5
(n=8) p
Impact on daily life activities
My choice of clothing is affected 2 2 1 2 2 0
My physical activities are affected 2 2 1 2 2 0.01
My hobbies are affected 2 2 2 2 1 0.15
My work is affected 2 2 2 2 2 0.27
I worry about the additional activities in dealing with my 
condition
2 2 2 2 2 0.03
My holidays are affected (e.g. planning, activities) 2 1 1 2 2 0
Psychosocial impact
I feel nervous 2 2 2 2 2 0.08
I feel embarrassed 2 2 2 2 2 0.07
I feel frustrated 2 2 2 2 2 0.2
I feel uncomfortable physically expressing affection 
(e.g. hugging)
2 2 2 2 2 0.1
I think about sweating 2 2 2 2 2 0.03
I worry about my future health 1 1 1 1 2 0.04
I worry about people’s reactions 2 2 2 2 2 0.49
I worry about leaving sweat marks on things 2 2 2 2 2 0.02
I avoid meeting new people 1 1 1 0 1 0.01
I avoid public speaking (e.g. presentations) 2 2 1 1 2 0.03
My appearance is affected 2 1 1 2 2 0
My sex life is affected 1 1 1 0 1 0
Impact on daily life activities 12 10 9 11 10 0
Psychosocial impact 22 18 18 17 19 0
Overall scale 32 27 26 27 30 0
Note: Group 1: generalised sweating; group 2: Axillar, palmar and feet; group 3: palms and/or feet; Group 4: Head or face; Group 5: Axillary plus other areas
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Table 8.15: Comparison of individual items and total HidroQoL scores by site of hyperhidrosis (UK Sample)
Median KW
p-valueGroup1
(n=28)
Group2
(n= 48)
Group3
(n=29)
Group 4
(n=14)
Group 5
(n=8)
Impact on daily life activities
My choice of clothing is affected 2 2 2 2 2 0.67
My physical activities are affected 2 2 1 2 2 0
My hobbies are affected 2 2 2 1 2 0.49
My work is affected 1 2 1 1 2 0.43
I worry about the additional activities in dealing with my 
condition
2 2 1 2 2 0.19
My holidays are affected (e.g. planning, activities) 2 2 1 2 2 0.58
Psychosocial impact
I feel nervous 1 2 1 1 2 0.16
I feel embarrassed 2 2 2 2 2 0.23
I feel frustrated 2 2 2 2 2 0.12
I feel uncomfortable physically expressing affection 
(e.g. hugging)
2 2 2 2 2 0.42
I think about sweating 2 2 1 2 2 0.04
I worry about my future health 1 1 0 1 1 0.04
I worry about people’s reactions 2 2 2 2 2 0.53
I worry about leaving sweat marks on things 2 2 2 2 2 0.85
I avoid meeting new people 1 2 0 0 1 0.28
I avoid public speaking (e.g. presentations) 1 2 1 2 2 0.49
My appearance is affected 2 2 1 2 2 0.03
My sex life is affected 0 2 0 0 1 0.41
Impact on daily life activities 10 9 6.5 9 12 0.17
Psychosocial impact 18 20.5 14 16 19 0.2
Overall scale 30 30 21 25 31 0.13
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Table 8.16: Comparison of individual items and total HidroQoL scores by GQ Score (global life impact): USA sample
Items Median KW
Group 2 
(n = 9)
Group 3 
(n = 34)
Group 4 
(n = 46)
Group 5 
(n = 38)
p
Impact on daily life activities
My choice of clothing is affected 1 2 2 2 0
My physical activities are affected 1 1 2 2 0
My hobbies are affected 1 1 2 2 0
My work is affected 1 1 2 2 0
I worry about the additional activities in dealing with my 
condition
1 2 2 2 0
My holidays are affected (e.g. planning, activities) 1 1 1 2 0
Psychosocial impact
I feel nervous 1 2 2 2 0
I feel embarrassed 2 2 2 2 0
I feel frustrated 1 2 2 2 0
I feel uncomfortable physically expressing affection (e.g. 
hugging)
1 2 2 2 0.01
I think about sweating 1 2 2 2 0
I worry about my future health 0 1 1 1 0
I worry about people’s reactions 1 2 2 2 0.01
I worry about leaving sweat marks on things 1 2 2 2 0
I avoid meeting new people 0 1 1 2 0
I avoid public speaking (e.g. presentations) 0 1 1 2 0
My appearance is affected 1 1 2 2 0
My sex life is affected 0 1 1 2 0
Impact on daily life activities 6 8 9 12 0
Psychosocial impact 11 16 19 22 0
Overall scale 17 23 28 33 0
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The median total score was highest for the group with extremely large effect (33) and declined 
with lower levels of impact; and was lowest for patients experiencing a small effect (17). An 
analysis of the two domain scores also showed significant differences in both (p < 0.001, for both 
H-DA and H-PS). All items also showed statistically significant differences in scores across levels 
of overall impact. Similar analyses were carried out using the UK sample (Table 8.17). 
Table 8.17: Comparison of individual items and total HidroQoL scores by GQ Score 
(overall HRQoL impact) (UK sample)
Median MW test
Group1 
(n=14)
Group2 
(n=22)
z p
Impact on daily life activities
My choice of clothing is affected 2 2 -1.25 0.21
My physical activities are affected 2 2 -1.42 0.16
My hobbies are affected 1 2 -1.38 0.17
My work is affected 1 2 -0.85 0.39
I worry about the additional activities in dealing 
with my condition
2 2 -1.8 0.07
My holidays are affected (e.g. planning, 
activities)
1 2 -1.68 0.09
Psychosocial impact
I feel nervous 1 2 -1.79 0.07
I feel embarrassed 2 2 -1.98 0.05
I feel frustrated 2 2 -2.62 0.01
I feel uncomfortable physically expressing 
affection (e.g. hugging)
2 2 0.08 0.94
I think about sweating 1 2 -3.86 0
I worry about my future health 0 1 -2.28 0.02
I worry about people’s reactions 2 2 -1.86 0.06
I worry about leaving sweat marks on things 2 2 -1.82 0.07
I avoid meeting new people 0 1 -3.14 0
I avoid public speaking (e.g. presentations) 1 2 -0.98 0.33
My appearance is affected 2 2 -0.91 0.37
My sex life is affected 0 1 -1.66 0.1
Impact on daily life activities 8 9.5 -1.64 0.1
Psychosocial impact 14 19 -2.8 0.01
Overall scale 22 30 -2.47 0.01
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Due to the smaller number of patients in this group, participants were divided into two groups: 
Group 1, GQ score = 1-2, small to moderate effect; and Group 2, GQ = 4 - 5, large to extremely 
large effect. The overall HidroQoL score showed statistically significant differences between the 
two groups  (p = 0.01). As expected, the median score for group 2 (30) was larger than that for 
group 1 (22). One domain showed significant differences between the two patient groups (H-DA, 
p = 0.1, H-PS, p = 0.01). Four items showed significant differences across overall impact groups, 
including: I feel frustrated, I think about sweating, I worry about my future health and I avoid 
meeting people. These results demonstrate the ability of the HidroQoL to tap into the overall 
impact associated with hyperhidrosis.
Willingness to Pay
Patients were asked for their willingness to pay (WTP) for a treatment that would cure their 
sweating, with the following choices: £ 0; £ 1 - 49; £ 50 - 99; £ 100 - 199; £ 200 - 299; £ 300 or 
more. HidroQoL scores of patients choosing different WTP values were compared using the KW 
test. Three groups were formed based on patient’s WTP: group 1, £ 0 – 49; group 2, £ 50 - £199;
and group 3, £ 200 or more. In the USA sample, median HidroQoL total score of 32 was observed
in group 3; 29 in group two and 27 in group 1, reflecting decreases consistent with declining WTP 
values (Table 8.18). The KW test showed that the scale total score differences were statistically 
significant (p < 0.01). At the domain level, scores for both the impact on daily life activities and 
psychosocial impact domains showed statistically significant differences across the WTP-patient 
groups (p < 0.05 for both). Score differences were also explored at the individual item level. Four 
items showed statistically significant differences across patients based on their WTP group, 
including: my choice of clothing is affected (p < 0.05); my holidays are affected (p < 0.05); I worry 
about my future health (p < 0.01); and I avoid meeting new people (p < 0.01). 
Similar analyses were carried out on the UK sample. Due to the small size of the sample two 
groups were formed: Group 1,WTP = £0-99; and Group 2, WTP = £100 or more. No statistically 
significant differences in the HidroQoL scores were observed at the scale or domain levels 
between the two groups (Table 8.19). An analysis of the item scores also showed non-significant 
differences between WTP patient groups.
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Table 8.18: Comparison of individual items and total HidroQoL scores by patient’s WTP for complete cure for the sweating (USA 
sample)
Median KW
Group 1
(n =40)
Group 2
(n=56)
Group 3
(n=31)
p
Impact on daily life activities
My choice of clothing is affected 2 2 2 0.02
My physical activities are affected 2 2 2 0.33
My hobbies are affected 2 2 2 0.167
My work is affected 2 2 2 0.088
I worry about the additional activities in dealing with my 
condition
2 2 2 0.031
My holidays are affected (e.g. planning, activities) 1 1 2 0.036
Psychosocial impact
I feel nervous 2 2 2 0.668
I feel embarrassed 2 2 2 0.675
I feel frustrated 2 2 2 0.18
I feel uncomfortable physically expressing affection (e.g. 
hugging)
2 2 2 0.907
I think about sweating 2 2 2 0.625
I worry about my future health 1 1 2 0.001
I worry about people’s reactions 2 2 2 0.175
I worry about leaving sweat marks on things 2 2 2 0.208
I avoid meeting new people 1 1 2 0.004
I avoid public speaking (e.g. presentations) 1 2 2 0.098
My appearance is affected 1 2 2 0.524
My sex life is affected 1 1 1 0.175
Impact on daily life activities 9 9 11 0.011
Psychosocial impact 18 19 20 0.017
Overall scale 27 29 32 0.005
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Table 8.19: Comparison of individual items and total HidroQoL scores by patient’s WTP 
for complete cure for the sweating (UK sample)
Item Median MW test
Group1
(n=27)
Group2
(n=9)
z p
Impact on daily life activities
My choice of clothing is affected 2 2 -0.27 0.79
My physical activities are affected 2 2 0.9 0.37
My hobbies are affected 2 2 -0.93 0.35
My work is affected 1 2 -1.1 0.27
I worry about the additional activities in dealing 
with my condition
2 2 -0.26 0.79
My holidays are affected (e.g. planning, 
activities)
2 2 0.48 0.63
Psychosocial impact
I feel nervous 1 2 -1.12 0.26
I feel embarrassed 2 2 -0.74 0.46
I feel frustrated 2 2 -0.03 0.97
I feel uncomfortable physically expressing 
affection (e.g. hugging)
2 2 0.43 0.67
I think about sweating 2 2 -1.07 0.28
I worry about my future health 1 1 0.86 0.39
I worry about people’s reactions 2 2 0.13 0.89
I worry about leaving sweat marks on things 2 2 -0.33 0.74
I avoid meeting new people 1 1 -0.97 0.33
I avoid public speaking (e.g. presentations) 2 2 -0.64 0.52
My appearance is affected 2 2 0.78 0.44
My sex life is affected 0 1 -1.19 0.23
Impact on daily life activities 9.00 12.00 -0.34 0.74
Psychosocial impact 16.00 18.00 -0.82 0.41
Overall scale 25 29 -0.44 0.66
The apparent difference in the relationship between WTP and QoL between the two patient 
groups, the USA and UK patient groups has numerous explanations. The first relates to the 
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practical limitations with the UK sample, one group had 9 observations only reducing power for 
observing any differences. Secondly, the UK and USA healthcare systems differ in the scope and 
magnitude of out of pocket health expenditures, leading to differences in nominal values patients 
are willing to spend as well as a different valuation of those nominal monetary figures. For 
example, an expenditure amounting to a 100 pounds in the UK might be valued differently in 
the USA, more or less than its equivalent dollar value. Lastly, willingness to pay tends to be 
influenced by a subject’s ability to pay (Drummond et al. 2005)
Daily time spent in managing the condition (DMT)
The patients were asked to report the amount of time they spent in dealing with the condition 
each day (reported in minutes). Three patient groups were created based on the reported time: 0 
to 59 minutes (group 1); 60 – 90 minutes (group 2) and those spending greater than 90 minutes 
(group 3). Differences in HidroQoL scores across these groups were explored using KW test. 
Statistically significant differences were observed in the overall score across the three groups (p 
< 0.01), in the US sample (Table 8.20). Group 3 (32) had the largest median overall scale score; 
while that for group 1 was the smallest (24). Comparisons were also made in scores at the domain 
level. Significant differences were seen in the scores of both the impact on daily life activities
(H-DA) and the psychosocial impact (H-PS) domains (p < 0.01 for both). 
Similar comparisons were carried out on the UK sample. Patients were divided into two groups: 
group 1, DMT below 30 minutes; and group 2, DMT of 30 minutes or greater. The overall score 
and a single domain showed statistically significant differences (overall score, p = 0.01, H-DA, 
p = 0.06, H-PS, p = 0.00) (Table 8.21). At the individual item level, five showed differences of 
statistical significance: I worry about the additional activities in dealing with my condition (p = 
0.03); I feel nervous (p = 0.01); I think about sweating (p = 0.02); I avoid meeting new people
(p = 0.01); My appearance is affected (p = 0.03). A univariate regression analysis was also 
performed for further insights into the nature of relationship between DMT and the HidroQoL 
score. The analysis was performed in the US sample only, as the UK sample was considered 
small for this analysis.
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Table 8.20: Comparison of individual items and total HidroQoL scores by daily time spent in managing sweating (USA sample).
Median KW
Group 
1(n=61)
Group 
2(n=30)
Group 
3(n=36) p-value
Impact on daily life activities
My choice of clothing is affected 2 2 2 0
My physical activities are affected 1 2 2 0
My hobbies are affected 1 2 2 0
My work is affected 1 2 2 0.01
I worry about the additional activities in dealing with my condition 2 2 2 0
My holidays are affected (e.g. planning, activities) 1 1 2 0
Psychosocial impact
I feel nervous 2 2 2 0.04
I feel embarrassed 2 2 2 0.07
I feel frustrated 2 2 2 0
I feel uncomfortable physically expressing affection (e.g. hugging) 2 2 2 0.03
I think about sweating 2 2 2 0.03
I worry about my future health 1 1 1 0
I worry about people’s reactions 2 2 2 0.43
I worry about leaving sweat marks on things 2 2 2 0.06
I avoid meeting new people 1 1 1 0.02
I avoid public speaking (e.g. presentations) 1 2 2 0.01
My appearance is affected 1 2 2 0
My sex life is affected 1 0.5 1 0.06
Impact on daily life activities
9 11 12 0
Psychosocial impact
17 19.5 20.5 0
Overall scale
24 30.5 32 0
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Table 8.21: Comparison of individual items and total HidroQoL scores by daily time spent 
in managing sweating (UK Sample).
Median MW
Group 1
(N = 21)
Group 2
(N = 15)
z p
Impact on daily life activities
My choice of clothing is affected 2 2 -0.64 0.52
My physical activities are affected 2 2 -2 0.05
My hobbies are affected 2 1 -1.63 0.1
My work is affected 1 1 -0.602 0.55
I worry about the additional activities in dealing 
with my condition
2 2 -2.24 0.03
My holidays are affected (e.g. planning, 
activities)
2 2 -1.77 0.08
Psychosocial impact
I feel nervous 1 2 -2.73 0.01
I feel embarrassed 2 2 -1.63 0.1
I feel frustrated 2 2 -1.77 0.08
I feel uncomfortable physically expressing 
affection (e.g. hugging)
2 2 -1.37 0.17
I think about sweating 2 2 -2.38 0.02
I worry about my future health 1 1 -1.34 0.18
I worry about people’s reactions 2 2 -1.49 0.14
I worry about leaving sweat marks on things 2 2 -0.37 0.71
I avoid meeting new people 1 1 -2.77 0.01
I avoid public speaking (e.g. presentations) 2 1 -1.61 0.11
My appearance is affected 2 2 -2.15 0.03
My sex life is affected 0 2 -0.59 0.55
Impact on daily life activities 9 9 -1.9 0.06
Psychosocial impact 17 20 -2.88 0
Overall scale 27 31 -2.69 0.01
The regression model was significant (F-statistic = 11.23; p = 0.001). DMT explained 8.2% of 
variability in the HidroQoL scores. The positive B-coefficient (B = 0.008) indicates a positive 
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relationship between HidroQoL scores and DMT (Table 8.22). A scatter plot of the two variables 
shows a wide variation in HidroQOL scores below 200 minutes and a clear pattern indicating a 
positive relationship above that cut-off (Figure 8.8). The greater HRQoL impairment in patients 
spending more time in managing their condition reflects the lost utility from the time taken from 
enjoyable activities that the patients are not able to undertake. It is also possible that time spent 
managing the condition is associated with a level of discomfort e.g. patients being reminded of 
their condition. These results suggest that the HidroQoL can distinguish patients according to an 
important aspect of disease experience and impact.
Table 8.22: Univariate regression analyses of HidroQoL score against daily time spent 
with hyperhidrosis.
M Ind. Var N F( df) p R2 Adj R2 Dep Var ß SE t p Beta
1 HidroQoL 
Score 
127 11.23 
( 1, 125)
0.001 0.082 0.075 DMT 0.008 0.002 3.35 0.001 0.287
C 26.008 0.657 39.57 0
Note:  
M: model; Ind. Var.: Independent Variable; p: p-value; Adj. R2: Adjusted r-squared; Dep. Var.: dependent 
variable; ß: Coefficient for dependent variable; DMT: Daily time spent dealing with hyperhidrosis; C: constant.
Figure 8.8: The relationship between the HidroQoL Score and daily time spent in 
managing the condition
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Treatment history
The socio-demographic data collected from patients also included some information related to 
treatment history, particularly whether patient had been; treated for hyperhidrosis in the last 6 
months; was currently receiving treatment; had received surgical therapy for hyperhidrosis
previously; had received inter-dermal injection with Botox in the last six months. For each of the 
aspects patients either affirmed (yes) or rejected the notion (no). Scores of patients belonging to 
the two groups were compared along each aspect using the Mann-Whitney Test. 
Treatment within last 6 months
In the US sample overall HidroQoL score (H-total) showed no statistically significant differences 
between those treated for hyperhidrosis in the last six months and those who were not (p = 0.07)
(Median total score: Treated = 31; Not-treated = 28) (Table 8.23). The domain scores also indicated 
non-significant differences (H-DA, p = 0.23; H-PS, p = 0.09). In the  UK sample, the contrary was 
observed, the overall score as well as scores for the two domains showed significant differences
(total scale, p = 0.01, H-DA, p = 0.04, H-PS, p < 0.001) (Table 8.24). The median overall score 
was larger for those treated in the last 6 months (30), compared to those who had not been treated 
(23). Greater QoL impairment might have motivated patients to seek for treatment.
Table 8.23: Comparison of HidroQoL Scores by treatment history: US sample
Median MW test
Yes No z p
Treated for HH in last 6-months H-DA 10 9 1.208 0.23
H-PS 20 19 1.694 0.09
H-total 31 28 1.92 0.05
Currently receiving treatment for HH H-DA 9 10 0.11 0.91
H-PS 20 19 1.21 0.23
H-total 30 28 0.90 0.37
Treated with inter-dermal Botox 
injection within the last 6 months 
H-DA 11 10 1.15 0.25
H-PS 20 19 1.19 0.23
H-total 32 28 1.42 0.16
Have been treated with surgery H-DA 12 9 2.57 0.01
H-PS 20 19 1.38 0.17
H-total 32 28 1.83 0.07
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Current treatment
A comparison of those currently being treated and those getting no treatment showed no significant 
differences in the USA sample, both for the overall scale score (p = 0.37) and for the domain scores 
(H-PS, p = 0.23; H-DA, p = 0.91). However, the contrary was observed in the UK sample, 
differences of a statistical significance were observed for the scale score (p < 0.01) and also for 
the two domain scores (H-PS, p = 0.02; H-DA, p < 0.001).
Surgical intervention
Differences in the HidroQoL scores between patients who had received surgical therapy before 
and those who had not, were explored. The overall score and the psychosocial domain scores did 
not show statistically significant differences in the US sample. Significant differences were seen 
only on the impact on H-DA domain score (p < 0.01) only. In the UK sample, on the other hand, 
the overall score as well as the two domain scores showed non-significant differences. 
Inter-dermal injection by Botox
In the US group, comparisons between patients previously treated with Botox injection and those 
not showed non-significant differences in the overall scale score; and the two domain scores. 
Similar findings were obtained in the UK group.
Table 8.24: Comparison of HidroQoL Scores by treatment history: UK Sample
Median MW test
Yes No z p
Treated for HH in last 6-months H-DA 11.00 9.00 3.02 0
H-PS 20.00 15.00 2.05 0.04
H-total 30 23 2.51 0.01
Currently receiving treatment for HH H-DA 12.00 9.00 3.11 0
H-PS 20.00 15.00 2.38 0.02
H-total 31 23 2.75 0.01
Treated with inter-dermal Botox 
injection within the last 6 months
H-DA 12.00 9.00 1.9 0.06
H-PS 18.50 16.50 0.88 0.38
H-total 31 25 1.04 0.3
Have been treated with surgery H-DA 8.50 9.50 -1.66 0.1
H-PS 17.00 17.50 -0.66 0.51
H-total 26 29 -1 0.32
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Co-morbidities
Differences in the HidroQoL scores across patient with a co-morbidity and those without one 
were explored using the MW test. In both the USA and the UK samples, having or not having 
thyroid disorder; psychiatric or neurologic disorders; menopausal related complaints; diabetes 
and hypertension showed non-significant differences in the overall scale score and in the two 
domain scores (Table 8.25, Table 8.26). The impact on daily life activities domain score showed 
significant differences between participants reporting psychiatric or neurologic disorders and 
those without, in the USA group (p = 0.03). 
As the diagnosis of primary hyperhidrosis involves ruling out the role of a secondary condition 
(Solish et al. 2008). it is expected that the measurement of HRQoL impairment resulting from 
hyperhidrosis should not be influenced by co-morbidities where they are present. Thus the 
current results are consistent with this notion. Finding significant differences would have meant 
that either the sample used in this study included patients with hyperhidrosis caused by other 
primary conditions; or that the measure was picking up something else other than the impacts of 
HH. Dysfunction of the sympathetic nervous system is known to play a role in hyperhidrosis 
(Hornberger et al. 2004). The link between psychological disorders such as social anxiety, and 
hyperhidrosis is quite strong, palmar sweating has been described as a symptom of social anxiety 
(Ruchinskas 2007), even though studies empirically investigating this matter have not found 
pathologic levels of psychological problems as social anxiety in HH patients (Weber et al. 2005).
Part II: Convergence and Divergence Validity
Further validation of the HidroQoL scores in assessing quality of life in hyperhidrosis involved 
developing and testing a number of hypothesis on how the scores of the HidroQoL relates to 
scores of other established measures of QoL based on the theoretical understanding of how the 
construct measured by the HidroQoL (QoL impairment in HH) related to the variable being 
measured by the external instrument. The descriptive score distribution of the each of the 
measures is presented in Table 8.27.
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Table 8.25: Comparison of HidroQoL Scores by patient’s co-morbidity (USA sample)
Median MW
Comorbidity no-comorb. p-value
Thyroid disorder H-DA
10 10
0.71
H-PS
20 19
0.49
H-Total
28 29
0.55
Psychiatric or neurologic disorders H-DA
11 9
0.03
H-PS
19 19
0.84
H-Total
31 29
0.36
Menopausal related complaints H-DA
11 10
0.24
H-PS
19 19
0.57
H-Total
31 29
0.33
Diabetes H-DA
12 10
0.10
H-PS
19 19
0.35
H-Total
31 29
0.2
Hypertension H-DA
11 10
0.50
H-PS
19 19
0.97
H-Total
28 29
0.93
Table 8.26: Comparison of HidroQoL Scores by patient’s co-morbidity (UK sample)
Median MW
Comorbidity
No 
comorbidity Z-score P-value
Psychiatric or neurologic disorders H-DA 10.5 9 1.13 0.26
H-PS 17 17.5 0.1 0.92
H-Total 27.5 28 0.63 0.53
Hypertension H-DA 9.00 10.00 -1.3 0.19
H-PS 16.00 18.00 -0.28 0.78
H-Total 24 29 -0.64 0.52
Hypothesis 1: Impairment in hyperhidrosis-QoL has a positive association with disease 
severity: Patient’s HDSS score is positively correlated with the HidroQoL score.
Testing this hypothesis involved assessing the degree and direction of association between the 
HDSS score and the HidroQoL’s overall and domain scores. Spearman’s rank sum correlation 
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analyses were performed between the two measures. The coefficient of the spearman’s rank sum 
correlation showed significant association between the HDSS score and the HidroQoL overall
scale score, in the US sample (rho = 0.653, p < 0.01) (Table 8.28). The HDSS score also showed 
correlation with the scores of the two domains (H-DA, rho = 0.655, p < 0.01; and H-PS, rho = 
0.550, p < 0.01). The focus of the HDSS on both severity and on interference in daily life 
activities, places it closer to the content of the daily life activities domain than the psychosocial 
domain, explaining the small difference in the magnitude of the correlations. Similar analysis 
were carried out in the UK sample. The HDSS score was correlated with the HidroQoL total 
score (rho = 0.564, p < 0.01) as well as the two domain scores, daily life activities (rho = 0.518, 
p < 0.01) and psychosocial domain (rho = 0.551, p < 0.01) (Table 8.29).
Condition specific-QoL instruments given their attention on issues peculiar to a particular 
disease condition tend to have a greater connection to clinical outcomes (Salek 1998). In this 
study, the HidroQoL has demonstrated a strong association with a standard clinical measure in 
hyperhidrosis, the HDSS. Moreover, it is noteworthy that the strong correlation has been 
achieved despite the absence of items related to ‘symptoms’ in the HidroQOL; highlighting the 
strong relevance of the items as a reflection of impacts arising from the symptoms of 
hyperhidrosis. Not only is the initial set hypothesis confirmed but these findings also give some 
preliminary indications on the capabilities of the instrument to detect change in patients over 
time.
Hypothesis 2: The overall impact of HH on the patient’s life is related to their 
hyperhidrosis-specific QoL
Hypothesis 2 was assessed by estimating a Spearman’s rank correlation between HidroQoL 
scores and patient’s GQ scores. The correlation coefficient showed an association between the 
GQ score and the HidroQoL overall score (rho = 0.610, p < 0.01). The two domains also showed 
a positive and strong correlation (impact on daily life activities, rho = 0.595, p < 0.01; 
psychosocial aspect, rho = 0.521, p < 0.01). Similar results were obtained from the UK sample
(overall score, rho = 0.557, p < 0.01; impact on daily life activities, rho = 0.496, p < 0.01 and 
psychosocial impact, rho = 0.574, p < 0.01).
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Table 8.27: Summary description of HidroQoL, DLQI, Skindex-17, EQ-5D scores.
HidroQoL DLQI Skindex-17 EQ-5D
mobility self-care Usual-
activities
Pain/
discomfor
Anxiety/
depressio
US UK US UK US UK US UK US UK US UK US UK US UK
N 127 36 126 36 126 36
12
7
36
12
7
36
12
7
36
12
6
36
12
7
36
Minimum 2.0 1.0 .0 .0 1.0 .0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Maximum 36.0 35.0 30.0 24.0 32.0 31.0 4.0 4.0 5.0 4.0 5.0 5.0 5.0 5.0 4.0 4.0
Range 34.0 34.0 30.0 24.0 31.0 31.0 3.0 3.0 4.0 3.0 4.0 4.0 4.0 4.0 3.0 3.0
Mean 27.0 25.6 10.4 9.7 13.9 15.8 1.4 1.7 1.2 1.3 1.8 2.2 1.7 2.1 2.0 2.2
SD 6.9 7.5 7.7 6.3 6.5 8.8 .7 1.1 .6 .7 1.0 1.2 1.0 1.4 1.0 1.0
Median 29.0 28.0 9.0 10.0 14.0 16.5 1.0 1.0 1.0 1.0 1.0 2.0 1.0 1.0 1.0 2.0
25th Percentile 22.0 21.5 4.0 4.0 12.0 9.5 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 2.0 2.0
75th percentile 32.0 31.0 16.0 13.5 16.0 23.0 1.0 2.5 1.0 1.0 2.0 3.0 2.0 3.0 2.0 2.0
Skewness -1.0 -1.3 .4 .2 .2 -.3 2.1 1.3 4.2 2.9 1.1 .7 1.3 .9 1.1 .9
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The essence of the global question is to capture the overall impact of the disease on the patient’s
life. Presumably patients would reflect on those aspects of disease they consider to be affected 
when responding to this question. Thus, assessing the relationship between the score of the GQ 
provides an opportunity to see whether the HidroQoL is indeed useful as a measure of disease 
impact in hyperhidrosis. Beyond this, establishing that such a relationship exists implies that the 
content of the measure is appropriate and has the right emphasis for capturing quality of life 
impacts in hyperhidrosis. The current results support the construct and the content validity of the 
HidroQoL. 
Hypothesis 3a: Hyperhidrosis-specific QoL is related to dermatology-specific QoL: 
Patient’s HidroQoL score was positively correlated with the DLQI score
Hypothesis 3a was assessed by estimating a Spearman’s rank sum correlation between the 
HidroQoL scores and the DLQI score. In addition, regression analysis was carried out. In the US 
sample, the correlation of DLQI score with the HidroQoL overall score was 0.572 (p < 0.01). 
The DLQI score had a correlation of 0.517 (p < 0.01) with the impact on daily life activities
domain; and a correlation of 0.505 (p < 0.01) with the psychosocial impact domain. 
Similar results were obtained from the UK sample. The DLQI total score correlated with the 
HidroQoL overall scale (rho = 0.562, p < 0.01) as well as with the two domain scores (impact 
on daily life activities, rho = 0.578, p < 0.01 and psychosocial impact, rho = 0.530, p < 0.01). 
The regression analysis was carried out on the US sample only. The UK sample was considered 
too small for this. The model as a whole was statistically significance (F-statistic = 53.37, p < 
0.001) indicating a relationship between the HidroQoL and the DLQI scores (Table 8.30). 
HidroQoL score explained 30% of variability in patients DLQI score. The beta coefficient 
showed that a 1 SD increase in HidroQoL score, resulted in an increase of 0.55 SD in the DLQI 
score. This demonstrates that hyperhidrosis-QoL was positively related to dermatology-QoL. 
This relationship was further illustrated in the scatter-plot between the two variables (Figure 
8.9).
Hypothesis 3b: Patients HidroQoL scores were positively correlated with the Skindex-17
scores
Hypothesis 3b was tested by assessing the relationship between HidroQoL scores and the 
Skindex-17 scores using Spearman’s rank sum correlation and using regression analysis.
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Table 8.28: Multiple correlations between the HidroQoL scores and the Skindex, the DLQI, EQ-5D, general health, the HDSS, 
patients’ WTP, and time spent in the daily management of the sweating (USA Sample)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
hqdaily (1) 1.000
hqpsy (2) .582** 1.000
hqtotal (3) .802** .943** 1.000
Skpsy (4) .436** .573** .584** 1.000
Sksym (5) .173 .289** .276** .196* 1.000
Sktotal (6) .415** .536** .551** .856** .588** 1.000
Dtotal (7) .517** .505** .572** .758** .342** .764** 1.000
Eqmobility(8) .097 .011 .043 .063 .228* .139 .196* 1.000
Equsual (9) .299** .230** .278** .207* .166 .242** .325** .496** 1.000
Eqselfcare(10) .044 .058 .040 .086 .085 .100 .162 .472** .340** 1.000
Eqpain (11) .271** .215* .254** .234** .353** .339** .378** .275** .339** .255** 1.000
Eqanxiety(12) .339** .363** .387** .498** .298** .534** .488** .175* .258** .165 .301** 1.000
gq (13) .595** .521** .610** .488** .253** .492** .559** .131 .303** .053 .248** .321** 1.000
HDSS (14) .655** .550** .653** .447** .201* .445** .405** .066 .252** -.099 .200* .281** .676** 1.000
wtp (15) .251** .225* .257** .335** .052 .276** .301** .043 .086 -.041 .053 .254** .278** .263** 1.000
minute (16) .569** .372** .474** .388** .275** .434** .488** .102 .215* .157 .295** .361** .482** .386** .185* 1.000
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Table 8.29: Multiple correlations between the HidroQoL scores and the Skindex, the DLQI, EQ-5D, general health, the HDSS, 
patients’ WTP, and time spent in the daily management of the sweating (UK Sample)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
hqdaily (1) 1.000
hqpsy (2) .669** 1.000
hqtotal (3) .852** .946** 1.000
Skpsy (4) .543** .742** .720** 1.000
Sksym (5) .378* .381* .376* .407* 1.000
Sktotal (6) .559** .719** .702** .938** .680** 1.000
Dtotal (7) .578** .530** .562** .648** .622** .754** 1.000
Eqmobility(8) -.059 .029 .004 .054 .088 .077 .191 1.000
Eqselfcare(9) -.090 .049 -.003 -.040 -.323 -.143 -.014 .430** 1.000
Equsual (10) .041 .135 .100 .321 .343* .349* .289 .497** .345* 1.000
Eqpain (11) -.042 -.173 -.130 -.096 -.023 -.079 .107 .622** .502** .409* 1.000
Eqanxiety(12) .465** .638** .583** .570** .556** .653** .631** .111 0.000 .338* -.105 1.000
gq (13) .496** .574** .557** .570** .548** .638** .784** .237 .114 .412* .126 .633** 1.000
HDSS (14) .518** .551** .564** .469** .505** .537** .498** .155 -.014 .324 .115 .598** .764** 1.000
wtp (15) .117 .171 .134 .163 .316 .244 .196 -.168 -.189 .185 -.158 .367* .303 .321 1.000
minute (16) .364* .440** .437** .426** .202 .399* .477** .096 .141 .233 .105 .439** .532** .410* .120 1.000
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Table 8.30: Results of univariate regression analyses of DLQI, Skindex, EQ-5D 
dimensions regressed on HidroQoL score.
M Ind. Var F( df) p R2 Adj R2 Dep. Var B SE t p Beta
1
EQ-
Anxiety/
depression 18.56 (1, 125) 0.00 0.13 0.12 H- Score 0.00 0.01 4.31 0.00 0.36
Constant 0.65 0.32 2.01 0.05
2
EQ-
Mobility 0.42 (1, 125) 0.52 0.00 0.00 H- Score 0.01 0.01 0.65 0.52 0.06
Constant 1.18 0.26 4.45 0.00
3
EQ-Self-
care 0.19 (1, 125) 0.66 0.00 0.01 H- Score 0.00 0.01 0.44 0.66 0.04
Constant 1.09 0.21 5.24 0.00
4
EQ-Pain/
discomfort (1, 125) 8.65 0.00 0.07 0.06 H- Score 0.04 0.01 2.94 0.00 0.26
Constant 0.71 0.35 2.05 0.04
5
EQ-Usual-
activities 12.17 (1, 125) 0.00 0.09 0.08 H- Score 0.04 0.01 3.49 0.00 0.30
Constant 0.67 0.33 2.05 0.04
6
Skindex-17
Score 35.41(1, 124) 0.00 0.22 0.26 H- Score 0.44 0.07 5.95 0.00 0.47
Constant 1.95 2.06 0.94 0.35
7 DLQI score 53.37 (1, 124) 0.00 0.30 0.30 H- Score 0.60 0.83 7.31 0.00 0.55
Constant -5.84 2.30 -2.54 0.01
Figure 8.9: Scatter plot illustrating the relationship between DLQI score and the 
HidroQoL score
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In the US sample, the Skindex total score correlated with HidroQoL total score (rho = 0.551, p 
< 0.01) (Table 8.28). The Skindex total score also showed correlation with the two HidroQoL 
domain scores (daily life activities, rho = 0.415, p < 0.01; psychosocial score, rho = 0.536, p < 
0.01). Similar analyses in the UK sample showed slightly higher correlations: HidroQoL total 
score, rho = 0.702 (p < 0.01); daily life activities, rho = 0.559 (p < 0.01) and psychosocial score, 
rho = 0.719 (p < 0.01) (Table 8.29). 
Analyses were also carried out between the Skindex-17’s two domains scores and the 
HidroQoL’s scores. In the US sample, the HidroQoL overall score correlated with the Skindex-
17 psychosocial scale (rho = 0.584, p < 0.01) as well as the Skindex-17 symptom scale (rho = 
0.276, p < 0.01). Correlations of comparable magnitude and direction were similarly observed 
in the UK sample (Skindex-daily life, rho = 0.720, p < 0.01; Skindex-symptom, rho = 0.376, p 
< 0.01). The lower correlations between the HidroQoL overall score and the Skindex-symptom, 
clarifies the focus of the HidroQoL (as a measure of QoL impact and not symptoms). On the 
other hand, the higher magnitude of the correlation between ‘psychosocial scale’ of the 
HidroQoL and the total Skindex score, serves to highlight the strength of the HidroQoL in 
addressing psychosocial impacts which largely underlie patients dermatology-QoL. Further 
analysis was carried out by regressing the skindex-17 overall score on HidroQoL overall score, 
using responses. This analysis was carried out for the US sample only, the UK sample was 
considered too small. The model as a whole was statistically significant (F-statistic = 35.41, p <
0.001). The HidroQoL score explained 22% of variability in the Skindex-17 scores, which was 
comparable to the results obtained with the DLQI. The inclusion of symptom related items might 
have been an influence (Table 8.30, model 6; Figure 8.10). Results on hypothesis 3 demonstrate 
that the HidroQoL captures aspects of QoL impairment which relate to patient’s dermatology-
QoL.
The relationship between the EQ-5D scores and the HidroQoL scores
The EQ-5D-5L, is a generic health status measure comprised of a five domain descriptive 
component and a VAS scale assessing overall health status (Brooks 1996). Each of the five 
domains are scored on a five point scale (from no-problems to extreme problems/inability to do 
function).
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Figure 8.10: Scatter plot illustrating the relationship between HidroQoL score and 
Skindex-17 score
The EQ-5D was completed by patients taking part in this study alongside other measures. Two 
hypotheses were tested based on comparisons of the EQ – 5D domain scores and the HidroQoL 
scores.
Hypothesis 6a: The HidroQoL scores are not correlated with EQ-5Ds ‘mobility’ and ‘self-
care’ domain scores. 
Spearman’s rank sum correlation analysis was used to assess the relationship between the 
HidroQoL scores and EQ-5Ds ‘mobility’ and ‘self-care’ domain scores. In the US sample, the 
scores for EQ-5Ds ‘mobility’ domain showed no correlation with the HidroQoL overall score; 
nor with the two HidroQoL domain scores (p > 0.05 in all instances). Similarly, the EQ-5Ds self-
care domain score did not correlate with any of the HidroQoL scores, the total as well as the 
domain scores (Table 8.28).
The relationship between the HidroQoL scores and the EQ-5D was also explored in the UK
sample. Scores of the HidroQoL (overall as well as domain scores) again showed no correlation 
with the EQ-5Ds “self-care” or the “mobility” domain scores (Table 8.29).
Univariate regression analyses of each of the two EQ 5Ds domains, “mobility” and “self-care”, 
with the HidroQoL total score yielded non-significant models (F-statistic = 0.42, p = 0.52; F-
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statistic = 0.19, p = 0.66) (Table 8.30). This shows an absence of any statistically significant 
relationship between the two EQ-5D domains and the HidroQoL scores. The hypothesis set 
initially is therefore confirmed: the HidroQoL’s total and domain scores are not related to the 
‘mobility’ and ‘self`-care’ items supporting the divergence validity of the HidroQoL, as the two 
EQ-5D domains deal with themes that are unrelated to the impacts of HH.
Hypothesis 6b: The HidroQoL scores are correlated with EQ-5D-5L domains on ‘usual 
activities’, ‘anxiety/depression’ and ‘pain or discomfort’.
Spearman’s rank sum correlation analysis was used to assess the relationship between the 
HidroQoL scores and domain scores of the EQ-5D-5L  related to ‘usual activities’, 
‘anxiety/depression’ and ‘pain or discomfort’. In the US sample the EQ-5D-5L score for ‘usual 
activities’ domain correlated with the HidroQoL scores (overall score, rho = 0.278, p < 0.01, 
impact on daily life activities domain, rho = 0.299, p < 0.01, psychosocial impact domain, rho = 
0.230, p < 0.01). Significant correlations were also observed between the EQ-5Ds 
‘anxiety/depression’ domain scores and HidroQoLs scores (HidroQoL total score: rho = 0.387, 
p < 0.01; impact on daily life activities domain: rho = 0.339, p < 0.01 and; psychosocial impact
domain, rho = 0.363, p < 0.01). Similarly, the ‘pain/discomfort’ EQ-5D domain score correlated 
with the HidroQoL overall score (rho = 0.254, p < 0.01) as well as with the HidroQoL’s two 
domain scores (impact on daily life activities domain, rho = 0.271, p < 0.01; psychosocial impact
scale: rho = 0.215, p < 0.01). In the UK sample scores for EQ-5D-5L’s ‘usual activities’ and 
‘pain/discomfort’ were uncorrelated with HidroQoL’s total score and the scores of the two 
domains. The ‘anxiety/depression’ domain showed correlation with the HidroQoL total score 
(rho = 0.583, p < 0.01), the HidroQoL daily life activities domain (rho = 0.465, p < 0.01) and 
HidroQoL psychosocial scale (rho = 0.638, p < 0.01). Further analyses employed univariate 
regression technique. Each of the three EQ-5Ds domain scores (usual activities, pain/discomfort 
and anxiety/depression) were regressed on HidroQoL total score. Only the regression model 
involving “anxiety/depression” was significant (F-statistic = 18.56, p < 0.0001); the HidroQoL 
explained 13 % of the variance in the EQ-5D “anxiety/depression” score.
311
Hypothesis 7: Greater impairment in quality of life is associated with more time spent in 
managing the condition
Living with a long term condition usually involves patients regularly taking treatment to address 
either symptoms or impacts of their condition, in addition to other measures to adapt to their 
condition. Both of these may be time consuming. Thus, the relationship between patient’s quality 
of life (assessed by the HidroQoL score) and daily time spent in managing the condition 
(measured in minutes) was assessed using Spearman’s rank correlation analysis. 
In the US sample, the HidroQoL score showed moderate correlation with daily management time 
(overall scale score, rho = 0.474, p > 0.01, impact on daily life activities domain, rho = 0.569, p 
< 0.01; and the psychosocial domain score, rho = 0.372, p < 0.01). In the UK sample, the daily 
management time (DMT) showed correlation with the HidroQoL overall score (rho = 0.437, p < 
0.01) as well as the two domain scores (impact on daily life activities, rho = 0.364, p < 0.01, and 
psychosocial domain score, rho = 0.44, p < 0.01).
This underscores the findings already observed on the link between global impact on patient’s
life and the HidroQoL scores, by demonstrating an equally strong correlation with a more 
specific aspect of the burden. Beyond this, the link between daily time spent in caring and 
impairment in hyperhidrosis has a relevance to the understanding of potential determinants of
QoL, which is explored thoroughly in the next section.
Hypothesis 8: Greater HRQoL impairment is associated with higher WTP values.
Testing hypothesis 8 involved assessing how the HidroQoL scores relate to the patients WTP for 
a new cure. Spearman’s rank sum correlation analysis was used for assessing the association 
between the HidroQoL scores and patient’s WTP values. In the US sample, the HidroQoL scores 
had a weak correlation with WTP values (overall scale score, rho = 0.257, p < 0.01; impact on 
daily life activities domain, rho = 0.251, p < 0.01; and psychosocial impact domain, rho = 0.225, 
p < 0.01). Similar findings were obtained from the UK sample.
These findings partially confirm the null hypothesis, showing that impairment in HRQoL as 
reflected in HidroQoL scores is positively correlated with patient’s WTP. On a broader basis, 
these findings offer insights into the nature of the relationship between hyperhidrosis-specific 
QoL and generic HRQoL. The two are weakly related. This was also noted earlier on the EQ-
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5D-5L usual activities and pain scales. This underscores the uniqueness of hyperhidrosis-specific 
QOL and its role in understanding the impacts of disease. Nonetheless, in comparison with other 
tools for assessing generic HRQoL, WTP suffers a number of handicaps, the values obtained 
might be influenced by a range of factors, for example, the patient’s ability to pay, cultural 
context, in this case in relation to the financing of health care services e.g. the proportion of out 
of pocket payments (Drummond et al. 2005).
Part III: Predictors Of HRQoL in Hyperhidrosis
Understanding the determinants of HRQoL in hyperhidrosis patients is of importance in both 
clinical and policy settings. In order to identify and address the health care needs of hyperhidrosis 
patients, factors that influence key patient outcomes offers opportunity for intervention during 
treatment or designing and planning of care. Multivariate regression analyses were carried out 
using stepwise and hierarchical regression techniques to identify factors influencing patient’s 
HidroQoL score. The HidroQoL overall score was the dependent variable and independent 
variables used in the model included: the HDSS score, GQ score, DMT measured in minutes; body 
site affected; additional out of pocket expenditure on hyperhidrosis; treatment history (treatment 
within the last 6 months; currently receiving treatment; treated with surgery; treated with BTX-
A); co-morbidities (thyroid disorder; psychiatric or neurologic disorders; diabetes; hypertension).
a) hierarchical regression analysis
In the hierarchical regression analysis, variables were sequentially added to the regression, one at 
a time, to facilitate the understanding of how much each contributed to explaining variance in 
patients HRQoL. The HDSS score (representing disease severity) explained the most variance in 
the HidroQoL score (38.74 %) (Table 8.31, Table 8.32). Other variables making significant 
contributions to explaining the HRQoL included: the GQ score (global impact) (7.9%); location 
of the hyperhidrosis (4.3%); patient’s age (1.9%); co-morbidity: having thyroid disorders (1.8%). 
Overall the model explained 58% of the variance in the total score.
b) backward stepwise regression
In the backward stepwise regression, the regression model was estimated sequentially, first 
estimating a model with all variables; then estimating subsequent models by removing the least 
significant regressor if its significance level was ≥ 0.1 at each step, until there was no variable to 
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be excluded. The final model retained the following predictors: HDSS score, GQ score, co-
morbidities: psychiatric or neurologic disorders, thyroid disorders; body site affected; age (Table 
8.33). These predictors were jointly statistically significant in explaining the variability in the 
HRQoL of patients with HH, explaining 55.5% of the variation. However, only coefficients for the 
HDSS score, GQ score, and age were statistically significant:
- The HidroQoL Score of patients with HDSS score of 4, was 7.82 higher than those with 
HDSS score of 2.
- Patients with a GQ score of 3, 4, and 5 had respectively higher HidroQoL scores of 4.36, 
6.84 and 7.44 than in patients with a GQ score of 2.  
- HRQoL scores of patients with palmar, feet and axillar sweating were 3.53 lower than 
those with generalised sweating; those with head or facial sweating were 3.96 lower than 
those with generalised sweating.
Due to size of the UK sample, only the stepwise regression analysis was performed. Following 
estimation, only one predictor, the HDSS, remained in the model which was also significant. The 
model explained 33.7% of variance in QoL (Table 8.34). Model diagnostics analysis were carried 
out to see whether the OLS regression assumptions had been met. The residuals from the 
regression met normality assumptions and were homoskedastic (reflected equal variance) across 
the fitted values. 
DISCUSSION
Apart from influencing the integrity of inferences, the lack of validity may have severe 
consequences for patient care, for example, misdiagnosis of patients, where a measure is used 
for screening purposes; or over-and-under treatment where an instrument is used for screening 
in patient management. This reflects the necessity of establishing the construct validity for 
measures of HRQoL. Thus, this chapter intended to provide evidence based on various tests, 
supporting the hypothesis that the HidroQoL accurately assesses HRQoL in patients with 
hyperhidrosis. The affirmation of the HidroQoL (response option a little or very much) exceeded 
80% for most items reflecting on the relevance and importance of the content of the measure to 
hyperhidrosis patients.
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Table 8.31: Predictors of HRQoL in hyperhidrosis (all variables included) based on the US 
sample (n = 127)
B SE t p-v Beta
HDSS 
HDSS = 3 2.39 1.43 1.68 0.1 0.17
HDSS = 4 7.35 1.88 3.91 0 0.51
GQ Score
GQ Score = 3 4.85 2.08 2.33 0.02 0.31
GQ Score = 4 7.49 2.26 3.32 0 0.52
GQ Score = 5 7.76 2.63 2.95 0 0.51
DMT (minute) 0 0 0.8 0.43 0.06
Location
Palmar, feet & Axillar -3.93 1.33 -2.95 0 -0.28
Palms and/or feet -2.71 1.49 -1.82 0.07 -0.16
Head -4.02 1.9 -2.12 0.04 -0.18
Axilla plus other -3.41 2.15 -1.58 0.12 -0.12
Monthly Expenditure (£) 0 0 -0.42 0.67 -0.03
Age -0.08 0.04 -1.96 0.05 -0.16
WTP
WTP = £ 50 to 199 1.31 1.17 1.11 0.27 0.09
WTP = 200 or more 1.13 1.42 0.8 0.43 0.07
Female -0.81 1.36 -0.6 0.55 -0.04
Treatment history
Not treated within last 6 months -0.95 1.2 -0.79 0.43 -0.07
Never received surgical therapy before 0.45 1.44 0.31 0.76 0.02
Never received Botox therapy before -1.31 1.59 -0.82 0.41 -0.06
Not  undergoing treatment currently 0.17 1.19 0.14 0.89 0.01
Co-morbidities reported absent:
Thyroid disorder -3.41 1.84 -1.85 0.07 -0.13
Psychiatric or neurologic disorders -2.41 1.4 -1.72 0.09 -0.13
Menopausal related complaints 1.25 1.72 0.73 0.47 0.05
Diabetes -0.39 2.02 -0.19 0.85 -0.02
Hypertension 0.01 1.44 0.01 1 0
Constant 28.14 4.95 5.69 0 .
F( 24,   102) = 5.89; P < 0.001; R-squared = 0.58; Adj. R-squared = 0.48; Root MSE = 
5
Note:1. The following groups were used as reference for comparing the influence of the 
dummy variables: HDSS = 4; GQ Score= 2; Generalised HH; WTP = £ 49 or less; Male; 
Co-morbidities confirmed; 2. B: coefficient; SE - standard error; t: t-statistic; p: p-value; 
Beta: beta coefficient
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Table 8.32: Contribution of predictors included in ‘all variables model’ to explaining the 
variance in the HidroQoL Scores; with hierarchical inclusion of variables (USA sample)
Model fit statistics Impact of change on model
Model R-sq F(df) p-value R2 Change F(df) change p-value
1 0.39 38.741(2,124) 0
2 0.46 20.918(5,121) 0 0.079 5.95(3,121) 0.001
3 0.47 17.491(6,120) 0 0.003 0.66(1,120) 0.42
4 0.51 12.052(10,116) 0 0.043 2.54(4,116) 0.043
5 0.51 10.883(11,115) 0 0 0.11(1,115) 0.737
6 0.53 10.659(12,114) 0 0.019 4.53(1,114) 0.036
7 0.54 9.395(14,112) 0 0.011 1.39(2,112) 0.255
8 0.54 8.699(15,111) 0 0 0.06(1,111) 0.809
9 0.54 8.200(16,110) 0 0.004 0.87(1,110) 0.354
10 0.55 7.683(17,109) 0 0.001 0.28(1,109) 0.6
11 0.55 7.277(18,108) 0 0.003 0.71(1,108) 0.401
12 0.55 6.840(19,107) 0 0 0.09(1,107) 0.764
13 0.57 6.926(20,106) 0 0.018 4.41(1,106) 0.038
14 0.58 6.862(21,105) 0 0.012 2.98(1,105) 0.087
15 0.58 6.546(22,104) 0 0.002 0.54(1,104) 0.464
16 0.58 6.206(23,103) 0 0 0.04(1,103) 0.845
17 0.58 5.889(24,102) 0 0 0.00(1,102) 0.995
Variables included in model
Model 1 Constant (C); hdss (a)
Model 2 C; a; gq
Model 3 C; a; gq; m (m)
Model 4 C; a; gq; m; location (l);
Model 5 C; a; gq; m; l; expenditures (£)
Model 6 C; a; gq; m; l; £; age;
Model 7 C; a; gq; m; l; £; age; wtp
Model 8 C; a; gq; m; l; £; age; wtp; gender (g)
Model 9 C; a; gq; m; l; £; age; wtp; g; dm4
Model 10 C; a; gq; m; l; £; age; wtp; g; dm4; dm5
Model 11 C; a; gq; m; l; £; age; wtp; g; dm4; dm5; dm6;
Model 12 C; a; gq; m; l; £; age; wtp; g; dm4; dm5; dm6; dm7
Model 13 C; a; gq; m; l; £; age; wtp; g; dm4; dm5; dm6; dm7; dm13;
Model 14 C; a; gq; m; l; £; age; wtp; g; dm4; dm5; dm6; dm7; dm13; dm14
Model 15 C; a; gq; m; l; £; age; wtp; g; dm4; dm5; dm6; dm7; dm13; dm14; dm15
Model 16 C; a; gq; m; l; £; age; wtp; g; dm4; dm5; dm6; dm7; dm13; dm14; dm15; dm16
Model 17 C; a; gq; m; l; £; age; wtp; g; dm4; dm5; dm6; dm7 dm13; dm14; dm15; dm16; dm17
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Table 8.33: Predictors of hyperhidrosis-QoL based on stepwise backward regression 
analysis (USA sample, N = 127)
Coef. SE t p-value
[95% Confidence 
Int.]
HDSS = 3 2.71 1.34 2.03 0.05 0.06 5.36
HDSS = 4 7.89 1.71 4.62 0.00 4.51 11.27
GQ Score = 3 4.36 1.88 2.32 0.02 0.64 8.08
GQ Score = 4 6.84 1.97 3.48 0.00 2.95 10.74
GQ Score = 5 7.44 2.30 3.24 0.00 2.89 11.99
_Idm14_2
Location:
Palmar, feet & Axillar -3.53 1.23 -2.86 0.01 -5.97 -1.08
Palms and/or feet -2.70 1.41 -1.92 0.06 -5.49 0.08
Head -3.96 1.74 -2.28 0.02 -7.41 -0.52
Axilla plus other -3.48 2.01 -1.73 0.09 -7.46 0.51
Co-morbidities reported absent:
Psychiatric or neurologic disorder -2.28 1.29 -1.77 0.08 -4.83 0.28
Thyroid disorder -3.24 1.71 -1.90 0.06 -6.62 0.14
age -0.09 0.03 -2.80 0.01 -0.16 -0.03
Constant 28.23 3.09 9.12 0.00 22.10 34.36
F( 12,   114) 11.88
Prob > F 0
R-squared 0.5557
Adj R-squared 0.5089
Root MSE 4.8676
Table 8.34: Predictors of hyperhidrosis-QoL based on stepwise backward regression 
analysis (UK sample, N = 36)
B SE t p-value [95% CI]
HDSS = 3 6.61 2.63 2.51 0.017 1.26 11.97
HDSS = 4 10.52 2.58 4.07 0 5.27 15.77
Constant 19.64 1.90 10.33 0 15.77 23.50
F(  2, 33) 8.38
Prob > F 0.0011
R-squared 0.3369
Adj R-squared 0.2967
Root MSE 6.3017
Some items such as my choice of clothing is affected and I feel embarrassed showed extremely 
high endorsement rates, reflecting the high prevalence of these issues during interviews carried 
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out in the qualitative study reported in chapter 3. This shows that the items of the HidroQOL 
reflected issues of importance to patients. No responses were missing in both samples (UK & 
USA) used in the study, an advantage of electronic collection of data, which allowed use of a 
number of feature, such as prompts and reminders, to ensure all questions were responded to 
(Dillman 2006).
HidroQoL scores were compared across groups of patients on a number of various patient 
characteristics including gender, age, site of hyperhidrosis, co-morbidity, disease severity 
(HDSS score) and global impact to hyperhidrosis (GQ score). Significant differences in 
HidroQoL scores were observed across patients with differing sites of hyperhidrosis; but not
across gender or age-groups. Previous work, though bearing little comparability with the current 
study, is still insightful. Amir et al. (Amir et al. 2000) observed lower quality of life in females 
than males, in an Israeli sample (N = 48); on the other hand Wolosker et al. (Wolosker et al. 
2010) found no gender differences in the HRQoL of patients with Palmar HH awaiting surgery.
This is similar to observations related to self-reported disease severity. While Kirimian-Teherani 
et al (Karimian-Teherani et al. 2009) found higher level of self-assessed severity in women;  
studies by Lear et al. (Lear et al. 2007), US and Canadian clinic samples, and Strutton et al. 
(Strutton et al. 2004), based on US households, could not find any gender differences. Thus while 
hyperhidrosis is most prevalent in the active working age group (Strutton et al. 2004, Lear et al. 
2007), its impact is rather common across the board.
Differences in QoL based on the site of HH have been previously noted. Hamm et al. (2007) 
found greater QoL impairment in patients with axillary HH than in those with palmar HH, based 
on a German clinic sample.  Patients with different sites of hyperhidrosis seem to differ in a 
number of important ways, with potential implications on how they experience the disease. For 
instance, palmer-plantar hyperhidrosis has onset in childhood or before puberty while axillary 
often starts during or post-puberty (Lear et al. 2007). Treatment pathways and their 
corresponding effectiveness differ by location of hyperhidrosis (Solish et al. 2007), leading to 
differences in the levels of control of the condition. Axillar hyperhidrosis for example has more 
treatment options which have demonstrated effectiveness, in comparison to craniofacial 
hyperhidrosis, which not only faces limited treatment options, but also has limited effectiveness 
information on the same. Additionally, the extent of visibility of the sweating is variable across 
different sites of hyperhidrosis; those with sweating involving the head/face or underarms may 
be more exposed than those with plantar hyperhidrosis (involving the feet).
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For instruments used for discriminatory purposes, it is crucial to demonstrate the capability to 
distinguish between patients experiencing severe vs. those with milder forms of a condition, 
(Guyatt et al. 1992). Testing the HidroQoL for this capability was done by comparing scores 
from patients with differing levels of disease severity (HDSS score); also those with differing 
levels of overall impact of HH (GQ score). The HidroQoL scores showed significant differences 
in patient groups according to the HDSS score and the GQ score. Even more reassuring is that 
discriminative ability was also seen in all items, across both severity and overall impact. 
Capability to discriminate across different levels of disease severity is also an important early 
indication of the ability to detect important changes in patients condition (Fayers and Machin 
2007). Taken together this suggests that the HidroQoL would be useful in the clinic, for the 
diagnosis as well as management of hyperhidrosis. 
Further construct validation of the HidroQoL involved evaluating convergence and divergent 
validities. Convergence validity is demonstrated where an instrument correlates with other scales 
assessing a similar construct; on the other hand, discriminant validity is seen where an instrument 
does not correlate with instruments assessing un-related constructs (DeVellis, 2011). The 
HidroQoL score correlated with scores of the DLQI and Skindex-17, measures of dermatology-
specific quality of life. The observed degree of relationship seemed consistent for measures 
assessing related but distinct constructs. Evidenced by higher correlations between the DLQI 
and the Skindex, which measure the same construct. Although therapeutic area instruments such 
as the DLQI offer better versatility and comparability across a therapeutic area as they deal with 
issues that have relevance across a group of related disease (Salek 1998), the potential for 
omissions of key items or irrelevant inclusions of items with respect to specific disease 
conditions may still be quite unavoidable. For instance items like ‘skin hurts’ or ‘skin condition 
bleeds’ in the Skindex-17 seem irrelevant in hyperhidrosis. The HidroQoL, on the other hand, as 
a disease specific instrument by definition and design contains content relevant only to 
hyperhidrosis. Moreover, the early development of the HidroQoL (See Chapter 3) actively 
involved hyperhidrosis patients, to ensure the measure’s content reflects themes of importance 
to them and; capture using the very expressions the patients use. 
The lack of significant correlations between the HidroQoL scores and EQ-5D-5L’s  ‘mobility’ 
and ‘self-care’ subscales demonstrates the divergent validity of the HidroQoL, as those domains 
are not relevant for HH patients let alone dermatology. On the other hand weak correlation with 
the other EQ-5D-5L items (usual activities, pain/discomfort and anxiety/depression) seems to 
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suggest that these aspects may have some relevance in HH, as expected, though convergence 
validity is not supported. It is encouraging that the magnitude of correlation between these three 
domains (aspects of generic QOL) and the HidroQoL, is smaller in comparison to that with 
Skindex and DLQI, measuring dermatology-specific QOL, a construct more closely related to 
hyperhidrosis-specific QOL. 
The HidroQoL showed moderate-strong correlations with disease severity (HDSS score); overall 
global impact (GQ score); and daily time spent in dealing with the condition (measured in 
minutes) a further support of the convergence validity. Weak correlation was found between 
HidroQoL and patient’s WTP. Although various studies have successfully demonstrated that 
WTP is indeed responsive in patients with skin disease, Müller and Augustin (Muller and 
Augustin 2013) found WTP to be non-responsive to change in disease severity; and uncorrelated 
to patient therapeutic benefit, in a sample of German outpatients with hyperhidrosis (n = 96). 
The relationship between WTP and self-reported disease severity and QoL has been explored in 
other skin conditions. WTP has shown significant correlations with the Psoriasis Disability Index 
(r = 0.42) in a sample of psoriasis patients (Finlay and Coles 1995), acne disability score (r = 
0.229, p < 0.005) (Motley and Finlay 1989) and with the DLQI (r = 0.249) in patients with 
rosacea (Beikert et al. 2013). The current results suggests a limited usefulness of WTP in patients 
with hyperhidrosis.
Time spent on treatment has been previously used for studying the impacts of skin disease such
as psoriasis and atopic dermatitis. Positive correlations have been confirmed between time spent 
on treatment and the Psoriasis Disability Index (r = 0.37) in psoriasis patients (Finlay and Coles 
1995) and with IDQoL/DLQI (unclear whether CDLQI was used in this paper) in children with 
atopic dermatitis (r = 0.31) in (Jemec et al. 2006). This confirms a strong relationship between 
time spent on treatment and disease impacts on the patients. Moreover, (Holm and Jemec 2004)
have reported on the test-retest reliability of time spent on treatment in atopic dermatitis patients. 
The results from the current study suggests that time spent on treatment represent an important 
measure of disease impacts in hyperhidrosis, consistent with observations in other skin 
conditions.
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This study also looked into the predictors of HRQoL in hyperhidrosis patients, by exploring the 
determinants of the HidroQoL score. The majority of the variance in the patients was explained 
by the regression models (All-variables model: explained 58% of variance; backward stepwise 
regression explained 55%). Significant and important predictors included patient’s disease 
severity; global life impact; site of hyperhidrosis; and age. This has not been explored previously 
in hyperhidrosis patients, nonetheless this is consistent with other skin conditions, for instance 
Psoriasis, where the most important predictors of HRQoL have been reported to be daily 
treatment time, disease severity; and patient benefit (Blome et al. 2010). 
SUMMARY
 This chapter has reported on a validation study of the new HRQoL measure for 
hyperhidrosis, the HidroQoL, involving known-groups, convergent and divergent 
validities.
 The HidroQoL scores showed significant differences across patients with hyperhidrosis 
involving varying sites, but not across gender or age group.
 Patients with higher HDSS scores (level of disease severity) registered significantly 
higher HidroQoL scores. 
 Patients with a higher GQ score (higher overall impact of disease on life) showed 
significantly higher HidroQoL scores.
 There was a significant difference in HidroQoL scores of patients who spent less than 1 
hour; at least 1 hour but no more than 1.5 hours and; more than 1.5 hours in managing 
their condition daily. 
 Scores of the daily life activities domain of the HidroQoL showed a significant difference 
w.r.t. to one aspect of treatment history (receiving surgery).
 There was no difference in HidroQoL scores with respect to co-morbidities, except for 
‘psychiatric or neurologic disorders’.
 Convergence validity of the HidroQoL was demonstrated through positive moderate 
correlations with the Skindex scores; the DLQI scores; Global impact score; disease
severity; and daily time spent in dealing with condition.
 Divergent validity was demonstrated by lack of correlation between the HidroQoL Scores 
and the EQ-5D’s ‘mobility’ and ‘self-care’ scale scores.
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CHAPTER 9
Responsiveness and Interpretation of the Hyperhidrosis Quality 
of Life Index (HidroQoL) Scores
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INTRODUCTION
Where an instrument is used in a longitudinal context, for example for monitoring the condition 
of individual patients over time, further psychometric attributes apart from internal consistency, 
reliability and construct validity may be required to ensure valid measurements. The measure must 
be capable of detecting important changes taking place in the patient’s condition even if they are 
small, an attribute referred to as responsiveness (Guyatt et al. 1987). The assessment of 
responsiveness requires an external measure as a criterion for determining whether the patient’s 
condition has changed, improved or worsened (Revicki et al. 2008). Previous clinical trial results, 
on differences between placebo and active treatment; or known distribution properties of the target 
patient population may also be useful as basis for assessing responsiveness.
Guyatt and colleagues (Guyatt et al. 1987) have argued that responsiveness is quite separate from 
validity and reliability, drawing the conclusion that an instrument can be responsive without being 
either valid or reliable. Demonstrating a measure’s ability to capture score changes, without 
evidence that those changes are linked to the intended construct or the extent of measurement error 
in the change scores, would put the usefulness and relevance of such ‘responsiveness’ into question 
(Hays and Hadorn 1992). Considering construct validity as a “process by which empirical evidence 
from several validation procedures is assembled to support the inference that a particular 
instrument measures what it purports to measure” (Salek 1998), the evidence for responsiveness 
is one of such pieces of information, relating to the instrument’s use in a longitudinal context. 
Establishing responsiveness requires demonstrating that the observed score changes reflect true 
changes in the concept being measured (longitudinal validity) and that such changes are not merely 
random variability (longitudinal reliability) (Terwee et al. 2003). Moreover, as measurement error 
increases, larger and larger magnitude of change might be required to demonstrate any treatment 
effect (Guyatt et al. 1987), reflecting an inverse relationship between reliability and 
responsiveness, similar to the observation on construct validity.
Establishing that an instrument produces reliable and valid measures and that it is responsive, is 
not sufficient to render it useful in routine clinical practice or in clinical research. Information 
facilitating assigning of easily understood meaning to an instrument’s quantitative scores must also 
be available (Lohr 2002). Rather than just knowing whether patient scores have changed in a 
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statistically significant way, of relevance to patient management is whether a change in scores is 
clinically significant i.e. whether the change in scores is large enough to have an implication for 
patient care (Wyrwich et al. 2005). Such a cut-off change score is considered as the minimum 
clinically important difference (MCID) (Guyatt et al. 2002).  Also, for a given absolute score, 
clinicians may want to know its implication on the patients’ condition, whether it represents a mild, 
moderate or severe state of the patient’s condition. In widely used dermatology QoL instruments 
such as the Skindex and DLQI both score categorisation and qualitative descriptors for each band 
have been provided (Hongbo et al. 2005; Prinsen et al. 2009). In addition, values for minimum 
clinically important difference (MCID) have been reported (Both et al. 2007; Basra et al. 2008).
Nevertheless, efforts to ensure that QoL scores are interpretable are not limited to the above, results 
of clinical trials and statistical characteristics of samples where the measure was previously used 
and comparative data from non-diseased populations may be useful. Availability of any of such 
data is therefore considered among the important psychometric attributes of an instrument.
OBJECTIVES
Objectives of this study were to:
 Assess whether the HidroQoL is sensitive to change in patients whose condition had 
changed.
 Evaluate whether the HidroQoL was capable of discriminating between patients 
experiencing different levels of change in their sweating.
 Establish the MID value of the HidroQoL.
 Develop and propose scale banding for the interpretation of the HidroQoL scores.
METHODS
This study followed a prospective longitudinal study design with patient’s assessed on two
occasions, at baseline (assessment 1) and during a follow-up assessment (assessment 2) at least 21 
days after initial assessment. There is no recommendation regarding the best interval between 
assessments in responsiveness studies. However, as a construct validation procedure, groups of 
patients expected to change should be identified a priori. 
The study used the patient population used in the previous chapter.
Inclusion criteria:
 Patients with self-reported excessive sweating problems;
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 Experiencing interference in their daily life (HDSS ≥ 2);
 Onset of hyperhidrosis in teenage years or early adulthood years;
 Aged 17 or above.
Exclusion criteria:
 Patients not experiencing any excessive sweating;
 Excessive sweating was not causing any interference in daily life (HDSS = 1);
 Onset of hyperhidrosis was after age of 30; and patient reporting a co-morbidity 
(hypertension, diabetes, PM hormonal disorders, and psychological disorders).
 Aged below 17.
Outcome measures
Apart from the HidroQoL, data were also collected on the patient’s disease severity using the 
HDSS and on dermatology-specific QoL using the DLQI and the Skindex-17. In addition, two 
general questions were administered: an overall-impact global question (GQ), scored on a 5 point 
Likert scale; and a patient global assessment of change (PGA), also scored on a 5-point Likert
scale. Further details on these measures are available in Chapter 2. 
Procedures
After completion of the first assessment, patients received communication containing information 
on their follow-up assessment due in 21 days. On the 20th day following their initial assessment 
patients were sent an email containing the access details for their follow-up assessment (due in a 
day). 
Data processing and analysis 
All data analysis were performed using SPSS 20, STATA and MS Excel. Scale scores were tested 
for normality using Q-Q plots, histograms and the Shapiro-Wilk test. A paired t-test was used to 
assess whether the HidroQoL is capable of detecting any change in patient’s condition from 
baseline (assessment 1) to follow-up (assessment 2). Significant score changes (p < 0.05) were 
expected in patient-groups that had minimally worsened or improved. Non-significant changes 
were expected for the no-change group (p > 0.05) was expected in the no-change group based on 
the anchor variables (PGA score and HDSS-change-score). The magnitude of change in the 
HidroQoL scores from baseline to follow-up assessment in each patient group was estimated using 
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the Effect sizes (ES) and Standard Response Mean (SRM). Cohen’s Effect Size is estimated as the 
ratio of the mean score change (test 1 – test 2) to the standard deviation (SD) of baseline scores 
(Streiner and Norman 2008). SRM is given by the ratio of the mean score change (in each patient 
group) to its SD (Streiner and Norman 2008). In addition, the HidroQoL’s efficiency at detecting 
change in patients was compared with that in of the DLQI and the Skindex using the relative 
efficiency index (REI). The REI indicates how much more or less valid and responsive an 
instrument is, relative to the comparator instrument (Ware et al. 1998) and is estimated as the ratio 
t-statistics of the target measure to the comparator (Fayers and Machin 2007). Oneway ANOVA 
was used to assess the HidroQoLs ability to discriminate among patients experiencing different 
levels of change from baseline to follow-up. F-statistics are calculated to test for differences in the 
mean changes in scale scores across groups (Ware et al. 1998).
A categorisation of the HidroQoL overall score was carried out by mapping scores of the HidroQoL 
to the GQ score; with the descriptors of GQ scores providing the descriptors for the bands. This 
involved first estimating the mean, mode and median of the GQ scores for each of the HidroQoL 
scores. The HidroQoL overall scores ranges associated with each mean GQ score was identified 
such that each score was allocated a unique band. To test the banding system, the level of 
agreement between the patients GQ scores and the banding (GQ predicted from the patients 
HidroQoL scores) was assessed using Intra-class correlations (ICC). In addition to assessing 
measurement error, the ICC also captures systematic bias among raters, thus measuring absolute 
agreement rather than consistency only (Streiner and Norman 2008). Its interpretation is similar to 
that of the kappa coefficient, where agreement is considered ‘almost perfect’ if at least 0.81, 
‘substantial’ for 0.61-8, ‘moderate’ at 0.41- 6, ‘fair’ for .21-4. ‘slight’ for 0.00 – 0.20  and ‘poor’ 
for less than 0.00 (Landis and Koch 1977).
The MCID for the HidroQoL was estimated using three approaches:
1) Using an external anchor: the mean score change from baseline to follow-up in the minimally 
improved patient group (according the anchor) (Revicki et al. 2008). 
2) Based on distribution of scores: One third standard deviation and one half standard deviation 
translate the effect sizes of 0.33 and 0.5, respectively, into the units of the scores being 
assessed (Yost and Eton 2005).  Standard error of measurement (SEM) is calculated as (
Standard Deviation (1 − reliability) ) provides a relatively consistent measure of 
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precision across samples and settings (Wyrwich et al. 2005).   One SEM is consistent with 
effect size of 0.5 when a measure’s reliability is 0.75, and 0.33 when reliability is about 0.9
(Yost and Eton 2005). 
3) Integrating anchor-based and distribution based methods: Upper bound of a 1-tail 95% CI 
for the mean score change in the patient group which did not change (de Vet et al. 2007).
Part I: Responsiveness Of The HidroQoL
Characteristics of the study participants
A total of 89 participants completed the HidroQoL questionnaire, on two occasions, 15 to 35 
days apart. Fifty-four patients (60.7%) were from the USA and seventeen (19.1%), the UK (Table 
9.1). The mean age of patients from the US was 37 (±12) with a range of 18 – 73, while those 
from the UK had a mean age of 38 (±13), ranging from 20 to 62. The largest age group was the 
31 to 40 group in the both the USA (N = 19, 35.2%) and UK (N = 6, 35.3%) samples. Ninety-
nine percent (N = 53) of patients from the US and one-hundred percent (N = 17) of those from 
the UK had previously sought for medical attention regarding their sweating (Table 9.2). Thirty 
five percent (N = 19) of the US patients, fifty nine percent (N = 10) of the UK sample, had been 
treated for their hyperhidrosis in the last 6 months, with a lower proportion being currently 
treated (USA, 29.6%, N = 16; UK, 47 %, N = 8). Oral systemic drugs (in pill-form) were the 
most common form of treatment (US, N = 7, 13%; UK, N = 4, 23%). The majority of participants 
did not have any co-morbidities, the most common were psychiatric and neurological disorders 
(US, N = 8, 14.8%; UK, N = 1, 5.9%).
Distribution of scale scores
The mean HidroQoL scores were 26.64 (± 7.14) and 25.08 (± 8.38), for baseline (test 1) and 
follow-up (test 2) assessments, and the range was 1 – 36 for both assessments (Table 9.3). The 
mode scores were 33 (test 1) and 32 (test 2), suggesting high levels of QoL impairment in both 
assessments. The DLQI mean scores were 10.13 (± 6.87) and 9.55 (± 6.96), during the first and 
second assessment; with ranges of 0 to 25 and 0 to 26, respectively. This reflects moderate to very 
large life impacts, lower cut-off for very large effect QoL effect for the DLQI is 11 (Hongbo et al. 
2005). Most patients had low to moderate scores, as reflected in the inter-quartile range (5 – 16) 
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and (4 to 15) for both the first and second assessment, respectively, with no patients towards the 
upper extremity. The DLQI scores showed a slightly positive skew.
Table 9.1: Sociodemographic characteristics of the patients
Characteristic USA Sample
(n = 54)
UK Sample
(n = 17)
Pooled Sample*
( N = 89)
Gender, n (%)
Male 9 (16.7%) 3 (17.6%) 18 (20.2%)
Female 45 (83.3%) 14 (82.4%) 71 (79.8%)
Age (years)
Mean, SD 37, 12 38, 13 37, 12
Median 34 39 34
Mode 20 40 31
Range 18 – 73 20 – 62 16 - 73
Age (years), n (%)
17 to 30 17 (31.5%) 5 (29.4%) 28 (31.9%)
31 to 40 19 (35.2%) 6 (35.3%) 33 (36.7%)
41 to 50 10 (18.5%) 3 (17.6%) 16 (17.8)
51 to 60 5 (9.3%) 1 (5.9%) 7 (7.8%)
> 60 3 (5.6%) 2 (11.8%) 5 (5.6%)
Body site involved, n (%)
Generalised 11 (20.4%) 6 (35.3%) 20 (22.5%)
Palms, feet & axilla 21 (38.9%) 4 (23.5%) 28 (31.5%)
Palms and feet 8 (14.8%) 1 (5.9%) 16 (18%)
Head, Face 3 (5.6%) 2 (11.8%) 6 (18%)
Axilla 10 (18.5%) 2 (11.8%) 15 (16.9%)
Palms 1 (1.9%) 1 (5.9%) 3 (3.4%)
Trunk & rest of body 0 (0%) 1 (5.9%) 1 (1.1%)
Employment, n (%)
Employed 38 (70.4%) 10 (58.8%) 61 (68.5%)
Unemployed 9 (16.7%) 3 (17.6%) 13 (14.6%)
Retired 3 (5.6%) 2 (11.8%) 5 (5.6%)
Full time student 4 (7.4%) 2 (11.8%) 10 (11.2%)
*Country of residence
USA 54 (60.7%)
UK 17 (19.1%)
Canada 8 (9%)
Australia 5 (5.6%)
Other 15 (5.6%)
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Table 9.1 (continued)
USA Sample
(n = 54)
UK Sample
(n = 17)
Pooled Sample
( N = 89)
Disease severity (HDSS score), n
1 0 0 0
2 28 17 51
3 63 32 120
4 51 24 89
Global impact (GQ score), n
No effect 0 2 2
Small effect 9 5 18
Moderate effect 37 17 65
Large effect 53 33 106
Extremely large effect 43 16 69
Table 9.2: Patients’ treatment history and disease characteristics
USA Sample
(n = 54)
UK Sample
(n = 36)
Pooled 
Sample (n = 89)
Seen medical practitioner regarding 
hyperhidrosis, n (%)
53 (98.1 %) 17 (100%) 87 (97.8%)
Have received Surgical treatment, n (%) 4 (7.4%) 3 (17.6%) 12 (13.5%)
Received Botox within last 6 months, n (%) 7 (13%) 0 (0%) 8 (9%)
Received treatment within last 6 months, n (%) 19 (35.2%) 10 (58.8%) 36 (40%)
Currently receiving treatment*, n (%) 16 (29.6%) 8 (47.1%) 27 (30.3%)
Oral-systemic drugs (pill-form) 7 (13%) 4 (23.5%) 11 (12.4%)
Iontophoresis 5 (9.3%) 4 (23.5%) 10 (11.2%)
Aluminium Chloride Topical treatment 4 (7.4%) 0 (0%) 5 (5.6%)
Non-prescription/cosmetic preparations 5 (9.3%) 3 (17.6%) 8 (10%)
Other 4 1 6 
Co-morbidities, n (%)
Thyroid disorders 3 (5.1%) 0 (0%) 3 (3.4%)
Psychiatric of neurologic disorders 8 (14.8%) 1 (5.9%) 9 (10%)
Menopausal related complaints 4 (7.4%) 1 (5.9%) 6 (6.7%)
Diabetes 6 (11.1%) 0 (0%) 6 (6.7%)
Hypertension 4 (7.4%) 0 (0%) 5 (5.6%)
Other 9 (16.7%) 4 (23.5%) 14 (15.7%)
* Some patients were on more than one of the listed treatments.
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Table 9.3: Distribution of the scale scores, in pooled sample
HidroQoL DLQI Skindex
test1 test2 test1 test2 test1 test2
Mean 26.62 25.08 10.13 9.55 17.27 16.42
SD Mean 7.14 8.38 6.87 6.96 8.26 8.44
SE  Mean 0.76 0.89 0.73 0.74 0.88 0.89
95% CI 14, 35 9, 35 0, 22 0, 22 1, 27 0, 29
Range 1-36 1-36 0-25 0-26 0-31 0-30
IQR 22-33 18-32 5-16 4-15 14-14 12-22
Median 27 26 10 8 18 17
Mode 33 32 6 0 17 0
Skewness -.914 -.770 .275 .424 -.690 -.423
SE skewness .255 .255 .255 .255 .255 .255
Kurtosis .775 -.055 -1.002 -.741 -.410 -.572
SE kurtosis .506 .506 .506 .506 .506 .506
Ceiling, N (%) 2 (2.2%) 1 (1.1%) - - - -
Floor, N (%) - - 5 (5.6%) 10(11.2%) 4 (4.5%) 8 (8.9%)
In contrast, the score range used by the HidroQoL was wider and most patients were within the 
upper third of the scale. The distribution of the HidroQoL showed a negative skew, for both 
baseline and follow-up assessments. Kurtosis in all three scales shows minimal departure from 
that of a perfect bell-shape normal distribution (with kurtosis = 0).
Assessing the usefulness of the anchors
At baseline, the majority of USA patients (N = 22) had an HDSS score of 3, reflecting sweating 
that was barely tolerable and frequently interfered with their daily activities (Table 9.4). Among
UK patients, there were equivalent numbers of patients with HDSS score of 3 and 4 at baseline, 
N = 6, for each. An HDSS score of 4 reflects intolerable sweating that always interferes with 
daily life activities. In the pooled sample, seventy-one percent of the patients (N = 64) had 
experienced no change in their condition, from baseline to follow-up, based on their HDSS-
change-score (HDSS-cs = 0) (Table 9.5). Twenty-one percent of the patient (N = 19) had 
experienced a small improvement in their condition (HDSS-cs = -1) while only 6.7% (N = 6) 
had experienced a small deterioration (HDSS-cs = 1). No patient had experienced a major 
improvement or major deterioration i.e. an HDSS-cs of 2 or -2. Based on the second anchor, the 
patients global assessment (PGA), the proportion of patients reporting no change in their 
condition (PGA score = 3) was higher, seventy-four percent (N = 67) in the pooled sample (Table 
5.1). Only eleven-percent of the patients (N = 10) reported a small improvement, while ten-
330
percent (N = 9) reported a slight deterioration. Two patients reported a major deterioration while 
one experienced a major improvement. 
Table 9.4: Distribution of the HDSS score
Number of patients (N), %
USA UK Pooled Sample
HDSS 
Score
Baseline Follow-up Baseline Follow-up Baseline Follow-up
2 13 (24.1%) 19 (35.2%) 5 (29.4%) 6 (35.5%) 19 (21.3%) 27 (30.3%)
3 22 (40.7%) 21 (38.9%) 6 (35.3%) 6 (35.5%) 41 (46.1%) 38 (42.7%)
4 19 (35.2%) 14 (25.9%) 6 (35.3%) 5 (29.4%) 29 (32.6%) 24 (27%)
Table 9.5: Distribution of the anchors: HDSS change score and PGA score
Anchor Score USA UK Pooled Sample
HDSS score 
change
- 1 13 (24.1%) 4 (23.5%) 19 (21.3%)
0 39 (72.2%) 11 (64.7%) 64 (71.1%)
1 2 (3.7%) 2 (11.8%) 6 (6.7%)
PGA 1 1 (1.9%) 1 (5.9%) 2 (2.2%)
2 4 (7.4%) 1 (5.9%) 9 (10%)
3 41 (75.9%) 14 (82.4%) 67 (74.4%)
4 8 (14.8%) 1 (5.9%) 10 (11.1%)
5 0 (0%) 0 (0%) 1 (1.1%)
Table 9.6: Correlation of the HDSS and the PGA with the HidroQoL scores
1 2 3 4 5 6 7
HDSS (baseline) - 1 1.000
HDSS (follow-up) - 2 .765** 1.000
HDSS change score) - 3 -.287** .393** 1.000
PGA - 4 .166 .032 -.166 1.000
HidroQoL (baseline) - 5 .607** .580** .001 .108 1.000
HidroQoL (follow-up) - 6 .529** .605** .142 -.022 .822** 1.000
HidroQoL change score - 7 -.049 -.217* -.244* .132 .023 -.501** 1.000
*. Correlation is significant at the 0.05 level (2-tailed).
**. Correlation is significant at the 0.01 level (2-tailed).
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External measures used as anchors, for capturing the clinical change in the patient’s condition need 
to be easy to understand and intuitive to interpret, must correlate with the target scale as basis for 
confidence that they measure the target construct (Guyatt et al. 2002). The HDSS change score 
(HDSS-cs) had a correlation of - 0.244 (p = 0.021) with the HidroQoL change score (HidroQoL-
cs) (Table 9.6). The PGA, on the other hand, had a correlation of 0.132 (p = 0.217).The two 
anchors, the HDSS-cs and the PGA had a correlation of - 0.166 (p = 0.12) with each other. Further 
evaluation of the anchor measures, HDSS change score and the PGA involved cross-tabulation of 
patients under the two measures. 
Seventy-five percent of the patients (n = 48) with HDSS-cs of 0 also rated themselves as not 
experiencing any change in their condition (PGA = 3) (Table 9.7) Eighty percent of patients 
reporting a slight improvement (n = 8), PGA = 4, had not registered any change on their HDSS-
cs. On the other hand, eighty-four percent of patients with a small improvement in their condition 
i.e. HDSS-cs = -1, reported no change (PGA = 3). The observed lack of agreement between 
changes in patients’ disease severity (HDSS-cs) and how patients perceived their condition (PGA) 
suggests that changes in perceived overall impact are unique from changes in disease severity.
Responsiveness of the HidroQoL
Patients were grouped according to the change in the HidroQoL between the two assessments, as 
follows: based on HDSS change score and the PGA score. Three groups were formed, patients not-
experiencing any change (HDSS-change-score = 0; PGA = 3), patients minimally deteriorating 
(HDSS-change-score = 1; PGA = 2) and minimally improving (HDSS-change-score = -1; PGA = 
3). The groups with major improvement (PGA = 5) and major deterioration were not considered.
Assessment of change in the HidroQoL Scores in patient groups
A paired t-test was carried out to assess the HidroQoL’s sensitivity to change in each of the three 
patient groups: no-change, minimally worsened and minimally improved. First, the test was 
performed on the pooled sample, with the patients grouped based on the PGA. 
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Table 9.7: A comparison of the PGA against the HDSS change score in their comparison of 
patients.
HDSS change score
Total
-1 0 1
PGA
1 0 1 1 2
2 1 6 2 9
3 16 48 3 67
4 2 8 0 10
5 0 1 0 1
Total 19 64 6 89
Note: 
For HDSS change score, -1 is minimally improved, 0 is no-change, 1 is minimally worsened. For 
the PGA, 5 is sizeably improved, 4 is minimally improved, 3 is no-change, 2 is the minimally 
worsened and 1 is sizeably worsened.
The HidroQoL’s - psychosocial domain (H-DA) score (p < 0.05) and the overall HidroQoL score 
(p < 0.05) significantly increased in the ‘slight-improvement’ group (Table 9.8). HidroQoL score 
changes in the ‘slightly deteriorating’ group were not statistically significant. Surprisingly, the ‘no-
change’ group also showed a significant change in the domain as well as overall scores. 
Similar analysis were carried out with patients grouped according to their HDSS change scores. 
Patients in the minimally improving group showed significant change in their HidroQoL-PS 
domain score (p < 0.01) and the total HidroQoL score (p < 0.01). The HidroQoL-DA domain score 
showed no significant changes in this group (p = 0.08). On the other hand, patients in the minimally 
worsening group did not change in a significant way (p > 0.05) in their total and domain HidroQoL 
scores. The magnitude of the mean change scores between the ‘minimally improved’ and the 
‘minimally deteriorating’ were comparable (mean score change, 3.1±3.85 and -3±5.25 
respectively) indicating some asymmetry. However, the ‘no-change’ group still showed 
unexpected change. 
Relative efficiency of the HidroQoL at detecting change
Further, the HidroQoL’s ability to detect change in the different patient groups was compared to 
that of the Skindex-17 and the DLQI using the relative efficiency index (REI).
Where patients were grouped based on the PGA, the REI for HidroQoL - DLQI in the minimally 
improved group was below 1, for the total HidroQoL score as well as for the two domains 
(HidroQoL-DA and HidroQoL-PS) (Table 9.9). The DLQI was more efficient at detecting change
than the HidroQoL.
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In contrast the HidroQoL seemed more efficient than the Skindex-17 in this patient group, REI > 
2 for the HidroQoL total score as well as the domain scores. On the other hand, when patients were 
grouped based on HDSS-change-scores, the HidroQoL scale was more efficient than both the 
Skindex-17 and the DLQI in the minimally improved patient-group. Only the HidroQoL-DA 
domain score performed less efficiently than Skindex-17 (REI = 0.8), the total score and the 
HidroQoL-PS had REI greater than 1.2 with Skindex. These results were mirrored in the group 
worsening.
Table 9.8: Sensitivity of the HidroQoL scores in patients experiencing ‘no change’, ‘slight 
improvement’ and ‘slight deterioration’ based on paired t-test, in the pooled sample
Anchor Patient-group Score Mean SD SE
mean
95% CI t df p-
value
Lower Upper
PGA No change (n=67) HidroQoL-DA 0.63 2.33 0.29 0.06 1.2 2.2 66 0.03
HidroQoL-PS 0.97 2.93 0.36 0.25 1.69 2.71 66 0.01
HidroQoL 1.6 4.5 0.55 0.5 2.69 2.91 66 0
Minimally worsened 
(n= 9)
HIdroQoL-DA -0.44 1.88 0.63 -1.89 1 -0.71 8 0.5
HidroQoL-PS 1.33 3.61 1.2 -1.44 4.1 1.11 8 0.3
HidroQoL 0.89 4.94 1.65 -2.91 4.68 0.54 8 0.6
Minimally improved 
(n=10)
HIdroQoL-DA 1.5 2.46 0.78 -0.26 3.26 1.93 9 0.09
HidroQoL-PS 1.3 1.77 0.56 0.04 2.56 2.33 9 0.05
HidroQoL 2.8 3.85 1.22 0.04 5.56 2.3 9 0.05
HDSS No-change (n = 64) HidroQOL-DA 0.64 2.24 0.28 0.08 1.2 2.29 63 0.03
HidroQoL-PS 0.94 2.96 0.37 0.2 1.68 2.53 63 0.01
HidroQoL 1.58 4.49 0.56 0.46 2.7 2.82 63 0.01
Minimally worsened 
(n = 6)
HidroQOL-DA -1.5 1.64 0.67 -3.22 0.22 -2.24 5 0.08
HidroQoL-PS -1.5 3.83 1.57 -5.52 2.52 -0.96 5 0.38
HidroQoL -3 5.25 2.14 -2.51 8.51 1.4 5 0.22
Minimally improved 
(n = 20)
HidroQOL-DA 1.05 2.44 0.55 -0.09 2.19 1.93 19 0.07
HidroQoL-PS 2.05 2.48 0.55 0.89 3.21 3.7 19 0
HidroQoL 3.1 3.85 0.86 1.3 4.9 3.6 19 0
Note: HidroQoL-DA is HidroQoL daily activities domain, HidroQoL-PS is HidroQoL psychosocial impact domain
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Table 9.9: A comparison of the HidroQoL’s ability to detect change with that of the DLQI 
and Skindex in the pooled sample
Patient-group PGA HDSS-change-score
H-total H-DA H-PS H-total H-DA H-PS
DLQI Minimally improved 0.8 0.7 0.8 2.3 1.2 2.3
Minimally worsened -0.5 0.7 -1.0 5.4 8.6 3.7
Skindex-17 Minimally improved 2.5 2.1 2.6 1.4 0.8 1.5
Minimally worsened 1.9 -2.5 3.8 2.7 4.4 1.9
Note: H-total, HidroQoL total Score; H-DA, HidroQoL impact on daily life activities domain score; 
H-PS, HidroQoL psychosocial impact domain; 
Magnitude of change HRQoL using standard response mean and effect size
In order to estimate the magnitude of change from baseline (assessment 1) to follow-up 
(assessment 2) standard response mean (SRM) and effect size (ES) coefficients were calculated. 
Where the PGA was used as an anchor, minimally improving patients showed a small to moderate 
effect size on the total HidroQoL score (ES = 0.37) (Table 9.10). Patients in the ‘no change’ group 
had a small effect size on the total HidroQoL score (ES = 0.22). A comparable pattern was observed 
with regard to the SRM, although these figures tended to be higher. Similar analyses were carried 
out based on HDSS anchored patient groups. The HidroQoL showed a moderate effect size (ES = 
0.47) in the minimally improving group. The DLQI and the Skindex, on the other hand, had small 
effect sizes (DLQI, ES = 0.21; Skindex, ES = 0.25). Although for the HidroQoL the ES for the 
slightly improving group remains largely the same regardless of the choice of anchor, the change 
in ES for the DLQI and Skindex-17 seems dramatic.
Testing for the HidroQoL’s responsiveness: USA sample 
Responsiveness of the HidroQoL was also assessed in the USA and the UK samples separately. 
The minimally improving group, showed non-significant difference in the two HidroQoL domains 
scores as well as the overall scale score scores (Table 9.11). The ‘no change’ group on the other 
hand showed significant differences between the baseline and the follow-up assessment. 
Nonetheless, the mean HidroQoL overall score change was greater in the minimally improving 
group (2.63± 4.14) than in the no change group (1.83±5.05). 
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Similar analyses were carried out using the HDSS change score as an anchor. The minimally 
improving group showed a significant difference in the HidroQoL overall score and the 
psychosocial domain score but not in the daily life activities domain score. On the other hand, the 
no-change group showed significant differences in the HidroQoL total score and in the daily 
activities domain score but not in the psychosocial score.
Comparing sensitivity to change among measures (DLQI, Skindex, HidroQoL).
The responsiveness of the HidroQoL was compared with that in other measure, the Skindex-17 
and the DLQI using the relative efficiency index in patients from the USA sample. The DLQI was 
more efficient at detecting changes (REI < 1) where the minimally improving group was based on 
the PGA (Table 9.12). The HidroQoL showed greater efficiency at detecting change in patients, 
when the HDSS change score was used as an anchor. REI was greater than two for the overall 
scale and psychosocial domain score, except for the daily activities domain. These results are 
highly comparable to results obtained from the pooled sample.
Magnitude of change in HRQoL using standard response mean and effect size
The magnitude of change from baseline (assessment 1) to follow-up (assessment 2) was also 
analysed at the subgroup level for the USA. It was not possible to carryout similar analysis on the 
UK sample due to the size of the sample.
According to the PGA anchor, the group experiencing minimal improvement had a small-to-
moderate effect size (ES) for the HidroQoL score (ES: HidroQoL total score, 0.33, daily life 
activities domain, 0.61 and psychosocial domain, 0.2) (Table 9.13). This is only slightly smaller 
than the observed figure for the pooled sample. ES in the no change group was similar (ES = 0.3). 
This is consistent with the observation on the paired t-test where the no-change group showed 
highly significant differences. Standard Response Mean was also slightly smaller than figures 
observed in the pooled sample (SRM: HidroQoL total, 0.63, daily life activities domain, 0.54, 
Psychosocial domain, 0.69). Where the HDSS was used as the anchor, the ES in the minimally 
improving group was higher than in the pooled sample (ES: HidroQoL overall score, 0.52, H-DA 
score, 0.44, H-PS score, 0.47). 
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Table 9.10: Estimating the responsiveness of the HidroQoL based on standardised response mean and effect size with patient groups
(pooled sample)
Anchor Patient group Scores Test 1 Test2 Test 1 - Test 2 SRM ES
Mean SD Mean SD Mean SD Est. 95% CI Est. 95% CI
Lower Upper Lower Upper
PGA No change HidroQoL-DA 8.87 2.95 8.24 3.21 0.63 2.33 0.27 0.02 0.51 0.21 0.02 0.41
HidroQoL-PS 17.84 4.85 16.87 5.28 0.97 2.93 0.33 0.09 0.57 0.2 0.05 0.35
HidroQoL 26.7 7.34 25.1 8.13 1.6 4.5 0.36 0.11 0.6 0.22 0.07 0.37
Minimally worsening HidroQoL_DA 8 2.24 8.44 3.28 -0.44 1.88 -0.24 -1.01 0.53 -0.2 -0.84 0.45
HidroQoL-PS 16.22 3.77 14.89 6.47 1.33 3.61 0.37 -0.4 1.14 0.35 -0.38 1.09
HidroQoL 24.22 5.47 23.33 9.62 0.89 4.94 0.18 -0.59 0.95 0.16 -0.53 0.86
Minimally improving HidroQoL-DA 9.9 2.38 8.4 3.84 1.5 2.46 0.61 -0.11 1.32 0.63 -0.11 1.37
HidroQoL-PS 17.3 5.48 16 6.15 1.3 1.77 0.74 0.02 1.45 0.24 0.01 0.47
HidroQoL 27.2 7.57 24.4 9.89 2.8 3.85 0.73 0.01 1.44 0.37 0.01 0.73
HDSS No change HidroQoL-DA 8.91 2.87 8.27 3.15 0.64 2.24 0.29 0.04 0.54 0.22 0.03 0.42
HidroQoL-PS 17.52 5.08 16.58 5.64 0.94 2.96 0.32 0.07 0.57 0.18 0.04 0.33
HidroQoL 26.42 7.52 24.84 8.49 1.58 4.49 0.35 0.1 0.6 0.21 0.06 0.36
Minimally worsening HidroQoL-DA 9.67 1.86 11.17 1.6 -1.5 1.64 -0.91 -1.96 0.14 -0.81 -1.73 0.12
HidroQoL-PS 18 3.63 19.5 3.73 -1.5 3.83 -0.39 -1.44 0.66 -0.41 -1.52 0.69
HidroQoL 27.67 4.97 30.67 5.13 -3 5.25 -0.57 -1.62 0.48 -0.6 -1.71 0.51
Minimally improving  HidroQoL-DA 8.75 2.9 7.7 3.47 1.05 2.44 0.43 -0.04 0.9 0.36 -0.03 0.76
HidroQoL-PS 17.9 4.24 15.85 5.54 2.05 2.48 0.83 0.36 1.29 0.48 0.21 0.76
HidroQoL 26.65 6.58 23.55 8.66 3.1 3.85 0.8 0.34 1.27 0.47 0.2 0.75
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Table 9.11: Sensitivity of the HidroQoL scores (USA sample)
Anchor Patient-group Instrument Mean SD SE
mean
95% CI t df p
Lower Upper
PGA Minimally 
improving ( n = 8)
HidroQoL 2.63 4.14 1.46 -0.84 6.09 1.79 7 0.12
H-DA 1.5 2.78 0.98 -0.82 3.82 1.53 7 0.17
H-PS 1.13 1.64 0.58 -0.25 2.5 1.94 7 0.09
No-change (N = 41) HidroQoL 1.83 5.05 0.79 0.23 3.43 2.32 40 0.03
H-DA 0.71 2.18 0.34 0.02 1.4 2.08 40 0.04
H-PS 1.12 3.46 0.54 0.03 2.21 2.08 40 0.04
HDSS Minimally 
improving (n = 13)
HidroQoL 3.08 4.01 1.11 0.65 5.5 2.77 12 0.02
HidroQoL-DA 1.08 2.56 0.71 -0.47 2.63 1.51 12 0.16
HidroQoL-PS 2 2.45 0.68 0.52 3.48 2.94 12 0.01
No-change (n = 39) HidroQoL 1.8 5.04 0.81 0.16 3.43 2.22 38 0.03
HidroQoL-DA 0.72 2.14 0.34 0.02 1.41 2.1 38 0.04
HidroQoL-PS 1.08 3.5 0.56 -0.06 2.21 1.92 38 0.06
Note: The minimally worsening group was excluded from analysis due to the small sample size
Table 9.12: Relative efficiency Index of HidroQoL with DLQI and Skindex-17 in detecting 
change in the minimally improving group.
Patient-
group
PGA HDSS-change-score
HidroQoL HidroQoL-
DA
HidroQoL-
PS
HidroQoL HidroQoL-
DA
HidroQoL-
PS
DLQI 0.77 0.66 0.83 4.62 2.52 4.9
Skindex-17 2.89 2.47 3.13 2.10 1.14 2.23
The ability of the HidroQoL to discriminate patients experiencing different levels of change
The HidroQoL’s ability to discriminate across groups of patients differing in various characteristics 
such as level of disease severity, amount of daily time spent in managing the condition,  has been 
previously demonstrated (See Chapter 7). In longitudinal HRQoL measurement, it is important for 
an instrument to be capable of discriminating between patients experiencing different levels of 
change over time (Stratford and Riddle 2005). A oneway ANOVA test of the change scores across 
patient groups showed non-significant differences in the overall score as well as domain scores of 
the HidroQoL (overall score, p = .63; H-PS, p = 0.9; H-DA, p = 0.192) (Table 9.14).
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Table 9.13: Estimating the responsiveness of the HidroQoL based on standardised response mean and effect size (USA sample)
Anchor Patient group Scores Test 1 Test2 Test 1 - Test 2 SRM ES
Mean SD Mean SD Mean SD Est. 95% CI Est. 95% CI
Lower Upper Lower Upper
PGA No change (n = 41) HidroQoL 27.59 6.00 25.76 7.82 1.83 5.05 0.36 0.05 0.68 0.30 0.04 0.57
HidroQoL-DA 9.17 2.54 8.46 3.13 .707 2.18 0.32 0.01 0.64 0.28 0.01 0.55
HidroQoL-PS 18.41 4.14 17.29 5.02 1.12 3.46 0.32 0.01 0.64 0.27 0.01 0.53
Minimally improving (n = 8) HidroQoL 26.75 7.89 24.13 10.23 2.63 4.14 0.63 -0.20 1.47 0.33 -0.11 0.77
HidroQoL-DA 9.88 2.48 8.38 4.14 1.50 2.78 0.54 -0.3 1.38 0.61 -0.33 1.54
HidroQoL-PS 16.88 5.74 15.75 6.16 1.13 1.64 0.69 -0.15 1.52 0.20 -0.04 0.43
HDSS No change (n = 39) HidroQoL 27.36 6.45 25.56 8.24 1.795 5.04 0.36 0.03 0.68 0.28 0.02 0.53
HidroQoL-DA 9.31 2.61 8.59 3.17 .718 2.14 0.34 0.01 0.66 0.28 0.01 0.54
HidroQoL-PS 18.05 4.46 16.97 5.37 1.08 3.5 0.31 -0.02 0.63 0.24 -0.01 0.50
Minimally improving
(n = 13)
HidroQoL 26.15 5.93 23.08 8.26 3.08 4.01 0.77 0.16 1.37 0.52 0.11 0.93
HidroQoL-DA 8.54 2.47 7.46 3.38 1.08 2.57 0.42 -0.18 1.02 0.44 -0.19 1.06
HidroQoL-PS 17.62 4.29 15.62 5.21 2.00 2.45 0.82 0.21 1.42 0.47 0.12 0.81
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Similar analyses were carried out utilising the HDSS change score (HDSS-cs) as an anchor. 
Significant differences were obtained on the overall score and the psychosocial domain score 
(overall HidroQoL score, p = 0.026; psychosocial domain score, p = 0.035; impact on daily
activities, p = 0.05) showed non-significant differences. 
Analyses were also carried out for the USA and the UK samples, separately. In both samples, there 
were no statistically significant differences in the HidroQoL change scores among patients who 
were minimally improving, minimally worsening and experiencing no change, based on the two
anchors, PGA and HDSS-cs. 
The relationship between change scores from the HidroQoL, the DLQI and the Skindex
The ability of the HidroQoL to assess valid change i.e. longitudinal validity was assessed using 
Spearman’s rank sum correlation. The HidroQoL change score showed a correlation of 0.254 with 
the HDSS change score, 0.263 with the DLQI change score and 0.203 with the Skindex-17 (Table 
9.15). Correlations varied across the samples (UK, USA and pooled samples). The correlation of 
HidroQoL scores with the DLQI and the HDSS was highest in the USA sample, while that with 
the Skindex-17 was the highest in the pooled group. The correlations involving the HidroQoL total 
scores was higher than that involving the domains. On the other hand, the daily life activities 
domain showed lower correlation than the psychosocial domain or the total, for all instruments.
Part II: Development of A Banding System Using An Anchor-Based Approach 
The analyses reported in this section to establish the scale banding for the HidroQoL used the 
sample from the reliability study reported in Chapter 7. A total of 260 participants completed the 
HidroQoL and the global question (GQ) on overall impact of hyperhidrosis on patient’s life. One 
hundred and forty two patients (54.6%) were from the USA and seventy three (28.1%) were from 
the UK. A detailed description of the socio-demographic characteristics of this patient population 
are described in Chapter 7. 
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Table 9.14: Comparison of amount of change in patients between those with ‘slight 
deterioration’, ‘no-change’ and patients with ‘slight improvement’: Pooled sample
Anchor
Sum of 
Squares df
Mean
Square F Sig.
PGA HidroQoL Between Groups 18.61 2 9.306 .465 .630
Within Groups 1662.61 83 20.031
Total 1681.22 85
HidroQoL-DA Between Groups 17.94 2 8.972 1.683 .192
Within Groups 442.39 83 5.330
Total 460.34 85
HidroQoL-PS Between Groups 1.77 2 .887 .105 .900
Within Groups 700.04 83 8.434
Total 701.81 85
HDSS HidroQoL Between Groups 171.98 2 85.99 4.433 0.015
Within Groups 1687.41 87 19.396
Total 1859.39 89
HidroQoL-DA Between Groups 30.60 2 15.302 3.004 .055
Within Groups 443.18 87 5.094
Total 473.79 89
HidroQoL-PS Between Groups 59.76 2 29.878 3.493 .035
Within Groups 744.20 87 8.554
Total 803.96 89
Table 9.15: Correlation of the HidroQoL score with the HDSS, DLQI and Skindex-17
Sample a b c d e f
DLQIcs (a) Pooled 1
US 1
UK 1
HDSScs (b) Pooled .133 1
US .144 1
UK .227 1
HidroQoL-DA ( c ) Pooled .198 .205 1
US .273* .211 1
UK .003 .065 1
HidroQoL-PS ( d ) Pooled .249* .230* .478** 1
US .214 .281* .561** 1
UK .371 -.030 .308 1
HidroQoL ( e ) Pooled .263* .254* .821** .894** 1
US .267 .285* .829** .928** 1
UK .174 .035 .898** .696** 1
Skindex ( f ) Pooled .522** .192 .228* .133 .203 1
US .479** .256 .272* .073 .172 1
UK .579* .069 -.028 .276 .106 1
Note: **. Correlation is significant at the 0.01 level (2-tailed); *. Correlation is significant at the 0.05 level 
(2-tailed); Pooled, N = 89; US, N = 54; UK, N = 17
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Distribution of the scale scores (HidroQoL, HDSS and GQ)
In the pooled sample, forty six percent of the patients (n = 120) had an HDSS score of 3, indicating 
that their sweating was barely tolerable and frequently interfered with their daily activities (Figure 
9.1). Forty-one percent of the patients (n = 106) had a GQ score of 3, indicating that the largest 
number of patients were experiencing a large effect on their lives (Figure 9.2). The mean HidroQoL 
total score was 27 (±6.8) with a range of 1 to 36 in the pooled sample (Table 9.16). The 5-95th
percentile shows that most patients had scores in the upper half of the scale range, indicating a 
positively skewed score distribution (Figure 9.3, Figure 9.4).  This is reflected in the mode score 
of 31, suggesting high QoL impairment.  Four percent of pooled sample (n =  11) achieved 
maximum score while the minimum score was achieved by none. This indicates that there were no 
ceiling or floor effects associated with the scale. The distribution of the HidroQoL scores in this 
sample shows a skew to the left. Kurtosis reflects a slightly tighter curve with steeper tails
reflecting minor departure from that of a perfect bell-shape as would be expected for a normal 
distribution. This was only of particular concern for the UK patient population (Kurtosis = 1.53).  
Figure 9.1: Distribution of the Hyperhidrosis Disease Severity Score (HDSS)
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Figure 9.2: Distribution of GQ Score
Table 9.16: Distribution of the HidroQoL scores
Sample
USA UK Pooled
N 142 73 260
Mean 27 26 27
Std. Deviation 6.76 6.98 6.76
Std. Error of Mean .57 .82 .42
Range 2_36 1_36 1_36
Median 29 28 29
Mode 31 29 30
IQR 23 - 32 22 - 32 22 - 32
05-95% 15 - 35 16-36 15 - 35
Skewness Stat. -1.08 -1.00 -0.95
Skewness SE 0.2 0.3 0.2
Kurtosis Stat. 1.09 1.53 0.88
Kurtosis SE 0.40 0.56 0.30
Ceiling, N (%) 5 (3.5%) 5 (6.8%) 11 (4.2%)
Floor, N (%) - - -
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Scale banding for the HidroQoL
Ultimately, an understanding as to what a certain score represents to the patient or clinician, is 
essential for the application of HRQoL measures in clinical decision-making (Terwee et al. 2007). 
Figure 9.3: Distribution of the HidroQoL total scores using box and whisker plot (USA, N = 
142; UK, N = 73)
Figure 9.4: Distribution of the HidroQoL total score using a Histogram (pooled sample, N = 
260)
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Not only does such information enhance the practicality of the instrument, especially in routine 
clinical practice, but the process of establishing interpretability offers an opportunity for further 
insight into how the measure and its scores relates to other key measures of disease impact. Thus
a categorisation of the HidroQoL scores into bands, related to levels of overall impact experienced 
by patients was explored. A simple mapping of HRQoL scores to the GQ scores was carried out. 
The frequency, mean, mode and median GQ score was calculated, for each HidroQoL score. Based 
on the integer-value of the mean GQ score, each HidroQoL was classified under one GQ score.
HidroQoL-score ranges related to each of the five GQ scores were identified, providing the scale-
banding cut-offs. Each HidroQoL score was classified into a single band, corresponding to a level 
of overall HRQoL impact from Hyperhidrosis: ‘no effect at all’ (GQ = 0), ‘a small effect’ (GQ = 
1), ‘moderate effect’ (GQ = 2), ‘large effect’ (GQ = 3), ‘extremely large effect’ (GQ = 4). Each 
band corresponded to a single GQ score (Aawar, 2011). Although previous chapters demonstrated
the invariance of the factorial structure (Chapter 5) and item calibration (Chapter 6) of the 
HidroQoL across countries (UK and USA), separate banding systems were explored for the UK 
and the USA.
HidroQoL Scale banding for the USA sample
The HidroQoL scores of patients from the USA are presented in Table 9.17 and Figure 9.5. For 
each score, the distribution of GQ scores is presented including, the mean; its integer-value 
(mean2); median; and mode. A simple sorting of the HidroQoL score - GQ score table according 
to the GQ score (integer-value of the mean), allowed the identification of score ranges associated 
with each GQ score. This provided score bands representing different levels of overall impact of 
disease on patients’ life. A number of HidroQoL scores might have been classified in either of 
adjacent bands, reflecting the discrepancy between mode, mean and median GQ score. For 
example, scores 15 and 19 could have been included in band one or band two, scores 20 and 22 
could have been classified under band two or band three. Similarly scores 30, 31 and 33 could 
have been included in band three or band four. This means that a number of alternative bands were 
feasible (Table 9.18). The level of agreement between the banding (representing predicted level of 
overall impact based on patient’s score) and the GQ score (actual level of impairment) was 
estimated for each set using ICC. In addition, the accuracy of the banding in classifying patients 
across their GQ scores (actual level of overall impact) was considered. The highest ICC (0.726) 
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was seen on the banding 0 to 1, 2 to 11, 12 to 22, 23 to 32, 33 to 36 (set 2 in Table 9.18). This 
banding also provided the most accurate classification of patients across GQ scores (level of 
overall impact of condition) 
Table 9.17: Frequency, mean, mode and median of GQ scores for each HidroQoL score 
(USA Sample).
HidroQoL
Number of patients GQ Scores
Patient-totalGQ =0 GQ =1 GQ =2 GQ =3 GQ =4 mean mean2 median mode
0 NA NA NA NA
1 NA NA NA NA
2 1 1 1 1 1 1
3 NA NA NA NA
4 NA NA NA NA
5 NA NA NA NA
6 1 1 1 1 1 1
7 1 2 2 2 2 1
8 NA NA NA NA
9 NA NA NA NA
10 NA NA NA NA
11 NA NA NA NA
12 1 2 2 2 2 1
13 NA NA NA NA
14 2 2 2 2 2 2
15 2 1 1 1.75 2 1.5 1 4
16 1 2.00 2 2 2 1
17 1 2 1 2.00 2 2 2 4
18 1 2.00 2 2 2 1
19 1 1 1 2.00 2 2 1,2,3 3
20 2 2 2.50 3 2.5 2,3 4
21 4 2 2.33 2 2 2 6
22 3 3 2.50 3 2.5 2,3 6
23 2 3 2.60 3 3 3 5
24 1 2 2.33 2 3 3 3
25 1 1 3.50 4 3.5 3,4 2
26 2 5 1 2.88 3 3 3 8
27 1 2 2 3 2.88 3 3 4 8
28 1 5 1 3.00 3 3 3 7
29 1 4 3 3.25 3 3 3 8
30 3 2 4 3.11 3 3 4 9
31 3 4 5 3.17 3 3 4 12
32 2 8 2 3.00 3 3 3 12
33 1 4 5 3.30 3 3.5 4 10
34 2 2 7 3.45 3 4 4 11
35 1 6 3.86 4 4 4 7
36 5 4.00 4 4 4 5
Patient-total 0 9 37 53 43 142
Notes: NA, not applicable, no patient with that reported score 
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Figure 9.5: Relationship between the HidroQoL score and the mean, median and mode of the GQ score for USA patients
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Table 9.18: Alternative HidroQoL score banding for the USA sample
Set Range of HidroQoL scores ICC
Band 0 Band 1 Band 2 Band 3 Band 4
1 0 to 1 2 to 6 7 to 24 25 to 34 35 to 36 0.712
2 0 to 1 2 to 11 12 to 22 23 to 32 33 to 36 0.726
3 0 to 1 2 to 6 7 to 22 23 to 29 30 to 36 0.687
4 0 to 1 2 to 11 12 to 22 23 to 29 30 to 36 0.689
5 0 to 1 2 to 6 7 to 21 22 to 33 34 to 36 0.718
6 0 to 1 2 to 6 7 to 21 22 to 32 33 to 36 0.715
7 0 to 1 2 to 10 11 to 20 21 to 30 31 to 36 0.669
HidroQoL Scale banding for the UK sample
Similar analysis were carried out on the U.K. sample. For each score of the HidroQoL, from 0 to 
36, the number of patients with each score and the distribution of their GQ scores (mean, median, 
mode) was calculated (Table 9.19, Figure 9.6). A number of HidroQoL scores could have 
potentially fitted in either of adjacent bands. For example, score 15 could have fitted band one, 
two or three; score 23 could have fitted band two, three or four; score 31 could have fitted band 
three or four; score 33 could have been in band two or three. This entails multiple ways of 
categorising the scores into bands of varying overall life impact (Table 9.20). For each possible 
banding, the level of agreement with actual overall life impact (GQ score) was estimated. The level 
of agreement ranged from 0.652 to 0.726. Further, the accuracy of each alternative banding in 
classifying patients to their actual level of overall impact was also analysed. The banding 0 to 1, 2 
to 10, 11 to 23, 24 to 33, 34 to 36 (0.726) (set 3) had the highest level of agreement with actual 
level of overall life impact experienced by patient. This banding also offered the best accuracy in 
classifying patients. This, therefore, was the recommended categorisation of the HidroQoL scores 
in patients from the UK
Universal banding system for the HidroQoL
Considering the intended universal use of the HidroQoL across multiple countries, a scale banding 
system that would apply across different cultures would be advantageous in a number of ways in 
supporting international clinical trials; and would facilitate comparison of results across countries. 
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The first step in exploring a universal banding scale was to assess the level of agreement between 
the two banding systems, calibrated on the UK and USA samples, respectively.
Table 9.19: Frequency, mean, mode and median of GQ scores for each HidroQoL score
(UK patients)
H-
Score
Number of patients GQ Scores Patient-
totalGQ = 0 GQ = 1 GQ = 2 GQ =3 GQ = 4 mean Mean2 median mode
1 1 0 0 0 0 1
2 NA NA NA NA
3 NA NA NA NA
4 NA NA NA NA
5 NA NA NA NA
6 NA NA NA NA
7 NA NA NA NA
8 1 1 1 1 1 1
9 NA NA NA NA
10 NA NA NA NA
11 1 2 2 2 2 1
12 NA NA NA NA
13 NA NA NA NA
14 NA NA NA NA
15 NA NA NA NA
16 1 1 1 2 2 2 1,2,3 3
17 2 2 2 2 2 2
18 NA NA NA NA
19 1 3 3 3 3 1
20 1 1 2 1 2.20 2 3 3 5
21 1 1.00 1 1 1 1
22 3 2 2.40 2 2 2 5
23 1 1 1 3.00 3 3 2,3,4 3
24 2 3 2.60 3 3 3 5
25 1 1 2 2.25 2 2.5 3 4
26 1 3.00 3 3 3 1
27 1 3.00 3 3 3 1
28 3 2 3.40 3 3 3 5
29 1 3 2 3.17 3 3 3 6
30 1 2 1 3.00 3 3 3 4
31 1 2 2 3.20 3 3 3,4 5
32 1 4 1 3.00 3 3 3 6
33 2 2 2.50 3 2.5 2,3 4
34 NA NA NA NA
35 1 3 3.75 4 4 4 4
36 2 3 3.60 4 4 4 5
Patient-
total
2 5 17 33 16 73
Notes: H-Score, HidroQoL score; mean2, integer-value of the mean for GQ score
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Figure 9.6: Relationship between the HidroQoL score and the mean, median and mode of the GQ score for UK patients
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Table 9.20: Alternative HidroQoL score banding based on the UK sample
Set Range of HidroQoL scores ICC
Band 0 Band 1 Band 2 Band 3 Band 4
1 0 to 1 2 to 10 11 to 22 23 to 30 31 to 36 0.692
2 0 to 1 2 to 16 17 to 23 24 to 32 33 to 36 0.691
3 0 to 1 2 to 10 11 to 23 24 to 33 34 to 36 0.726
4 0 to 1 2 to 11 12 to 22 23 to 32 33 to 36 0.704
5 0 to 1 2 to 10 11 to 18 19 to 34 35 to 36 0.670
6 0 to 1 2 to 10 11 to 20 21 to 30 31 to 36 0.652
A near perfect agreement was observed between set 2 (US calibrated) and set 3 (UK calibrated) in 
both the US sample (ICC = 0.947) and the UK sample (ICC = 0.951). This justified the 
development of a universal banding system for the HidroQoL, for potential application in the UK, 
the USA and beyond. Following the approach used in the UK/USA banding systems, for each 
HidroQoL score, from 0 to 36, the corresponding number of patients and the distribution of GQ 
scores (mean, median and mode) were estimated (Table 9.21, Figure 9.7). A simple sorting of the 
HidroQoL score – GQ score table based on the GQ score, was applied to identify the ranges of the 
HidroQoL score corresponding to each level of overall impact. This provided the banding of the 
HidroQoL scores, with each score allocated into a single band. There were a few HidroQoL scores 
where adjacent bands were equally appropriate. For example HidroQoL scores 16, 19 and 20 could 
have been included in band 2 or band 3. HidroQoL scores 27, 31 and 34 could have been 
appropriately classified under band three or band four. Thus, there was more than one possible 
banding-system (Table 9.22). For each banding system the agreement between bands (reflecting a 
prediction of patients level of impact based on patients score) and patients’ GQ scores 
(representing actual level overall impact) was estimated using ICC. This ranged from 0.633 (set 
7) to 0.712 (set 2). Further consideration was made of the accuracy with which the bands classified 
patients into their actual level of overall QoL impairment (GQ score). These analyses are presented 
in the next section. The banding system 0 – 1, 2-10, 11-22, 23-32, 33-36 (ICC = 0.679) provided 
the most accurate classification of patient to their true level of overall impact, and was therefore 
the recommended banding.
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Table 9.21: Frequency, mean, mode and median of GQ scores for each HidroQoL score 
(pooled sample)
H-
score
Number of patients GQ score Patient
-TotalGQ=0 GQ=1 GQ=2 GQ=3 GQ =4 mean mean2 median mode
0 NA NA NA NA
1 1 0 0 0 0 1
2 1 1 1 1 1 1
3 NA NA NA NA
4 NA NA NA NA
5 NA NA NA NA
6 1 1 1 1 1 1
7 1 2 2 2 2 1
8 1 1 1 1 1 1
9 NA NA NA NA
10 NA NA NA NA
11 1 2 2 2 2 1
12 1 2 2 2 2 1
13 NA NA NA NA
14 3 2 2 2 2 3
15 3 1 1 1.60 2 1 1 5
16 1 2 2 2.20 2 2 2,3 5
17 1 4 3 2.25 2 2 2,3 8
18 3 2.00 2 2 2 3
19 1 1 2 2.25 2 2.5 3 4
20 1 1 5 4 1 2.25 2 2 2,3 12
21 1 5 2 2.13 2 2 2 8
22 1 6 5 1 2.46 2 2 2 13
23 4 5 1 2.70 3 3 3 10
24 1 3 5 2.44 2 3 3 9
25 1 1 3 1 2.67 3 3 3 6
26 2 6 2 3.00 3 3 3 10
27 1 2 4 4 3.00 3 3 3,4 11
28 2 10 4 3.13 3 3 3 16
29 2 8 5 3.20 3 3 3 15
30 4 9 6 3.11 3 3 3 19
31 4 7 8 3.21 3 3 4 19
32 3 13 3 3.00 3 3 3 19
33 2 2 6 5 2.93 3 3 3 15
34 1 3 5 8 3.18 3 3 4 17
35 4 11 3.73 4 4 4 15
36 2 9 3.82 4 4 4 11
Patient-
Total
2 18 65 106 69 260
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Figure 9.7: Relationship between the HidroQoL score and the mean, median and mode of the GQ score for pooled sample
0
0,5
1
1,5
2
2,5
3
3,5
4
4,5
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
HidroQoL Score
mean
median
mode
Banding
353
Table 9.22: Alternative HidroQoL score banding based on the pooled sample
Range of HidroQoL scores ICC
Set Band 0 Band 1 Band 2 Band 3 Band 4
1 0 to 1 2 to 8 9 to 22 23 to 30 31 to 36 0.666
2 0 to 1 2 to 15 16 to 22 23 to 33 34 to 36 0.712
3 0 to 1 2 to 16 17 to 23 24 to 31 30 to 36 0.677
4 0 to 1 2 to 10 11 to 22 23 to 32 33 to 36 0.679
5 0 to 1 2 to 6 7 to 25 26 to 33 34 to 36 0.699
6 0 to 1 2 to 10 11 to 22 23 to 34 35 to 36 0.700
7 0 to 1 2 to 10 11 to 20 21 to 30 31 to 36 0.633
Assessing accuracy of banding system (pooled sample)
The accuracy of the various banding systems for the pooled sample (presented in Table 9.22) was 
assessed using the cross-tabulation of each banding (score predicted level of overall impact) 
against GQ scores (actual level of overall impact). For accurate classification, the majority of 
patients in each band, must have the corresponding GQ score. On the other hand, for each GQ 
score, the majority of patients must be captured by the corresponding band. This simple notion 
embodies key criteria in optimal identification of test cut-offs, that of maximising sensitivity and 
specificity. For example, situations where the majority/largest group falling in a band are not the 
corresponding GQ score indicate high false positive rate i.e. poor sensitivity. Conversely, situations 
where a band does not ‘capture’ the largest number of patients in a GQ score, reflect a high false 
negative rate, i.e. poor specificity.
GQ-score – banding cross tabulation
The scale banding 0-1, 2-8, 9-22, 23-30, 31-36 (set 1) showed optimal classification of patients 
across the bands (Table 9.23). For each band, patients with the corresponding GQ score were the 
majority. In band 0, GQ = 0 had the highest number of patients. In band 1, GQ = 1 had the highest 
number of patients.
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Table 9.23: Distribution of GQ scores for proposed scale banding (set 1)
GQ Score
Total0 1 2 3 4
Band
0 1 0 0 0 0 1
1 0 3 1 0 0 4
2 1 9 32 19 2 63
3 0 3 20 50 23 96
4 0 3 12 37 44 96
Total 2 18 65 106 69 260
The same applies to bands two, three and four. On the other hand, across the GQ scores, the 
corresponding band had the most patients only for GQ score two, three and four. Overall, this 
banding system classifies a disproportionately high number of patients as experiencing extremely 
high impact (band 4), while allocating a disproportionately smaller than expected number of 
patients into the ‘small effect’ bracket (band 1). 
The distribution of GQ scores across the banding scale 0 to 1, 2 to 15, 16 to 22, 23 to 33, 34 to 36 
(Set 2) is presented in Table 9.24. Bands zero, two, three, four, showed the optimal distribution of 
GQ scores i.e. the respective GQ scores (zero, two, three, four) had the largest number of patients. 
In band one, patients with GQ score two were in majority (n = 7). The distribution of bands within 
each GQ score was as expected only for GQ score three, where most patients were in band three 
(n = 29). This banding system had most patients classified under band three (indicating large 
effect). 
The tabulation of the banding 0-1, 2-16, 17-23, 24-31, 32-36 (set 3), against GQ scores is presented 
in Table 9.25. In bands zero, two, three and four, the associated GQ scores showed the highest 
number of patients. This patterns was disturbed only in band one where GQ score 2 showed the 
highest number of patients. On the other hand, within each GQ score, the corresponding bands had 
the highest number of patients, except for GQ score zero. Bands zero and two had a single patient 
each, in band zero. Overall this offered a balanced distribution of patients across bands comparable 
to distribution of GQ scores.
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Table 9.24: Distribution of GQ scores for proposed scale banding (set 2)
GQ Total
0 1 2 3 4
Band
0 1 0 0 0 0 1
1 0 6 7 1 0 14
2 1 6 26 18 2 53
3 0 5 29 76 39 149
4 0 1 3 11 28 43
Total 2 18 65 106 69 260
Table 9.25: Distribution of GQ scores for proposed scale banding (set 3)
GQ Score Total
0 1 2 3 4
Band
0 1 0 0 0 0 1
1 0 7 9 3 0 19
2 1 5 28 21 3 58
3 0 3 20 52 30 105
4 0 3 8 30 36 77
Total 2 18 65 106 69 260
The relationship between GQ scores and banding system 0 to 1, 2 to 10, 11 to 22, 23 to 32, 33 to 
36 (set 4) is shown in Table 9.26. All bands showed expected pattern i.e. the matching GQ score 
had the highest number of patients. Similarly, an analysis of the spread of bands within each GQ 
score showed expected pattern for GQ scores one, two, three, four. In GQ score 0 band zero and 
band two had a single patient each. This banding system offers a well-balanced and spread of 
patients across the different bands reflecting the spread in patients GQ score.
The distribution of GQ scores across the banding 0 – 1, 2 – 6, 7 – 25, 26 – 33, 34 – 36 (Set 5) is 
presented in Table 9.27. This banding scale showed a proportional spread of GQ scores across the 
bands, such that in each band, the corresponding GQ score had the highest number of patients. In 
contrast, the vertical pattern of the matrix was not as expected for GQ scores zero, one and four. 
For patients with GQ score 0 there were equal numbers falling in bands zero (n = 1) and two (N = 
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1), as previously noted. The highest number of patients with GQ score one was classified into band 
two, while among those with GQ score four, band three was the most prevalent.
Table 9.28 shows the distribution of GQ score across the banding 0 to 1, 2 to 10, 11 to 22, 23 to 
34, 35 to 36 (Set 6). The spread of GQ scores across the bands was proportional i.e. for each band 
the highest number of patients showed the matching GQ score. Further the distribution of bands 
for each GQ score was also assessed. Only for GQ scores one and three showed the highest number 
of patients in the matching bands (band one and band three). GQ scores zero and three showed 
equal numbers of patients in bands zero and band two; and in bands two and three, respectively. 
Overall this banding resulted in a disproportionally large number of patients placed in band three 
at the expense of all other bands. 
Table 9.26: Distribution of GQ scores for proposed scale banding (set 4)
GQ Total
0 1 2 3 4
Bands
0 1 0 0 0 0 1
1 0 3 2 0 0 5
2 1 9 35 24 3 72
3 0 3 20 52 30 105
4 0 3 8 30 36 77
Total 2 18 65 106 69 260
Table 9.27: Distribution of GQ scores for proposed scale banding (set 5)
GQ Total
0 1 2 3 4
Bands
.00 1 0 0 0 0 1
1.00 0 2 0 0 0 2
2.00 1 12 41 32 4 90
3.00 0 3 21 63 37 124
4.00 0 1 3 11 28 43
Total 2 18 65 106 69 260
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Table 9.29 presents the distribution of GQ scores across the banding system 0 – 1, 2 – 10, 11 to 
20, 21 to 30, 31 - 36 (set 7). In each band, the corresponding GQ score was most prevalent. This 
pattern however was not portrayed in the distribution of bands within each GQ score. Bands zero 
and two had a single patient each in GQ score zero, band two had the highest number of patients 
in GQ score one. GQ two had most patients allocated in band three. Although this was the most 
practical banding it led to a higher proportion of patients being classified in band three and four 
disproportionately more than the distribution of GQ scores. 
The distribution of GQ scores for the banding 0 – 1, 2 – 10, 11 – 22,  23 - 32, 33 – 36 (set 8) is 
presented in Table 9.30
.
Table 9.28: Distribution of GQ scores for proposed scale banding (set 6)
GQ Total
0 1 2 3 4
PB6
.00 1 0 0 0 0 1
1.00 0 3 1 0 0 4
2.00 1 9 32 19 2 63
3.00 0 6 32 81 47 166
4.00 0 0 0 6 20 26
Total 2 18 65 106 69 260
Table 9.29: Distribution of GQ scores for proposed scale banding (set 7)
GQ Total
0 1 2 3 4
Bands
.00 1 0 0 0 0 1
1.00 0 3 1 0 0 4
2.00 1 7 21 12 1 42
3.00 0 5 31 57 24 117
4.00 0 3 12 37 44 96
Total 2 18 65 106 69 260
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Table 9.30: Distribution of GQ scores for proposed scale banding (set 8)
GQ Total
0 1 2 3 4
Bands
.00 1 0 0 0 0 1
1.00 0 3 1 0 0 4
2.00 1 9 32 19 2 63
3.00 0 3 27 70 34 134
4.00 0 3 5 17 33 58
Total 2 18 65 106 69 260
The spread of GQ scores for each band appears balanced, the corresponding GQ score had the 
highest number of patient. Furthermore, the vertical pattern of the matrix was assessed for the 
distribution of bands in each GQ score. The band corresponding to the GQ score showed the 
highest number of patients only for GQ score two (n = 32) and GQ score three (n = 70).
Return Operating Characteristic Curve Analysis
An analysis using a Receiver Operating Characteristic curve was carried out to assess the accuracy 
of each HidroQoL score, as a cut-off for different levels of overall disease impact (based on GQ
scores). This method is used for assessing the internal validity of diagnostic tests, by plotting 
sensitivity against 1- specificity for each score.
Sensitivity captures the true positive rate, the probability of detecting cases i.e. correct diagnosis 
of those with a condition (Kumar and Indrayan 2011). On the other hand, specificity measures the 
false positive rate, probability of correctly identification of non-cases (Kumar and Indrayan 2011). 
As there are five GQ scores, to carry out the ROC analysis, these were regrouped in multiple ways:
 Grouping 1: GQ score 0 vs. GQ scores 1- 4
 Grouping 2: GQ score 0 -1 vs. GQ scores 2 – 4
 Grouping 3: GQ score 0 – 2 vs. GQ scores 3 – 4
 Grouping 4: GQ score 0 – 3 vs. GQ score 4
Separate ROC curves were estimated for each groupings, to identify the most optimal HidroQoL 
score cut-offs for classifying patients within each grouping. ROC analysis for grouping 1 was not 
carried out due to the number of patients with GQ score 0 (n = 2). The ‘proportion of correctly 
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classified’ was used to identify optimal HidroQoL score cut-off. In addition, the score with the 
highest Youden Index (specificity + sensitivity – 1) is considered to offer the highest 
discrimination.
Cut-off between GQ score 0 – 1 and GQ scores 2 – 4
According to the area under the curve (AUC) for the ROC curve for grouping 1 (Figure 9.8), the 
HidroQoL scores provided a better classification of patients between GQ score 0 – 1 and GQ scores 
2 – 4 than a random guessing (Area under ROC curve = 0.78) (Table 9.31). This means the scores 
of the HidroQoL were able to classify patients between those experiencing no or small impact and 
those experiencing a greater overall impact. HidroQoL score cut-offs >= 7 and > = 11 offered the 
highest accuracy in classifying patients (percent correctly classified = 93.5% for both scores)
(Table 3.2). However, a cut-off score of >= 26 was considered most discriminating (Youden Index 
= 47.9).
Figure 9.8: Receiver operating characteristic curve for classifying patients between GQ 0-1 
and GQ 2 – 4 using the HidroQoL
Table 9.31: Area under curve for the ROCs for each grouping
AUC (CI) Std. Err.
Grouping 2 cut-off 0.78 (0.66, 0.91) 0.06
Grouping 3 cut-off 0.78 (0.72, 0.83) 0.03
Grouping 4 cut-off 0.79 (0.73, 0.84) 0.03
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ROC for grouping 3, GQ score 0 – 2 vs. GQ scores 3 – 4
The ROC for the HidroQOL for grouping 3 (GQ scores 0 - 2 vs. GQ score 3 – 4) shows a 
statistically significant classification (AUC = 0.78) (Figure 9.9). The cut-off score >23 showed the 
highest proportion of accurately classified patients (77.3%) although its discriminatory power was 
not the highest (Youden Index = 43.3%) (Table 9.32). A cut-off score of >=26 showed the greatest 
discriminatory power although its accuracy was not superior (Youden Index = 46.5%, percent 
correctly classified = 75.4%).
ROC for grouping 4, GQ score 0 – 3 vs. GQ score 4
The HidroQoL provided a statistically significant discrimination of patients according to their GQ 
score (GQ scores 0 – 3 vs. GQ score 4) (Area under ROC = 0.79, Figure 9.10). The highest 
proportion of patients was correctly classified at cut-off >= 35 although this did not have the 
highest discriminatory power (Youden Index = 25.9%). The highest discriminatory power was 
seen on cut-off ≥ 27 (Youden Index = 42.1%, proportion of patients correctly classified = 61.5%).
Part III: Establishing MCID for The HidroQoL
The relationship of the HidroQoL with HDSS change score and the PGA was explored in the 
previous section, a small-to-moderate correlation (r = -0.244, p = 0.021) was reported for the 
HDSS-cs, while that for the PGA was small (r = 0.142, p = 0.186). The relationship between the 
HidroQoL and the PGA raises questions over its validity as measure of change in hyperhidrosis-
QoL, threatening its relevance as an anchor. Thus for estimation of the MID, in this study, only the 
HDSS-cs was used as an anchor. 
Anchor-based approach
The estimation of the MID based on the anchor approach involved first grouping patients 
according their HDSS-cs, score of -1, as slightly improved, score of 0, as experiencing no-change, 
score of 1, as slightly deteriorating. The mean score change in the slightly improving group 
provides the MID estimate (Crosby et al. 2003). 
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Table 9.32: Operating characteristics of the HidroQoL score cut-offs in classifying patients 
according to their GQ score.
H-Score Grouping 1 Grouping 2 Grouping 3
Sn Sp Class. y Sn Sp Class. y Sn Sp Class. y
( >= 1 ) 100% 0% 92.3% 0.0% 100% 0% 67.3% 0.0% 100% 0% 26.5% 0.0%
( >= 2 ) 100% 5% 92.7% 5.0% 100% 1% 67.7% 1.2% 100% 1% 26.9% 0.5%
( >= 6 ) 100% 10% 93.1% 10.0% 100% 2% 68.1% 2.4% 100% 1% 27.3% 1.1%
( >= 7 ) 100% 15% 93.5% 15.0% 100% 4% 68.5% 3.5% 100% 2% 27.7% 1.6%
( >= 8 ) 100% 15% 93.1% 14.6% 100% 5% 68.9% 4.7% 100% 2% 28.1% 2.1%
( >= 11 ) 100% 20% 93.5% 19.6% 100% 6% 69.2% 5.9% 100% 3% 28.5% 2.6%
( >= 12 ) 99% 20% 93.1% 19.2% 100% 7% 69.6% 7.1% 100% 3% 28.9% 3.1%
( >= 14 ) 99% 20% 92.7% 18.8% 100% 8% 70.0% 8.2% 100% 4% 29.2% 3.7%
( >= 15 ) 98% 20% 91.5% 17.5% 100% 12% 71.2% 11.8% 100% 5% 30.4% 5.2%
( >= 16 ) 97% 35% 91.9% 31.7% 99% 16% 72.3% 15.9% 100% 8% 32.3% 7.9%
( >= 17 ) 95% 40% 90.8% 35.0% 98% 20% 72.7% 18.3% 100% 10% 34.2% 10.5%
( >= 18 ) 92% 45% 88.5% 37.1% 97% 26% 73.5% 22.5% 100% 15% 37.3% 14.7%
( >= 19 ) 91% 45% 87.3% 35.8% 97% 29% 74.6% 26.0% 100% 16% 38.5% 16.2%
( >= 20 ) 90% 50% 86.5% 39.6% 95% 32% 74.6% 27.2% 100% 18% 40.0% 18.3%
( >= 21 ) 85% 60% 83.5% 45.4% 93% 40% 75.4% 32.6% 99% 24% 43.9% 22.6%
( >= 22 ) 83% 65% 81.2% 47.5% 91% 47% 76.9% 38.5% 99% 28% 46.9% 26.8%
( >= 23 ) 78% 70% 76.9% 47.5% 88% 55% 77.3% 43.3% 97% 35% 51.2% 31.7%
( >= 24 ) 73% 70% 73.1% 43.3% 85% 60% 76.5% 44.6% 96% 39% 54.2% 34.9%
( >= 25 ) 70% 75% 70.4% 45.0% 82% 65% 76.2% 46.4% 96% 44% 57.7% 39.6%
( >= 26 ) 68% 80% 68.9% 47.9% 79% 67% 75.4% 46.5% 94% 47% 59.2% 40.8%
( >= 27 ) 64% 80% 65.0% 43.8% 75% 69% 73.1% 44.3% 91% 51% 61.5% 42.1%
( >= 28 ) 60% 85% 61.5% 44.6% 70% 73% 71.2% 43.2% 86% 54% 62.7% 40.0%
( >= 29 ) 53% 85% 55.4% 37.9% 62% 75% 66.5% 37.6% 80% 61% 65.8% 40.4%
( >= 30 ) 47% 85% 49.6% 31.7% 55% 78% 62.3% 32.5% 72% 66% 67.7% 38.4%
( >= 31 ) 39% 85% 42.3% 23.8% 46% 82% 58.1% 28.6% 64% 73% 70.4% 36.5%
( >= 32 ) 31% 85% 35.0% 15.8% 38% 87% 53.9% 24.8% 52% 79% 71.5% 30.7%
( >= 33 ) 23% 85% 27.7% 7.9% 29% 91% 48.9% 19.2% 48% 87% 76.5% 34.7%
( >= 34 ) 18% 95% 23.5% 12.5% 22% 95% 46.2% 17.6% 41% 92% 78.5% 32.7%
( >= 35 ) 11% 100% 17.7% 10.8% 15% 100% 42.7% 14.9% 29% 97% 78.9% 25.9%
( >= 36 ) 5% 100% 11.9% 4.6% 6% 100% 36.9% 6.3% 13% 99% 76.2% 12.0%
( >  36 ) 0% 100% 7.7% 0.0% 0% 100% 32.7% 0.0% 0% 100% 73.5% 0.0%
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Figure 9.9:  Receiver operating characteristic curve for classification of patients between 
GQ 0-2 and GQ 3 – 4 using the HidroQoL
Figure 9.10: Receiver operating characteristic curve for classification of patients between 
GQ score 0-3 and GQ 4 using the HidroQoL
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Table 9.33: Mean HidroQoL score change in the ‘slightly improving’ patient group as an 
estimate of the MID
Site 
affected
Sample N Mean
(Test 1-Test 2)
SD 
Mean
SE
Mean
95% CI of 
Mean
All types Pooled 19 2.84 3.78 0.87 1.02 4.66
US 13 3.08 4.01 1.11 0.65 5.50
Localised Pooled 16 2.63 3.67 0.92 0.67 4.58
US 11 2.45 3.91 1.18 -0.17 5.08
Axillary pooled 14 2.93 4.08 1.09 0.57 5.29
US 10 3.10 4.56 1.44 -0.16 6.36
Integrated approach
The MID for the HidroQoL was also estimated by integrating the anchor-based and distribution-
based methods i.e. using statistical characteristics of patient groups defined based on the external 
anchor. The upper bound for 95% CI of the mean HidroQoL-cs of the group that had not changed 
was estimated as a measure of MCID (Table 9.34) (de Vet et al. 2007). Including all patients in the 
pooled sample (all types of hyperhidrosis) gave an MID estimate of 2.5, while the corresponding 
USA and UK estimates were 2.5 and 3.55, respectively. Patients with generalised hyperhidrosis 
showed MID of 2 in the pooled sample and 1.81 in the US sample. For localised hyperhidrosis, 
patients from the UK had the most conservative MID estimate, 5.17, while the pooled sample had 
a MID estimate of 2.94. Due to a small sample size the MID estimate in some patient sub-groups 
of the UK-sample (generalised and axillary hyperhidrosis) would not be calculated
Distribution-based approach
A third approach used in establishing cut-offs for important change utilised the statistical 
characteristics of the sample of baseline patient responses (N = 64). Specifically, the standard 
deviation (1/2 SD and 1/3SD) and standard error of measurement were estimated. The pooled 
sample, including all types of hyperhidrosis showed a SEM of 2.14 and ½ SD of 3.39. These 
compared to the figures observed for the U.S (SEM = 2.16, ½ SD = 3.41) and the UK (SEM = 
2.22, ½ SD = 3.51). The mean HidroQoL baseline scores of patients generalised hyperhidrosis 
from the US showed a ½ SD of 2.6 and SEM of 1.65 while a similar group from the UK had ½ SD 
of 4.12 and SEM of 2.6. For the U.S. patient population with localised hyperhidrosis, SEM 
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Table 9.34: Upper-bound of 1 tailed 95% CI for the mean HidroQoL-cs in the ‘no-change’ 
patient group as an estimate of the MCID
Site 
affected
Sample N Mean
(Test1-
est2)
SD 
Mean
SE 
Mean
Mean 95%
CI
mean + 
1.645*SE
Lower Upper 1-tail, 95% CI
All types pooled 64 1.58 4.49 0.56 0.46 2.70 2.50
US 39 1.79 5.04 0.81 0.16 3.43 3.12
UK 11 1.91 3.30 1.00 -0.31 4.13 3.55
Generalised Pooled 15 0.93 2.55 0.66 -0.48 2.34 2.02
US 8 0.13 2.90 1.03 -2.30 2.55 1.81
UK 5 1.40 2.07 0.93 -1.17 3.97 2.93
Localised Pooled 49 1.78 4.93 0.70 0.36 3.19 2.94
US 31 2.23 5.41 0.97 0.24 4.21 3.83
UK 6 2.33 4.23 1.73 -2.10 6.77 5.17
Axillar pooled 20 2.35 5.45 1.22 -0.20 4.90 4.36
US 12 3.25 5.96 1.72 -0.53 7.03 6.08
UK 5 3.00 3.39 1.52 -1.21 7.21 5.49
Palmo-
plantar Pooled
45 1.38 3.99 0.59 0.18 2.58 2.36
US 28 1.32 4.50 0.85 -0.42 3.07 2.72
UK 8 1.63 3.02 1.07 -0.90 4.15 3.38
of 2.30 and ½ SD of 3.42 were observed. In the comparable group in the UK, SEM of 1.99 and ½ 
SD were observed. Estimates for patients with axillary and palmo-plantar hyperhidrosis in the US 
and the pooled samples were very similar to those observed for localised hyperhidrosis. In patients 
with axillary hyperhidrosis from the UK sample the estimate for ½ SD was 2.3 while that for SEM 
was 1.45. On the other hand, the UK patients with palmo-plantar hyperhidrosis showed a ½ SD of 
3.29 and SEM of 2.08
DISCUSSION
There is consensus regarding the impairment on patient’s QoL resulting from skin disease (Finlay 
and Ryan 1996). Numerous skin-specific and disease-specific questionnaires have, therefore, been 
developed and validated for assessing QoL impairment. The formal measurement of HRQoL using 
standardised instruments, however, is yet to be fully integrated into the dermatology clinic (Finlay 
2011). This state of affairs might be attributable to a number of issues, institutional (the 
organisation and delivery of care within the clinic), behavioural (physicians’ views and outright 
inertia) as well as technical (quality and appropriateness of QoL questionnaires in routine clinical 
practice) (Lohr and Zebrack 2009). 
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Table 9.35: Measures of precision of the HidroQoL, Standard deviation and Standard 
Error of Measurement (SEM) as MCID estimates.
Site of hyperhidrosis Sample N Mean SD SE 1/3 SD 1/2 SD SEM*
All sites Pooled 234 27.14 6.77 0.44 2.26 3.39 2.14
US 137 27.15 6.82 0.58 2.27 3.41 2.16
UK 56 27.11 7.03 0.94 2.34 3.51 2.22
Generalised-hyperhidrosis Pooled 79 29.30 6.13 0.69 2.04 3.07 1.94
US 53 29.62 5.21 0.72 1.74 2.60 1.65
UK 20 28.20 8.24 1.84 2.75 4.12 2.60
Localised-hyperhidrosis Pooled 155 26.03 6.83 0.55 2.28 3.42 2.16
US 84 25.58 7.27 0.79 2.42 3.63 2.30
UK 36 26.50 6.30 1.05 2.10 3.15 1.99
Axillar Pooled 71 26.80 6.84 0.81 2.28 3.42 2.16
US 46 26.11 7.22 1.07 2.41 3.61 2.28
UK 10 29.60 4.60 1.45 1.53 2.30 1.45
Palmo-plantar Pooled 113 25.58 6.79 0.64 2.26 3.39 2.15
US 64 25.38 7.23 0.90 2.41 3.62 2.29
UK 21 25.05 6.58 1.44 2.19 3.29 2.08
Reliability (internal consistency) = 0.9
* SEM = SD * SQRT (1 - Reliability)
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Figure 9.11:Estimates for MCID for the HidroQoL across different patient sub-populations and reflecting multiple analytical 
approaches
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Technical issues directly pertains to psychometric attributes of a measure overall and those that 
are particular for clinical integration of measures e.g. practicality, applicability and interpretability. 
Instruments used to measure HRQoL in the clinic, for example, in monitoring the patient’s 
condition over time, must have demonstrated the ability to capture important changes in the 
patient’s condition over time regardless of how small they are (Guyatt et al. 1987). Furthermore, 
additional information may be required for the conversion of the abstract scores into clinically 
meaningful values that can be incorporated into clinical decision-making (Sampogna and Abeni 
2011). The current study, therefore, assessed whether the HidroQoL is capable of capturing change 
in the patient’s condition, even when such change is small. An additional aim was to provide 
information to facilitate the interpretation of its scores particularly providing estimates for minimal 
clinically important differences (MCID) and a banding-system for the scores.
In this study, patient’s HRQoL was assessed on two occasions, at baseline and on a follow-up visit, 
two to four weeks apart. Change in the patient’s condition was assessed using two external 
measures. The patient’s global rating of change (PGA), where patients rated their perception of the 
amount of change they experienced from baseline to follow-up, and the HDSS. The validity, 
reliability and responsiveness of the HDSS has been previously demonstrated (Kowalski et al. 
2004; Lowe et al. 2007). A 1-point change is comparable to a 50% change in sweating while a 2-
point change is associated with a 80% change in the level of sweating (Solish et al. 2007).
Responsiveness was analysed using multiple approaches including paired t-tests, change 
magnitude coefficients (Effect size, Standard Response Mean); longitudinal discriminant validity 
based of change scores assessed using ANOVA; and spearman’s correlations. This permitted a 
more refined definition of the change construct, not only evaluating the capability to detect change 
in patients, but also the capability to differentiate between patients experiencing different levels of 
change (Stratford et al. 1996). 
The results of the paired t-test in the pooled, USA and UK samples, shows that the HidroQOL was 
sensitive to changes in the patient condition for those who improved, both when change in patients 
condition was defined using the PGA or using the HDSS. The HidroQoL was more efficient at 
detecting these changes, relative to the DLQI and the Skindex-17, where change in patient’s 
condition was defined based on the HDSS. Nonetheless, where the PGA was used in defining the 
patient’s condition, the performance of the HidroQoL was comparable to, though slightly worse 
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than, that of the DLQI, and still more efficient than that of the Skindex-17. The HidroQOL 
discriminated between patients experiencing different levels of change.  The small-to-moderate 
effect sizes obtained in the minimal improvement group are as expected and demonstrate that the 
HidroQoL can detect change consistent with true changes in the patient’s conditions.
A major concern when applying responsiveness results is whether the capability of a measure to 
detect change is underpinned by longitudinal validity i.e. that the observed changes in a scale 
reflect true-changes in the underlying construct (Terwee et al. 2003). The HidroQoL change scores 
correlated with change scores for the DLQI, Skindex and the HDSS. In addition, previous 
validation studies (reported in CH 3 – CH 7) reported content validity, dimensional structure and 
inter-temporal stability of the HidroQoL. These results suggest that the evaluative use of the 
HidroQoL scores is supported.
The holy-grail to the use of HRQoL in routine clinical practice is the ability of being able to 
interpret scores: an understanding of what changes in the score from one visit to the next actually 
means in clinical terms and how the interpretation of change in those scores influences treatment 
decision-making (Salek and Kamudoni 2013). There are no rules regarding what information 
serves this purpose, as long as there is a rationale for its validity and clinical relevance. Examples
include, reference scores from research studies with similar patients or from the general or healthy 
populations; comparison with previous scores from patients; scale banding for different levels of 
impairment; and MCID cut-offs (Snyder et al. 2012). These may be established in a cross-sectional 
or longitudinal set-up, although the latter is especially suitable for defining ‘important’ score 
change, MID (Crosby et al. 2003).  In this study, a scale banding-system for different levels of 
impairment associated with HH and MCID cut-offs were established.
To develop the scale banding-system, patients’ responses on the HidroQoL were mapped to a 
global question (GQ) on patients’ perception of the overall impairment on their life resulting from 
hyperhidrosis. This provided score-bands corresponding to the levels of the GQ question (no 
effect, small effect, moderate effect, large effect and very large effect). An alternative to this 
approach is to create score categories based on distribution characteristics of the sample using 
techniques such as mixture modelling. Although such an approach may seem robust (i.e. offering 
an efficient means to determining the appropriate number of categories and cut-offs based on 
model-fit) (Nijsten et al. 2009), the meaning attached to score categories remains arbitrary given 
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that the assigned interpretation is not underpinned by any patient or clinical input. The main 
advantage of the approach followed in this study, therefore, was that the qualitative meaning to the 
score ranges was rooted in patient’s judgement. 
The banding-system 0 – 1, 2 – 10, 11-22, 23 – 32 and 33 – 36 (rs = 0.679) was proposed. This 
provided the most accurate classification of patients according to their actual level of impairment 
i.e. the majority of the patients were placed in the band that would have been predicted by their 
GQ score (Aawar 2011). There were a number of patients with either a low or high GQ score for 
their score-range (or the reverse, a high/low score-range for their GQ score). This is possibly a 
consequence of the particular anchor question used (Prinsen et al. 2011), which might have been
interpreted differently by different patients given its generic nature. On the other hand, the 
questionnaire enabled patients to reflect on aspects of their life in greater detail, picking up issues
missed on a generic question. Thus it was possible for a patient showing minimal impairment on 
the generic question to end up showing greater impairment (and similarly, the opposite was equally 
possible). Ultimately, this is an inherent feature of any categorisation system; and the degree to 
which misclassifications are minimised provides a measure of the rigor of any categorisation 
system. 
The definition of the magnitude of important change score is central to the application of HRQoL 
instruments because, rather than simply knowing that a given change in the scores is beyond that 
which may be attributable to chance (i.e. is statistically significant), clinical decisions are based 
on the clinical significance of those changes. Therefore, the MCID score for the HidroQoL was 
explored, using anchor-based approach, distribution-based (standard deviation – SD; Standard 
error of measurement - SEM) of the baseline assessment and an integration of the two. Applying 
both anchor-based and distribution-based methods provided confidence for the proposed estimate. 
The two approaches provided answers to different questions, namely: what value of the minimal 
change-score that would be considered important ?; and ‘is the instrument capable of detecting 
such a value ?’(De Vet et al. 2006). Therefore estimates of 1-SEM or ½ SD, representing the 
Minimum Detectable Change (MDC) score (De Vet et al. 2006). 
Across all patient sub-groups the 1-SEM and 1/3 SD, was smaller than anchor-based MID or the 
one based on integrated approaches. As previously noted, the 1/3SD closely reflected 1-SEM 
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estimate as expected in a measure with reliability of 0.9 (Yost and Eton 2005). This ranged from 
1.65 (USA, generalised hyperhidrosis) to 2.3 (USA, localised hyperhidrosis). Using the anchored 
approach MID ranged from 2.45 (USA, localised hyperhidrosis) to 3.1 (U.S.A axillary). On the 
other hand, MID for the the integrated approach ranged from 1.81 (U.S.A, generalised) to 6.08 
(U.S.A, axillary). Patients with generalised hyperhidrosis showed slightly lower MID estimates in 
comparison to those with localised hyperhidrosis, on both the anchor-based and distribution-based 
estimate. Due to the small size of some patient groups (UK palmo-plantar patients, minimally 
deteriorating patients, minimally improving UK patients, generalised hyperhidrosis) anchor-based 
MCID estimates were not established. Taking into account practicality considerations and the 
available evidence, an MCID of 3 was proposed for the HidroQoL.
SUMMARY
 This study has developed and proposed a banding system for interpreting the scores of the 
HidroQoL scale.
 Separate banding-scales were proposed for generic and localised hyperhidrosis, however, 
a strong level of agreement between the two banding systems supported use of a common 
banding across the different countries.
 An anchor-based approach was used based on a global question (GQ) on the overall 
HRQoL impact of hyperhidrosis on patient’s life, ensuring that the proposed banding is 
patient-centred and not arbitrary.
 In addition to facilitating the integration patient-centred care into routine clinical practice 
through greater engagement with the patient on issues affecting them, the banding system 
suggested may be an important tool in minimising decision uncertainty faced by clinicians 
especially in assessing their patient’s condition.
 The MID of the HidroQoL has been established using anchor and integrated approaches.
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CHAPTER 10
General Discussion
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In disorders related to the skin, the subjective experience of patients, particularly in relation to 
impairment in QoL are regarded as a vital sign of disease activity (Chren 2005). First, the severity 
of most chronic skin conditions is mainly linked to the impact on social life, patient discomfort 
and psychosocial functional limitations (Grob 2007). Second, ‘hard’ endpoints such as clinical 
measures or symptoms like redness or lesion size may be challenging to measure and interpret
(Grob 2007). In hyperhidrosis, for example, gravimetric measurement is used for determining
severity of disease based on the amount of sweat produced. Not only is the procedure cumbersome 
for routine clinical practice, but also the amount of sweat produced has shown great intra and inter-
individual variability(Wörle et al. 2007). Moreover, the threshold amount of sweating for the 
diagnosis of hyperhidrosis is unclear (Hund et al. 2002). 
Apart from concerns over symptoms, patients may have greater worries regarding their 
diminishing QoL which might be the main driver in seeking medical attention. The ability of PROs 
such as HRQoL to take into account a broader spectrum of impacts experienced by the patient
beyond just symptoms is not only useful in reducing uncertainty associated with clinical decision 
making but provides a better framework for evaluating the risks and benefits from therapy. 
Given the foregoing, there has been a rapidly growing role of humanistic outcomes in recent years 
not only in patient management but also in assessment of efficacy of therapies, in health services-
audit and epidemiological studies. This suggests that the way in which QoL information is 
gathered, processed, interpreted, presented and utilised needs to transition from being an art to a 
science (Finlay 2011). However, the development of a unified conceptual framework for QoL and 
its measurement has often been hampered by the subjective nature of QoL, including the fact that 
it is an abstract concept which is associated with personal perception, beliefs and values (Spilker 
and Revicki 1996). For example, QoL may change over time, even without a corresponding change 
in the patient’s underlying condition, depicting ‘response shift’. This makes ensuring objectivity 
in the measurement process quintessential. Fisher (2000) has discussed two main elements of 
objectivity in measurement, methodological and social. The former requires that results from 
measurement are not dependent on the object being measured. On the other hand, social objectivity 
reflects consensus and agreement on standards and their interpretation as applied to the units of 
measurement. In the context of QoL, one can translate this as attaining a unified conceptual 
framework on QoL, guidelines on its measurement and its interpretation. While ‘objective 
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measurement’ may be considered idealistic and unattainable in practice, it provides a benchmark 
and standard for rigorous instruments. This issue is taken up later.
One of the major objectives of this research, therefore, included to evaluate instruments used in 
assessing QoL in hyperhidrosis. Various types of instruments have been applied in hyperhidrosis, 
generic, skin-specific and disease-specific. Not all instruments identified measured the concept 
QoL as claimed, suggesting a wider issue relating to the lack of clarity, consensus and transparency 
in the definition of the conceptual framework for hyperhidrosis-QoL. Among the generic and the 
skin-specific measures, only the IIRS, the DLQI and the PBI had been validated in hyperhidrosis 
patients. Furthermore, the majority of instruments lacked patient’s input in their content 
development. This has implications for content validity and applicability, reflected in poor 
coverage of core issues or lack of appropriate emphasis. Such instruments may particularly be 
difficult to use in the clinic (Higginson and Carr 2001). A promising measure, the HHIQ was not 
developed for use in routine clinical practice, lacked applicability and interpretability. The need 
for a clear and transparent conceptual framework for QoL in hyperhidrosis; and a new disease-
specific instrument for its measurement was made clear through the review. The new instrument 
would aim to be useful in clinical research, but also adapted and refined for routine clinical 
practice. Thus it would need to be short, have a simple scoring procedure, psychometrically sound 
and responsive in individual patient evaluation, with data facilitating the interpretation of scale 
scores provided.
The position of patients as experts on their condition makes their account of how they experience 
their disease a rich and important source of information. A literature search of studies investigating 
the impacts of hyperhidrosis using qualitative research methods was carried out. Only one study 
recruiting females only was found. The rest of the studies were based on quantitative methods 
which may not provide information on the inner perceptions, values and beliefs of patients (e.g. 
underlying patient’s self-image, their health needs and priorities). This indicated a need for a 
qualitative investigation into the experiences of patients living with hyperhidrosis, especially how 
their life is affected. This would offer a unique opportunity to understand phenomena from the 
eyes and voice of the subjects, capturing inner thought processes as well as the context influences 
such as cultural and social norms and beliefs (Bowling 2009). Most crucially, this recognises that 
long-term QoL outcomes in patients is subject to many influences besides therapy including coping 
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strategies and accommodation of the disease, internalisation of negative social stereotypes, 
patient’s level of self-esteem; importance attached to appearance (Greenhalgh 2009). Moreover, 
during the development of a new patient reported outcome measure qualitative investigation into 
the experiences of patients provides a means for their involvement in content development. The 
data gathered from patients, particularly, how their condition affects them is useful in defining the 
conceptual framework of the instrument. The actual phrasing used by patients to describe their 
condition may also be useful in formulating the items, ensuring that the content is not only relevant 
but also appropriate, comprehensible and interpretable by the target patient population. 
Documentation of the evidence demonstrating the link between items in the measure and the 
impacts experienced by patients is particularly important for instruments used to assess therapeutic 
benefit in clinical studies submitted to the FDA (Rothman et al. 2009).
In this study, data collection used a triangulation of focus groups, interviews and survey ensuring 
a balance in the strengths and weakness associated with each method. The interviews conducted 
were semi-structured, starting with an open question allowing the patient to recall all their 
experiences and to narrate them according to their perception and prioritisation, ensuring that the 
final data was authentic. A similar approach was taken during focus group discussions where 
patients were invited to share their experiences and talk about how their lives had been affected. 
The interference of the interviewer to the patients’ description was minimal and limited to prompts 
for more clarity. Their phrasing was also such that the patients would not be influenced to provide 
a particular answer. If anything, the passive listening ear might have encouraged the patients to be 
candid in their explanation allowing them to share more.  Patients initiated discussion on a number 
of issues e.g. about new upcoming treatments and underlying causes of hyperhidrosis. . Overall 
the patients were enthusiastic about the discussions/interviews and saw this as an opportunity to 
contribute towards the general good of all other patients with hyperhidrosis. Participants to the 
focus groups were grateful for the opportunity to discuss their condition with other sufferers.
Although the selection of patients in qualitative research need not necessarily be probabilistic, this 
ought to be at least purposive, in order to achieve a sample that reflects all the key characteristics 
of the target patient population. The overriding consideration is whether the sample is ‘adequate’
to supply all information needed for a comprehensive analysis (Yardley 2008). Achieving 'data 
saturation' helps to demonstrate this. In this study data saturation was demonstrated; data collection 
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continued even after saturation was reached, and no new additional themes emerged. This ensured 
the thoroughness and depth in the information collected. 
The QoL issues reported by patients reflected strong social underpinnings. The most frequent 
emotional distresses such as anxiety were associated with patient’s uncertainty about when the 
sweating would start and how other people would react to it. Patients often felt embarrassed 
particularly because they thought others had noticed their sweating. The importance of anxiety in
hyperhidrosis is reflected in earlier theories on the condition, which considered it to be primarily 
a psychological condition (e.g. social anxiety) (Ruchinskas 2007). This is understandable 
considering that palmar hyperhidrosis is a key symptom of pathological social anxiety. 
Patients have reported physical discomforts related to hyperhidrosis, for example having drenched 
clothes and the related unpleasant body odour. Patients with plantar hyperhidrosis (affecting the 
feet) reported discomfort associated constant wet feet, often leading to bad feet odour and to 
athletes feet in a few. The condition also had an impact on patient’s work-life and career choices. 
Patients suffered reduced productivity due to challenges with using computers, smart screens or 
working with paper document. Relating with colleagues or clients was taxing. Patients had their 
own ‘little rituals’ just to keep dry or to avoid their sweating from being noticeable, which required 
extra effort, work and time e.g. showering more than once a day, changing clothes more than once 
a day, carrying a towel everywhere. Patients with hyperhidrosis spend 15 to 60 minutes in 
managing the symptoms of the condition and more than 50% change their clothes more than twice 
a day (Hamm et al. 2006). Comparable experiences have been reported in other skin diseases. In 
psoriasis, daily time needed for treatment was found to be the strongest predictor of HRQoL, in a 
cross-sectional study involving 1210 patients in 130 dermatology practices in Germany (Blome et 
al. 2010). The reported impacts did not seem to diminish with age of patient, suggesting that the 
amount of accommodation taking place might be minimal
The impacts of hyperhidrosis cross-cut multiple areas of life with a common linkage to patient’s 
social life. Amir  (Amir et al. 2000) using regression analysis showed that impairment in social 
functioning alone explained 81% of subjective suffering in hyperhidrosis patients, based on 48 
Israeli patients attending a dermatology clinic. This emphasises the need for tools that 
comprehensively address such multidimensionality in disease-impacts and in particular e.g. 
assessing HRQoL to understand the broad impacts of the condition on multiple aspect of the 
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patient’s life, simultaneously. Modern society’s emphasis on healthy skin as part of sexy-perfect-
body image; the high visibility of skin; and the importance of skin to self-identity provide some 
explanation for the high impairment in QoL suffered by patients with skin disease (Beltraminelli 
and Itin 2008). For hyperhidrosis, patients also deal with the fact that sweating in and of itself is 
associated with lack of hygiene. The results of the qualitative study provided a rich source of 
material for the development of a conceptual framework for QoL in hyperhidrosis and a new 
instrument for its measurement. A clear and structured process was followed in the development 
of the first version of the new instrument from the identified QoL issues, to ensure not only the 
appropriate coverage and emphasis in its content but also technically quality.
Clarity regarding the internal structure of an instrument not only reflects the rigor of the conceptual 
framework and its translation into measurement, but also provides the rationale for combining the 
items into domain or overall scale scores (Lohr 2002). The developmental version of the HidroQoL 
underwent field testing in the target population (comprised of patients from the U.S. and the UK) 
to test its internal structure as well as the relevance and acceptability of the content. This also 
facilitated the revision of the instrument, eliminating items not contributing to measurement and 
retaining those such a contribution. The study population used had self-assessed hyperhidrosis and 
the majority (85%) had previously seen a doctor for their condition. 
In order to perform item reduction using the classical test theory approach, the subjects were 
divided into two groups. The first, comprising of patients from the USA, was used for the 
exploratory factor analysis (EFA), and the second group, made up of patients from the UK, was 
used for confirmatory factor analysis (CFA). Prior to the EFA, redundant items were removed 
based on results of correlation analysis, consideration of content coverage and importance of the 
issue to patients.  For example the item my self-confidence is affected and my self-esteem is affected
were highly correlated. The self-confidence item was more prevalent during the qualitative study, 
making it the preferred item. EFA was then carried out on the remaining 36 items to explore the 
number of factors underlying the HidroQoL, as well as to assess the role of the items to 
measurement. Items not meeting criteria were sequentially removed, with 21 items retained. These
items showed optimal fit to both a single-factor as well as a two-factor structure. Although the 
single factor solution was based on parallel analysis (considered a more robust factor extraction 
approach), the two factor solution, offered more insight into the nature of hyperhidrosis impacts.
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Moreover, the two factors were interpretable as impact on daily life activities and psychosocial 
impact.
Although EFA is informative as an exploratory tool, confirming hypothesised number of factors 
can only be undertaken using confirmatory factor analysis. As such, the CFA carried out on the 
UK subsample tested the single and two factor solutions observed from the EFA. Both the single 
factor and two factor solutions showed optimal fit. Still, the latter showed better fit, which might 
be due to the inclusion of more parameters than the single factor solution.
Rasch analysis was carried out on the 36-item HidroQoL (following the removal of multi-collinear 
items). Performing the analysis on this version of the HidroQoL ensured comparability with the 
EFA; and guaranteed that the first stage of item reduction still incorporated qualitative 
consideration. Items showing poor fit to the Rasch model (RM) were identified and removed. This 
was done sequentially, one item at a time, taking into account impacts on content validity, 
impairment continuum covered by the scale and impact on the reliability. This provided thorough 
insights into the contribution of each item to the conceptual definition of the target construct. The 
Rasch analysis allowed the conceptualisation of hyperhidrosis-QoL as a construct relevant to all 
types of hyperhidrosis. Therefore the realised conformity to the RM demonstrated the 
unidimensionality of the HidroQoL.
In as much as recommendation on the most optimal response categorisation for QoL instrument 
exist, and suggest seven (plus/minus 2) (Streiner and Norman), such guidance must consider the 
target population and concept being measured. The consequences of an inappropriate 
categorisation are costly both in terms of measurement efficiency and time (response burden). 
Following the Rasch model the number of response categories was reduced from 5 to 3, such that 
the responses for items were ‘no, not at all’, ‘a little’ and ‘very much’. Based on the RM, this new 
response categorisation minimised ambiguity. 
The item calibration of the HidroQoL on the RM was cross-validated on a fresh sample, comprised 
of patients from the UK. A comparison of item hierarchies showed that the majority of items 
retained their level of difficulty, five items showed a shift in their item difficulty locations. For 
example, the item I worry about people’s reactions was slightly difficult for the UK group, while 
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the item I feel frustrated seemed easier. Taken literally, this may mean UK patients cared less about 
other people's reactions compared to the US patients, while they easily got frustrated in comparison 
to their US counterparts.  An alternative approach to invariance compared the item calibrations 
from the two samples using a scatter plot and quality control lines, accounting for measurement 
error. This showed that all items except one, were invariant within measurement error. The 
observed differences in item difficulties in some of the items might have been a result of the small 
size of the UK sample. The results from the analysis taking into account measurement error 
supports this.
Using two alternative approaches in establishing dimensionality was important, not only as a 
means for cross-validating results from the two approaches, but also because the two methods 
provide slightly different perspectives on the same issues. In the RA, for example, all 
hyperhidrosis-site-specific item showed poor fit suggesting that they were not assessing the same 
Rasch latent variable (hyperhidrosis-QoL). During the EFA these items all belonged to a single
factor. The EFA, however, would not indicate whether this factor was part and parcel of a broad 
QoL construct relevant for all forms of hyperhidrosis or not. 
Although the Rasch analysis and EFA produced slightly different instruments, eleven items were 
common. The major difference was in items assessing the psychosocial impact domain. One reason 
for this might be the fact that the Rasch model assesses whether an item is used consistently, in 
line with Rasch probabilistic condition i.e. whether patients with greater impairment have a higher 
probability of a higher score than those with a lower impairment (Tennant et al. 2004). 
Furthermore, the RM conceptualises the latent variable as a linear metric measuring the latent 
variable/construct from a low to high severity level; with items placed hierarchically on the metric 
according to their level of difficulty (Pallant and Tennant 2007). In contrast, the FA linear model 
does not accommodate the latent variable’s severity dimension; it makes no consideration of item 
difficulty; and thus lacks the capability to deal with item redundancy. Since FA assesses items 
based on shared covariation, those where this is low may be penalised despite their contribution to 
overall scale for example, the item My sex life is affected.
The final version of the HidroQoL utilised the taxonomy from the EFA to provide two sub-scales, 
impact on daily life activities and psychosocial impact, in addition to the overall scale. The choice 
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of items was based on the Rasch analysis, in order to simultaneously take into account the entire 
continuum of impairment in HRQoL and realise a unidimensional construct. Three items were 
added on the fifteen selected based on RA optimisation, my physical activities are affected, I feel 
embarrassed and my choice of clothing is affected. The first two, were included in the FA reduced 
instrument. Although the RM showed some response dependence between the item my physical 
activities are affected and my hobbies are affected, the two items represent separate and mutually 
exclusive concepts. The items I feel embarrassed and my choice of clothing is affected emerged as 
the most prevalent themes during qualitative research, thus their omission might have negatively 
impacted content validity and applicability of the instrument. Thus the process of selecting items 
for the final version of the HidroQoL and the development of a measurement model, explicitly
addressed the friction between the qualitative and quantitative methods as well as between the 
classical test theory and modern test theories, applied in this study. The most statistically viable
measurement model was implemented, but not at the neglect priorities of patients.
The internal structure of the construct of hyperhidrosis-specific Quality of Life has been previously 
explored. Kuo et al. (Kuo et al. 2004) using EFA, identified five domains including: functional, 
psychological, social, affective and physical function explaining 69% of QoL, with the functional 
domain explaining most of the variance (42%). The contents of all domains, except for the
‘physical domain’, are covered by the HidroQoL. Amir et al. (2000), on the other hand, included 
six domains (functional, social, inter-personal, emotional-self, emotional-other and conditions) in 
their conceptualisation of hyperhidrosis-QoL. Results of a regression analysis they carried out 
showed subjective suffering from hyperhidrosis to be explainable by three factors (social, 
interpersonal and emotional-other); with the social domain accounting for 80% of the variation. 
The studies by Kuo et al. and Amir et al. included items site-specific questions e.g. items relevant 
for palmar or plantar hyperhidrosis only. The findings from the current study have shown that 
special considerations might be required for including such items if the intention is to measure 
HRQoL across patients with hyperhidrosis of different sites.
The final phase of the study involved establishing the psychometric properties of the final 
HidroQoL version, testing its reliability, construct validity and responsiveness. In addition 
information facilitating interpretation of scores was generated. Patients with all types of 
hyperhidrosis, according to body site affected, were included. This is particularly important given 
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that the HidroQoL is intended for use in all forms of hyperhidrosis. Moreover, the different sites 
of hyperhidrosis tend to have slightly differing prognosis and impact. In this research the level of 
impact reported by patients with generalised hyperhidrosis was the highest while those 
experiencing sweating of the hands and feet were the least affected. 
Reliability was tested by assessing the internal consistency and test-retest reliability of the domain 
scores as well as the full scale score. In view of the influence of sample distribution characteristics, 
for example heterogeneity of sample, on reliability, separate analyses were carried out for patient 
from UK and USA patients, in addition to analysis in a pooled sample. The obtained results
supported homogeneity of the domain overall scale score and the two domains (impact on daily 
life activities impact and psychosocial impact domains). These results demonstrate the clarity with 
which the construct being assessed by the HidroQoL has been defined.
Test-retest reliability particularly relevant for measures used in a longitudinal context. Its 
assessment needs to take into account a number of issues which may confound reproducibility. 
The period of time between baseline and follow-up should be close enough to ensure that the 
underlying construct does not change, but not too close to avoid carry-over effects from initial 
assessment (Streiner and Norman 2008). A period of three to fourteen days has been recommend, 
with a one week offering a good balance (Salek and Luscombe 1992; Streiner and Norman 2008). 
The choice of the correlation coefficient has to be appropriate, the ICC fits the purpose, as it also 
captures systematic bias. In this study, time interval from baseline to follow-up ranged from 5 to 
25 days. The ICC was the choice coefficient, the results showed strong test-retest reliability for the 
individual item scores, the domain scores; and the overall score. This provides confidence that the 
HidroQoL can be used for evaluative purposes as change taking place in the patient’s life would 
not be obscured by measurement or systematic errors.
The validity of the construct underlying the HidroQoL (hyperhidrosis-specific QoL) was 
thoroughly evaluated by testing various a priori hypothesis, on how the HidroQoL scores relates 
to other measures of constructs related to the hyperhidrosis-specific QoL. A moderate to strong 
correlation was obtained between scores of the HidroQoL and scores of the DLQI and the Skindex-
17. This confirmed the apriori hypothesis that hyperhidrosis-QoL is related to skin-specific QoL.
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Disease-specific scales are expected to reflect issues of particular concern to patients with a given 
condition(Guyatt et al. 1993). Therefore a moderate to strong relationship was expected between 
the scores of HidroQoL and other measures of disease severity and impact in hyperhidrosis. The 
HidroQoL showed expected relationship with level of disease severity (HDSS score), overall 
impact of hyperhidrosis on patient’s life and the amount of time spent in managing the sweating 
daily. The results observed suggests that the content of the HidroQoL: addresses those features of 
QoL which are linked to level of disease severity, is representative of those issues pertinent to 
hyperhidrosis patients such as overall life impact and the daily amount of time spent in managing 
hyperhidrosis. This suggests that impairment in patient’s QoL, as measured by the HidroQoL, 
would be a plausible indicator of disease activity in hyperhidrosis, providing the justification for 
its use as a primary endpoint in clinical trials.
Application of a measure for evaluative purposes presupposes that it has an ability to detect 
clinically meaningful changes (Guyatt et al.). The HDSS score change and a retrospective patient’s 
global change assessment were used as anchors to determine the degree to which the patient’s 
condition had changed. Baseline to follow-up HidroQoL score changes were as expected for 
patients whose condition had minimally improved; but not in the ‘no change’ or ‘minimally 
worsening’ groups.  The HidroQoL was capable of discriminating between patients only where the 
HDSS change scores was used as an anchor. Although this may be regarded as a sign of poor 
specificity, it is, nonetheless, equally plausible that the anchors were not offering the best 
discrimination among patients. The moderate correlation observed between the change scores of 
the HidroQoL and those of the Skindex-17 and DLQI offered confidence that score change were 
valid. This evidence demonstrates that the HidroQoL has the capability to detect important changes 
even if they were small.
Interpretation of QoL scores may require different types of information, addressing the various 
applications that a measure might be subjected to. Clinicians want to know what a given magnitude 
of score tells them about how their patient is doing. For example consideration of whether a score 
change seen in patients from one visit to the next is clinically significant, may require estimates of 
minimal clinically important difference (MCID). To facilitate the interpretation of the HidroQoL, 
MCID cut-off scores and a scale banding system have been proposed. Two anchors were used, the 
HDSS, for establishing the MCID; and the GQ, for the development of a scale score categorisation. 
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Both anchors were easily understood by the subjects, interpretable and showed adequate 
correlation with the target measure (Guyatt et al. 2002). The HDSS scale, apart from being widely 
validated and used in hyperhidrosis, is used in routine clinical practice. A 1-point change represents 
a 50% reduction in sweat production while a 2-point change relates to an 80% change in the 
amount of sweating (Solish et al.). A 2-point improvement on the HDSS is also used in establishing 
the MCID cut-off values for the DLQI (Kowalski 2007). On the other hand, the general question 
(GQ) used in this study is an adaptation of similar question used in establishing the scale banding 
for the DLQI; and the Renal Quality of Life Profile (Hongbo et al. 2005; Aawar 2011)
Caution is needed in applying MCID cut-off scores. Estimates based on minimally improving 
patients might differ from those based on minimally worsening patients; for example a larger 
magnitude of change might be needed for patients to feel that their condition has deteriorated 
(Testa 2000). On the other hand, patients with high baseline scores (i.e. high level of impairment) 
are likely to show greater improvement than those with low baseline scores (low level of 
impairment). Considering the high baseline level of impairment in this sample, MCID estimate 
might have been lower in a patient group with less impairment. The use of multiple approaches in 
the calculation of MCID (e.g. the integrated approach based on the ‘no change’ patients) provided 
a means to control for such biases. 
Being able to interpret QoL score has practical and conceptual implications on the application of 
QoL scales, whether in routine clinical practice, in clinical research or in health policy decision-
making. The proposed banding may facilitate screening and diagnosis of hyperhidrosis. Its 
simplicity avails a means for capturing the subjective experience of the patient into the 
consultation. The additional information provided by the banding may also alert the clinician to 
the severity of QoL impairment, which may influence treatment strategy. The scale score 
categorisation may offer a useful common language for describing hyperhidrosis, which may aid 
in minimising decision uncertainty on the part of the clinicians, aligning some practice variations 
in management and handling of hyperhidrosis patients. All in all the interpretability information 
will provide a bridge between the scores and appropriate actions to be taken. These issues are 
expounded upon below.
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First, the HidroQoL might be applied in routine clinical practice as a screening tool. Considering 
that diagnosis of hyperhidrosis also relies on the degree of impairment experienced by patients in 
their day-to-day life. A one-off completion of the HidroQoL suffices for this purpose.  Patients 
may have to complete the HidroQoL prior to their consultation, either at home or while waiting 
for their consultation in the clinic. Their scores may then be made available to the clinician during 
consultation alongside other records. The provided scale banding may help clinicians in 
determining magnitude of impact.
The HidroQoL may also be useful in detailing the specific functional areas patients might be 
experiencing problems. Despite the known high prevalence of psychosocial problems among 
dermatology patients, these tend to go unnoticed (Picardi et al.). Identifying problem areas may 
encourage clinicians to discuss the highlighted issues or to refer patients to other health 
professionals for psychiatric support or counselling. 
The HidroQoL may be useful in patient management as a tool for monitoring the patient’s
condition over time.  Information provided through the instrument would be used alongside other 
pieces of information to determine whether a treatment strategy was working, allowing for 
precisely planned treatment strategies (Hahn et al. 2007). For example, the MCID cut-off values, 
can be applied in deciding whether an observed change score necessitates a review of treatment 
strategy. Patients would have to complete the HidroQoL prior to or during their visit to the clinic, 
in order for the information to available during consultation. The data would have to be 
systematically stored, to facilitate longitudinal comparisons on later visits. 
Bringing patients to the centre of the process of care has characterised recent reforms of the NHS 
in the UK and in other health care systems, for example in Sweden and the U.S. A key component 
of patient centred care is to empower patients to self-manage their condition. This enables patients 
to play a more active and central role for example in monitoring their symptoms and QoL;
complying to treatment; and in decision-making on risk and benefit assessment of treatments 
(Frost et al. 2007a). In this context the HidroQoL may allow patients to voice their concerns, 
priorities and needs bringing them to the clinical agenda (Higginson and Carr 2001). This may be 
in the form of discussions on particular issues, collaborative setting of treatment goals or choice
of therapeutic management strategy (Marshall et al. 2006). This may require the patient completing
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the HidroQoL and interpreting score results on their own before visiting the clinic, to self-assess 
their disease severity, form their own priorities and to bring such information to the consultation.
The simplicity of the HidroQoL scoring and the scale banding provided would facilitate such a 
process. 
Use of PROM to advance patient-centred care, is of course contingent upon the instrument chosen 
having optimal applicability, adequate coverage and emphasis on the issues of most relevance to 
patients. Using a measure whose content is of low priority to the patients may achieve the contrary, 
aggravate feelings by the patient that their needs are not being met (Lohr and Zebrack 2009). 
Evidence provided in this research, indicates the patient rooting of the HidroQoL’s content, 
guaranteeing that its items are representative of the views, experiences and priorities of the patients 
with the phraseology used reflecting language used by patients. Patients seek to learn more about 
their disease condition especially regarding its causes, prognosis, impact on their QoL, available 
treatments and their related effectiveness, the impact of treatment on QoL (Brundage et al. 2005). 
In this context, results from clinical trials applying the HidroQoL scores as an endpoint may also 
serve wider patient education objectives. Such data may facilitate the understanding of the how 
various therapies may affect patient’s QOL, as they reflect those outcomes patients might be more 
familiar with and care about most. 
Symptoms or disease severity consideration alone may fail to capture the full therapeutic benefit 
and risks to be considered in choice of therapies given the known adverse events and complications
associated with the majority of hyperhidrosis treatments, Botox, Iontophoresis and ETS surgery.
The approach taken in the HidroQoL in measuring hyperhidrosis QoL, may offer a more 
comprehensive framework. 
The comprehensive development and validation of the HidroQoL makes it potentially important 
as a PROM for hyperhidrosis within the National Patient Reported Outcome Programme (Black 
2013), if the program is extended to cover dermatology. In particular, the HidroQoL scores may
be used as a performance indicator in service contracts or in evaluating performance of providers 
for hyperhidrosis treatment. Quality of care from different service providers and outcomes from 
different interventions may be compared across the entire NHS, which might be useful in decision-
making related to commissioning of services, choice of provider or interventions to be covered 
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(Devlin and Appleby 2010). Further, the possibility of adding up items at the domain and overall 
scale level suggests that the HidroQoL might also be useful as an outcome measure in disease 
registries on hyperhidrosis.
The dilemma on how to measure health not only complicates efforts at identifying population
health needs but also presents challenges in the provision of care that is of good quality, effective, 
accessible and satisfactory to the patients (Dalgard and Finlay 2006). For example, the accuracy 
and efficiency in the measurement of quality of life impairment is central to decision-making in 
both resource allocation and clinical management settings. The HidroQoL may, in this regard, be 
used to investigate disease burden from hyperhidrosis in the wider population. This may facilitate
the monitoring of health disparities across regions, based on outcome/indicator of most relevance 
to patients. In addition the HidroQoL may facilitate economic evaluation of interventions in 
hyperhidrosis, for example, by using responder definitions that are based on the HidroQoL’s
composite scores are used or where Quality adjusted life year (QALY) using the HidroQoL scores 
by mapping of the HidroQoL score to the scores of a preference based measures like EQ-5D.
The presentation and communication of data from QoL instruments has an impact on how this 
information is interpreted and used. For the HidroQoL, the scores for the domains and the overall 
scale can be calculated by simple summation of individual items. For cross sectional or one-off 
use of the HidroQoL, for example in patient-screening, patient score may be compared against the 
scale banding provided. Patient’s absolute score may be presented as a point on a cascading bar 
(with different colours reflecting the different levels of impairment). For evaluative use, involving 
longitudinally collected scores, patient-scores from different assessments spread over time might 
be compared. A line graph of the mean scores over time can be used for presentation. Patients have 
shown a preference for this format over others (such as stacked graphs, text data, or side by side 
bar graphs) (Frost et al. 2007a).   Although the individual items provide insights on the specific 
areas patients may be experiencing impairment, the current findings do not support their 
application in hypothesis testing. 
The limited access and challenge associated with obtaining permission to use many PRO 
instruments is a reality many researchers know only too well. Additionally, clear, transparent and 
easy to use instruction on how to use, interpret and present information collected from the scales 
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are often also missing for many instruments. In order to facilitate the use of the HidroQoL, 
documentation on all the necessary information pertaining to the known psychometric information, 
target population in which the HidroQoL might be applied, scoring system of the HidroQoL, will 
be provided through a User’s Manual developed for the measure. A special website will be
developed through which the User’s Manual and the instrument will be made available for 
download. This will also host the web-version of the instrument.
The HidroQoL was developed for assessing hyperhidrosis-specific QoL in clinical research and in 
routine clinical practice. The different applications demand slightly different qualities. In a clinical 
research situation where analyses are at the group level, the greater availability of expertise and 
resources for data collection and analysis may permit a lengthier and complex questionnaire. On 
the other hand, in routine clinical practice resources might be limited, making other considerations 
such as suitability, appropriateness and acceptability, interpretability at the individual patient level, 
responsiveness to change at the individual level (Higginsons and Carr, 2001). Furthermore, such 
instruments must also emphasise on issues that patients consider relevant and that are most likely 
to be influenced by therapy. The HidroQoL, with 18 items, is short and fits on a single sheet of 
paper.  The web-version fits a single screen shot. This avoids the risk that some questions might 
be left unattended. The fact that patients do not feel overwhelmed by the number of sheets may 
contribute towards the quality of answers obtained. Furthermore, the organisation of the items and 
responses was done such that subjects flow naturally through the questionnaire, from left to right, 
down the instrument. The actual item stems were short, not exceeding 7 words except for 2 items; 
furthermore they were expressed in the first person. The response categorisation is simplistic, with 
the number of options and their descriptors, highly unambiguous. Moreover all items use a 
common categorisation.
During field testing patients highlighted the ease of completion of the HidroQoL. Even with the 
field-testing version patients considered the completion time to be acceptable. Furthermore, 
another strong advantage attributable to patient involvement in the early development of the 
measure, was the relevance of the items to patients. Involvement of patient population from 
multiple countries enhanced the universality of the instrument, avoiding cultural colloquialisms. 
This suggests high translatability of the HidroQoL. 
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A number of disease-specific QoL instruments for hyperhidrosis are available, including the 
HDSS, the HHIQ, the Hyperhidrosis Scale (HS), the Hyperhidrosis Questionnaire (HQ), and the 
Hyperhidrosis Quality of Life Questionnaire. Although the HDSS and the HS have been used as 
HRQoL instruments, they assess the level of disease severity and interference in daily life activities 
caused by hyperhidrosis (Keller et al. 2001). The former has one item assessing impairment in 
daily activities (Solish et al. 2005) while the latter has 15 items assessing distress with a range of 
daily activities (Keller et al. 2001); issues related to the social and psychological burden of 
hyperhidrosis are not included in either scales. The validity, test-retest reliability and 
responsiveness of the HDSS have been demonstrated (Kowalski et al. 2004; Solish et al. 2005), 
while for the HS internal consistency, sensitivity and specificity for the HS scale has demonstrated 
(Keller et al. 2001; Keller et al. 2009).  
The HQ assesses disease-specific QoL in hyperhidrosis covering four domains (functional domain, 
psychological domain, social domain, affective domain, physical domain). The content of the 
physical domain seems more related to side effects of surgical treatment than hyperhidrosis per se. 
In addition, a few items included in this measure seem to be relevant only to a sub-population sub-
population of patients such as those with palmar or plantar hyperhidrosis. While construct validity 
and internal consistency was reported, test-retest reliability and responsiveness have not been 
assessed (Kuo et al. 2004). Another measure, the HLQLQ, disease-specific QoL using four 
domains (functional/social domain, personal domain, emotional-self or others, sweating under 
special circumstances). The use of this instrument has largely been restricted to patients with 
surgical treatment. Although the application studies (de Campos et al. 2003; Ambrogi et al. 2009)
report sensitivity results (in terms of t-test of before and after surgery) this is hardly interpretable 
without clear demonstration of construct validity or reliability. In comparison to the domain 
‘sweating under different circumstances’ (7 items) the content addressing emotional impacts is 
rather narrow (2 items). The issue relating to hyperhidrosis-type specific items was also observed
here i.e. the construct was not defined in a way that the content would be relevant in the target 
population otherwise the fact that some items were type-specific was not addressed in the scoring 
system. The definition of the construct disease-specific QoL in hyperhidrosis offered in the existing 
measures, therefore, seems to be at a level not accommodating all types of hyperhidrosis.
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The most promising instrument, the HHIQ, has reported the involvement of hyperhidrosis patients 
in its early development (Teale et al. 2002). Its test-retest reliability, construct validity and 
responsiveness have been reported (Naumann et al. 2002; Hamm et al. 2006). Nonetheless, the 
HHIQ does not cover key emotional issues in hyperhidrosis such as impacts on ‘self-image’ or
‘embarrassment’. Evidence on its scoring procedures is not available. In addition, the baseline 
questionnaire includes 42 items, reflecting the purported use of the instrument in clinical trials 
rather than in routine clinical practice. 
The key issues in the current measures identified through the review may be summarised as 
follows. First, the definition of the construct ‘disease-specific QoL’ reflect inadequate conceptual 
frameworks and a lack of patient involvement, as the appropriate balance and emphasis is lacking 
in the content. Internal structure was assessed only for a single instrument (the HQ).  Most of the 
instruments reviewed lacked some key psychometric information. Thus, the HidroQoL fits into a 
space none of the current disease specific measures cover, starting with its conceptualisation, its 
qualitative development process and the validation of the final instrument. Its conceptualisation is 
based on patient experiences, and a literature review, its development combined multiple studies 
to provide various psychometric information, and finally the end-product (the instrument) is 
relevant to all forms of hyperhidrosis (with special attention paid to achieve this). Therefore the 
HidroQoL is applicable and practical enough for use in both routine clinical practice and in 
research settings. 
Apart from involving patients to obtain input for a new measure, the use of a patient population 
from online social networking sites means that the views and issues that underpin the HidroQoL 
represent the experience of a hard-to-reach patient population often overlooked during typical 
clinic-based research. Although (Cinà and Clase 1999) used a population from an email discussion 
panel to validate the IIRS; during the current study these shaped the actual design of the 
questionnaire.
A key aspect of the current research was the use of patient populations from online social 
networking communities throughout all phases. As a novelty, a number of issues are still 
outstanding. Online social networking sites like the rest of the world wide web are not exempt 
from falsification of information and identity theft (Bilge et al. 2009). Of greatest interest was 
whether participants were indeed who they claimed to be or whether they indeed suffered from the 
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condition under study (Redmond 2010). This is not only of interest when considering the validity 
of data collected, but even more importantly the suitability of the participants for a given study. 
While it is counter intuitive that a falsified identity will be used to engage in social networking 
sites medical research, it is still necessary to put in place some validity checks. Firstly, additional 
avenues/channels which can be used to reach the participants e.g. telephone or physical address 
can be sought. In this study patients who responded to the online open questionnaire were asked 
if they would be willing to participate in an interview and, if so, to provide a telephone. Another 
alternative is to ask patients to supply medical records related to the condition under study(Lenert 
and Kaplan 2000). Considering that this requires extra effort some participants are likely to be put 
off. Finally, modern test theory models such as the Rasch Model hold a lot of promise for 
identifying participants with response patterns that are unexpected or out of the norm as a result 
of guessing, carelessness. Such patterns might be likely for persons using other people’s identity 
to complete the instrument (Lenert and Kaplan 2000). 
Ethical considerations represent the final hurdle online social networks must overcome to achieve 
a wider proliferation as a research tool. Of particular importance are issues related to patient 
consent, users’ privacy expectations, confidentiality and data anonymisation (Zimmer 2010). The 
Helsinki declaration requires that informed consent be obtained from human subjects for their 
participation in medical research. The main challenge for social networking sites such as Facebook 
is that it may be possible to access personal data of users and their friends without their explicit 
acknowledgement (Redmond 2010). Use of such data for clinical or health outcomes research 
would be considered unethical. Even where the data were to be willingly provided by user through 
their use of various “Applications or platforms”, such data can only be ethically used for medical 
research if the user granted specific consent for that purpose. The ethical standard for SNS research 
is to ensure that expectations and intent of users in relation to their personal data are understood 
and respected (Zimmer 2010). While it is understandable that collecting patient consent using 
traditional methods, pen and paper, may actually be challenging for SNS based research, other 
alternatives for achieving the same are available and widely accepted (Lenert and Kaplan 2000).
Informed consent can be obtained online by providing a web-version of traditional consent forms, 
where an electronic signature is used. In this study we applied both the traditional written consent 
and we also made use of an electronic signature.   
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Availability of a rigorously developed PRO measure does not guarantee automatic application. 
Translating the ‘basic science’ of QoL measurement into application in routine clinical practice, 
clinical research or in health system development is at the mercy of numerous factors, 
practical/logistical, behavioural and methodological, affecting the actual measurement, analysis of 
data, or how the data is actually employed. Also, various stakeholders, sources of information (the 
patient), analysts (researchers/nurses/clinicians) and end-users of information may influence the 
process.
The introduction of systematic QoL data collection has resource and organisational implications, 
which might not be available or possible in the context of the clinic. For example, restricted 
budgets would imply such resources would have to be drawn from elsewhere unless time spent 
collecting, analysing and using QoL information would be reimbursed (Greenhalgh 2009). 
Moreover, the initial introduction  of QoL may be associated substantial fixed costs, for example 
the need for staff-training, changes in the clinic flow (Fung and Hays 2008). For computer 
based/electronic systems, new equipment such as computers and service support may be required. 
Further challenges may relate to the choice of instrument and means of data collection (instrument
administration). The instrument chosen must not only be psychometrically sound, but must be 
suitable for intended use i.e. application in the routine clinical practice requires necessary 
adaptation. The majority of HRQoL instruments have not been developed for use in routine clinical 
practice (Higginson and Carr 2001). For example, generic instruments may seem inappropriate for 
clinical trials or use in routine clinical practice in dermatology. Clinical feasibility has to be 
reflected not only in the response and administration burden but in key psychometric properties,
i.e. whether validity in the clinic population or individual patient analyses is established. A 
fundamental issue also relates to the ease of attaching meaning to the scores, PROs may be 
irrelevant without the ability of being able to interpret scores in terms of what change in scores 
from one visit to the next may mean (Salek and Kamudoni 2013).
The role of producers and end-users of QoL information in the process of measuring health 
outcomes cannot be ignored. The views, beliefs, practices of the patients and clinicians seems 
central in this regard. Clinicians may be not be interesting/willing to use QoL instruments, where 
they are unconvinced of the benefit of routine QoL measurement to patient management or where 
they view the understanding of psychosocial or daily life impact of disease as irrelevant to the 
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clinic context (Greenhalgh and Meadows 1999). Even in situations where there is an interest in 
understanding the QoL impairment experienced by the patients, they may still be unwilling to 
measure QoL using an instrument where they mistrust or question the credibility of existing QoL 
instruments. Furthermore, having collected QoL information based on validated instruments 
clinicians may still be at loss as to the most appropriate response and action. Thus, clear decision 
aids on the most appropriate action on the patient’s QoL may be necessary. There is currently a 
paucity of such add-ons to PROMs.
In spite the tendency for clinicians to trust their own adhoc assessment of patients QoL impact, 
they are not able to always accurately predict this (Basra and Shahrukh), especially for patients 
experiencing either extremely low or high level of impairment. Furthermore, fears that integrating 
PROs may be excessively costly or require more time are often contrary to current evidence. The 
thinking that subjectivity of PRO information implies a lack of reliability may also be unfounded. 
There is evidence that the level of precision and predictive ability of PRO is comparable to that of 
clinical variables (Hahn et al. 2007). These issues require deliberate effort at providing information 
that might help to allay some of the fears, for example as part of general clinician education or 
through change management processes (these are discussed later on).
Considering the resources implications of implementing PROs, whether in terms of fixed costs 
associated with initial set up, the training of staff, the reformulation of flow in the clinic, a clear 
demonstration of the added value of routine measurement is a prerequisite. Routine QoL 
measurement should not only make sense from a theoretical or conceptual point of view, but should 
also lead to tangible benefits on the process and outcomes of care. This would be key in 
establishing the case for PRO measurement to clinicians or other consumers of PRO information. 
The patient, being the source of the PRO information, cannot be left out of the equation. Their 
motivation has an influence on the quality of the information collected and their enthusiasm may 
provide a push-factor to the physicians, broadening what is possible and feasible with PROMs. At 
the moment, QoL-discussions within consultation tend to be initiated by the clinician (Davies et 
al. 2008), which highlights potential for greater involvement and changing role of the patient. 
Patient education emphasising patient self-efficacy and their participation in treatment decision-
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making may present PROMs as a means to these aims (Luckett et al. 2009), facilitating a shift in 
how patients view routine PROM measurement (Valderas et al. 2008).
The appropriateness of PRO instruments for routine PRO measurement in the clinic has been 
highlighted. The need for the harmonisation of guidelines for the development and validation of 
disease-specific dermatology questionnaires has also been highlighted.  Two areas are particularly 
important when it comes to the development of disease specific instruments, one relates to ensuring 
that measures are rooted in the experience of patients and thus retain relevance and applicability 
to the target patient population. This has a bearing on not only the level of motivation patients will 
have in completing the questionnaire, but also how much clinicians will deem the measure useful 
as comprehensively capturing the unique disease impacts. Indeed, these elements may favour 
disease specific questionnaires over generic instruments. 
Another consideration affecting the use of a measure, especially in the clinic, is whether the scales 
can be added together to form composite scores, an aspect of practicality (Lohr 2002). This should 
be evidence-based, showing that items indeed tap into a common construct. Some investment into 
the development and assessment of a scale’s measurement model is required. Supporting the 
internal structure of the instrument is not only relevant for justifying the use of composite score, 
but forms a key part of the construct validity of the measure. Also, this evidence is used in 
subsequent validity test, for example, identifying an external measure which measures the same 
construct as a given instrument. 
A prerequisite to the application of QoL-questionnaires, once reliability, validity and 
responsiveness are adequately demonstrated is the ability to attach qualitative meaning in terms 
that are relevant for patient management. Already much development has been undertaken 
regarding this issue in assessing QoL in dermatology. However, interpretation should not end at 
identifying the MCID, as is the current practice. The connection between such cut-off and specific 
clinical decisions or action should be established (Testa 2000). This means estimating chance of 
QoL improvement or worsening for alternative treatments, in populations taking into account 
broader range of factors such as health-care resources and costs in addition to benefit (Testa 2000).  
Apart from reporting what the cut-off estimate for MCID is, a further analysis may then indicate 
that, for example 23 % of patient receiving AC and 16% who received Botox would have remained 
stable (change of less than 2.15) had they received surgical treatment. Essentially using the MCID 
to explain the risks-benefits associated with each treatment. The second level information provides 
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connection between QoL impairment and clinical decisions or use of resources. This might offer 
more assistance in a decision-making context. For example would a 10 % risk of worsening QoL 
be worth the extra hospital days or resource expenditure.
A focus on methods to facilitate clinical interpretation of scale scores and the development of 
guidelines for the development of disease-specific QoL measures were singled out as being key to 
the next generation of dermatology QoL in the special issue of Dermatology Clinic journal on QoL 
measurement, published in 2012 (DeLong and Chen 2012). Earlier recommendations of the 
International Dermato-Epidemiology Association (IDEA) from 2008 Nottingham meeting raised 
similar issues, emphasising the need for streamlining HRQoL instruments given the current 
mushrooming of disease-specific measures, to ensure consensus on methods and to facilitate 
identification of optimal instruments for measuring disease-specific QoL in various settings in 
dermatological diseases (Chen 2012; DeLong and Chen 2012). Apart from ensuring that 
instruments have rigorously tested psychometric properties, instrument development guidelines
would usher in clarity in the conceptual framework of QoL in dermatology at large. This may also
encourage transparency in measurement, crucial to achieving truly objective measurement.
Finally, as with all new innovations, taking QOL measurement from bench to application in the 
clinic has to be carefully managed. How such a process is managed has a bearing on the uptake 
and acceptance of QOL measurement. Without careful consideration there could be a backlash 
from the physicians, especially if they perceive QoL as invading their professional judgement or 
autonomy. Such sentiments have been reported especially clinicians perceiving a push from the 
research community (Greenhalgh 2009). This may require paying attention to several issues. First, 
the engagement of clinicians or clinical researchers in the process, ensuring their active ownership 
of the change process, would mean that they are active in planning and implementing the necessary 
changes to research design or clinic flow, identifying possible limitations together with instrument 
developers and other stakeholders. In this context clinicians and researchers work together to 
develop action plans to address barriers identified by physicians and other health professionals. 
This would increase the chance that QOL is useful in the clinics, in addition to reinforcing change 
in practice, which may not be possible through clinician training alone. 
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Implications of the study
 Given the mushrooming number of disease-specific QoL instruments in dermatology, a 
thorough evaluation of their attributes in urgently needed, to provide guidance on the 
optimal choice (DeLong and Chen 2012). Not only would this facilitate comparison of 
clinical trial results, but might create greater consensus regarding methods of assessing 
disease-specific QoL in various disease areas, which might smoothen the process of 
integrating QoL assessment into the clinic. The review of literature and measures used in 
assessing HRQoL in hyperhidrosis undertaken in this research, serves this purpose, within 
hyperhidrosis. This means researchers and clinicians now have a resource to aid their 
choice of the most appropriate end-point in hyperhidrosis, while being made aware of the 
limitations to the data obtained.
 The qualitative research undertaken as part of this research has provided deep insights into 
the experiences of patients with hyperhidrosis, particularly the impairment in their QoL. 
Although previous accounts used quantitative approaches, the qualitative methods applied 
in this study means that the perceptions and beliefs of the patients, were captured using the 
patient’s own words.
Patients revealed perceptions that the general public is mostly unaware of hyperhidrosis. 
One patient contrasted hyperhidrosis to diabetes, with the later receiving much sympathy 
from the public in comparison with hyperhidrosis while another suggested that 
hyperhidrosis was not ‘sexy’ enough for researchers either. Also reported were frustrations 
with how general practitioners were ignorant about the condition. Thus, patients expressed 
much excitement at the ongoing research study and were quiet enthusiastic about the 
opportunity to make a contribution to the cause of hyperhidrosis. Most often patients 
inquired about the future direction of the study and whether they would be able to take part. 
For most patients, this was the first time they ever discussed the experience of living with 
the condition, reflecting on how their life had been affected. Most patients mentioned just 
carrying on with life and not giving their condition much thought. From that perspective, 
this study accorded the patients a real opportunity to reflect on how their life might have 
been affected and to talk about those experiences. Patients taking part in the focus group 
discussion found the experience to be beneficial as some patients had never met anyone 
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with their condition before. Therefore, not only did the study serve the research objectives 
but the actual process of data gathering also had positive side effects on the patients. 
 The evidence generated in this research provided clarity regarding the definition of the 
concept ‘hyperhidrosis disease-specific QoL’ and its constituents ‘psychosocial impact’ 
and ‘daily life activities impact’. This is not only relevant for future theoretical 
development to the understanding of hyperhidrosis, but also provides greater reason for 
dermatologists to pay close attention to these consequences in their management of 
patients. An even greater imperative is that the means to accurately measure these 
constructs has been provided. 
 This research has provided a framework for the development of a new generation of QoL 
measures, utilising a mix of qualitative and quantitative methods ensuring that the resultant 
measure was efficient, applicable and content valid. The advantages of using factor 
analysis in parallel to Rasch analysis rather in sequence, were demonstrated. The balanced 
application of these methods avoided over-reliance on statistical approaches while 
addressing potential frictions that arose
 Considering that this is the first hyperhidrosis QoL instrument to undergo a thorough 
development and evaluation, the HidroQoL has potential to profoundly affect patient 
management in hyperhidrosis. 
 The confidence in the scores of the HidroQoL and their interpretation provides a new 
opportunity to incorporate HRQoL considerations in hyperhidrosis in patient management, 
for self-efficacy, by epidemiological studies of disease burden and in health-care-service 
planning. For example the MCID score cut-off values may facilitate the examination of the 
efficacy of various treatment strategies by allowing the estimation and valuation of 
population risk and benefit of deteriorating QoL, according to the clinical significant cut-
offs. 
 The findings from this research offer an important rationale and basis for revisiting 
treatment guidelines in hyperhidrosis for example redefining treatment goals in terms of 
HRQoL
 The use of patient populations from online social networking community might be a 
particularly useful approach for disease conditions with a low prevalence rate, a situation 
characterising most orphan diseases, where it is challenging to accumulate sufficient 
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patient numbers locally around a single study centre. This study has provided demonstrated
the feasibility of such an approach. The current study also suggests that a virtual 
hyperhidrosis disease registry established in collaboration with the existing patient support 
groups might be feasible.
Through the use of the online SNS it was possible to recruit patients under varying 
treatment modalities, most critically including those under self-treatment (taking OTC 
medications) as well as those not on any treatment. Patients who had not yet sought for 
medical attention for their condition despite experiencing QoL impairment, were included. 
Limitations
 Data collection in all phases of this research were undertaken using electronic means, 
including telephone, videoconferencing, internet, with no clinic visits involved. One idea 
during the design phases was to request patients to provide records that would demonstrate 
that they had the diagnosis of hyperhidrosis in the form of a prescription receipt for 
hyperhidrosis medication or historical medical records. However, such an approach was 
not implemented as it was seen to impose an excessive burden on the study participants, 
which might have scared away potential participants. Thus it is possible that this study 
included subject who might not have had hyperhidrosis. Nonetheless, given that nearly all 
patients had seen a clinician regarding hyperhidrosis, with almost half treated over the last 
6 months for their condition, helped to reduce the number of subjects with symptoms of 
hyperhidrosis but did not have the actual diagnosis. Moreover, only a small proportion of 
patients reported having co-morbidities known to cause excessive sweating.
 The use of the internet for both the recruitment and the data collection processes means it 
is not possible to calculate response rates. The only statistic showing how well the 
questionnaire was responded to is the completion rate, among those who registered how 
many completed the assessments. 
 The reliability and responsiveness studies involved longitudinal data collection. Ideally all 
patients completing the baseline assessment should have completed the follow-up 
assessments as well. This was not the case, even after a follow-up email a large minority 
still did not complete the assessments. Nonetheless, the number of patients responding was 
sufficient to perform all planned analyses. 
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 The use of an internet based patient population raises other concerns. For example, 
Langenbruch et al. (Langenbruch et al. 2010) in a study using an internet-based psoriasis 
patient population to collect data on treatment and therapeutic benefit contrasted their 
results with those from of comparable clinic-based study. Although the clinical attributes 
seemed similar, patients in the online study showed greater dissatisfaction with treatment 
and less patient defined benefit. This may reflect a form of self-selection, where patients 
who are more impaired may engage more in online health-sites and in research than less 
impaired patients. On the other hand, similar self-selection can also be seen in clinic 
populations. Patients who seek for medical attention tend to have greater impairment than 
non-seekers, similarly those volunteering for research participation may differ from non-
participants (Bland 1995). 
 A more serious source and form of selection bias, however, is the need for computer 
literacy and access to internet, required to fall into our study population. This may pose a 
threat to extending the generalisability of results to those without computer literacy and 
without internet access. This limitation however may be irrelevant. With current figures on 
internet usage at 82% (UK) and 77.2% (USA) (World Bank, 2013), it is those without the 
internet and without computers who might not be representative of the majority of patients. 
 In as much as patients reported whether they were on active treatment or not, patients did 
not receive an ‘active’ therapy in this research, thus responsiveness could not be measured 
based on hypothesis relating to therapy of known treatment effect.
 The development and validation of a new PRO instrument is a lengthy, tedious and 
resources intensive task, with whole teams dedicated to such effort, for instance the 
EUROQOL group or the EORTC group, to mention but a few, with budgets of up to half a 
million dollars. This illustrates the stringent conditions under which the HidroQoL was 
developed, in terms of time, finances and human resources. There is no doubt that the 
amount and quality of data collected, might have been enhanced without the said 
constraints. Nonetheless, the thorough and systematic process followed ensured rigor of 
the new instrument in spite of such limitations
Future work
 Although the patient population used in this research, recruited through the online social 
networks, included sub-groups representing key disease characteristics, a study to test the 
psychometric properties of the HidroQoL in a patient population recruited from the clinic 
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is planned. 
 The responsiveness of the HidroQoL was firmly established utilising multiple analytical 
approaches. Nonetheless, evaluating responsiveness in a clinical trial by assessing 
treatment-effect of a therapy of known efficacy, might further provide confidence regarding 
the use of the measure in clinical trial situations.
 Given the controversy surrounding the long-term ‘effectiveness’ of various treatments in 
hyperhidrosis and on the other hand the restriction of the NHS to cover two cycles of 
BOTOX, the development of a PROM disease registry for hyperhidrosis would be valuable 
as a resource for assessing the real-life long-term benefits of the various available 
treatments. 
 This research provided evidence on the psychometric properties of a web-version of the 
HidroQoL. Building on this, a comprehensive website containing the HidroQoL, where 
patients can self-assess their condition, obtain a total score as well as its interpretation on 
a scale banding, is planned. Such a website can integrate other valuable information which 
patients seek such as the causes of hyperhidrosis or available treatments and their efficacy 
(included on the basis of QoL).
 Given the tight financial climate in Europe as well as the UK, health-care budgets are under 
high pressure as never before. This suggests an ever growing role of bodies such as NICE, 
which assess pharmaceuticals in terms of their value, as a basis for reimbursement 
decisions. To facilitate provision of pharmacoeconomic information on hyperhidrosis 
therapies, a future study could perform a mapping of the HidroQoL score to a preference 
based measure such as the EQ-5D, in order to develop a conversion algorithm that might 
be used to easily translate information from clinical trials using the HidroQoL in future, 
and utilise such information in pharmacoeconomic evaluation studies. 
 The current research has developed and validated an English version of the HidroQoL. 
Studies to perform the cultural adaptation of the instrument into German and Portuguese 
are planned. With the efforts made to ensure universality and translatability of the measure, 
this process should be less complex.
 The HidroQoL w-s designed and developed for use in routine clinical practice, with the 
simple structure, the number of items and the scoring system intended to support this. In 
order to establish whether this intention was achieved it would be useful to assess the 
HidroQoL’s feasibility in the clinic. Evaluating how clinicians utilise the instrument, its 
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impact on the consultation and in patient management. Such a study can also study whether 
ultimately the use of the HidroQoL makes any differences in outcomes realised by the 
patient. 
 The banding scale proposed in this study needs to be confirmed in a larger patient 
population. Information on how the banding may vary across for example cultural groups 
might also provide a form of conceptual invariance test. Similarly, further studies may be 
needed to confirm the MID in other patient populations.
 An initial understanding evaluating the impact of the measure might focus on for example, 
how training general practitioners in the use of the measure affected the treatment decision-
making and patient satisfaction with the consultation encounter.
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1. Background and Rationale 
Hyperhidrosis is a skin-disorder characterised by excessive sweating beyond thermo-regulation 
requirements of the body and it affects 1-2% of the population. The impact of hyperhidrosis on 
the quality of life of its sufferers has been previously studied.  Patients have reported suffering 
emotional distress, considerable impairment in relation to performance of work-related as well 
as household tasks, and dysfunctional social life (Hamm et al. 2006; Solish et al. 2006, Strutton 
et al., 2004). Various questionnaires were utilised in these studies including those specific for 
hyperhidrosis (HDSS, HHIQ and HS), those for all skin-disorders, measuring dermatology 
specific quality of life (e.g. DLQI) and more generic questionnaire measuring health related 
quality of life in general (e.g. SF-12).  These studies underscore the importance or relevance of 
understanding the quality of life of hyperhidrosis patients, as an important component of any 
efforts at improving the care and treatment of hyperhidrosis patients. Considering the patients’ 
subjective experience with the disease and their personal account of how it affects them also 
reflects the WHO’s concept of health, where health is defined holistically beyond clinical 
measures of disease (See Review Paper for Ref.). 
Most hyperhidrosis specific instruments are appropriate and validated for sub-groups of 
hyperhidrosis patients, mostly based on location of the disease or the treatment strategy received 
(e.g. Hyperhidrosis Scale). The promising few (e.g. Hyperhidrosis Impact Questionnaire) seem 
more fitting for research settings rather than daily routine clinical practice.  As such a gap still 
exists for a disease specific tool, generic enough to cover all types of hyperhidrosis (according 
to body location), concise enough for use in routine clinical practice. While previous studies 
have reported negative impact of hyperhidrosis on quality of life, an in-depth investigation of 
quality of life issues of hyperhidrosis patients using a triangulation of various qualitative 
methods has not been done. Additionally a comparison across various sub-groups (between UK
and German patients) has also not been done.
A novel disease specific questionnaire covering all forms of hyperhidrosis will enhance the 
understanding of the impact of hyperhidrosis on the life of patients. We expect that this will 
assist in improving the diagnosis and clinical management of hyperhidrosis. Additionally an in-
depth understanding of the impact of hyperhidrosis on the patients’ quality of life would reveal 
the treatment needs of hyperhidrosis patients, particularly pointing towards additional care or 
services that these patients require. The potential implication is a modification of current 
treatment guidelines for hyperhidrosis based on the new evidence that this study would create.
2. Research Question and Objectives
The aim of this study is to develop and validate a disease specific questionnaire for measuring 
the impact of hyperhidrosis on the quality of life of patients. Additional secondary objectives 
will also be achieved, this includes to investigate the impact of hyperhidrosis on the daily lives 
of patients; and to conduct sub-group comparisons of the impact of hyperhidrosis on the quality 
of life of patients across cultures (in particular between U.K and Germany).
3. Study design and methodology
This study will utilise a variety of methodologies combining qualitative and quantitative 
approaches. Document research (review of literature), semi-structured interviews and focus 
groups will be used in the first part of the study. The latter steps will include Quantitative 
approaches - survey questionnaire. The study will involve patients with clinically diagnosed 
hyperhidrosis, recruited from Germany and from the UK Multiple steps will be followed, 
including conceptualisation, qualitative data collection, and qualitative development of 
questionnaire, pre-testing, and validation reflecting the complex process of developing new 
questionnaires. Each step is elaborated on below:
3.1. Step 1: Conceptualisation
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Conceptualization will involve extensive review of the literature on the impact of hyperhidrosis 
on the health related quality of life of patients, including reviewing questionnaires previously 
used in studies evaluating quality of life of hyperhidrosis patients. The main output of this stage 
is a conceptual framework of quality of life issues in hyperhidrosis patients. 
3.2. Step 2: Qualitative data collection 
A triangulation of qualitative data collection approaches will be applied for this phase 
combining the use of the internet, telephone and postal mail. Online text based focus groups 
will be organised via secure, password protected online discussion platform designed for this 
purpose. Interviews will be held via telephone or through online Instant Messaging facilities 
(Skype & Facebook). Additionally, postal and online surveys (containing open questions) will 
also be used.  
At least 70 hyperhidrosis patients will be sampled for this phase. We anticipate this phase to 
take 8 weeks. Given that the goal in qualitative analysis is to gain deep insight in an issue rather 
than make statistical inference, there is no recommendable sample size or formulae for deriving 
one. Nevertheless, a general rule of thumb is to continue sampling until a ‘saturation point’ is 
reached i.e. where no additional themes and issues are emerging from additional subjects 
(Bowling 2009, p.410). The proposed sample size is based on studies addressing similar 
research question. 
In consideration of the clear differences between online patient populations and patients 
accessing care in the clinic (Langenbruch et al. 2009) a purposive sampling strategy will be 
employed, in order to obtain patients via various channels. This is a deliberate strategy to 
minimise bias in the collection of issues. Thus patients will be recruited via online patient 
support groups and forums as well as through the dermatology practices or clinics (primary care 
and secondary care setting) through doctors. 
This process will take place in parallel, for the U.K and German patients.
3.3. Step 3:  Qualitative development of questionnaire
This phase will involve a structured content analysis of the transcripts of the focus group and 
interview as well as the data collected via the open questions of postal survey information with 
the aim of identifying major themes and issues emerging from both the UK and German 
patients. This process will again take place in parallel, for the English and German patient 
groups. Two panels, one English-speaking and the other for German speaking, comprised of 
dermatologists and patients will be asked to review the themes and issues identified.  The first 
drafts of the English and German versions of the questionnaire will be prepared based on this 
review.
3.4. Step 4: Pre-testing
The first draft of the questionnaire will be pretested in a sample of 30 patients. Purposive 
sampling strategy will be used to ensure that representativeness based on type of hyperhidrosis 
is maintained, in both the German and English patient groups. Patients will firstly be asked to 
complete the draft questionnaire, followed then by an interview on their understanding of the 
questions as well as their evaluation of other aspects of the questionnaire e.g. 
comprehensiveness, relevance of questions, flow of questions. 
Patients in Germany will be recruited via primary care physicians and will complete the paper-
and-pencil version of the questionnaire while the interviews will be conducted via telephone. 
For UK patients the same process will be completed using electronically sent questionnaires 
(E-Mail) and telephone for the interviews. 
3.5. Step 5: Field-testing
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This will mainly focus on establishing the questionnaire’s construct validity, reliability and 
sensitivity.  The questionnaire will be given to at least 250 patients recruited through the 
dermatologists or general practitioners; and through online-patient support groups.
Construct Validity
Construct validity is one of the core psychometric properties that a valid questionnaire must 
posses. It reflects the theoretical relationships of items to each other and to the hypothetical 
scale (Basra et al. 2007). This will be assessed using factor analysis. A purposive sample of 400 
patients will be drawn, including German (n=200) and English (n=200) patients. Same channels 
used to recruit patients in the qualitative data collection phase will be applied in this phase also.
Convergence Validity
Besides the new questionnaire, patients will also be asked to complete a second questionnaire 
– the DLQI (this instrument was also developed by Cardiff University – approval from license 
holder is yet to be obtained. We expect that the patients’ skin quality of life to be related to the 
quality of life based on the disease specific measure. The DLQI score should therefore be 
correlated with the score of the new measure.
Reliability
A questionnaire’s ability to produce consistent and reproducible results reflects its reliability 
properties. Intra-class correlations among items within and with other scales will be used in 
assessing internal consistency of the new questionnaire. Data already collected for construct 
validity assessment will be utilised in establishing this. Assessment of reliability over time, test-
retest reliability, will be done by asking the patients sampled for field testing to complete the 
new questionnaire again 7 – 10 days after initial completion.
Sensitivity
The ability of a questionnaire to detect existing differences between individual or groups of 
patients (Fayers 2007, p.101) reflects its sensitivity. Such a property is very useful especially in 
discriminative instruments intended for use in diagnosing patients i.e. identification of clinically 
relevant differences (Ibid). This will be assessed by measuring the standard response means 
based on the data already provided by the patients for construct validation. Disease-free 
subjects, German (n = 50) as well as English (n = 50), will be recruited to act as a control group, 
in further analyses of the instruments sensitivity.
4. Patient Selection
Participants for steps 2 to 5 of this study must fulfil the following inclusion criteria; 
 Must have a medically confirmed diagnosis of hyperhidrosis except for the control group 
recruited in the sensitivity done in step 5;
 Be seeking for treatment for the hyperhidrosis.
 Aged 16 and above.
 Able to understand and read German (in the case of the German patients).
 Able to understand and read English (in the case of UK patients)
 Capable of giving informed consent.
5. Ethical Considerations
As this study does not involve any interventions, the risk to which the study participants will 
be exposed is minimal. Nevertheless considerations have been given to the studies research 
processes and how possible effects on patients can be minimised.
 Qualitative data collection will involve discussing the impact of hyperhidrosis on the 
patient’s everyday life. The participant’s consent will be obtained before the start of 
interview/focus group. We envisage that personal and embarrassing issues may arise in 
the process. Should a participant feel uncomfortable to proceed with the discussion, they 
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will be free to withdraw their consent, which will lead to a prompt termination of 
interview/focus group and deletion of information collected as per participants’ wishes. 
 Written consent will also be sought from patients responding to both the survey 
administered as part of qualitative data collection and the questionnaires completed in 
both the pre- and field testing. Patients will be given the opportunity to ask questions 
via contacts provided on the information sheet. The set of documents sent to the patients 
both via post and electronic will include an information sheet and a consent form which 
the patients will be asked to enclose together with their questionnaires in their reply.
 While the study does not confer direct immediate benefits to the participants, we believe 
this research will lead to better management and treatment of hyperhidrosis patients, 
thus enhancing their quality of life.
 Handling of the personal data will be in line with both Germany and UK personal data 
and privacy laws. All data received through electronic means will be stored in a 
password protected server/database and will be only accessible to the research team. 
Similarly all data collected in paper and pencil format will be stored in a secure storage 
location, only accessible to the research team. All data from patients will be confidential 
and thus will not be shared outside the research team. The data collected will be held 
for a period of 6-12 months after the completion of the project.
6. Communication of results
 Results of the structured content analysis will be presented at international conferences 
– and also published in a peer reviewed journal under the title: “comparison of quality 
of life issues between German and UK patients.”
 The major themes/issues identified from the structured content analysis will form the 
input for the questions in the new questionnaire (English and German versions).
 The results from the pre-test and field-testing phase will be presented at international 
conferences, and will also lead to publications of the various aspects of the psychometric 
properties of both the English-version and the German version of the questionnaire.
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Appendix III
Informed Consent Form for Hyperhidrosis patients being invited to participate in a focus 
group discussion/interview on the impact of hyperhidrosis on your daily life. 
09 August 2011
This Informed Consent Form has two parts:
 Information sheet (to give you the background to this study)
 Certificate of Consent (to show your acceptance to take part in this study).
Part I: Information Sheet
Introduction
Hyperhidrosis, excessive sweating beyond physiological and environmental requirements of 
the body is known to have a number of unpleasant effects on the patients. Previous research 
has observed its impact on the patients’ everyday life and well-being. Assessing the impact of 
hyperhidrosis on daily life of patients is at the heart of the process of diagnosis of hyperhidrosis
Purpose of research
We would like to develop an easy to use hyperhidrosis-specific instrument for evaluating the 
impact of hyperhidrosis on quality of life that can be applicable across all severity of the 
disease and appropriate in evaluating all treatment strategies. To do this we are interested in 
learning from your experiences with hyperhidrosis. We would like to know the different ways 
in which hyperhidrosis affects your daily life and quality of life.
Type of Research Intervention
This research will involve your participation in an focus group discussion/interviews.
Voluntary Participation
Be aware that your participation in this research is entirely voluntary.
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Procedure
If you accept the invitation to participate in this research you will be asked to take part in an 
online discussion with other persons also experiencing problems with excessive sweating. The 
online discussion will require a few minutes daily to read the discussion board to take note of 
the discussion topic, to respond to the issue introduced by the moderator and also respond the 
posts made by other respondents. Once the discussion is concluded you will be asked to verify 
a summary list of main themes/issues discussed (this may happen at about seven days after the 
discussions are concluded).
Duration
The online discussion will run for a period of 14 days.
Confidentiality
The experiences you share will be treated anonymously. Your personal information will not be 
shared outside the research team. Your information will only be identified by an ID number 
instead of your name. To ensure this, right from the beginning your will choose a user name 
which you can be identified with in all the discussions, to follow your contributions.
Use of Results
The knowledge gained from the discussion will be used as input into a new 
questionnaire/instrument. Our summary of the issues from the discussions will first be shared 
with you before the final instrument is developed and shared with the public.
442
Part II: Certificate of Consent
I have read the foregoing information in part I. I have had the opportunity to ask questions 
where I had my doubts. All issues and questions I raised have been addressed to my 
satisfaction. I consent voluntarily to be a participant in this study.
Name: _______________________________________________________
Signature: ____________________________________________________
Date: ________________________________________________________
I confirm that the participant was given an opportunity to ask questions about the study, and 
all their questions and concerns have been addressed and to the best of my ability. I confirm 
that the participant was not coerced into giving consent, and the consent has been given freely 
and voluntarily.
A copy of this ICF has been provided to the participant.
Name of Researcher: Paul Kamudoni, MSc.
Signature: ____________________________________________________
Date: ________________________________________________________
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Appendix IV
Topic guide for focus group discussion/interviews
9 July 2011
 Tell me a bit about yourself e.g. how long you have had hyperhidrosis and any background 
information in relation to the disease.
 Can you tell me about your experience of the first time you got diagnosed with hyperhidrosis i.e. 
How difficult was it for your physician/doctor to diagnose you with hyperhidrosis?
 What was it about the sweating that made you seek for medical attention i.e. what specific factors 
did you consider in judging that your sweating is problematic [what issues does the patient consider 
in evaluating the severity of his/her sweating]
 Which areas of your life have been most affected by hyperhidrosis?
[probes based on previous studies]
− Treatment history & Level of satisfaction with past treatments.
− Physical ailment. 
− Functional e.g. writing, manual work 
− Limitation on daily life/ everyday life e.g. at home, dressing.
− Social life
− Psychological well-being,
− Personal domain or affection – hugging, intimate touching
− Therapy
− Satisfaction with life
− Impact on employment and productivity
− Special circumstances e.g. writing exams, 
− Special effects particular/specific to sweating of hands, feet or underarms or any other special 
area.
 Can you describe how each of the areas you have mentioned has been affected?
 Which usual daily activities are you uncomfortable to do due to your hyperhidrosis?
 What aggravates your hyperhidrosis? 
 How satisfied are you with your life? [am not interested in general satisfaction with life of patient 
per se]
 Can you share with me about the treatments you have taken for your hyperhidrosis 
[Interest here is to get the patient to talk about how they feel about the treatments they have taken]
− What are your views and feelings on the currently available treatments for hyperhidrosis?
 How are you currently managing your excessive sweating i.e. treatment or any efforts to control its 
effects?
 How have you adapted your life to living with hyperhidrosis? [this may reflect a combination of 
limitations in functioning and other psychological limitation]
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Appendix VI
Content validation Questionnaire   
(Only first three pages included)
20 January 2012
Name : ______________________________________
Thank you for agreeing to take part in questionnaire feedback process as part of content validation.
Each item on the questionnaire needs to be assessed for language clarity, completeness, and relevance 
and scaling.
The following definitions are provided to ensure standardisation so that each person has the same 
understanding of the criteria.
Please rate each of the items on the following:
A. Language clarity: The sentences and wording should be clear, understandable, straightforward 
and simple. Phrases and wording should be unambiguous and jargon free and should be 
understood by someone with a reading ability of 12 years.
B. Completeness: The sentences should be complete, not broken and should end appropriately.
C. Relevance: Each statement should be relevant to the subject area of the target population
D. Scaling: Scaling refers to the scoring system, with the five response options. Panel members 
should rate whether the response options fit the statement or not.
Statement 1: My choice of clothing is affected
Strongly
agree
Agree Agree Strongly 
disagre
Language Clarity ☐ ☐ ☐ ☐
Completeness ☐ ☐ ☐ ☐
Relevance ☐ ☐ ☐ ☐
Scaling ☐ ☐ ☐ ☐
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Statement 2: My choice of footwear is affected
Strongly
agree
Agree Agree Strongly 
disagre
Language Clarity ☐ ☐ ☐ ☐
Completeness ☐ ☐ ☐ ☐
Relevance ☐ ☐ ☐ ☐
Scaling ☐ ☐ ☐ ☐
Statement 3: My holiday is affected
Strongly
agree
Agree Agree Strongly 
disagre
Language Clarity ☐ ☐ ☐ ☐
Completeness ☐ ☐ ☐ ☐
Relevance ☐ ☐ ☐ ☐
Scaling ☐ ☐ ☐ ☐
Statement 4: I have difficulties gripping objects
Strongly
agree
Agree Agree Strongly 
disagre
Language Clarity ☐ ☐ ☐ ☐
Completeness ☐ ☐ ☐ ☐
Relevance ☐ ☐ ☐ ☐
Scaling ☐ ☐ ☐ ☐
Statement 5: I have difficulties handling money
Strongly
agree
Agree Agree Strongly 
disagre
Language Clarity ☐ ☐ ☐ ☐
Completeness ☐ ☐ ☐ ☐
Relevance ☐ ☐ ☐ ☐
Scaling ☐ ☐ ☐ ☐
Statement 6: I have difficulties with physical contact with others
Strongly
agree
Agree Agree Strongly 
disagre
Language Clarity ☐ ☐ ☐ ☐
Completeness ☐ ☐ ☐ ☐
Relevance ☐ ☐ ☐ ☐
Scaling ☐ ☐ ☐ ☐
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Statement 7: My hobbies are affected
Strongly
agree
Agree Agree Strongly 
disagre
Language Clarity ☐ ☐ ☐ ☐
Completeness ☐ ☐ ☐ ☐
Relevance ☐ ☐ ☐ ☐
Scaling ☐ ☐ ☐ ☐
Statement 8: I avoid speaking with groups of people
Strongly
agree
Agree Agree Strongly 
disagre
Language Clarity ☐ ☐ ☐ ☐
Completeness ☐ ☐ ☐ ☐
Relevance ☐ ☐ ☐ ☐
Scaling ☐ ☐ ☐ ☐
Statement 9: My physical activities are affected
Strongly
agree
Agree Agree Strongly 
disagre
Language Clarity ☐ ☐ ☐ ☐
Completeness ☐ ☐ ☐ ☐
Relevance ☐ ☐ ☐ ☐
Scaling ☐ ☐ ☐ ☐
Statement 10: My outdoor activities  are affected
Strongly
agree
Agree Agree Strongly 
disagre
Language Clarity ☐ ☐ ☐ ☐
Completeness ☐ ☐ ☐ ☐
Relevance ☐ ☐ ☐ ☐
Scaling ☐ ☐ ☐ ☐
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Appendix VIII
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Appendix XI
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Appendix XII
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Appendix XIII
No. item 
Skindex-17
Description of the item
In the last 4 or 1 weeks, how frequent have you experienced 
the following….. 
Scoring†
1* My skin hurts [ ] Never      [ ] Rarely     [ ] Sometimes    [ ] Often     [ ] All the time
2+ My skin condition makes it hard to work or do hobbies [ ] Never      [ ] Rarely     [ ] Sometimes    [ ] Often     [ ] All the time
3+ My skin condition affects my social life [ ] Never      [ ] Rarely     [ ] Sometimes    [ ] Often     [ ] All the time
4+ My skin condition makes me feel depressed [ ] Never      [ ] Rarely     [ ] Sometimes    [ ] Often     [ ] All the time
5+ I tend to stay at home because of my skin condition [ ] Never      [ ] Rarely     [ ] Sometimes    [ ] Often     [ ] All the time
6* My skin itches [ ] Never      [ ] Rarely     [ ] Sometimes    [ ] Often [ ] All the time
7+ My skin condition affects how close I can be with those I love [ ] Never      [ ] Rarely     [ ] Sometimes    [ ] Often     [ ] All the time
8+ I tend to do things by myself because of my skin condition [ ] Never      [ ] Rarely     [ ] Sometimes    [ ] Often     [ ] All the time
9* Water bothers my skin condition (bathing, washing hands) [ ] Never      [ ] Rarely     [ ] Sometimes    [ ] Often     [ ] All the time
10+ My skin condition makes showing affection difficult [ ] Never      [ ] Rarely     [ ] Sometimes    [ ] Often     [ ] All the time
13* My skin is irritated [ ] Never      [ ] Rarely     [ ] Sometimes    [ ] Often     [ ] All the time
11+ I am embarrassed by my skin condition [ ] Never    [ ] Rarely     [ ] Sometimes    [ ] Often     [ ] All the time
12+ I am frustrated by my skin condition [ ] Never      [ ] Rarely     [ ] Sometimes    [ ] Often     [ ] All the time
14+ My skin condition affects my desire to be with people [ ] Never   [ ] Rarely     [ ] Sometimes    [ ] Often     [ ] All the time
15+ I am humiliated by my skin condition [ ] Never      [ ] Rarely     [ ] Sometimes    [ ] Often     [ ] All the time
16* My skin condition bleeds [ ] Never      [ ] Rarely     [ ] Sometimes    [ ] Often     [ ] All the time
17+ My skin condition interferes with my sex life [ ] Never      [ ] Rarely     [ ] Sometimes    [ ] Often     [ ] All the time
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